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Although the stereochemistry of most atropisomers arises from slow rotation about a C–C bond, the 
ability of the nitrogen atom to adopt a planar geometry promotes conformational rigidity in anilides 
and aryl ureas. Diarylamines are closely related in architecture to the conformationally stable diaryl 
ethers and sulfides. However, atropisomerism in this class of compounds had not been reported. Using 
Dynamic NMR and HPLC techniques, we investigated the factors determining the rates of bond 
rotation and established the requirements for atropisomerism in diarylamines (Chapter 1).  
Common methods to synthesise diarylamines, namely metal-catalysed couplings and nucleophilic 
aromatic substitution reactions, lack tolerance of steric hindrance or generality in structures available, 
restricting the availability of poly-substituted diarylamines. We developed a N-to-N’ Smiles 
rearrangement of anthranilamides affording atropisomeric diarylamines with exceptional steric 
demand (Chapter 2). Incorporating the amide nitrogen of the substrate into a ring allowed the 
synthesis of 9–12 membered heterocycles by ring expansion. The products adopted a chiral ground 
state with an intramolecular, transannular hydrogen bond. Their rate of interconversion was found to 
heavily depend on solvent polarity, ring size and proximate steric hindrance (Chapter 3). 
Introducing axial chirality into diarylamine-based pincer ligands was attempted in order to study the 
possibility of atropisomerism to induce enantioselectivity in transition metal-catalysed reactions with 
this class of ligands (Chapter 4). 
Finally, restricted rotation in the C–N bonds of anilides was used on rigid aromatic scaffolds to control 
the relative conformation of extended structures over long distances by dipole repulsion and gain 
insight on the impact of distance the communication of stereochemical information by dipoles 
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I.1.1. Atropisomerism: History and definition  
In 1922, Christie and Kenner reported the isolation of two optically active compounds from the  
co-crystallisation of biaryl 1.1 with brucine (Figure 1).[1] As compound 1.1 does not have a chiral centre, 
the authors proposed a structure which allowed the existence of enantiomers, where the aryl rings 
lay perpendicular to each other. In this case, an axis of chirality is generated, and rotation by 180° of 
one aryl ring provides the opposite enantiomer. 
 
Figure 1: First representation of atropisomerism by Christie and Kenner (taken from [1]) 
These compounds were coined atropisomers by Kuhn,[2] from the Greek a (not) and tropos (turn) and 
are stereoisomers which can be distinguished by the mean of rotation around an axis. Ōki defined 
atropisomers as ‘physically separable species when they interconvert with a half-life of more than 
1000 seconds (about 17 min) at a given temperature’, corresponding to a Gibbs free energy of rotation 
of 93 kJ mol–1 or more at room temperature.[3] 
A major field in which atropisomers have contributed in modern chemistry is asymmetric catalysis. 
The use of BINAP (Scheme 1) as a ligand in the asymmetric hydrogenation of C=C and C=O bonds, for 
example, was highlighted in the 2001 Nobel Prize to Ryōji Noyori ‘for [his] work on chirally catalysed 
hydrogenation reactions’.[4] A powerful example of the use of BINAP is the industrial synthesis of  
(−)-menthol, where the key intermediate enamine is produced in 96–99% ee on large scale from 
diethylgeranylamine (Scheme 1), while extraction from natural resources only provides with an 
intermediate in 80% ee[4] This process was used to produce 1000 tons of (−)-menthol per year, 
corresponding to a third of the world demand in 2001.[4] 
 
Scheme 1: Key step in the synthesis of (−)-menthol by Takasago Internation[4] 
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I.1.2. Biaryl atropisomers 
Compound 1.1 is a member of the extensively studied class of biaryl atropisomers.[5] Because of the 
planarity of aromatic rings and the relatively short length of the CAr–CAr bond, it is not possible for 
biaryls to lie coplanar in the ground state.[6] While conjugation favours coplanarity of the rings, steric 
interactions of the ortho-substituents destabilise this conformation. In the ground state of biphenyl, 
even the two aryl rings with only small hydrogen atoms at the ortho-positions, are estimated to be 
twisted by about 45° in the gas phase.[7] While the main factor playing a role in the barrier to rotation 
of biaryls is steric hindrance ortho to the chirogenic axis, all three different positions on the ring have 
an influence on the half-life of the atropisomer, as described below. The impact of substitution on the 
barrier to rotation of several biaryls was observed by Sternhell and co-workers.[8] By installing a gem-
dimethyl group as a diastereotopic 1H and 13C NMR probe in a series of biaryls 1.2, the authors 
monitored the change in free energy of a series of compounds with different ortho-substituents by 
variable-temperature NMR. Systematic comparison of the barrier to rotation against the van der 
Waals radius of each ortho-substituent R showed a clear trend between the free energy and the steric 
demand at the ortho-position (Figure 2). 
  
Figure 2: The barrier to rotation of 1.2 against the van der Waals radius of R[8] 
Inspired by Westheimer et al.,[9] the authors also studied the outcome of a buttressing effect on similar 
compounds (Table 1). A bromine atom meta to the CAr–CAr bond results in an increase in the barrier to 
rotation of biaryls 1.3b, 1.3d and 1.3f (entries 2, 4 and 6). The increase of energy on the barrier to 






Entry Compound R R’ ΔG‡340 K (kJ mol–1) 
1 1.3a F H 59.6 
2 1.3b F Br 67.9 
3 1.3c Cl H 78.5 
4 1.3d Cl Br 87.7 
5 1.3e NO2 H 72.8 
6 1.3f NO2 Br 81.2 
Table 1 : Buttressing effect at the meta-position in biaryls[8] 
Although the steric demand of a group in para-position does not contribute to the barrier to rotation, 
the electronic properties of the substituent at this position have a significant effect. Roussel et al. 
showed the importance of the substitution at this position in a series of para-substituted biphenyls 
1.4a–e (Table 2).[10] The addition of one or two electron-donating groups lowered the barrier to 
rotation by 6 and 8 kJ mol–1, respectively (entries 2 and 3). This effect was thought to be due to the 
increase of the conjugation of both aryl rings by resonance, stabilising the coplanar transition state 
and increasing electron density at the carbon atoms in the pivot bond, thus enabling the out-of-plain 
bending in the transition state. 
Entry Compound R R' ΔG‡T (kJ mol–1) 
1 1.4a H H 109.2 (332 K) 
2 1.4b NH2 H 103.1 (320 K) 
3 1.4c NH2 NH2 101.0 (320 K) 
4 1.4d NO2 H 110.2 (334 K) 
5 1.4e NO2 NO2 113.2 (340 K) 
Table 2: Electronic effect at the para-position in diarylamines[10] 
Electron-withdrawing groups have an opposite effect on the barrier to rotation by decreasing the 
electronic density at the pivot carbon as in biaryls 1.4d and 1.4e, although two nitro groups were 
needed for a significant change in the barrier to rotation (entries 4 and 5). 
I.1.3. Non-biaryl atropisomers 
Other classes of conformationally stable, axially chiral molecules have been described as well.[11]  
Non-biaryl atropisomers have attracted much attention over the past twenty years, not only by virtue 
of restricted rotation around a C−C bond, as C−O,[12] C–N[13] or C–S[14] atropisomers have also been 
described. Amongst non-biaryl atropisomers with a C–Heteroatom stereogenic bond, comprehensive 
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work has been done on the conformational restriction of biaryl ethers and thioethers.[15] One of the 
most notable examples is the natural product Vancomycin (Figure 3). This macrocyclic peptide, used 
as an antibiotic against Gram-positive bacteria, is produced by the soil bacteria Amycolatopsis 
orientalis.[16]With 18 stereocentres and 3 axis of chirality, Vancomycin has been fully synthesised in 
1998 by the Evans and co-workers.[17] Two atropisomeric diaryl ethers A and B and a biaryl C are 
embedded in the macrocycles. Rotation around these bonds is highly restricted, with barriers to 
rotation of up to 125 kJ mol–1. 
 
Figure 3: Structure of Vancomycin and barriers to rotation[17] 
The Clayden group has performed extensive research on the synthesis, conformational analysis and 
use of diaryls ethers and thioethers.[12,14,18] Provided great steric hindrance was introduced at the 
ortho-positions, atropisomerism was observed in several series of diaryl ethers, sulfides and sulfones, 
although sulfur-based atropisomers have a rather low conformational stability (Table 3). The longest 
half-lives measured for sulfide 1.5a and for sulfone 1.5c were 14 h and 6 d, respectively. Sulfoxide 1.5b 
showed a lower conformational stability, with a half-life of 70 s, presumably because of the longer C−S 
bond in sulfoxides. 
Entry Compound X ΔG‡T (kJ mol–1) 
1 1.5a S 100.8 (313 K) 
2 1.5b S(O) 86.3 (290 K) 
3 1.5c S(O)2 106.5 (323 K) 
Table 3 : Influence of the nature of the sulfur atom on the barrier to rotation[14] 
Greater barriers to rotation were obtained in the diaryl ethers series, with half-lives of up to thousands 
of years. A selected series of compound is shown below for comparison of barrier to rotations  
(Table 4). In general, exchanging a sp3 carbon at the ortho-position for a trigonal planar atom lowered 
8 
 
the barrier to rotation (entries 1 vs. 2). Isopropyl groups were barely bulky enough to block rotation 
around the CAr−O bond such as in compound 1.6a. However, substitution for a tert-butyl group in 1.6c 
allowed the isolation of conformationally stable compounds. Interestingly, the barrier to rotation of 
diaryl ethers 1.6d having one symmetrical ring could only be estimated with a value below  
38 kJ mol–1 (entry 4). Even two isopropyl groups were not enough to observe restricted rotation as the 
diastereotopic signals could not be resolved at low temperature by 1H NMR. This drop in the energy 
of interconversion was thought to be due to the existence of a low-energy geared rotation in 
compounds with symmetrical rings, where none of the ring has to go through a very demanding, 
decoupled 180° rotation.  
Entry Compound R R’ R’’ ΔG‡298 K (kJ mol–1) 
1 1.6a iPr H CH2OH 90.9 
2 1.6b iPr H CHO 78.5 
3 1.6c tBu H CH2OH 113.5 
4 1.6d iPr iPr CH2OH <38 
Table 4 : Atropisomerism in some diaryl ethers[12] 
Atropisomerism around C−X bonds, as seen previously, has been largely studied in oxygen and sulfur-
based compounds, both in natural products and synthetic molecules. Nevertheless, both cyclic and 
acyclic aromatic amines have demonstrated the existence of slow rotation in C−N bonds too. 
I.1.4. C−N atropisomers 
Restricted rotation around C−N bonds has been observed in heterobiaryl natural compounds. 
Ancisheynine (Figure 4, natural counter-anion unknown) was isolated as a racemate from the 
Congolese liana of the Dioncophyllaceae and Ancistrocladaceae families.[19] Murrastifoline F  
(Figure 4), of which the absolute configuration is unknown, was first synthesised in 2001 by Bringmann 
et al.[20] Although its two stereoisomers were never separated, its barrier to rotation was calculated 
to be around 165 kJ mol–1.  
Various groups have designed classes of synthetic C–N, bicyclic atropisomers such as N-aryl imides 
(Figure 4),[21] or N-aryl tetrahydroquinolines.[22] In the former, conjugation of the nitrogen lone pair 




Figure 4: Structure of Murrastifoline F,[20] Ancisheynine,[19] and some synthetic C–N atropisomers[21,22] 
C−N bond atropisomerism in acyclic structures has been widely studied in N-aryl amides, or anilides. 
Seminal work by Sutherland et al.[23] explored the impact of substitution of the nitrogen atom of 
anilines on restricted rotation. Both steric demand and pyramidalisation of the nitrogen played a role 
in barrier to rotation. While compounds 1.7 and 1.8, of which the nitrogen possess some sp3 character, 
had a relatively low barrier to rotation, the increase in conjugation of the nitrogen atom enhanced the 
ability to slow down interconversion, as shown in compounds 1.9 (Table 5).  
Entry Compound ΔG‡273 K (kJ mol–1) 
1 1.7 62.0 
2 1.8 65.3 
3 1.9 80.8 
Table 5 : Influence of the geometry of the nitrogen on atropisomerism in toluidine derivatives[23] 
Stewart et al.[24] demonstrated that atropisomerism in anilides could be achieved by introducing a 
bulky group at the ortho-position (Table 6). Later work by Curran and co-workers showed that a tert-
butyl at this position significantly increased the barrier to rotation, obtaining atropisomers at room 
temperature.[25,26] 
Entry Compound ΔG‡298 K (kJ mol–1) 
1 1.10 93.4 
2 1.11 106.3 
3 1.12 121.4 
Table 6 : Energy of C−N bond rotation in anilides[24] 
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Origin of atropisomerism at the C−N bond in hindered anilines  
During the second half of the 1980s, Lunazzi and co-workers described the conformational properties 
of several tertiary 1-naphthylamines. While the compounds studied at the time were not 
atropisomers, this series of papers shed light on the dynamic processes occurring both at the ground 
and transition states of such compounds and provided proof that atropisomerism could be achieved 
in anilines. Steric effects were observed in anilines 1.13a–e, where an increase of the barrier to 
rotation resulted from an increase of the size of the alkyl group at the ortho-position (Table 7,  
entries 2 to 4).[27] Substitution at the peri position has a larger contribution to the barrier to rotation, 
as a methyl group is sufficient to make compound 1.13e an atropisomer with a barrier to rotation of 
90.4 kJ mol–1 (entry 5). Unfortunately, the temperatures of calculation of the barriers to rotation were 
not reported, precluding comparison with other systems. 
Entry Compound R R’ ΔG‡T (kJ mol–1)a 
1 1.13a H H 34.7 
2 1.13b Me H 65.7 
3 1.13c iPr H 72.0 
4 1.13d tBu H 82.1 
5 1.13e H Me 90.4 
a: determined by coalescence of the diastereotopic signal for CH2CH3 by VT 1H NMR.  
Table 7 : Barrier to rotation of various ortho-substituted N-methyl-N-ethyl-1-naphthylamines[27] 
The stereomutation of tertiary diarylamines 1.14a–d was also studied by Lunazzi et al. (Table 8).[28] 
The energy of rotation around the N-phenyl bond (called ‘rotation’, in red) and the barrier to 
enantiomerisation, achieved by rotation around the N−Cnaphthyl bond (in blue), were determined by 
variable-temperature 1H NMR. Because of the low steric demand around the phenyl ring compared to 
the naphthyl group, it was expected that diarylamines 1.14a–d adopt a ground state conformation in 
which the naphthyl ring lays perpendicular to the other two nitrogen substituents, and where the 
phenyl ring is in conjugation with the nitrogen lone pair. 
Decrease of the barrier to rotation around the phenyl ring when replacing a methyl group for an ethyl 
(Table 8, entries 1 and 3) could be explained by the destabilisation of the ground state by disruption 
of the conjugation with the lone pair of the nitrogen atom, lowering the energy difference with the 
transition state. Increasing the steric bulk with an isopropyl group forces deconjugation of the phenyl 
ring in the ground state, leading to a twisted conformation of which the barrier to interconversion is 
raised due to steric demand (entry 5). 
11 
 
Entry Compound R R’ Motion ΔG‡T (kJ mol–1) 
1 1.14a Me H Rotationa 29.7 (153 K) 
2 1.14b Me Et Enantiomerisationb 36.8 (186 K) 
3 1.14c Et H Rotationa 27.2 (142 K) 
4 1.14c Et H Enantiomerisationc 42.7 (215 K) 
5 1.14d iPr H Rotationa 32.7 (169 K) 
6 1.14d iPr H Enantiomerisationc 46.0 (234 K) 
a Calculated by coalescence of the diastereotopic 13C signals of carbons 2 and 6 in Me2O. b Calculated by coalescence of the 
diastereotopic 1H signals of Et in CD2Cl2. c Calculated by coalescence of the diastereotopic 1H signals of R in CD2Cl2. 
Table 8 : Barrier to rotation of various N-alkyl-N-phenyl-1-naphthylamines in dimethyl ether[28] 
Conversely, increase of the size of the nitrogen substituent leads to a growth of the barrier to rotation 
of the naphthyl ring in each example, in agreement with a twisted N–Cnaphthyl bond in the ground state.  
Atropisomerism in diarylamines was also observed by the Kawabata group in naphthylamine 1.15a–e 
(Table 9).[29] Half-lives to racemisation ranging from few seconds to a couple of years have been 
achieved by finely tuning the physicochemical properties of the compounds (Table 9). The steric 
demand around the CAr–N axis was increased by introducing a methyl group at the peri position of the 
naphthyl group (entry 2 vs. 6). The highest barriers to interconversion were obtained by strengthening 
the intramolecular hydrogen bond, as increasing the hydrogen bond donor ability of the amine by 
decreasing its electron density improved the barrier to rotation (entry 3 and 4). The electron-donating 
ability of the imine also influenced the strength of the hydrogen bond, and thus the barrier to rotation 
(entries 4 and 5). Half-lives to racemisation of up to 2 years at room temperature could then be 
reached with this design. 
Entry Compound R R’ R’’ ΔG‡T (kJ mol–1) t1/2a 
1 1.15a H iPr H 80.8 (365 K) 10 s 
2 1.15b NO2 iPr H 97.1 (295 K) 2.3 h 
3 1.15c Me 4-(MeO)Ph Me 104.2 (295 K) 2.4 d 
4 1.15d NO2 4-(MeO)Ph Me 113.9 (353 K) 133 d 
5 1.15e NO2 iPr Me 118.1 (353 K) 720 d 
a At 295 K 
Table 9 : Barrier to rotation of various diarylamines with an intramolecular hydrogen bond[29] 
NOE experiments showed that, in solution, the imine nitrogen of compounds 1.15a–e points towards 
the diarylamine nitrogen to form an intramolecular hydrogen bond in a 6-membered pseudo-ring 
(Figure 5, compound 1.15a).[30] However, blocking the possible interaction as in compound 1.15aMe 
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resulted in a significant reduction of the barrier to rotation, as two CAr–N bonds freely rotate. By 
showing that the barrier to interconversion of most compounds present a large solvent dependency, 
the authors concluded that enantiomerisation of diarylamines with a small barrier to interconversion 
proceeded by rotation of the imine group followed by free CAr–N bonds rotation, with large negative 
activation entropy in polar solvents. However, as compounds 1.15d–e did not undergo a similar high 
activation entropy process, it was inferred that the barrier to racemisation of these diarylamines was 
due to the slow rotation around a single CAr–N bond without disruption of the strong, intramolecular 
hydrogen bond (Figure 5). 
 
Figure 5: Mechanism of racemisation of anilido-aldimines with low barriers to racemisation[30] 
Although the compounds designed by Kawabata and co-workers were diarylamines, the strong 
intramolecular hydrogen bonding makes the aromatic nitrogen part of a pseudo-ring. It has been 
shown that enantiomerisation occurred without cleavage of the hydrogen bond in the highly 
conformationally stable examples. Thus, these diarylamines can be compared to bicyclic structures 
such as binaphthyls, with only one rotatable C–N bond. 
During the course of the work described in this thesis, the Kitagawa group published their work on the 
conformational stability of some axially chiral, tertiary diarylamines.[31] Building on their previous work 
on N-aryl tetrahydroquinolines (Figure 4), the authors were able to design and prepare atropisomeric 
diarylamines bearing a highly congested 2-tert-butyl-6-methylphenyl ring at the nitrogen by 
palladium-catalysed cross-coupling followed by N-methylation.[31] The absence of sterically 
demanding functional group at the para-substituted aryl ring led to free rotation of the corresponding 
CAr–N bond, while the steric demand at the highly substituted ring, together with substitution of the 
nitrogen slowed down rotation of second CAr–N bond, permitting the elaboration of conformationally 





Entry Compound R ΔG‡298 K (kJ mol–1) t1/2 (d)a 
1 1.16a NO2 123.0 2475 
2 1.16b CO2Et 118.0 304 
3 1.16c H 110.9 19.0 
4 1.16d Me 109.2 9.2 
5 1.16e NH2 103.8 1.0 
a At 298 K 
Table 10: Barrier to C–N rotation in N-aryl-2-tert-butyl-6-methyl anilines[31] 
While N-methyl-2-tert-butyl-6-methylaniline 1.16a was conformationally stable at room temperature, 
with a half-life to racemisation of 19 days (entry 3), modification of the electronic properties of the 
phenyl ring displayed a great influence on the barrier to rotation, even-more-so than in the biaryl 
series (cf. Table 2). Electron-withdrawing groups significantly increased the barrier to rotation around 
the hindered C–N bond, while electron-donating groups gave the opposite effect, with the difference 
of the Gibbs free energy correlating with the substituent Hammett constant. Thorough calculations of 
the racemisation pathways and ground state conformation led the authors to postulate that in lower 
energy compounds, faster interconversion is possible with the para-substituted phenyl ring sitting in 
a twisted geometry in relation with the hindered ring. In the more stable examples, a stronger 
resonance in the phenyl ring forces it into a coplanar, more hindered conformation.  
 
I.2. Results and discussion 
I.2.1. Aim 
Recent advances in Buchwald–Hartwig couplings allow the synthesis of severely congested 
diarylamines.[32–34] However, when starting this project, no study had been done on the 
conformational properties of these highly hindered systems and their ability to retain a stable, chiral 
conformation. By analogy to the diaryl ethers and sulfides explored by our group, this work aimed to 
unravel the potential for atropisomerism in secondary diarylamines. Considering the importance of 
this scaffold in catalysis,[35] life sciences[36,37] and materials,[38] we investigated in detail the factors 
which determine the rates of bond rotation, and hence the structural requirements for 
atropisomerism. This work focussed on the steric effects of simple, secondary diarylamines bearing 
only alkyl substituents, as previous work showed the extreme influence of electronic properties of the 
aromatic rings.  
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I.2.2. Investigation of the barrier to interconversion of secondary diarylamines 
Simple diarylamines bearing different alkyl substituents at the ortho-positions were synthesised 
(Figure 6). Shaughnessy et al. reported the use of trineopentyl phosphine (PNp3) as an efficient ligand 
for the Buchwald–Hartwig coupling of sterically hindered diarylamines.[32,39] As this palladium-
catalysed coupling between an aniline and aryl halides seemed the most powerful strategy for the 
synthesis of hindered diarylamine at the time, we envisaged the construction of a library of simple 
diarylamines by this method, with a systematic modification of the substitution pattern. 
 
Figure 6: Synthesis of the target diarylamines 
Synthesis of the substrates 
Sterically hindered anilines still pose a synthetic challenge, and different routes were investigated for 
the synthesis of the highly hindered 2-tert-butyl-6-methylaniline 1.20. Following recent reports,[40,41] 
Smiles rearrangement of ether 1.19 to 1.20 was attempted in a one-pot procedure starting  from 
amide 1.17 and phenol 1.18 (Scheme 2). However, even after prolonged reaction time at high 
temperature, no intermediate 1.19 was observed. Presumably, the high steric demand of the 
substrate prevented formation of the intermediate, suggesting that the O-to-N rearrangement would 
be even more challenging because of the unfavourable electron-density of the aryl ring.  
 
Scheme 2 : Synthesis of highly hindered ortho-substituted anilines by Smiles rearrangement 
An alternative strategy was then followed using a Boc moiety as a directing group for a directed ortho-
metalation, followed by quench with methyl iodide as reported by Zhu et al. with aniline  
(Scheme 3).[42] Similar conditions were tried on N-Boc protected 2-isopropyl aniline 1.23b and 2-tert-




Scheme 3 : Synthesis of highly hindered ortho-substituted anilines by ortho-lithiation 
Following the reported procedure, using methyl iodide overnight at –20 °C after addition of tert-butyl 
lithium unreacted starting material was fully recovered. Deprotonation at room temperature with  
n-butyl lithium and subsequent quench only provided a mixture of the N-methylated carbamate and 
unreacted substrate. Presumably, both isopropyl and tert-butyl groups at the ortho-position force the 
Boc group out of the plane of the aryl ring and restricts its rotation, therefore preventing the ortho-
metalation step.[43] 
Alternatively, unsymmetrical anilines 1.25 and 1.27 bearing a tert-butyl groups in the para-position 
were synthesised in good yield by nitration of 3,5-di-tert-butylbenzene[44] and 3,5-di-tert-butyl 
toluene[45] followed by reduction of the nitro group into the corresponding amine, following reported 
procedures (Scheme 4).  
 
Scheme 4 : Synthesis of highly hindered ortho-substituted anilines by nitration of corresponding aryl 
Synthesis of sterically hindered diarylamines  
The synthesis of the ligand (PNp3) proved to be tedious. While the use of neopentyl magnesium 
chloride has been described in the literature,[46] reports of its synthesis are vague. Every attempt to 
prepare the Grignard reagent (under standard conditions, with dibromoethane as an activating agent, 
under pressure, or by using a freshly prepared magnesium anthracene THF complex[47]) failed, and the 
commercially available – but expensive – solution in THF was used instead (Scheme 5). Although 
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described,[48] the synthesis and separation of PNp3 from its phosphine oxide by-product only 
succeeded in a poor yield, because of difficulties of purification. 
 
Scheme 5 : Synthesis of PNp3 
Although the reaction conditions for the Buchwald–Hartwig coupling of sterically hindered substrates 
were reported by Shaughnessy and co-workers,[32] these had to be modified to obtain conversion in 
our case. The quality of the sodium tert-butoxide used in the reaction was critical for the reaction, as 
only Sigma-Aldrich ‘extra pure’ sodium tert-butoxide gave conversion. Furthermore, distillation of the 
solvent was necessary, as degassing toluene by freeze-pump-thaw did not yield any product. Failure 
to follow these conditions would yield protodehalogenation of the aryl bromide. The reaction time 
was also systematically changed to 16 h and the catalyst loading increased to 1 mol%. With these 
conditions, a series of hindered diarylamines was synthesised with gradual increase of the bulkiness 
of the ortho-substituents (Scheme 6).  
The couplings produced diarylamines in good yield, and generally proceeded smoothly. When the 
yield of product was low, good recovery of the aniline and aryl bromide was usually observed. 
Couplings yielding di- and tri-ortho-substituted diarylamines gave the corresponding products in good 
to excellent yield (1.28a–n). Moderately hindered aryl bromides such as 1-bromo-2-
methylnaphthalene were also tolerated (1.28r–s and 1.28u–v), even when coupled to some di-ortho-
substituted diarylamines. 
Introduction of a tert-butyl motif proved to be more challenging. A drastic reduction of the yield was 
observed in the synthesis of tri-ortho-substituted diarylamines 1.28o–q, 1.28t, and 1.28w–y. The near-
quantitative yield obtained for 1.28n dropped below 10% when substituting the methyl group for a 
bigger phenyl, isopropyl or tert-butyl group. Tetra-ortho-substituted diarylamines bearing at least one 
tert-butyl group proved even harder to obtain, as only 1.28t and 1.28x were obtain in poor yield. The 
non-reacted aniline could be retrieved and, in some cases, hindered aryl bromides could be isolated 




a The reaction time was 48 h. 




Investigation of the barrier to rotation of congested diarylamines 
The barrier to rotation at a given temperature ΔG≠T (kJ mol–1) and the half-live of racemisation t1/2 (s) 
can be calculated from the rate of enantiomerisation kenant (s–1, equals half the rate of racemisation 
krac) by using the Eyring equation (Equation 1), with R the gas constant, T the temperature, kB the 
Boltzmann constant, and h the Planck constant: 
Δ𝐺𝑇









Equation 2: Half-life to enantiomerisation of the rate of enantiomerisation 
In order to calculate barriers to rotation, dynamic analytical techniques are needed. Among the large 
choice available,[49] three different methods were used for the determination of barrier to rotation of 
diarylamines: lineshape analysis of variable-temperature 1H NMR spectra (VT-NMR), variable-
temperature HPLC (VT-HPLC), and decay of enantiomeric excess of an enantioenriched sample. The 
barriers to rotation which can be calculated from these three techniques go from 20 kJ mol–1 to a 
virtually infinite range.[49]  
Dynamic NMR is a technique which allows the study of bond rotation of events with a barrier to 
interconversion from 20 and up to 90 kJ mol–1.[49] While a mixture of enantiomers is impossible to 
distinguish by NMR without any external source of chirality, diastereotopic nuclei can act as an NMR 
probe to monitor stereodynamics in solution. Interconversion of one conformer or enantiomer can be 
observed by broadening and then coalescence of these diastereotopic signals by gradually increasing 
the temperature (Figure 7), as rotation around the axis becomes faster and the signals become 
equivalent by fast exchange on the NMR timescale.  
 
Figure 7 : Evolution of a diastereotopic signal in by VT NMR. Figure obtained from [49] 
At the coalescence temperature Tc (Figure 7), the rate constant k of two exchanging singlets of equal 
intensity is defined as follow, where Δυ (Hz) is defined as the chemical shift separation: 
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Equation 3: Calculation of the rate of enantiomerisation at the coalescence temperature 
However, this value only provides information about the free energy at the coalescence temperature. 
To calculate a barrier to interconversion at any temperature, VT-NMR is needed. Lineshape analysis 
using a modelling software such as SpinWorks allows the determination of the rate constant k at a 
given temperature by comparison with the spectrum at slow exchange (Figure 7). The Eyring equation 
(Equation 1) is then used to calculate the barrier to rotation at any given temperature. Plotting 
𝑙𝑛(𝑘 𝑇⁄ ) against 
1
𝑇⁄  (Eyring plot) gives a straight line from which the enthalpy of activation ΔH
‡ and 
entropy of activation ΔS‡ can be calculated by regression as follows, where a is the slope of the linear 
regression and b its intercept: 
Δ𝐻‡ = −𝑅 ∗ 𝑎 




Equation 4: Calculation of the enthalpy of activation and entropy of activation using an Eyring plot 
Using the Gibbs equation (Δ𝐺𝑇
‡ = Δ𝐻‡ − 𝑇 ∗ Δ𝑆‡), the barrier to rotation can then be calculated at 
any given temperature. 
 
Figure 8: Lineshape analysis of the 1H NMR (500 MHz) spectrum compound 1.28j in DMSO-d6 
Appearance of diastereotopic signals into an AB system in the 1H NMR spectra of 1.28g, 1.28h and 
1.28j (Figure 8) provided evidence that the congested diarylamines adopt a chiral ground state at room 
temperature. Calculation of the barrier to rotation of compounds rapidly interconverting was possible 
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using an ethyl or isopropyl group as a diastereotopic 1H NMR probe. Lineshape analysis of the signal 
reaching coalescence allowed the calculation of the compounds rate of enantiomeriation at various 
temperatures. Using an Eyring plot (Figure 8), both enthalpy ΔH‡ and entropy ΔS‡ were calculated, and 
the corresponding Gibbs free energy ΔG‡ and half-life to enantiomerisation t1/2 were found at room 
temperature.  
Dynamic 1H NMR, though, is limited to substrates with a relatively low barrier to interconversion. 
These substrates were naturally the first prepared as their moderate steric hindrance made them 
easier to synthesise. Typical barriers to rotation determined in this series were in the 60–70 kJ mol–1 
range (Table 11). 
 
Entry Compd. ΔH‡ (kJ mol–1) ΔS‡ (J mol–1 K–1) ΔG‡ (kJ mol–1)a kenant (s–1)a t1/2 (ms)a 
1b 1.28e 58.3 –21.4 65.4 28.5 16.1 
2b 1.28g 65.0 7.5 62.8 62.2 5.6 
3b 1.28h 49.6 –53.7 65.7 19.2 18.0 
4c 1.28j 53.4 –47.7 67.3 9.9 35.0 
5b 1.28k 64.5 –21.0 70.7 2.5 137.8 
a At 298 K. b In toluene-d8. c in DMSO-d6. 
Table 11 : Barriers to rotation, rates of exchange and half-lives of racemisation calculated by lineshape analysis 
2,2’-Di-ortho-substituted diarylamines 1.28a–d were insufficiently hindered for slow rotation around 
the C–N bonds to be evident by 1H NMR. Even at low temperature (–40 °C), no diastereotopic signals 
could be observed, suggesting that the chiral ground state conformers interconvert rapidly on the 
NMR timescale. Interestingly, while a single ortho-tert-butyl group is enough to retain conformational 
stability in anilides,[26] the lack of conformational restriction in 1.28c demonstrates how much more 
flexible these diarylamines are in comparison. This may be due to an interconversion through geared 
rotation, which is of higher energy in anilides due to the conjugation of the carbonyl group with the 
nitrogen lone pair. While calculating the entropy of activation by dynamic NMR is notoriously 
unreliable,[50] the strong, negative ΔS‡ determined in Table 11 for 1.28h, 1.28j and, to some extent, 
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1.28e and 1.28k, is indicative of a highly ordered transition state typical for the enantiomerisation of 
biaryls,[49] possibly by alignment of the π system of one of the rotating aryl ring and participation of 
the nitrogen lone pair.  
When coalescence could not be reached, VT-HPLC was used instead. It proved to be complementary 
to dynamic NMR, although its lower detection limit was attained by compound 1.28f, for which 
routine VT-NMR could not reach temperature high enough for determination of its barrier to 
enantiomerisation. Molecules racemising within minutes can be difficult to study by VT-NMR due to 
their particularly high temperature of coalescence (T > 373 K). In addition, such near-atropisomers 
cannot be efficiently separated by preparative chromatography at room temperature. In this case, VT-
HPLC is a suitable method to investigate their barrier to rotation. Specifically, variable-temperature – 
chiral – HPLC is a convenient tool for compounds with barriers to rotation of around 85 up to 100 kJ 
mol–1. Elution of a compound partially interconverting within its retention time gives signals with a 
plateau between the two enantiomerical peaks (Figure 9). 
 
Figure 9: a) Temperature-dependant peak profiles b) Parameters for peak-shape analysis. Obtained from ref [49] and [51] 
In 2006, Trapp demonstrated the use of a ‘Unified Equation’ for the calculation of rate constants by 
variable-temperature chromatography. By mathematically separating each non-interconverting peak 
from the plateau (of interconverting peaks), the rate of enantiomerisation can be calculated from the 





, ωXh the peak width of X at half height (s), tRX the retention time of the peak of X (s), N 
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Equation 5: Calculation of the rate of enantiomerisation using the 'Unified Equation' 
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As for VT-NMR, calculation of the rate of enantiomerisation at different temperatures allows the use 
of an Eyring plot (Equation 4) and the calculation of ΔG≠T at any temperature.  
Generally, tri-ortho-substituted diarylamines with a tert-butyl group interconverted during the course 
of an HPLC run, with half-lives to enantiomerisation of a few minutes. These compounds displayed the 
typical ‘Batman’s hat’ peaks due to the apparition of an interconversion plateau between each 
enantiomer peak (Figure 10). 
 
Figure 10: VT-HPLC profile of compound 1.28o 
While the enthalpy of activation of the compounds resolved by chiral HPLC is comparable to that of 
those determined by VT-NMR (Table 12), their entropy of activation is considerably larger, whilst still 
being negative, and accounts for most of the increase in the barrier to rotation. 
Unless one of the substituents was a tert-butyl group, half-lives for interconversion of tri-ortho-
substituted diarylamines were typically of the order of milliseconds (Table 11). While increasing the 
steric demand by replacing a methyl group for an isopropyl group led to a threefold increase of the 
half-life to enantiomerisation in 1.28g and 1.28h, replacement of an ethyl group for an isopropyl group 
only showed minor changes the barrier to rotation in 1.28e and 1.28h, with a maximum of a twofold 
difference in the rate of enantiomerisation in 1.28f and 1.28i (Table 12). The same order of magnitude 
was seen in symmetrical compounds 1.28j and 1.28k which, unlike diaryl ethers, did not seem affected 
by the symmetry of the aryl ring, as a tenfold difference in the half-life was observed between  
1.28g–h and symmetrically substituted 1.28j–k. A great increase in the barrier to interconversion was 
found when exchanging an isopropyl group for a tert-butyl group, with a difference of more than 20 
kJ mol–1 in the barrier to rotation of 1.28e and 1.28f as well as 1.28h and 1.28i, making these 
compounds near-atropisomers. The relative position of each bulky substituent was also critical, as 
seen in the twofold increase of the rate of enantiomerisation of 1.28j and 1.28n compared to 1.28h 




Entry Compound ΔH‡ (kJ mol–1) ΔS‡ (J mol–1 K–1) ΔG‡ (kJ mol–1)a kenant (s–1)a t1/2 (min)a 
1b 1.28f 53.2 –109.6 85.8 5.6 10–3 1.0 
2c 1.28i 51.8 –121.5 88.0 2.3 10–3 2.5 
3c 1.28n 37.9 –166.7 87.6 2.8 10–3 2.1 
4c 1.28o 40.8 –165.9 89.9 1.1 10–3 5.3 
5c 1.28q 45.0 –151.6 90.2 9.8 10–4 5.9 
a At 298 K. b In n-hexane/ethyl acetate. c In n-hexane/2-propanol. 
Table 12 : Barriers to rotation, rates of exchange and half-lives of racemisation calculated by VT-HPLC 
A single tert-butyl substituent on one of the rings allowed the separation of the enantiomers at room 
temperature, and racemisation could be observed with a moderately big isopropyl group on the 
second ring, such as in compounds 1.28i, compared to 1.28h. Similarly, compounds with a di-ortho-
substituted ring and at least a tert-butyl group could also be resolved at room temperature, even with 
substituents as small as a methyl group on the other ring (compounds 1.28n). A phenyl ring at the 
ortho-position gave a relatively high barrier to rotation, as its steric bulk seemed slightly greater than 
that of an isopropyl moiety (compounds 1.28q and 1.28o). 
2,6-Disubstituted diarylamines containing one tert-butyl group had a significantly higher barrier to 
rotation. Even mono-substitution of the other ring as in compounds 1.28n, 1.28o and 1.28q, although 
not sufficient to reach atropisomerism, allowed the racemisation to be observed at near-room 
temperatures by dynamic HPLC. However, more substituents were necessary to obtain 
conformationally stable diarylamines. 
A conventional method to access the barrier to rotation of atropisomers is to follow the rate of 
racemisation of an enantioenriched sample. The quantification of decay of enantiomeric excess over 
time was done by chiral HPLC, but the concept can be extended to any chiral spectroscopic technique 
such as circular dichroism[53] or optical rotation,[54] for example. Plotting the natural logarithm of the 
enantiomeric excess (ee) against time gives a straight line from which linear regression determines 
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the rate of enantiomerisation with the equation ln(𝑒𝑒t) = 2 ∗ 𝑘enant ∗ 𝑡 + 𝑒𝑒0, for a first order decay. 
A major drawback in this technique is the need to prepare enantioenriched material. Also, the barrier 
to interconversion obtained is given for a specific temperature. 
The only compounds which could be resolved with very high conformational stability were tetra-ortho-
substituted diarylamines. Compound 1.28m could regrettably not be separated by chiral HPLC. 
Compounds 1.28i and 1.28p, with a tert-butyl group on each ring, could be separated even at 40 °C, 
indicating high thermal stability. However, the poor resolution of their enantiomers prevented any 
isolation of an enantioenriched sample for calculation of barrier to rotation. Nevertheless, these 
results indicated that even moderately bulky groups such as an isopropyl can hinder bond rotation 
provided the other ring is highly congested and another group is present on the same ring. By repeated 
injections of a solution of 1.28x on a chiral analytical column, an enantioenriched sample could be 
isolated and its decay of enantiomeric excess was followed (Figure 11).  
 
Figure 11: Part of the VT-HPLC traces used to determine the ee of 1.28x during its racemisation  
At 100 °C in toluene, compound 1.28x racemised within 48 hours, allowing the calculation of its barrier 
to rotation at this temperature (Table 13). Similarly, enantio-enriched fractions of compound 1.28u 
could be isolated and the decay of its enantiomeric excess was followed at 25 °C in toluene. 
Compounds 1.28u and 1.28x proved once again the critical impact of the tert-butyl group. While 
compound 1.28u was only conformationally stable enough at room temperature for its rate of 
enantiomerisation to be calculated, heating up diarylamine 1.28x to 100 °C in toluene was required to 
observe racemisation, with a half-life of 20 hours at this temperature. Hence, compounds 1.28u and 
1.28x demonstrate that secondary diarylamines can adopt a chiral ground state, with a 





Entry Compound ΔG‡T (kJ mol–1) kenant (s–1) t1/2 
1a, b 1.28u 93.9 2.1 10–4 27.3 min 
2a, c 1.28x 145.0 4.3 10–7 20.3 h 
a In toluene. b At 298 K. c At 373 K. 
Table 13 : Barriers to rotation, rates of exchange and half-lives of racemisation of atropisomeric diarylamines 
An X-ray crystal structure of compound 1.28u was obtained by slow evaporation of a saturated 
solution of dichloromethane (Figure 12). The bond angles ∠CArNH = 116° for each aromatic ring and  
∠CArNCAr = 125°. The sum of these angles is 357°, indicating that the nitrogen adopts an almost planar 
conformation. The torsion angle between the naphthyl ring and the nitrogen plane is 45.4°, while it is 
47.6° between the aryl ring and the nitrogen plane, suggesting that the nitrogen lone pair electrons 
are partially delocalised in both rings. While steric repulsion forces the aromatic rings out of the plane 
of the nitrogen atom, conjugation of the π system with the lone pair mitigates this phenomenon. The 
lone pair of the central nitrogen is distorted from its apical position and points towards a share in the 
π system of each ring. 
 
Figure 12: Crystal structure of 1.28u 
Furthermore, the C–N bonds lengths are comprised between 1.40 and 1.41 Å, close to that of aniline 
(1.402 Å).[55] This detail is critical as bond length plays an important role in the barrier to rotation  
(as seen in the case of diaryl sulfoxide 1.5b) and shows that atropisomerism in diarylamines is not 
hampered by C–N bond lengths.  
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I.2.3. External effectors on the barrier to rotation of secondary diarylamines 
Effect of the solvent on the barrier to interconversion 
Because lineshape analysis, VT-HPLC and racemisation of enantioenriched samples were performed 
in different media, the effect of solvent polarity was investigated. Compound 1.28e was selected as 
its barrier to rotation was easily calculated by lineshape analysis, for which a wide range of deuterated 
solvents can be used. Its rate of enantiomerisation was calculated in various polar and non-polar, 
protic and aprotic solvents (Table 14). The barrier to enantiomerisation was independent of the 
solvent, with errors of ±2%, with a strong enthalpy/entropy compensation effect, even when using 
different signals of the same molecule. Large statistical errors can occur during the lineshape analysis 
which can lead to correlations between the errors in both enthalpy and entropy, then producing an 
artificial compensation. Although reported for the first time sixty years ago in the determination of 
the barrier to enantiomerisation of some biphenyls,[56] the solvent-driven enthalpy/entropy 
compensation in rate of enantiomerisation is, to date, still largely unexplained.[57] 
 
Entry Solvent Signal ΔH‡ (kJ mol–1) ΔS‡ (J mol–1 K–1) ΔG‡ (kJ mol–1)a 
1 Toluene-d8 Isopropyl 41.5 –80.0 64.7 
2 Toluene-d8 Ethyl 58.3 –21.4 65.7 
3 C2D5OD Isopropyl 31.7 –114.0 65.7 
4 C2D5OD Ethyl 35.8 –96.0 64.4 
5 CD3CN Isopropyl 31.9 –112.1 65.3 
6 CD3CN Ethyl ndb ndb ndb 
a At 298 K. b Not determined due to peaks overlapping. 
Table 14 : Solvent effect in barriers to rotation of 1.28e 
Effect of N-methylation on the barrier to interconversion 
Exploring the effect of increasing the steric demand on the nitrogen atom on conformational stability 
by addition of a third substituent proved to be more difficult than expected. Diarylamine 1.28j could 
be N-methylated by treatment with sodium hydride and methyl iodide in 50% yield (Table 15) but was 
completely unreactive towards any other electrophile such as ethyl iodide, benzyl bromide, acetyl 
chloride or Boc anhydride. N-methylation of any other diarylamines prepared in the previous section 
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with an excess of base and alkylating agent in refluxing THF did not yield any product, showing that 
the nitrogen atom is buried within the sterically demanding groups at the ortho-positions.  
 
Entry Compound ΔH‡ (kJ mol–1) ΔS‡ (J mol–1 K–1) ΔG‡ (kJ mol–1)a k (s–1)a t1/2a 
1 1.28j 53.4 –47.7 67.3 9.9 0.035 s 
2 1.29 71.7 –7.80 74.0 6.7 10–1 0.52 s 
a At 298 K. 
Table 15 : Effect of N-methylation 
A methyl substituent on the nitrogen slows down the half-life to enantiomerisation by more than a 
tenfold (Table 15). The great increase of enthalpy of activation, together with the low, negative 
entropy of activation suggest that the transition state is destabilised by the strain caused by the methyl 
substituent in the vicinity of the aryl ring coplanar with the nitrogen. 
Effect of electron-density on the barrier to interconversion 
Similarly to the study by Kitagawa et al. on the effect of the electronic properties of the para-position 
on the barrier to C–N rotation of congested, tertiary diarylamines,[31] we sought to introduce electron-
withdrawing and -donating groups at one or multiple para-positions of the congested diarylamines 
previously prepared. We focussed on the introduction of a nitro group, as this can be hydrogenated 
and further derivatised to tune the electronic properties of the products. 
Introduction of a nitro group was first attempted by nitration of diarylamine 1.28e by electrophilic 
aromatic substitution (Scheme 7). However, when using previously reported conditions for the 
nitration of electron-rich aromatics, a complex mixture of highly coloured compounds was formed.  
 
Scheme 7 : Aromatic nitration of 1.28e 
As 1.28e possesses three electrophilic carbons available for nitration, our attention then moved on to 
compounds 1.28s with four substituents to reach low rates of interconversion and a diastereotopic 
probes for potential use in lineshape analysis (Scheme 8). However, when subjecting aniline 1.28s to 
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standard nitration conditions (fuming nitric acid in acetic acid),[58] decomposition occurred rapidly. 
Milder condition with stoichiometric amounts of ammonium nitrate in trifluoroacetic anhydride 
resulted in the same complex mixture of products.[45]  
 
Scheme 8 : Aromatic nitration of 1.28s 
The nitro group on the diarylamine products raises the possibility of using SNAr reactions to synthesise 
these compounds. As the coupling was expected to be challenging, moderately hindered diarylamine 
1.31 was the selected target (Scheme 9).  
 
Scheme 9 : Attempt SNAr toward nitrated diarylamine 
However, using reported conditions for the synthesis of para-nitro diarylamines by SNAr, with 
potassium tert-butoxide in DMF at elevated temperature gave no conversion, probably because of the 
consequent steric hindrance around the nucleophilic centre. 
Instead, a new approach using the conditions used previously for the Buchwald–Hartwig coupling of 
sterically hindered substrates with PNp3 as a ligand was attempted (Table 16).[32] Coupling of electron-
poor 2-isopropyl-4-nitroaniline with electron-rich aryl bromides did not yield any product under the 
standard conditions, with prolonged reaction times. 
 
Entry R1 R2 R3 R4 Result 
1 2-iPr 4-NO2 2,3-benzoa 6-Me No conversion 
2 2-iPr 4-NO2 2,4-tBu 6-Me No conversion 
3 2,6-iPr – 2-Me 4-NO2 No conversion 
Table 16 : Attempted Buchwald-Hartwig reactions on para-nitro substrates 
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The electronic properties of the substrates were then exchanged in order to optimise their reactivity 
(Table 16). When using electron-deficient 2-methyl-4-nitrobromo benzene and sterically hindered  
2,6-diisopropylaniline, no coupling was observed either. 
Eventually, a final attempt to para-aminate one of the congested diarylamines was performed using 
a procedure by Crousse et al. (Scheme 10),[59] where treatment of diphenylamine with dibenzyl 
azodicarboxylate in hexafluoro-isopropanol (HFIP) results in a mild, para-selective amination in 
excellent yield. When 1.28s was subjected to the reaction conditions, a bright green precipitate 
formed instantly, with full consumption of the starting material. The reaction gave a complex crude 
mixture, and no product 1.32 was obtained after purification by flash column chromatography. 
 
Scheme 10 : Attempted amination with Benzyl-azodicarboxylate[59] 
Attempts to optimise the reaction by lowering the temperature to 0 °C, using a 1:1 mixture of HFIP 
and CH2Cl2, or performing a one-pot amination/hydrogenolysis of the resulting hydrazide with 
palladium over activated charcoal did not provide any product. 
Thus, introduction of electron-donating and -withdrawing substituents at the para-position of 
hindered diarylamines proved to be unsuccessful. Nitration or amination by electrophilic aromatic 
substitution yielded mixtures of products, possibly arising from the formation of an iminoquinone 
intermediate. On the other hand, neither nucleophilic aromatic substitution and transition metal-
catalysed reactions gave any conversion. 
Effect of protonation on the barrier to interconversion 
Sutherland et al. showed that the planarity of the nitrogen atom in anilides and conjugation of its lone 
pair with a delocalized π system is necessary for high conformational stability.[23] This effect was also 
demonstrated by Kitagawa et al. with an axially chiral, enantiopure N-arylated tetrahydroquinoline 
which, upon protonation by trifluoracetic acid, accelerates its rate of enantiomerisation 
significantly.[22] To explore this feature in diarylamines, solutions of 1.28e in different deuterated 
solvents were treated with a strong acid. Because of the low basicity of diarylamines (pKa ≈ 1 for 




Figure 13 : Line sharpening of the diastereotopic signals (1.45-0.90 ppm) of 1.28e upon protonation (500 MHz). From top 
to bottom: toluene-d8 + TfOH; toluene-d8; ethanol-d6 + TfOH; ethanol-d6; CD3CN + TfOH; CD3CN. 
Excessive line broadening of the samples (probably due to precipitation) precluded lineshape analysis 
of protonated 1.28e at low temperature. However, in all three solvents, the isopropyl CHMe2 signals 
centred around 1.22 ppm in toluene-d8 and 1.32 ppm in C2D5OD and CD3CN became significantly 
sharper upon protonation, implying an acceleration of the rate of enantiomerisation. Thus, 
pyramidalization of the nitrogen by protonation leads to destabilization of the ground state and 
reduction of the barrier to rotation around the C–N bonds. 
I.3. Conclusion 
Atropisomerism can be achieved in sterically hindered, secondary diarylamines. While di-ortho-
substituted diarylamines interconvert too rapidly for enantiomerisation to be observed at low 
temperature by 1H NMR, a third substituent slows down the rates of interconversion enough for the 
barriers to enantiomerisation to be calculated by lineshape analysis. Introduction of a tert-butyl group 
shows a critical effect on the rate of enantiomerisation. Tri-ortho-substituted diarylamines bearing 
such group can be separated by chiral HPLC at low temperature, although fast racemisation precludes 
their isolation as an enantiopure sample. Conformational stability was observed at room temperature 
when introducing four ortho-substituents, especially with one tert-butyl group. Diarylamine 1.28x was 
the most congested molecule prepared and displayed a barrier to rotation of up to 145.0 kJ mol–1 
corresponding to a half-life of circa 20 hours at 100 °C. Additional work is currently performed by 
collaborators to understand the mechanism by which this compounds racemise. 
However, the limits of the Buchwald–Hartwig coupling for the synthesis of congested diarylamines 
exhibiting atropisomerism were reached with highly hindered anilines and aryl bromides. As their 
post-functionalisation proved to be equally challenging, novel strategies to produce more complex 
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The study of the conformational stability of sterically congested diarylamines presented in Chapter 2 
was hampered by synthetic difficulties. The substrates of interest were not readily available, and the 
literature reports were insufficient for our needs. Consequently, we felt the need to develop new 
methodologies for the synthesis of this challenging class of molecules, aiming to develop an easily 
operated, efficient and robust protocol. 
II.1.1. Synthesis of diarylamines by transition metal-catalysed reactions 
The formation of C–N bonds using transition metal-catalysis has seen a significant progress since the 
pioneering work by Goldberg and Ullman more than a century ago.[60] Ever since, formation of 
diarylamines with modern methods have been improved to greater functional group tolerance and 
lowered catalyst loading.[61] The higher acidity of arylamines compared to alkylamines, together with 
a lack of unfavourable β-hydride elimination pathway make them an ideal coupling partner for this 
type of reactions.[33] 
 
Scheme 11 : General overview of transition metal-catalysed methods for the synthesis of diarylamines 
Historically, the most relevant transformation to access diarylamines is the Ullman condensation, later 
modified by Goldberg.[60] In this reaction, a stoichiometric amount of copper(I) is used in combination 
with a base to achieve the coupling of an aryl halide 2.2 with an aniline 2.1 (Scheme 12) through the 
formation of an organocuprate.[62] While this is a powerful reaction, the harsh conditions required for 
coupling, such as high temperature, the use of stoichiometric amount of copper, or the need for polar 
high boiling solvents limits its applicability. 
 
Scheme 12: Ullman coupling[62] 
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A modification of the Ulmann-conditions led to the development of the Chan–Lam reaction,[63,64] 
where either copper(II) or copper(III) (generated in situ) catalyses the coupling of an aryl boronic acid 
2.5 with an aniline 2.4, an alkylamine or an amide (Scheme 13).[65] This reaction has several 
advantages. It proceeds at room temperature, operates with low catalyst loading, and is performed in 
presence of air (to re-oxidise the catalyst).[66] The conditions and relatively low cost and toxicity of 
copper, make this reaction valuable for process chemistry. 
 
Scheme 13: Chan–Lam coupling[65] 
However, numerous side-reactions arise from the decomposition of the boronic acid starting material, 
such as protodeboronation, oxidation to the corresponding phenol or oxidative coupling to form diaryl 
ethers. Aryl–aryl homocoupling can also be observed.[67] Furthermore, the challenge of steric 
hindrance has only been addressed for the arylation of highly reactive imidazoles by Wentzel et al.[68] 
Over the past decades, the use of palladium in transition metal-catalysed C–N bond formation in the 
Buchwald–Hartwig coupling of an aryl halide with an amine has emerged as a powerful method to 
synthesise diarylamines.[69,70] The reaction takes place with low catalytic loading of palladium with a 
ligand and a base (Scheme 14).[71] The wide use of this transformation makes this reaction widely 
studied, and various groups have developed strategies to design and fine-tune ligands to achieve the 
desired transformation efficiently. Amongst them are Buchwald’s 2-biaryl dialkylphosphines,[34] but 
also trialkylphosphines,[32,72,73] N-heterocyclic carbenes[74] and bis-phosphines.[75]  
 
Scheme 14: Buchwald–Hartwig coupling[71] 
The major drawback of the previously discussed synthetic routes to diarylamines is that steric 
hindrance hampers the coupling.[32] While sterically demanding ligands promote consecutive steps of 
palladium-catalysed coupling reactions, this decreases the reactivity of sterically congested 
substrates. Furthermore, as aromatic amines are relatively poor nucleophiles compared to other 
amines,[76] ligand displacement on the palladium complex can be difficult.[33] For these reasons, 
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oxidative addition of bulky aryl halides is problematic. However, provided oxidative addition is 
favoured, protodehalogenation or oxidation of the C–X bond can also easily compete with the desired 
coupling.[77,78] 
A handful of research groups have come up with finely tuned ligands allowing the coupling of sterically 
hindered anilines with sterically hindered aryl halides to provide congested diarylamines such as  
N-(2,6-diisopropylphenyl)-2,6-dimethylaniline 2.11. The extensive work by Nolan et al. on the use of 
N-heterocyclic carbene-based precatalysts 2.12[74] (Scheme 15) unravelled the potential for this type 
of ligand to efficiently catalyse the Buchwald–Hartwig coupling of hindered starting materials at 
particularly low concentration of catalyst. Modularity of the scaffold permits fine tuning of the 
properties of the ligands, from steric bulk and flexibility to electronic properties or solubility.  
 
Scheme 15: Example of catalysts for the Buchwald-Hartwig coupling of hindered substrates[32,74,79] 
Jin reported a highly efficient β-diketiminato-palladium precatalyst 2.13.[79] Low catalyst loadings were 
achieved for the coupling of sterically hindered substrates, but the true highlight of their work is that 
coupling of aryl chlorides with anilines happens at room temperature in a few hours. However, this 
catalyst requires multistep synthesis, and work by Pӧrschke et al. suggests the complex might not be 
highly stable in solution.[80] It is worth noting that ‘Verkade superbases’, namely proazaphosphatranes, 
also catalyse this coupling in good yield.[81] However, their high price, difficult synthesis and moisture-
sensitivity make them poor candidate for larger-scale applications. 
Recently, Shaughnessy et al. reported a series of highly congested alkyl phosphines derived from the 
tri-tert-butylphosphine, for the synthesis of sterically hindered diarylamines such as 2.11.[32,72,73] 
Substituting the tert-butyl groups by neopentyl (methylene tert-butyl) groups afforded tri-
neopentylphosphine 2.14 (PNp3), a ligand of drastically increased the activity for the synthesis tetra-
ortho-substituted diarylamines with previously unattained levels of steric hindrance.  
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The unique tolerance of the Buchwald–Hartwig reaction for steric congestion requires deep 
mechanistic investigation in order to further develop new ligands. The general mechanism using a 
monodentate ligand is shown in Scheme 16.[33] First, ligand dissociation at the palladium to form 
mono-ligated complex LPd0 I (with L the ligand) is necessary for palladium with bulky ligands. This 
allows oxidative addition of the aryl halide on the active species, a common intermediate in palladium 
catalysed methods.[33] The palladium complex II thus formed is in fast exchange with a catalytically 
inactive dimeric species. Coordination of the amine decreases the pKa of the nitrogen[82] and 
deprotonation of III triggers the displacement of the halide to form IV. Reductive elimination leads to 
the final arylated amine with regeneration of the active palladium(0) complex.  
 
Scheme 16: General mechanism of the Buchwald–Hartwig coupling[39] 
The reaction relies on a fine balance of electronic and steric tuning of the active site by modification 
of the ligand. Ligand dissociation and oxidative addition are driven by the steric bulk of the ligands 
surrounding the palladium centre. Unhindered ligands such as triphenylphosphine lead to the 
formation of catalytically inactive L2Pd(Ar)X (L = triphenylphosphine, X = halide).[39] The other catalyst 
resting state μ is stabilised by the nature of the halide. While negligible when X = I or Br, this dimer is 
the major compound in solid state and in solution (benzene) when X = Cl.[83,84] 
Buchwald et al. showed the correlation between electron density at the ligand and the acidity of the 
amine-bound complex III.[82] As electron-deficient phosphines gave better conversion, the authors 
concluded that the palladium species made more cationic by ligation with an electron-deficient 
phosphine increased the acidity of the bound amine, leading to higher catalyst turnover.  
36 
 
Reductive elimination requires a fine balance of steric hindrance. While reactivity is reduced with great 
steric hindrance around the nucleophilic atom, this step reduces strain at the metal centre, and thus 
is promoted by electron-deficient, bulky ligands.[39] 
The uniqueness of PNp3 2.14 as a powerful ligand is due to its balance between highly bulky 
substituent and flexibility. The crystal structure of bis(PNp3)palladium(0) showed that the steric bulk 
of the neopentyl group is directed towards the metal centre, achieving maximum steric hindrance and 
activating the complex for oxidative addition.[32] The substituent flexibility allows for accommodation 
of bulky aryl groups by rotation of the CH2 group, while keeping enough steric hindrance to prevent 
the formation of inactive dimer. Although the steric bulk prevents the formation of a stable 
coordination complex III with the aniline,[39] its deprotonation is thermodynamically favoured by 
irreversible formation of a complex IV rapidly yielding the final product by reductive elimination. 
While PNp3 is probably the most powerful ligand for the Buchwald–Hartwig amination of hindered 
anilines, its use is far from trivial, as shown in Chapter 2. PNp3 itself is a stable, crystalline solid, but its 
synthesis is expensive, low yielding, and the lack of reproducible procedure for the preparation of the 
Grignard starting material makes its synthesis poorly practical. Moreover, the coupling reaction itself 
seems to be extremely sensitive of parameters such as the quality of reagents used.  
The coupling of secondary anilines is generally considered complicated due to steric constraints.[61] In 
addition, N-alkyl anilines are prone to β-hydride elimination and are less acidic.[33] Preparation of 
tertiary diarylamines using transition metal catalysis is therefore an undeveloped area of interest.  
II.1.2. Synthesis of diarylamines by Nucleophilic Aromatic Substitution 
Diarylamines can be made by nucleophilic aromatic substitution (SNAr) of a deprotonated aniline 
nucleophile onto an electrophilic aryl. This nucleophilic attack of the nitrogen-centred anion can 
displace the leaving group of an electron-deficient aromatic ring (Scheme 17, Nu = nucleophile).[61,85] 
Good leaving groups for SNAr include halogens (by order of nucleofugality F > Cl > Br > I), alkyl and aryl 
ethers, as well as mesylates.  
 
Scheme 17: General mechanism of the Nucleophilic Aromatic Substitution 
The reaction generally proceeds through a stepwise addition of the nucleophile at the ipso position of 
the leaving group which results in a dearomatized intermediate, the Meisenheimer complex, carrying 
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a formal negative charge in a delocalised π-system.[85] Rearomatisation of the intermediate by 
elimination of the leaving group at the newly formed sp3 carbon yields the product of substitution. 
Thus, a common requirement for SNAr to proceed is the activation of the electrophilic ring by strongly 
electron-withdrawing groups such as nitro at the ortho- and/or para-position to activate the 
electrophile, or through inherent electron-deficiency of certain heterocycles.[85] However, recent work 
by Jacobsen et al. suggests that SNAr reactions can go through a concerted mechanism depending on 
the nature of the leaving group, as well as the electron density of the electrophilic arene.[86] 
Anilines are common nucleophiles in SNAr reactions, even though their low basicity results in relatively 
poor nucleophilicity, therefore limiting their application.[61] Nevertheless, many groups have 
developed efficient methodologies to use deprotonated anilines in the synthesis of diarylamines by 
SNAr, mostly involving primary anilines as a nucleophile. While secondary amines are more 
nucleophilic than related primary amines in the aliphatic series, N-substituted anilines have a 
tendency to be less nucleophilic and react with slower rate than comparable primary anilines, mostly 
because of increased steric hindrance around the nucleophilic nitrogen atom.[87]  
Various classes of synthetically relevant diarylamines were made by SNAr of anilines on electrophilic 
arenes (Scheme 18). Addition of an electron-poor aniline to cyano-substituted aryl fluorides was 
possible under basic conditions, although the reaction was more sluggish than using phenol 
nucleophiles.[88] Substitution on ortho-nitrated aryl rings allowed the formation of diarylamine 2.16, 
an intermediate for the synthesis of carbazoles derived from natural products.[89] 
 
Scheme 18: Diarylamines made by SNAr[88,89] 
Researchers at Pfizer USA reported the coupling of anilines with 2-fluorobenzoic acid and amide 
derivatives. The reaction proceeded with the use of an excess of lithium amide (LiNH2) as a base at 
room temperature (Scheme 19).[90] The reaction tolerated primary anilines with a high degree of steric 
hindrance such as 2,6-diisopropylaniline, giving diarylamine 2.17 in good yield after 23 hours. While 
electron-rich anilines coupled smoothly, electron-withdrawing groups were detrimental to the 
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reaction. N-substitution, as well as the use of amide moiety was tolerated, although without any steric 
hindrance in the substrate. 
 
Scheme 19: N-aryl anthranilamides made by SNAr[90] 
Mino and co-workers demonstrated the applicability of SNAr to the synthesis of axially chiral ligands 
such as 2.22 (Scheme 20). The ingenious use of an electron-withdrawing phosphine oxide as an 
activating group allows the attack of lithium indolinate to aryl methyl ether 2.19.[91] Further reduction 
and resolution provided series of novel axially chiral ligands for palladium-catalysed asymmetric allylic 
alkylation. 
 
Scheme 20: Chiral palladium ligand made by SNAr[91] 
One feature of this last reaction is the relatively large steric hindrance of the product and substrates. 
The electrophile ring bears two ortho-substituents – a quaternary phosphine and an unsaturated ring 
– whereas the nucleophile is a secondary aniline with one ortho-substituent. Although SNAr has not 
been widely applied in the synthesis of sterically hindered diarylamines, the relative tolerance for 
steric demand of this reaction makes it a good candidate for the development of novel, general 
methods.  
After Zollinger’s exploratory work on the influence of steric hindrance on the rate of addition of 
various anilines to activated electrophiles, the Crampton group thoroughly described the key steric 
parameters dictating their reactivity.[87,92–94] Addition of aniline and N-methyl aniline to poly-nitro-
substituted aryl chlorides showed great discrepancies in the rate of substitution depending on the 
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substituent on the nitrogen. As these two amines have similar pKa in water (4.60 and 4.84, 
respectively), Zollinger hypothesised the difference in rate of addition is mostly due to the increase of 
steric demand around the nucleophilic centre. Indeed, as the degree of substitution on the 
electrophile increases, the ratio of addition rate of aniline over N-methyl aniline increases drastically. 
However, as the entropy of activation was constant for all electrophiles tested, the authors 
demonstrated that steric hindrance at the electrophilic species was not interfering with the formation 
of the dearomatized intermediate. In fact, a more electron-withdrawing groups at the ortho-position 
of the reactive carbon increases the rate of addition by a fourfold. 
II.1.3. Synthesis of diarylamines by Smiles rearrangement 
The Smiles rearrangement is the intramolecular displacement of an aromatic ring by a nucleophilic 
species to deliver a 1,4- or a 1,5-migration (Scheme 21).[95] The mechanism generally involves a 
Meisenheimer intermediate and the reaction is efficient for the migration of electron-deficient rings, 
and can be seen as an intramolecular SNAr reaction. However, some examples in the literature 
suggested that conformational preorganization of the substrate may promote intramolecular SNAr 
reactions of even neutral or electron-rich rings,[96] making the Smiles rearrangement advantageous 
over intermolecular SNAr reaction. 
 
Scheme 21 : General overview of the Smiles rearrangement 
The Smiles rearrangement has been used in the synthesis of both aryl amines and diarylamines by aryl 
transfer from easily prepared substrates, either by 1,4-migration of functionalised diaryl heteroatom-
species with a free nitrogen at one ortho position (Schemes 22 and 23), or through a flexible linker 
(Scheme 24). 
Smiles himself studied the formation of diarylamines by migration of 2-amino diarylsulfones 2.23 
(Scheme 22).[97] Although neither yields of pure products nor accurate protocols were reported, the 
important effect of the nucleophilicity of the nitrogen atoms was noted. While diarylsulfides did not 
undergo reaction under the reported conditions, diarylamine 2.24 was formed with a sulfinic acid 
group by migration of a nitro-substituted ring. By changing substitution pattern of the nucleophilic 
nitrogen, the author showed that acetylation of the nitrogen did not hamper rearrangement, while 
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sulfonylation slowed down the reaction, showing the impact of electron-density of the nucleophilic 
atom. N-methylation stopped the reaction and required increased concentration of base.  
 
Scheme 22: 1,4-Smiles rearrangement of diaryl sulfones[97] 
Sulfones are not the only suitable leaving group. Vierfon et al. found that under basic treatment in 
DMF, diarylsuphide 2.25 rearranged to its related diarylamine,[98] a substrate for the synthesis of 
phenothiazines (Scheme 23). Similarly, diaryl ethers such as 2.26 can be converted to their related 
diarylamine en route to medicinally relevant phenoxazines.[99]  
 
Scheme 23: Smiles rearrangement of diaryl ethers and diaryl sulfides[98,99] 
A recent method to synthesise diarylamines by Smiles rearrangement was developed by Wadia et al., 
where deprotonated anilides with an electron-deficient α-aryloxy group such as 2.29 rearranged with 
displacement of the oxygen tethered aryl ring to the deprotonated nitrogen by O-to-N migration 
(Scheme 24).[100] Zuo et al. improved this reaction by optimising a one-pot anilide formation/Smiles 
rearrangement /decarbonylation to form secondary diarylamines 2.30 from a phenol, an aniline and 
chloroacetyl chloride.[101–103]  
 
Scheme 24: Using a flexible, traceless for the Smiles rearrangement of diarylamines[102] 
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Although the reaction requires microwave heating, this process is particularly efficient considering the 
number of single steps. The authors also developed the scope of the reaction to include electron-rich 
migrating rings, avoiding the need for an electronic activation of the substrate. 
Insight on the particular effect of conformation on scope of ring migration was discussed by Bunnett 
and Maisey.[104,105] Bulky substituents in proximity of the reactive species were found to accelerate 
Smiles rearrangement in phenols.[104] Similarly, torsion of the starting material by Thorpe-Ingold effect 
can lead to migration of otherwise unreactive substrates.[105] 
While only a few examples of synthesis of diarylamines using the Smiles rearrangement can be found 
in the literature, the wide range of leaving groups tolerated makes this reaction promising  
(Schemes 22–24). Another attractive feature is the insensitivity to the steric hindrance of the coupling 
partners, suggesting that the Smiles rearrangement would be an ideal method for the synthesis of 
functionalised, sterically congested, atropisomeric diarylamines. In particular, recent progress has 
been made in the design of substrates allowing unconventional SNAr-like reactivity on unactivated or 
even deactivated ring by conformational predisposition of the intermediate.[106]  
 
II.2. Results and Discussion 
II.2.1. Initial discovery 
An original N-to-N’ aryl migration of anthranilamide 2.32 to the corresponding diarylamine 2.33 was 
discovered after the observation of co-workers Johnathan Matlock and George Whitcombe that  
ortho-lithiated N,N’-diarylurea 2.31 fully converts to a mixture of anthranilamide 2.32 and diarylamine 
2.33 (Scheme 25). Two separate reactions were taking place. First, the carbanion generated by lithium-
halogen exchange of the urea undergoes intramolecular attack of the urea carbonyl with cleavage of 
the related urea C–N bond to form anthranilamide 2.32Li by an anionic Snieckus–Fries 
rearrangement.[107] Then, the lithium amide generated through this rearrangement adds on the ipso 
carbon of the distal aryl ring by Smiles rearrangement, and forms diarylamine 2.33Li after C–N bond 
cleavage. Conveniently, while the first step occurs at –78 °C, the N-to-N’ aryl migration does not 
proceed at cryogenic temperatures, meaning that both steps can be optimised separately. Intriguingly, 





Scheme 25: Original discovery 
We therefore decided to investigate this reactivity, hoping that its lack of requisite for electronic bias 
would allow the synthesis of non-activated, bulky, and potentially atropisomeric diarylamines. 
Furthermore, this methodology would allow the transition metal-free synthesis of N-aryl anthranilic 
acid derivatives, a class of compounds marketed as anti-inflammatory agents for the treatment of 
rheumatic pain or dysmenorrhea[108] which also showed positive results in the treatment of cancer 
and Alzheimer disease.[109,110] 
II.2.2. Development of the rearrangement 
Optimisation of the Snieckus–Fries rearrangement 
Optimisation of the first step, the anionic Snieckus–Fries rearrangement, was performed using 
electronically ureas 2.34 and 2.35 (Table 17). Their gram-scale synthesis was achieved by coupling of 
2-halo-aniline with phenyl isocyanate followed by bis-methylation of the free nitrogen atoms with 
methyl iodide.  
Two side-products arose from the common intermediate depending on the operating conditions. 
Quenching of the carbanion formed by lithium-halogen exchange before full conversion to the 
rearranged product led to the formation of N,N’-dimethyl-N,N’-diphenyl urea 2.37H. When increasing 
the temperature to –40 °C, alkylation of the lithiated starting material was observed, forming 2.37Bu. 
Unfortunately, while the former side-product co-eluted during silica flash chromatography with the 





Entry X Base (eq.) Solvent t (h) T (°C) 2.36 (%)a 2.37H (%)a 
1 I n-BuLi (1.1) THF 16 –78 75 13 
2 I n-BuLi (1.3) THF 16 –78 60 17 
3 I n-BuLi (1.5) THF 16 –78 62 25 
4 I n-BuLi (1.1) THF 2 –78 71 18 
5 I n-BuLi (1.1) THF 24 –78 77 18 
6 I n-BuLi (1.1) Et2O 2 –78 10 73 
7 I n-BuLi (1.1) MTBE 2 –78 12 73 
8b I n-BuLi (1.1) THF 2 –40 36 26 
9 I s-BuLi (1.1) THF 2 –78 63 18 
10c I n-BuLi (1.1) THF 2 –78 67 22 
11 Br n-BuLi (1.1) THF 2 –78 77 4 
12b Br n-BuLi (1.1) THF 2 –40 56 8 
To a solution of 2.34 or 2.35 (0.15 mmol, 1.0 eq.) in solvent (0.2 M) was slowly added n-BuLi (1.44 M in hexanes) or s-BuLi 
(1.06 M in cyclohexane) at –78 °C. The reaction was stirred at the stated temperature and quenched with MeOH.  
a 1H NMR yields were calculated from the crude reaction mixture using 1,3,5-trimethoxybenzene as the internal standard.  
b Formation of 2.37Bu. c LiCl (3.0 eq.) used as an additive. 
Table 17: Optimisation of the Snieckus-Fries rearrangement 
Lower yield of 2.36 was observed when using an excess of the organometallic base after an overnight 
reaction (entries 2 and 3). When using only a slight excess of base, the reaction seemed to be complete 
within two hours (entry 4), but no decomposition was observed after prolonged exposure to the 
reaction conditions (entry 5). Apolar solvents such as diethyl ether and methyl tert-butyl ether (MTBE) 
drastically slowed down the reactivity and raising the temperature to –40 °C led to the formation of 
2.37Bu. Changing the base to sec-BuLi or using lithium chloride as an additive did not improve the 
reaction. Previous work by George Whitcombe and Johnathan Matlock also showed that addition of 
DMPU to the reaction mixture halts the rearrangement. Similar yields were obtained with bromo 
analogue 2.35, and it was decided to pursue the scope with brominated ureas.  
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Optimisation of the Smiles rearrangement 
Model substrate 2.36 was subjected to a range of conditions shown in Table 18. The Smiles 
rearrangement to form diarylamine 2.38 was confirmed by HMBC correlations, along with the 
appearance of the 3JNH–CH coupling in the amide group.  
Following the reaction conditions used in the previous step, n-BuLi was first tested as a base to 
promote rearrangement. No conversion was observed after 3 hours at room temperature in the 
absence of additive. Addition of 5 equivalents of DMPU to the reaction mixture promoted the reaction 
at room temperature. However, in these conditions, reproducibility of the experiment was unreliable 
(entries 2 to 4) and another unidentified compound was produced. 
 
 
Entry Base t (h) T (°C) Conversion (%)a 2.38 (%)a 
1 n-BuLib 3 0 0 0 
2 n-BuLib + DMPU (5.0 eq.) b 3 rt 54 37 
3 n-BuLib + DMPU (5.0 eq.)c 3 rt 79 62 
4 n-BuLib + DMPU (5.0 eq.)d 3 rt 85 48 
5 KOtBud 2.5 rt 86 21 
6 Cs2CO3d, e 16 80 44 19 
7 KHMDSc 2.5 rt >95 57 
8 NaHMDSc 2.5 rt >95 71 
9 NaHMDSd 4 rt >95 86f 
10 LiHMDSc 4 rt 25 6 
11 LiHMDSc 16 reflux >95 70 
12 LiHMDS[ + DMPU (5.0 eq.)d 4 rt >95 83 
To a solution of 2.36 (0.2 mmol, 1.0 eq.) in THF (0.2 M) was slowly added a base. The reaction was stirred at the stated 
temperature and quenched with MeOH. Bases : n-BuLi (1.44 M in hexanes), NaHMDS, KHMDS and LiHMDS (1.0 M in THF). 
a 1H NMR yields were calculated from the crude reaction mixture using 1,3,5-trimethoxybenzene as the internal standard.  
b Added at –78°C. c Added at 0 °C. d Added at rt. [ The solvent was DMF. f Isolated yield. 
Table 18: Optimisation of the Smiles rearrangement 
A change of the base and counter-cation proved to be critical for the reaction to proceed smoothly. 
The use of strong inorganic base KOtBu led to a complex mixture of products with decomposition of 
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the substrate (entry 5), and Cs2CO3 required DMF and heating to give conversion, although slow and 
low yielding (entry 6). Smiles rearrangement to diarylamine 2.38 was possible in good to excellent 
yields under several different sets of conditions, with sodium and potassium hexamethyldisilazide at 
room temperature providing the best yields of 86% (entry 4). The reaction proved to be reproducible 
with an excellent isolated yield of product upon scaling up to 6.0 mmol of substrate. LiHMDS required 
heating to reflux overnight or the addition of DMPU to promote the reaction at room temperature, 
showing the great impact of the nature of the counter-cation in this rearrangement (entries 10–12).  
With conditions optimised, a set of diaryl ureas with electronically and sterically diverse rings were 
synthesised to probe the scope and limitations of both the Snieckus-Fries and Smiles rearrangement.  
Synthesis of the starting materials 
The various diaryl ureas were synthesised according to previously described procedures  
(Scheme 26).[111] Condensation of 2-bromoaniline derivatives 2.39 with aryl isocyanates 2.40 in CH2Cl2 
led to the precipitation of the corresponding urea. Filtration followed by bis-methylation of the crude 
product afforded diaryl ureas 2.41a–o in moderate to excellent yield over two steps.  
 
Scheme 26: Scope of the urea formation/methylation 
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The transformation was particularly robust, as excellent yields are obtained with electronically varied 
isocyanates (2.41c and 2.41e). The nucleophilicity of the aniline, though, was critical for the urea 
formation, as addition of electron-deficient 2-bromo-4-trifluoromethylaniline formed urea 2.41h in 
poor yield. The urea intermediate in the synthesis of 2.41k was not alkylated under the standard 
conditions. Instead, the use of sodium hydroxide was a suitable alternative to obtain tetra-methylated 
urea 2.41k. However, stability of either the substrate or the product in these conditions was not 
optimal, and the product obtained in poor yield despite full conversion of the substrate. Poly-ortho-
substituted ureas 2.41l–n with particularly hindered aryl rings reacted smoothly in excellent yields, 
while the formation 2.41o proved to be more sluggish. The 1H NMR spectra of these products showed 
significant line broadening presumably due to slow rotation of the CAr–N bond. 
Using the previously optimised conditions for the Snieckus–Fries rearrangement, ureas 2.41 
rearranged to their corresponding anthranilamide (Scheme 27). The Snieckus–Fries rearrangement 
proceeded with good functional group tolerance for both electron-withdrawing and -donating groups 
on the distal aryl ring. 
 
a 2.1 equivalents of n-BuLi were used 
Scheme 27: Scope of the Snieckus–Fries rearrangement 
47 
 
Substitution at the meta-position of this ring was tolerated for a methoxy group, but a nitro group led 
to decomposition of the starting material (2.42f and 2.42g). Surprisingly, while decreasing electron 
density on the migrating ring with a CF3 group did not influence rearrangement of 2.41h, an electron-
donating group at the same position halted the rearrangement to 2.42i, yielding its 
protodehalogenated derivative quantitatively. Double migration of 2.41k was tolerated as well, and 
moderate to excellent yields were observed for particularly sterically hindered substrates 2.42l–o, 
with the need for longer reaction time.  
While no anthranilamide was formed in the reaction of urea 2.41d, biphenyl 2.43 was isolated 
(Scheme 28). This compound probably arises from an intramolecular SNAr reaction of the carbanion 
on the ipso carbon of the distal ring, through a 6-membered intermediate. Surprisingly, no trace of 
biphenyl product was observed during the rearrangement of electron-deficient urea 2.41c, showing 
the peculiar reactivity of the nitro derivative. 
 
Scheme 28: Unexpected reactivity of the nitro-derived urea 
Poly-substituted anthranilamide 2.46, bearing both sterically demanding substituents and an electron-
donating methoxy group on the anthranilamide ring, was made from the corresponding anthranilic 
acid by an a less elegant but successful sequence composed of acyl chloride formation, amide 
coupling, hydrogenation of the nitro group and methylation of the aniline by Chan–Lam coupling with 
methyl boronic acid (Scheme 29).  
 
Scheme 29: Synthesis of sterically congested anthranilamide 2.47. Ar = 2,6-iPrPh 
The 1H NMR spectra of anthranilamides 2.42l–o showed two sets of sharp, well resolved peaks. Steric 
demand on the amide aryl ring destabilises the preferred E amide conformer, and these substrates 
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exist as a pair of slowly interconverting conformers (Scheme 30). Anilides have been known to exhibit 
axial chirality, and a single ortho-tert-butyl group in related benzanilide 2.47 is sufficient to obtain 
atropisomerism, with a barrier to rotation around the CAr–N bond of 110 kJ mol–1 at 72 °C (Scheme 
30).[26] However, to the best of our knowledge, the barrier to rotation of the N–C(O) bond in tertiary 
benzanilides has not been reported yet. When triturating of 2.42n in pentane, a white solid of the 
enriched Z rotamers (assigned by the downfield shift of the N–CH3 singlet by 1H NMR) was isolated 
and used to study to rate of N–C(O) bond rotation (Scheme 30). 
 
Scheme 30 : Slow bond rotation in benzanilides 
Following the interconversion of the rotamers at room temperature by 1H NMR (Figure 14) in various 
solvents allowed the calculation of the forward and reverse rate of interconversion using the Equation 
6, where R0, rt and Req are the ratio of isomers at t = 0, at t, and at the equilibrium, respectively. Gibbs 




) = (𝑘𝐸−to−𝑍 + 𝑘𝑍−to−𝐸) ∗ 𝑡 
Equation 6: Calculation of the rates of exchange of diastereomers 
 
Figure 14 : Isomerisation of 2.42n by 1H NMR (bottom to top: t0, 5 h, 10 h, teq) and plot of its equilibration over the time 
The CAr–N bond of 2.42n was estimated to be stable enough not to interconvert at room temperature 
over the course of the experiment, as it is bulkier than in 2.47. Also, the CAr–C(O) bond in mono-ortho-
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substituted benzamides rotate at rates too high to be observed by this method.[113] Hence, only 
rotation around the N–C(O) bond would be in the adequate range to be observed. 
Over the course of 24 h, equilibrium was not reached. However, after only one hour, signals for the E 
isomer could be observed. Interestingly, while the E isomer was predominant in chloroform and 
methanol after equilibrium, the Z isomer was slightly in excess in toluene-d8. Barriers to rotation 
around 100 kJ mol–1 were found in all solvents, making the amide bond of 2.42n conformationally 
stable at room temperature. (Table 19)  
Solvent E/Z ratio kZ-to-E (s–1) kE-to-Z (s–1) ΔG‡Z-to-E (kJ mol–1)a ΔG‡E-to-Z (kJ mol–1)a 
CD3OD 1.7:1 5.22 10−6 2.92 10−6 102.1 102.8 
CDCl3 1.7:1 1.02 10−5 7.10 10−6 101.4 102.3 
Toluene-d8 1:1.1 2.94 10−5 2.35 10−5 98.8 98.5 
a At 298 K. 
Table 19 : Kinetic parameters of the E/Z isomerisation of 2.42n 
Scope of the Smiles rearrangement 
The Smiles rearrangement of anthranilamides is notable by the nature of its amide leaving group. 
Typical Smiles rearrangement occur with an oxygen- or sulfur-based leaving group.[85,95] Also, the 
insensitivity of this reaction to the electronic nature of the migrating ring turned out to be general 
(Scheme 31). This might be because of the preferred cis conformation of N-methylated 
benzanilides,[114–117] where torsion of the CAr–N bond forces deconjugation with the amide group and 
places the aryl ring into close proximity with the nucleophile. 
Excellent to quantitative yields of diarylamines were obtained for a range of substrates 2.48a–k 
whether the migrating ring was electron-deficient such as 2.48c or electron-rich such as 2.48l. When 
migrating the para-methoxyphenyl ring of anthranilamide 2.42e, hydrolysis of the amide group 
yielded decomposition products. Of more importance were the electronic properties of the nitrogen 
nucleophile. While the rearrangement proceeded in excellent yield with electron-rich aniline 2.42i, 
decreasing its electron-density with a para-trifluoromethyl group led to decomposition of the starting 
material to multiple unidentified side-products. Double Smiles rearrangement of 2.42k was used to 




a Compound prepared by Johnathan Matlock. 
Scheme 31: Scope of the Smiles rearrangement 
The anthranilamides studied had a methyl group at the nucleophilic nitrogen and were therefore only 
applicable to preparing tertiary amines. Synthetic methodologies for the N-demethylation of aniline 
are scarce,[118–120] and even more so for diarylamines. Test reactions to ‘deprotect’ compound 2.48a 
were not promising, and the best results were obtain using a procedure by Tang and Jiao[121] for the 
demethylation of N-methyl-N,N-diphenylamine under oxidative conditions.. Using their conditions on 
substrate 2.48a led to the isolation of secondary diarylamine 2.49 in moderate yield (Scheme 32). 
Optimization did not succeed, as the results were difficult to reproduce.  
 
Scheme 32: Demethylation of the Smiles product 
The scope of substituents on the nucleophilic nitrogen was then investigated. Condensation of the 
acyl chloride with N-methyl-1-naphthylamine 2.50 followed by hydrogenation gave anthranilamide 
2.51 in good yield over three steps. Installation of a benzyl group was possible by reductive amination 
of benzaldehyde, while introduction of a protecting SEM (2-(trimethylsilyl)ethoxymethyl) group to 




Scheme 33: Introducing protecting groups in the anthranilamide starting material. Ar = 1-naphthyl 
Introduction of highly bulky tert-butyl group on the nucleophilic nitrogen was also possible, although 
another route had to be used. Addition of tert-butyl amine nucleophile on an ortho-fluorinated 
benzanilide gave complex reaction mixtures, while amide bond formation on the acyl chloride of N-
tert-butyl anthranilic acid did not provide any conversion. Instead, unsymmetrically substituted urea 
2.56 was prepared by condensation of the carbamoyl chloride of aniline 2.54 with 1-naphthylamine, 
followed by N-methylation (Scheme 34). This three-step procedure was necessary as coupling of the 
same carbamoyl chloride with N-methyl-1-naphthylamine 2.50 was unsuccessful. Snieckus–Fries 
rearrangement of urea 2.56 cleanly afforded anthranilamide 2.57 in excellent yield.  
 
Scheme 34: Route to the N-tert-butyl anthranilamide starting material 
The primary aniline 2.51 did not rearrange to product 2.49 (Scheme 35). Instead, an intermolecular 
transamidation product was formed in approximately 50% conversion of the substrate, and no 
improvement was observed when using an excess of base or increasing reaction time. Attempt to in 
situ protect the nitrogen with trimethylsilyl chloride, followed by a second deprotonation and an acidic 
workup did not yield any product. Changing the nitrogen substituent to a benzyl group in 2.52 required 
longer reaction time and heating to reflux but resulted 2.58 in excellent yield. Hydrogenolysis of 2.58 
afforded secondary amine 2.49 in good yield. Increasing the steric hindrance further hampered the 
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reaction, as subjecting 2.57 to the reaction conditions at reflux temperature for 24 hours left the 
substrate untouched. 
 
Scheme 35: Scope of N-substitution for the Smiles rearrangement 
One-pot reaction 
The conversion of anthranilamide 2.37 to diarylamine 2.38 using n-BuLi with DMPU raised the 
possibility of using both the anionic Snieckus–Fries and Smiles rearrangements in tandem to form 
diarylamines from N,N’-diaryl ureas (Scheme 36). However, this approach was not optimal: 2.48j was 
synthesised in 58% yield upon treatment of 2.41j with n-BuLi at –78 °C followed by addition of DMPU 
(5 equivalents, warming to room temperature), while under similar conditions, 2.48b was formed in 
25% yield and 2.48a only in trace quantities.  
 














II.2.3. Mechanism of the transformation 
While the rearrangement proceeded smoothly with sodium and potassium bases, optimisation of the 
reaction showed that the use of lithium as a counter-cation halted the reaction. The need for a non-
coordinative additive such as DMPU or increased temperature for the rearrangement to take place 
indicated that the nature of the cation plays a role in the aryl migration. Work was conducted by 
Harvey Dale and Natalie Fey at the University of Bristol to explore possible reaction pathways 
computationally, using density functional theory (DFT), by comparison of the computed pathways for 
the rearrangement of deprotonated 2.42a to 2.48a mediated by either a lithium or sodium counter-
cation coordinated to molecules of THF solvent. 
For a lithium counter-cation, a stable complex was found for the deprotonated substrate, with 
chelation of lithium by the carbonyl and the deprotonated nitrogen (Figure 15). In comparison, the 
final product was thermodynamically less favourable by around 5 kJ mol−1. The reaction proceeds by 
concerted migration of the aryl group with a high energy of the single transition state of around  
121 kJ mol−1 relative to the deprotonated starting material, where the ipso carbon gains a strong 
tetrahedral character. The typical Meisenheimer complex observed in usual Smiles rearrangement 
was not found for this pathway.[86,96,122] 
 
 
Figure 15 : Mechanism with a lithium counter-cation. DFT calculations performed by Harvey Dale and Natalie Fey 
Using a sodium counter-cation, a different reaction pathway was observed (Figure 16). The product 
was now thermodynamically favoured by around 17 kJ mol−1. Coordination of the starting material to 
Na+ was weaker. The reaction proceeds in two steps, with an intermediate showing some 















ring. Despite the lack of anion-stabilising substituents, this intermediate is typical of a classical SNAr 
reaction, with localized single bonds on the formed, tetrahedral sp3-carbon. 
 
 
Figure 16 : Mechanism with a sodium counter-cation. DFT calculations performed by Harvey Dale and Natalie Fey 
The lower stability of the chelated reactant, together with the existence of a low-energy intermediate 
explains the difference in reactivity observed for the rearrangement using NaHMDS, as opposed to 
the used of lithium bases. 
II.2.4. Atropisomeric diarylamines by Smiles rearrangement 
One key feature of the transformation was that sterically encumbered anthranilamides 2.42l–p readily 
rearranged to diarylamines 2.48l–p (Scheme 37) with high levels of steric demand around the central 
nitrogen atom. The reactions were slower and required heating (sometimes in a sealed tube) for 
extended period but provided the products in good to excellent yields. X-ray crystal structures of 
2.48m and 2.48n showed bond angles around the central nitrogen atom of around 360°, indicating a 
planar nitrogen atom with its lone pair delocalized into the anthranilamide ring, as the other bulky 




a Compound prepared by Johnathan Matlock. b The reaction time was 96 h. c Based on recovered starting material.  
d Reaction performed in a microwave oven at 150 °C. The reaction time was 16 h. 
Scheme 37: Scope of sterically hindered substrate for the Smiles rearrangement 
The steric bulk around the central nitrogen atom of 2.48l–p is comparable to that of related 
atropisomeric diarylamines described in Chapter 1 (with an additional substituent on the nitrogen), 
making these compounds potentially atropisomeric. At room temperature, 1H NMR spectrum of 
amine 2.48l showed two well-resolved CHMe2 doublets which did not coalesce even at 100 °C in 
toluene-d8. The barrier to rotation of compound 2.48l was calculated using EXchange SpectroscopY 
(EXSY) at 25°C in toluene-d8 (Figure 17). Irradiation of the signal centred around 1.48 ppm gave a cross-
peak of same sign centred around 1.62 ppm, corresponding to partial interconversion of the irradiated 
nuclei during the mixing time. Extrapolation using the Eyring equation (Equation 1) allowed the 








Figure 17 : 1H NMR spectrum and 1H EXSY NMR spectrum of 2.48l (500 MHz, mixing time: 500 ms) 
Bulkier diarylamines bearing four ortho-substituent and/or a tert-butyl group were analysed by chiral 
HPLC. Compounds 2.48n and 2.48p could not be resolved. HPLC of 2.48m showed two resolved 
enantiomers using a chiral stationary phase at 0 °C. However, the broadness and poor resolution of 
the peaks prevented any calculation of a barrier to rotation.  
Both enantiomers of diarylamine 2.48o were resolved by HPLC. Following the first order decay of 
enantiomeric excess of an enantioenriched sample isolated by semi-preparative chiral HPLC (See 
Chapter 2), its barrier to C–N rotation was calculated at 333 K, with ΔG≠333 K = 106.5 kJ mol−1 in toluene, 
corresponding to a half-life to racemisation of 84 min (Scheme 38). Thus, diarylamines 2.48o, formed 
by the Smiles rearrangement of anthranilamide 2.47o is an atropisomer up to 60 °C. 
 
Scheme 38: Barrier to rotation of 2.48o and 2.60. HPLC traces of UV and optical rotation detectors (above and below) 
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Previous examples of atropisomeric diarylamines by Kawabata et al. featured an intramolecular 
hydrogen bond, locking rotation about one of the CAr–N bonds (see Chapter 1).[29,30] To confirm that 
the atropisomerism of 2.48o was only owed to steric hindrance, the potentially hydrogen bonding 
amide of 2.48o was alkylated to form compound 2.61. The barrier to rotation decreased only 
marginally to 104.4 kJ mol–1 at the same temperature, while disruption of the intramolecular hydrogen 
bonding in Kawabata’s examples reduced the barrier to rotation by 15.5 kJ mol–1. 
II.3. Conclusion 
In conclusion, both sterically hindered and unhindered diarylamines can be accessed in two steps from 
diaryl ureas using a novel, versatile Smiles rearrangement. No electronic activation of the migrating 
ring is required owing to the conformational preorganisation of the substrate. This transition metal-
free route to diarylamines derived of anthranilic acid is particularly notable for its functional-group 
tolerance and its compatibility with extremely hindered aryl rings. It provides a valuable alternative to 
metal-catalysed coupling for the synthesis of challenging compounds. This rearrangement allows the 
facile synthesis of sterically hindered diarylamines displaying atropisomerism owing to restricted 
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III.1.1. 3D structures in drug discovery 
Modern approaches to drug design have recently focussed on shape-based three-dimensional 
molecular descriptors in an effort to ‘escape from flatland’,[123,124] with good success in the prediction 
of the likeliness of clinical success.[125,126] Since the introduction by Lipinski of the ‘Rule of 5’ 
physicochemical properties to follow in order to develop drug-like molecules from hit to lead,[127,128] 
the community has been constantly surveying the properties of drug candidates during lead 
development. Among the properties considered are molecular weight, number of hydrogen bond 
donors and acceptors, number of rotatable bonds, or lipophilicity (as proposed by Lipinski), but also 
the polar surface area.[129] These properties are now benchmarks for the development of drug-like 
scaffolds and are scrutinised on preclinical candidates for the prediction of their absorption, 
distribution, metabolism, excretion and toxicity (ADME-Tox) profile.  
Due to the considerable increase in methods for the formation of Csp2–Csp2 bonds over the past 
decades, most notably by transition metal-catalysed reactions,[130] the pharmaceutical industry has 
focussed on creating libraries of easily assembled, highly aromatic compounds from commercially 
available substrates.[123,124] This trend has continued further with the development of high-throughput 
practice, allowing the rapid formation of libraries containing hundreds of thousands of compounds 
using robust procedures.[123] While these methods allow the facile introduction of chemical diversity 
on a given scaffold, the functional groups introduced this way are usually planar and aromatic, with a 
rod-like or discoid shape.[131] Hence, the chemical space which can be explored by such products is 
fairly restricted.  
Recently, it has been demonstrated that increasing the structural complexity of drug candidates – and 
driving them towards natural product-like scaffolds – correlates with successfully advancing from the 
hit discovery stage to a marketed drug.[125,132] Different descriptors defining the important 
physicochemical properties of the scaffold shape have been proposed, such as the radius of 
gyration.[125] Another popular metric is the quantification of the fraction of sp3 carbons in a 
molecule,[123] as saturation of a scaffold increases its topological complexity without compromising 
the molecular weight.  
Furthermore, various groups have shown that scaffolds exhibiting a higher degree of three-
dimensionality tend to have better solubility, as planarity of a substrate can lead to solid state crystal 
lattice packing.[133] Shape complexity also improves the selectivity towards the selected target, and 
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side-effects of highly three-dimensional molecules are considerably reduced as off-target binding by 
promiscuity is less favourable.[124] 
III.1.2. Medium-rings heterocycles 
Medium-sized rings in drug discovery 
Medium-sized rings – cyclic compounds comprising 8 to 12 atoms within a ring – are promising 
scaffolds for the development of small-molecule drugs with an extended three-dimensional  
shape.[134–136] While their relative flexibility is beneficial for enhanced binding affinity by induced fit 
compared to smaller rings, their well-defined conformation allows the organisation and finely-tuned 
orientation of key pharmacophores for improved interactions with the target, preventing the major 
entropic loss of binding of linear, flexible systems.[137] Furthermore, the restricted conformations of 
these substrates can ameliorate physicochemical properties such as bioavailability or cell 
permeability.[138] However, it is well recognised that unfavourable transannular interactions increase 
the enthalpy of transition states of reactions leading to medium-rings.[139] This makes their synthesis 
difficult, and consequently medium-rings are under-represented in screening libraries.[140,141] 
The potential of medium-size rings in drug development was recently highlighted by the drug 
candidate Lorlatinib, which was recently submitted to Phase 3 clinical trials for the treatment of lung 
cancer (Figure 18).[142] Its cyclic structure containing a reduced number of rotatable bonds as well as a 
shielded polar surface area was found to be particularly relevant for further development of central 
nervous system (CNS) penetrant drugs.[142] Other 8-, 9- and 12-membered benzannulated medium-
sized lactams have been discovered for the treatment of breast cancer,[143] as antibacterial agent[144] 
or against leukaemia,[145] respectively. 
 
Figure 18: Bioactive medium -rings 
Medium-size rings are also found in a plethora of natural products. Rhazinilam, a benzannulated 
lactam isolated from flowering plants from the Apocynaceae family,[146] is a lead compound for the 
development of new antitumor compounds. Its unusual heterobiaryl moiety embedded in a 9-
membered lactam ring procures rigidity, making the axially chiral Csp2–Csp2 bond configurationally 
stable. Aspercyclide A is an 11-membered diphenyl ether lactone isolated from Aspergillus sp. 
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inhibiting the binding of immunoglobulin E antibodies (IgE) to the human IgE receptor, therefore 
having potential application in the treatment of allergic disorders.[147] 
Synthesis of benzannulated medium-sized lactams by ring expansion 
Benzannulated medium-sized lactams such as Lorlatinib are an emergent class of drug-like scaffolds 
which can be access by new synthetic methods. Their higher stability towards hydrolysis compared to 
the related linear or 5- or 6-membered cyclic amides is an asset, as amide bond cleavage is a common 
pathway for drug metabolism.[148]  
Cyclisation reactions are common strategies for the formations of lactams and lactones. The use of 
intramolecular reactivity offers advantages over reactions such as cycloadditions, as only one bond 
forming step is key to the reaction.[149] Cyclisations to form 5- and 6-membered rings are generally 
more trivial than smaller rings, whose formation is impaired by significant enthalpic penalties due to 
the high strain of the product. While this is not a problem in cyclisations to generate macrocyclic 
structures, the long, flexible linker between the two reactive sites generally creates an unfavourable 
entropic cost upon ring formation. This leads to the possibility of intermolecular couplings, for which 
the main method of prevention is high dilution, limiting the application of macrocyclisations. 
Medium-ring synthesis suffers from both these limitations.[134] Illuminati et al. have found that the 
rate of lactonisation of various aliphatic bromo-carboxylic acids suffer from up to a millionfold 
decrease in the formation of 8- to 12-membered products compared to the cyclisation of the  
5-membered γ-butyrolactone.[139] It has been determined that torsional strain due to forced eclipsed 
conformations, as well as repulsive interactions between atoms across the scaffold leading to 
transannular strains are the major enthalpic penalties in the formation of medium-rings. Ring 
expansion provides an appealing alternative to access these heterocyclic rings, as not only is the 
transannular strain lessened in the transition state,[149] but also because smaller heterocycles are 
readily available. Consequently, various groups have developed methods for the synthesis of 
benzannulated medium-sized lactams by ring expansion. 
The Unsworth group reported the two-step synthesis of highly three-dimensional scaffolds 3.2 made 
through a 2-steps process via ring expansion (Scheme 39).[150] Tricarbonyl 3.1 was formed by 
magnesium-promoted C-alkylation of an amino acid derived acyl chloride with a cyclic β-keto ester. 
Deprotection of the pendant nitrogen under basic conditions triggers nucleophilic attack at the ketone 
which initiates ring expansion to yield lactams 3.2 by ‘stapling’ of the amino acid moiety within the 
main core. This method provides scaffolds with methylene chains of modifiable length allowing fine 
tuning of their structural complexity, as demonstrated by extensive calculations of the lead-like 




Scheme 39: Ring expansion of tricarbonyl compounds[150] 
Ring expansion by transamidation is also a popular alternative to macrocyclisations. Imides 3.3 were 
easily prepared by the acylation of the corresponding cyclic amide with para-nitrobenzyl-capped 
amino acid pentafluorophenol esters as coupling partners.[151] Upon acidic cleavage of the Boc group 
followed bytreatment with DIPEA in one-pot, the pendant nitrogen atom adds to the carbonyl position 
via a favoured 6-membered transition state similar to the previous example, this time on an imide 
moiety (Scheme 40). The imidic C–N bond cleavage then yields medium-sized anilides 3.4 with 
modulable ring size by tuning the methylene chain on the benzolactam substrate. 
 
Scheme 40: Ring expansion of cyclic imides (R = p-NO2Bn)[151] 
The Buchwald group developed their copper(I) methodology towards the synthesis of benzolactams 
by a one-pot transamidation/ring expansion strategy.[152] When attempting the copper-catalysed 
coupling of azetidinone 3.6 with 2-halobenzylamines 3.5, 8-membered lactam 3.7 was isolated in 
almost quantitative yield (Scheme 41, n = 1).  
 
Scheme 41: Copper-catalysed ring expansion of N-aryl azetidinones[152] 
Another strategy for the formation of medium-sized lactams by strain-relief was proposed by the 
Krasavin lab (Scheme 42).[153] 10-Membered lactams (3.9) with an embedded diaryl ether scaffold 
were made by ring expansion of easily prepared imidazoline-fused oxazepines 3.8 by hydrolytic ring 
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expansion. A one-pot procedure was devised to N-alkylate/ring expand in good to excellent yield, 
accessing heteroatom-rich structures 3.9. 
 
Scheme 42: Medium-rings by hydrolytic ring expansion[153] 
Although the substrate scope provided suggests that the reaction proceeds smoothly irrespectively of 
the substitution pattern, even tolerating heteroaromatic rings, the oxazepine ring itself is formed by 
a complex cascade reaction involving two SNAr steps and a Smiles rearrangement, limiting the scope 
of compounds amenable to the ring-expansion step. 
Smiles reaction in ring expansions 
The Smiles rearrangement was applied by Still and co-workers for the ring expansion of 7-membered 
dibenzazepinone 3.10 to form medium-ring heterocycle 3.11 (Scheme 43).[154] Upon deprotonation, 
incorporation of the amino acid into the core structure proceeded by nucleophilic attack at the ipso 
position of the aromatic amine. The reaction necessitates electronic activation and requires one or 
more nitro group on the aromatic ring. Additionally, only a 7-to-10-membered ring expansion 
proceeded. Indeed, acylation of the product 3.11 with alanine and iterative ring-expansion resulted in 
the reverse-Smiles rearrangement to the former 7-membered substrate.  
 
Scheme 43: Ring expansion by Smiles rearrangement,[154] R = CH2CO2tBu. (a) NaH, THF, DMF, then BocAlaO(p-NO2Ph).  
(b) TFA, CH2Cl2, Toluene 
Recently, our group described the use of the Smiles rearrangement of lithiated ureas in the ring 
expansion of common N-heterocycles (Scheme 44).[155] Upon deprotonation of the benzylic position 
of urea 3.12, an unconventional SNAr reaction occurs with attack at the ipso position of the 
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heterocycle. After collapse of the Meisenheimer intermediate, C–N bond cleavage provides 8- to  
12-membered medium-sized ureas 3.13 in excellent yields, constituting a formal N-to-C aryl migration.  
 
Scheme 44: Unactivated Smiles ring expansion of ureas[155] 
In comparison to the anthranilamide rearrangement presented in Chapter 3, this Smiles 
rearrangement is insensitive to electron-donating groups on the migrating aryl ring, suggesting that 
Smiles ring expansions do not necessarily require electronic activation of the substrate. 
III.1.3. Intramolecular hydrogen bonding in drug design 
Hydrogen bonding is a crucial concept in drug discovery, and a major phenomenon dictating the 
folding of proteins, mainly through bonding of the amidic N–H with carbonyls.[156] Consequently, 
binding of a drug-like small molecule to its target is strongly affected by its hydrogen bonding 
properties, which must be manipulated to offer strong, directed interactions. Thus, the introduction 
of polar groups with defined orientations is a key challenge in drug design. 
Controlling the active conformation with intramolecular hydrogen bonding 
More recently, the medicinal chemistry community identified the use of intramolecular hydrogen 
bonding as a way to introduce conformational bias to obtain a desired functional group arrangement 
without the need for a covalently bonded, rigid scaffold. Researchers from Novartis, for example, 
designed a mimic of PD166285,[157] a broadly active tyrosine kinase inhibitor developed by Pfizer  
(Figure 19); by moving the nitrogen atoms in the pyrimidine ring, and replacing the pyrimidone ring 
with a urea, a particularly stable, planar and conjugated pseudo six-membered ring was formed by 
intramolecular hydrogen bonding. Although less potent than PD166285, compound 3.14 retained a 
submicromolar activity against a wide range of tyrosine kinases.[158] 
 
Figure 19: Bioactive compound mimic by intramolecular hydrogen bonding[158] 
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New classes of biologically active chemotypes can thus be obtained by locking the active conformation 
as a molecular mimic, offering potentially different ADME-Tox profiles, easier methods of synthesis as 
well as new patentability. 
Hidden hydrophilicity 
When designing a new drug scaffold, one must pay attention to the polarity of the target compound. 
The ADME-Tox profile of a molecule is directly related to its polarity and ionizability. Polar and/or 
ionised molecules struggle to penetrate the cells lipid bilayer by passive diffusion and require active 
transporters to be absorbed.[159] This limits their design and introduces more challenges to their 
development. Furthermore, lipophilic compounds are metabolised and excreted at a significantly 
slower rather than their polar counterparts.[137] Yet, polarity is necessary to increase the solubility of 
the active ingredient in physiological media (i.e. aqueous solutions), and high lipophilic compounds 
have their own drawbacks, including poor bioavailability due to plasma protein binding, as well as 
unfavourable entropic costs to bind deeply solvated enzyme pockets.[129,138] Hence, the polarity of a 
drug molecule must be finely balanced to optimise its ADME-Tox properties. 
Polarity, however, can be a dynamic property. Trapoxins and Apicidins, two classes of 
cyclotetrapeptides metabolites isolated from fungi (Figure 20), have found application as anti-
protozoal agents by irreversible inhibition of histone deacetylase through their α-epoxyketone and 
alkyl ketone warheads, respectively.[160,161] Variable-temperature NMR analysis revealed that Apicidins 
possess a highly rigid 12-membered scaffold containing several intramolecular hydrogen bonds 
(designated by the red arrows in Figure 3-3).[161] This array of intramolecular hydrogen bonds is made 
possible by the D-Pip amino acid in the chain. Indeed, cyclotetrapeptides made from all-L-amino acids 
are known to be sensitive to hydrolysis and have multiple conformations in water because of the 
unfavourable strain induced by homochiral amino acids in the major all-trans conformation.[162] 
Cyclisation of small peptides generally improves lipid bilayer penetration by removing the charge at 
each terminus, thus making the peptides neutral at physiological pH.[132] Restricting the number of 
rotatable bonds also lowers the entropic costs of desolvation and can allow the formation of more 




Figure 20: Bioactive cyclic tetrapeptides. Intramolecular hydrogen bonds are highlighted by the red arrows 
Furthermore, evidence of the positive impact of intramolecular hydrogen bonding on cell wall 
permeation was observed by Lokey and co-workers.[132,163] Cyclic hexapeptide 3.15, containing both  
D- and L-amino acids crosses lipid bilayers with a ten-fold increase in its diffusion coefficient compared 
to its homochiral analogue.[163] This ratio increases to a hundred-fold when compared to a linear 
homologue. Careful investigation of the conformation of 3.15 in solution by 1H NMR analysis led to 
the conclusion that the absolute configuration of the amino acids and the cyclised nature of the 
scaffold allow the folding of the peptide into a tight structure comprising of four hydrogen bonds. In 
this conformation, the overall lipophilicity of the compound is increased by ‘hiding’ the polar moieties 
from the medium (Figure 21). 
 
Figure 21: Schematic representation of lipid bilayer permeation by hidden hydrophilicity in cyclic peptides 
Consequently, while the highly polar peptide is easily solvated by water molecules, the entropic cost 
of desolvation to cross the lipidic membrane is reduced by this intramolecular hydrogen bonding. The 
polarity of the compound is then easily modulated to adapt to the medium, rendering it dynamic.[163] 
The hundred-fold difference in membrane-crossing compared to the linear analogue highlights the 
importance of the structural preorganisation brought by cyclisation, while the homochiral, cyclic 
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analogue can only fold into a structure comprising of three intramolecular hydrogen bond, not as 
lipophilic as 3.15.[132] 
This particular ‘chameleonic behaviour’ was applied to design new transmembrane vectors to improve 
the ADME profile of small bioactive molecules.[164,165] Aminocoumarin 3.16 is a fluorescent, cytotoxic 
compound inducing reactive oxygen species in Cryptococcosis. Its poor cell permeability, however, 
restricts its application as an antiproliferative.[164] Conjugation of the molecule with a non-toxic 
tetrapeptide inspired from Trapoxins and Apicidins through a click reaction forms the bioconjugate 
molecule 3.16 (Figure 22).[165] Although its large molecular weight exceeds the limits defined by 
Lipinski’s ‘Rule of 5’, compound 3.16 crossed the lipid bilayer and is highly active against  
P. falciparum, as visualised by fluorescence spectroscopy. 
 
Figure 22: Application of the hidden hydrophilicity to molecular shuttling[165] 
Introducing intramolecular hydrogen bonds to improve the physicochemical properties of a bioactive 
substance is not limited to large, cyclic peptides. CI1021 is a carbamate-capped quaternary amino acid 
derivative with low nanomolar activities against the human neurokinin-1 receptor, a G protein-
coupled receptor found in the central nervous system.[166] This receptor is considered an attractive 
drug target as it mediates many biological processes such as pain transmission, activation of the 
immune system, as well as proliferation and migration of tumour cells.[167] However, as CI1021 is 
poorly soluble in aqueous media and barely crosses the blood-brain barrier, researchers at Pfizer have 
worked on improving its ADME profile while keeping activity by modifying the substitution pattern at 
the quaternary carbon.[168] This led to the discovery of the closely related derivative, 3.16 (Figure 23), 
which forms an intramolecular hydrogen bond between the new tertiary amine and the amidic proton, 
as evidenced by variable temperature 1H NMR analysis, together with computational modelling and 
X-ray crystal structure determination. This compound presented similar in vitro activity, the 
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protonable amine increased its solubility. Furthermore, the formation of this intramolecular hydrogen 
bond decreases the compounds apparent lipophilicity, resulting in noticeable improvement in CNS 
penetration. 
 
Figure 23: Improving ADME profile of a drug by intramolecular hydrogen bonding[168] 
It is clear that the design of flexible yet structurally defined pharmacophores which can accommodate 
one or many intramolecular hydrogen bonds can successfully lead to the improvement of the 
physicochemical properties of drug-like molecules.[137] The combination of this approach together 
with further emphasis on the three-dimensional shape of molecules has allowed medicinal chemists 
to go beyond the ‘Rule of 5’.[169] This permits the design of non-canonical drug chemotypes at a time 
where targeted diseases are harder to address, as only half of the pool of targets are estimated to be 
druggable within the ‘Rule of 5’ today.[138] 
 
III.2. Results and discussion 
III.2.1. Aim 
Tricyclic antidepressants (TCA) such as Imipramine and Dibenzepin (Figure 24) are broadly prescribed 
for the treatment of depression and schizophrenia.[170,171] Dibenzodiazepines possess a pair of rigid, 
rapidly interconverting enantiomeric ‘butterfly’ conformations, arising from the strain in the 
dibenzofused 7-membered heterocycle.[172,173] This interconversion is locked in telenzepine, of which 
one of the two atropisomers is 500 times more active than the other.[174] 
 
Figure 24: Examples of tricyclic antidepressants (TCA) approved by the FDA 
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Building on the work described in Chapter 3, we envisaged the rearrangement of anthranilamides 
where the amide nitrogen is tethered to its closest aryl ring (3.17, Scheme 45). Smiles rearrangement 
of such compounds would lead to n→n+4 ring expansion of the heterocyclic amide to generate 
medium-rings from simpler benzo-fused nitrogen heterocycles. The resulting heterocycle would also 
possess a hydrogen bond donor/acceptor pair in its core scaffold, making it a potential candidate for 
intramolecular hydrogen bonding, with different conformations accessible by modulating ring size. 
 
Scheme 45: Concept of the Smiles ring expansion of anthranilamides 
The anthranilamide substrates were all synthesised by Quentin Lefebvre, and their synthesis will only 
be briefly discussed. The Snieckus–Fries rearrangement reported in Chapter 3 unfortunately provided 
anthranilamides 3.17 in low yields and required long reaction times. In contrast, treatment of 
nitrogen-heterocycles 3.20 with NaHMDS in the presence of isatoic anhydrides 3.19 results in the 
addition of the deprotonated nitrogen to the carbonyl directly bonded to the aromatic ring, 
subsequently initiating ring opening (Scheme 46). Acidic workup of the resulting carbamic acid leads 
to decarboxylation to form anthranilamide 3.17 in poor to excellent yield, in one step. The reaction 
usually proceeds at room temperature and is typically complete within two hours. When not 
commercially available, isatoic anhydrides were made by reaction of triphosgene with the 
corresponding anthranilic acid followed by N-methylation. 
 
Scheme 46: Synthesis of the anthranilamides starting materials as performed by Quentin Lefebvre 
III.2.2. Development of the rearrangement 
Optimisation of the Smiles ring expansion was carried out on anthranilamide 3.17b (Table 20), made 




Entry Base Solvent T (°C) t Conv. (%) 3.18b (%) 3.21 (%) 
1 NaHMDS THF rt 16 h 66 <5 43 
2 NaHMDS THF 66 2 h >95 55 27 
3a NaHMDS THF 100 15 min >95 66 22 
4b NaHMDS THF 100 15 min >95 72c <5 
5b NaHMDS 2-MeTHF 100 15 min >95 67 <5 
6b NaHMDS MTBE 100 15 min 91 28 43 
7b NaHMDS Toluene 100 15 min 86 18 44 
8b LiHMDS THF 100 15 min 8 <5 <5 
9b KHMDS THF 100 15 min 89 62 <5 
10b KHMDS THF 100 30 min >95 45 29 
11b P4-tBu THF 100 15 min 28 0 0 
12b TDB THF 100 15 min 18 0 0 
13b KOtBu THF 100 15 min >95 0 73 
Reaction procedure: To a solution of 3.17b (0.2 mmol) in solvent (0.2 M) was added a base (0.22 mmol, 1.1 eq.). The 
reaction mixture was stirred at the given temperature and quenched with MeOH.  
1H NMR yields were calculated from the crude reaction mixture using 1,3,5-trimethoxybenzene as internal standard.  
a Reaction performed in a sealed tube. b Reaction performed in a microwave oven. c Isolated yield. 
Table 20: Optimisation of the Smiles ring expansion 
On treatment with NaHMDS in refluxing THF, 3.17b rearranged to the 10-membered lactam 3.18b in 
55% yield (entry 2). However, decomposition of the starting material to the corresponding N-methyl 
anthranilic acid (usually removed during work up) and tetrahydroquinoline (THQ, 3.21, Table 20) was 
also observed. Increasing the temperature to 100 °C in a sealed tube reduced the reaction time and 
improved the yield (entry 3). Microwave heating yielded a cleaner reaction, giving the product in  
72% yield with only trace amounts of THQ (entry 4).  
KHMDS gave comparable results, albeit proceeding at a slower rate, and decomposition of the product 
was observed over prolonged reaction time (entries 9 and 10). As mentioned in the previous chapter, 
the conversion was negligible when LiHMDS was used as the base (entry 8). Other bases investigated 
were either too weak, leaving the starting material untouched (entries 11 and 12), or too nucleophilic, 
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leading to decomposition (entry 13). Renewably-sourced 2-Methyl THF provided a good alternative 
solvent, with only a slight decrease in yield (entry 5), whereas toluene and MTBE led to decomposition 
(entries 6 and 7). 
Scope and limitations 
Ring expansion of 5- to 8-membered heterocycles was possible, providing 9- to 12-membered lactams 
(Scheme 47). Rearrangement of the smallest ring, the 5-membered indoline derivative 3.17a required 
more forcing conditions (4 hours at 120 °C) but yielded the corresponding 9-membered product 3.18a 
in excellent yield. Rearrangements of larger rings also proceeding smoothly and were cleaner, 
providing the corresponding 10- to 12-membered compounds 3.18b–d in excellent yields after short 
reaction times. In contrast to the organolithium bases, NaHMDS allowed good tolerance to halogen 
substituents at various positions of the aryl ring, with fluoro-, bromo-, and chloro-substituted products 
3.18e–j formed without decomposition. The reaction conditions were also compatible with a lipophilic 
trifluoromethoxy group (3.18k). In some examples, full conversion could not be reached despite 
heating at higher temperature or extending the reaction times. Moderate steric hindrance was 
somewhat tolerated. Fluorine atoms ortho to the nucleophilic nitrogen decreased the reactivity, as 
3.18g needed prolonged reaction time and did not go to full conversion. Its 7-membered ring 
analogue, 3.17h, though, reacted cleanly to give 3.18h in excellent yield. Steric demand ortho to the 
amide group, for example a methyl group (3.18l), had a dramatic effect, requiring a longer reaction 
time, and full conversion was not reached, whilst its 6-membered derivative did not rearrange at all 




a The reaction time was 4 h at 120 °C. b 3 mmol scale. c Based on recovered starting material. d The reaction time was  
45 min. e The reaction time was 1 h. f From the Boc-protected staring material, using 2.0 eq. NaHMDS followed by  
6.0 M HCl.  
Scheme 47 : Scope of the Smiles ring expansion 
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More complex products with functional groups on the contiguous methylenes chain were made by 
ring opening of various heterocycles. Ring opening of dibenzazepine afforded anilide 3.18m, 
containing an arylated side chain, in near-quantitative yield. Ring opening of a benzodiazepane – made 
by condensation of isatoic anhydride and N-methyl glycine, followed by reduction – yielded another 
nitrogen-rich medium-ring 3.18n in excellent yield. Ring opening of N-Boc protected quinoxaline was 
possible with longer reaction time. However, slow bond rotation of the Boc protecting group, together 
with interconversion of conformers by ring-flipping complicated analysis of the product. One-pot ring 
opening followed by Boc deprotection was then conducted, affording nitrogen-rich compound 3.18o 
in good yield. 
This reaction, however, showed some limitations. First, the solubility of the substrates for the 
formation of anthranilamide 3.17 sometimes proved to be a limitation to the extension of the scope. 
In general, benzo-fused or methoxylated isatoic anhydrides were insoluble in THF and DMF, the two 
solvents used for the N-methylation and anthranilamide condensation. This problem was also faced 
when trying to introduce a nitrogen atom in the isatoic anhydride ring to provide pyridyl derivatives. 
Insolubility of the anthranilamide substrate was also an issue when trying to add an amide  
N-heterocycle to isatoic anhydride (indolinone, isatin or quinolinone) or a nitro-substituted 
heterocycle. 
Introducing heterocyclic structure in the isatoic anhydride substrate was possible with thiophene 
rings. However, compounds 3.17s and 3.17t were unreactive under the ring expansion conditions. 
Heating up the reaction mixture to 150 °C for 2 hours left anthranilamide 3.17s untouched  
(Scheme 48), while amide bond cleavage was observed in 3.17t under the same conditions. 
This side-reaction appeared to be common. When solubility was not an issue, poor conversion or 
decomposition of the starting material was occasionally observed. A chlorine atom para to the amide 
moiety leads to no conversion of the starting material 3.17p, even at higher temperature and with 
longer reaction times. As stated earlier, a methyl group ortho to the amide moiety drastically slows 
down the conversion of the ring expansion of the 6-membered heterocycle 3.17q, to the advantage 
of the amide bond cleavage and formation of tetrahydroquinoline 3.21. Similarly, electron-rich 
benzoxazine, and pyridine-derived anthranilamides 3.17r and 3.17u were not stable under the 





Scheme 48 : Unsuccessful scaffolds for the Smiles ring expansion 
Although rearrangement of heterocyclic substrates seemed troublesome, we turned our attention to 
extending the scope to different core structures. Enamine 3.24 was accessed by modifying a previously 
reported procedure for the formation of enamines from trimethylsilyl acetylene derivative (Scheme 
49).[175,176] Formation of the acyl chloride of carboxylic acid 3.22 followed by condensation with THQ 
proved unfeasible. Instead, peptide coupling using DCC and DMPA furnished protected trimethylsilyl 
acetylene amide 3.23 (Scheme 49) in good yield. Stirring the alkyne with methylamine gave the 
corresponding enamine in quantitative yield, in a 3:1 ratio of cis/trans isomers, as determined by 1H 
NMR analysis of the product mixture. 
 
Scheme 49 : Synthesis of enamine 3.24 
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Submitting the resulting enamine to the reaction conditions, however, did not show any conversion 
(Scheme 50). As previously seen, increasing the temperature to 120 °C and extending the reaction 
time to 30 minutes led to the decomposition to tetrahydroquinoline. 
 
Scheme 50 : Attempted ring expansion of enamine 3.24 
Amide groups can be metabolically labile in physiological medium. A common isostere to the amide 
functionality is the sulfonamide group.[177] Modification of the anthranilamide substrates to replace 
the amide moiety for a sulfonamide could be achieved following a similar strategy to that described 
in Chapter 3. Coupling of the commercially available ortho-nitrobenzene sulfonyl chloride 3.26 with 
THQ under basic condition afforded sulfonamide 3.27 in good yield (Scheme 51). Sequential 
hydrogenation of the nitro group followed by Chan–Lam coupling with methylboronic acid afforded 
sulfonamide 3.28 in good yield after two steps. 
 
Scheme 51 : Synthesis of sulfonamide 3.28 
When subjecting sulfonamide 3.28 to the reaction conditions, no conversion was observed  
(Scheme 52). Raising the temperature to 120 °C and the reaction time to 2 hours offered no 
improvements. Modification of the amide moiety presumably changes the substrate 
conformation.[177] The sulfur atom is sp3 hybridised, in contrast to the sp2 hybridised carbon atom of 
the amide carbonyl. Consequently, the aryl ring of benzenesulfonamides (here in blue) lacks the 





Scheme 52 : Attempted ring expansion of sulfonamide 3.28 
Following a similar approach to the previous chapter, it was decided to improve the scope of the 
reaction by introduction of protecting groups at the nucleophilic nitrogen atom (i.e. replacing the 
methyl group). Although it was initially decided to use a benzyl group, this use of this group was 
rejected for two reasons: a) the benzyl group required drastic changes to the conditions for the acyclic 
Smiles rearrangement to happen, b) it was anticipated that the benzyl group would be too bulky to 
allow ring expansion. Instead, the moderately hindered allyl was selected for investigation. The allyl 
group was introduced in good yield by substitution of allyl bromide on primary aniline 3.30, which 
itself was made following a previously reported protocol (Scheme 53).[178] Heteroatom-containing 
protecting groups were also considered, including the MOM (methoxymethyl ether), SEM (2-
(trimethylsilyl)ethoxymethyl ether), and MEM (2-methoxyethoxy-methyl ether) protecting groups. 
Protection of the aniline nitrogen by a MOM group under basic conditions with sodium methoxide did 
not provide any product 3.32, with decomposition to THQ occurring instead. Introduction of a SEM or 
a MEM protecting group to yield 3.33 and 3.34, respectively, also proved difficult, with no conversion 
observed in both cases. 
 
Scheme 53 : Route to N-protected anthranilamides 
78 
 
The ring expansion was initially explored on the unprotected aniline 3.30. Whilst no reaction took 
place under the standard condition, increasing the temperature and reaction time led to a 
transamidation reaction, even at concentrations as low as 0.01 M. Subjecting the allyl-protected 
substrate 3.31 to the standard reaction conditions in 30 minutes, decomposition to 
tetrahydroquinoline was observed in 50% conversion (Table 21, entry 1).  
 
Entry Change in conditions Conversiona 
1 None 50%, 3.31/THQ 1:1 
2 DMPU (5.0 eq.) 50%, 3.31/THQ 1:1 
3 18-crown-6 (5.0 eq.) 50%, 3.31/THQ 1:1 
4 150 °C 85%, 3.31/THQ 1:6 
5 150 °C, in DMF (0.2 M) 90%, 3.31/THQ 1:9 
a 1H NMR yields were calculated from the crude reaction mixture using 1,3,5-trimethoxybenzene as internal standard. 
Table 21 : Ring expansion of N-allyl anthranilamide 
Modification of the conditions, including the use of additives such as DMPU as a decoordinating agent 
(entry 2) or 18-crown-6 as a potassium cation chelator (entry 3), raising the temperature to 150 °C and 
exchanging the solvent to DMF (entries 4 and 5). However, none of these conditions yielded any 
product. 
Post-functionalisation 
To demonstrate the versatility of the medium-ring products obtained by Smiles ring expansion in a 
drug discovery context, further transformations of the amide function were investigated. Alkylation 
of the amide nitrogen with methyl iodide proceeded in excellent yield to form tertiary amide 3.36 
(Scheme 54). However, attempts to functionalise the same medium-ring product to introduce a 
dimethylamino ethyl chain, as present in Dibenzepin, proved unsuccessful. The use of a chloro or 
triflate derivative of the alkylating agent led to no conversion to 3.37, and the alkylating agent was 
recovered. When using the more activated alkyl iodide derivative (made by Finkelstein halogen 
exchange), no substrate was recovered, presumably because elimination of the iodine by the strong 
base occurred instead. Switching to a weaker base such as potassium carbonate did not improve, and 




Scheme 54 : Alkylation of the medium-ring product amide 
Reduction of the amide of 3.18d to the respective amine did not proceed even under refluxing 
conditions with a large excess of lithium aluminium hydride in THF, but diamine 3.38 was obtained in 
good yield by reduction with borane dimethylsulfide while heating the reaction mixture in a sealed 
vial (Scheme 55). This reaction was optimised by Quentin Lefebvre. 
 
Scheme 55 : Reduction of the medium-ring product amide 
Introduction of an N-methyl piperazine amidine moiety to give 3.39, as encountered in TCA, was 
attempted by nucleophilic attack of the amine at both the chlorimine, formed by treatment of 3.18b 
with POCl3, and by a thionyl chloride mediated formation of the nitrile (Scheme 56). 
 
Scheme 56 : Diverse post-functionalisation of the medium-ring product 
However, in both conditions, the reverse-Smiles ring contraction gave anthranilamide 3.17b with full 
conversion. Similarly, attempted introduction of an aldehyde group on the aromatic ring by Vilsmeier–
Haack reaction only yielded anthranilamide 3.17b. 
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III.2.3. Intramolecular hydrogen bonding in the medium-sized ring products 
Conformation of the medium-ring products in the solid state and in solution 
Crystals of the medium-sized products suitable for X-ray analysis were obtained by either slow 
evaporation of a saturated solution of the corresponding compound in toluene, or by slow diffusion 
of pentane into a solution of the material in dichloromethane. A solid-state structure was obtained 
for each ring size, revealing the solid-state conformation of compounds 3.18a–d, as well as 3.18l and 
3.18m (Figure 25). 
 
Figure 25 : Top left to bottom right: crystal structure of 3.18a, 3.18b, 3.18c, 3.18d, 3.18l, and 3.18m 
The solid-state structures of the 9- to 12-membered compounds revealed great conformational 
intricacy, with the various substituents projected in all directions. Although not immediately obvious 
when represented by their structural formula, the medium-rings synthesised by this Smiles ring 
expansion have a complex, highly three-dimensional shape. Using the open-access computational tool 
‘Lead-Likeness and Molecular Analysis’ (LLAMA) provided by the University of Leeds,[179] the Principal 
Moment of Inertia (PMI) of each synthesised medium-sized heterocycle was plotted against the 
stripped down dibenzodiazepinone scaffold 3.41 (Figure 26). This descriptor measures the extent to 
which the scaffold has a rod-, disc- or sphere-shape, thereby indicating the three-dimensionality of a 
molecule. It is drawn as a ternary plot, with each vertex representing a model rod, disc or sphere (using 
butadiyne, benzene and adamantane, in the top-left, bottom and top-right corner, respectively). The 
closer to the ‘adamantane vertex’, the more spherical a molecule is. While natural products are usually 
spread all over the plot, with shapes often accumulating near the spherical vertex, synthetic drug-like 
molecules, often made by Csp2–Csp2 coupling or amide bond formation, usually lie in the ‘rod’ or 
‘discoid’ region, close to the axis.[133] Dibenzodiazepinones themselves are not planar, as their central 
7-membered ring is twisted, forcing the flanking aromatic ring outside of the plane in a typical 
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‘butterfly’ conformation. However, all medium-rings performed better than the reference scaffold, 




Figure 26: PMI plot of compounds 3.18a–d 
The forcing conditions required to synthesise compound 3.18a, which contains a 9-membered ring, 
can be explained by the deviation from planarity of its amide group. Its nitrogen atom possesses 
significant sp3 character, evidenced by its pyramidalization constant being χN = 47.8° and given that 
the sum of its bond angles is 343.4°.[180,181] Moreover, while the C(O)–N bond torsion angle is moderate 
(τ = 23.4°), the dihedral angle between the amide group and the adjacent aromatic ring (θAr–C(O) = 54°) 
prevents delocalisation. As depicted in the crystal structures, this behaviour seemed to ease in the 
larger rings, where the length of the methylene bridge has been increased (Table 22).  
Entry Compound dN−H−N (Å) θAr–C(O) (°) δN−H (ppm) 
1 3.18a 2.42 54 5.87 
2 3.18b 2.72 58 6.46 
3 3.18c 2.47 42 7.72 
4 3.18d 1.95 1.3 9.10 
5 3.18l 2.73 116 6.16 
Table 22 : Some conformation parameters of the solid-state structure of 3.18a–d and 3.18l 
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Larger rings have a sharper angle between the amide and its adjacent aryl ring. Indeed, coplanarity is 
achieved in the 12-membered ring containing compound, 3.18d. The amide hydrogen comes closer to 
the diarylamine nitrogen lone pair, suggesting the presence of a transannular hydrogen bond of 
varying strength depending of the ring size. Finally, the downfield shift of the N–H signal in the 1H NMR 
spectra of the products 3.18a–d in CDCl3 from 6.46 to 9.10 ppm when increasing ring size also 
indicated a progressively stronger hydrogen bond.  
DMSO titration 
The intramolecular hydrogen bonding can be measured by 1H NMR by titration with DMSO-d6 of a 
solution of the compound in a non-hydrogen-bonding solvent such as CDCl3. Increasing the proportion 
of DMSO-d6 in solution leads to interaction between the sulfoxide oxygen and the amide hydrogen, 
resulting in deshielding. However, if the amide is already participating in an intramolecular hydrogen 
bonding network, little to no change should be observed. 1H NMR spectra of solutions of 10 to 15 mg 
of compounds 3.18a–d in 600 μL CDCl3 were recorded after addition of known amounts of DMSO-d6 
(%v/v) (Figure 27). The chemical shift of the N–H signal was monitored, and its variation was plotted 
against the percentage of DMSO-d6 in the sample. 
 
Figure 27 : DMSO-d6 titration of CDCl3 solutions of A: 3.18a, B: 3.18b, C: 3.18c and D: 3.18d. The amide proton is denoted 
by a blue spot. 
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Addition of DMSO-d6 resulted in a strong downfield shift of the N–H signal of 9-membered 3.18a and 
10-membered 3.18b (Figure 3-10), while hardly any shift was observed for 11-membered compound 
3.18c, and compound 3.18d exhibited a moderate upfield shift. 
 
Figure 28 : N–H chemical shift drift of compounds 3.18a–d. Green: 3.18a ; Orange: 3.18b ; Purple: 3.18c ; Yellow: 3.18d 
These results suggest the persistence of an intramolecular hydrogen bond in solution in some 
medium-ring products. Flexible substrates 3.18c and 3.18d, in which the 1H NMR N–H signal was not 
affected by DMSO-d6, are involved in a strong intramolecular hydrogen bond. However, the smaller 
rings in 3.18a and 3.18b are presumably too strained to accommodate this bond, as seen by the large 
dihedral angle of the amide group and the long distance between the amide hydrogen and the 
diarylamine nitrogen lone pair. 
Quantifying rates of enantiomerisation by dynamic 1H NMR 
1 H NMR of all medium-ring products 3.18 showed diastereotopic signals for the methylenes chain 
within the ring, indicating that these heterocycles adopt chiral ground states whose enantiomeric 
conformations interconvert slowly on the NMR time scale. Variable-temperature 1H NMR analysis of 
compounds 3.18b and 3.18c in DMSO-d6 resulted in significant broadening of these signals  
(Figure 29). But without coalescence even at 100 °C, calculation of the barrier to enantiomerisation by 





Figure 29 : 1H NMR (500 MHz) at 100 °C of A: 3.18b and C: 3.18c and zoom in the alkyl region of C: 3.18b and D: 3.18c 
respectively, in DMSO-d6. 
However, rate constants of enantiomerisation of compounds 3.18a–d and 3.18l could be determined 
by variable-temperature exchange spectroscopy (VT-EXSY), a 2D-NOE experiment commonly used to 
calculate rates of conformational exchange. After excitation by a 1H pulse, the sample is left to stand 
for a given mixing time before the 1H spectrum is recorded. During this period, if interconversion 
occurs, a cross peak will appear for the exchanging protons (Figure 30), proportional to the mixing 
time and the rate of exchange (in this case, the rate of exchange equals the rate of enantiomerisation). 
For two equally populated sites with equal spin-lattice relaxation times, the rate of exchange k is 
calculated using the Equation 7, with τ the mixing time and r the ratio of the cross-peak integral to the 







Equation 7: Calculation of the rate of exchange by 1H EXSY NMR 
For unequal populations such as in diastereomerisation processes, the equation becomes too complex 
to manually calculate rates of interconversion. For convenience, the software EXSYCalc by MestreLab 






Figure 30 : A: 1H NMR EXSY spectrum of 3.18a in toluene-d8 at 60 °C, 0.5 s mixing time, B: 2.5-4.0 ppm region. 
Once suitable temperature T and mixing time were identified, two additional experiments at (T + 5) K 
and (T – 5) K were performed, and the rate of enantiomerisation at room temperature was calculated 
from an Eyring plot (Equation 4, Table 23).  
Entry Compound Solvent kenant (s–1) ΔG‡298 K (kJ mol–1) t1/2 298 K (s–1) 
1 
3.18a 
DMSO-d6/CD3OD – – – 
2 Toluene-d8 8.2 10-3 84.9 42.3 
3 
3.18b 
DMSO-d6 7.4 10-3 85.1 47.1 
4 CDCl3 1..9 10-3 88.5 180.9 
5 
3.18c 
DMSO-d6 1.6 10-1 77.5 2.1 
6 CDCl3 1.6 10-2 83.2 21.6 
7 
3.18d 
CD3OD 30.7 63.5 0.011 
8 CDCl3 3.6 69.2 0.076 
9 
3.18l 
DMSO-d6 4.9 10-2 80.4 7.0 
10 CDCl3 3.1 10-2 81.6 11.1 
Table 23 : Barrier to enantiomerisation of 3.18a–d and 3.18l in different solvents 
Large differences in the rate of enantiomerisation arise when varying the medium-ring size. In CDCl3, 
the largest 12-membered ring 3.18d inverts almost 300 times faster than 11-membered 3.18c and 
more than 2000 times faster than 10-membered 3.18b. This trend changes with 3.18a, which 
presumably inverts faster than 3.18b because of the raised ground-state energy of its non-planar 
amide. Interestingly, 11-membered rings 3.18l and its analogue 3.18c have similar rate of 
enantiomerisation despite the increase in steric hindrance provided by the ortho-methyl group in 





For 3.18b–d, a strong dependence on the nature of the solvent can be seen on the rates to 
enantiomerisation. The rate of enantiomerisation of 11-membered compound 3.18c is decreased 
tenfold in the hydrogen bond donating solvent DMSO-d6, suggesting that the intramolecular hydrogen 
bond governs the conformational stability of this compounds. These dramatic changes in the rate of 
conformational exchange correlate with the data on hydrogen-bonding deduced from the crystal 
structures and DMSO titrations, as barriers to enantiomerisation in larger rings 3.18c and 3.18d are 
more sensitive to solvent polarity than in 3.18b. Unfortunately, cross-peak overlaps precluded the 
calculation of barriers to rotation of compound 3.18a in polar solvents. 
Compound 3.18a also showed another interesting feature in its 1H NMR spectrum. Another set of 
peaks, attributed to a minor diastereoisomeric conformers, can be observed in different ratios when 
varying the solvent. This minor conformer is less abundant in toluene-d8 or CDCl3 (ratios of 7:1 and 
6:1, respectively) than in CD3OD and DMSO-d6 (ratios of 3:1), indicating that the major conformer of 
418a is somewhat stabilised by an intramolecular hydrogen bond.  
Similarly, 3.18l exists as a pair of inequivalent conformers in ratios of 3:1 in toluene-d8, 4:1 in CDCl3 
and 10:1 in CD3OD, displaying contrasting behaviour to 3.18a. This trend shows that while the ortho-
methyl group forces a perpendicular twist in the amide of 3.18l, the central 11-membered ring is 
flexible enough to allow an intramolecular hydrogen bond in solution, although only in the minor 
conformer. While the existence of two pairs of diastereoiomeric conformers in 3.18a may be due to 
the rigidity of the scaffold, an ortho-methyl group in the flexible 11-membered scaffold probably slows 
down bond rotation of the adjacent amide. 
Quantifying rates of diastereoisomerisation by dynamic 1H NMR  
These interconverting diastereomers presumably exist from the two relative orientations of the  
CAr–C(O) and CAr–N bonds highlighted in Scheme 57. The crystal structure of compound 3.18l  
(Figure 25) shows that the amide moiety is almost perpendicular to the aryl ring, and a strong 
downfield shift of the N–H signal from 6.12 ppm in CDCl3 to 7.84 ppm in DMSO-d6 indicates that the 




Scheme 57 : Interconversion of 3.18l 
However, 3.18l possesses a similar barrier to enantiomerisation as compound 3.18c (Table 23). As 
cross-peaks for the interconversion of the diastereomeric conformers of 3.18a and 3.18l were visible 
by EXSY NMR, their barriers to diastereomerisation in solvents with both low and high dielectric 
constant were calculated at room temperature (Table 24). As exchange is no longer equally populated, 
a short mixing time was selected to obtain an EXSY spectrum containing no cross-peaks, and 
diastereomeric ratio at slow exchange was compared to cross-peaks as fast exchange at various 
temperature. The data obtained from EXSYCalc was used to calculate the free energies of activation 
at room temperature using an Eyring plot (Equation 4). 
Compd. Solvent kmin-maj (s–1)a kmaj-min (s–1)b ΔG‡min-maj (kJ mol–1)a ΔG‡maj-min (kJ mol–1)b 
3.18a CD3OD 3.3 10-1 9.9 10-2 75.8 78.7 
 Toluene-d8 3.1 10-1 3.5 10-2 75.9 81.3 
3.18l DMSO-d6 5.2 10-4 2.2 10-4 91.7 93.9 
 CDCl3 8.3 10-3 2.6 10-3 84.8 87.8 
Rates and free energies of activation for conversion of the a minor-to-major and b major-to-minor conformer, at 298 K. 
Table 24 : Barrier to diastereomerisation of 3.18a and 3.18l in different solvents 
While the rate at which the minor diastereomer of 3.18a converts to the major shows no dependence 
on the solvent, the rate of the reverse process is three times as fast in CD3OD. This suggests that the 
major conformer can accommodate some interaction by intramolecular hydrogen bonding, stabilising 
its ground state. 
Unlike compound 3.18a, diastereomerisation of compound 3.18l is slower than enantiomerisation by 
a factor of almost four in CDCl3 and up to a hundred in DMSO-d6. The rates of diastereomerisation of 
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compound 3.18l (unlike those of enantiomerisation) are strongly solvent-dependent. Both the 
forward and reverse rate of enantiomerisation is decreased in DMSO-d6 relative to CDCl3. Because of 
the perpendicularity of the amide group and the adjacent aryl ring, diastereomerisation must occur 
through a transition state in which these two groups are coplanar. In non-hydrogen bonding solvents 
such as CDCl3, the barrier to diastereomerisation is lowered by a transient transannular hydrogen 
bond between the amide proton and the diarylamine nitrogen. In DMSO-d6, the relative energy of 
transition state becomes less favourable, decreasing the rate of enantiomerisation by more than a 
tenfold. Unlike compound 3.18a, for which enantiomerisation occurs through stepwise bond rotation, 
these higher values for diastereomerisation compared to enantiomerisation suggest that racemisation 
of compound 3.18l occurs through geared rotation of the CAr–C(O) and the CAr–N bonds. 
III.3. Conclusion 
Smiles ring expansion of anthranilamides provides medium-size heterocyclic analogues of 
pharmacologically-relevant dibenzodiazepinones. The use of microwave heating reduces reaction 
time to 15 minutes and decreases the amount of side-product formed, delivering 9- to 12-membered 
rings in good to excellent yields. The reaction tolerates sensitive functional groups and can be 
performed in a renewable solvent. However, no heterocycle could be introduced in the scaffold, and 
the nucleophilic nitrogen substitution could not be altered. Furthermore, post-functionalisation of the 
motif was difficult due to either underactivity or decomposition in a reverse-Smiles ring contraction. 
The product thus formed possess a transannular hydrogen bond resulting in ‘hidden hydrophilicity’ 
properties. Ring size or steric hindrance close to the amide group can modulate the strength of this 
hydrogen bond to control the stereodynamic properties of the medium-sized heterocycles, making 
this class of compounds a versatile tool of drug development. Furthermore, conformational 
diastereomers were observed in smaller structures or with bulky substituents. Two different 




























IV.1. Introduction  
Careful ligand design in transition metal-mediated catalysis can ameliorate the performance of a 
catalytic system by improving the activity of a complex, resulting in higher turnover number or lower 
catalyst loading.[183] Catalyst stability and selectivity, however, should not be impaired. Pincer ligands 
are tridentate ligands with a well-defined bonding to the metal centre, discovered by Shaw et al. more 
than forty years ago.[184] Their donors occupy adjacent binding sites in a metal centre, with a 
preference for a meridional geometry.[185] Compounds such as 4.1 (Figure 31),[184] comprising of an 
aryl carbanion flanked by two side arms bearing soft donors, are a common class of pincer ligands. 
These compounds are termed PCP in reference to the three chelating atoms. The strong σ metal-
carbon bond, together with the structural rigidity brought to the structure by the chelating side arms 
make these complexes particularly stable, as dissociation of the metal and further decomposition of 
the complex is reduced.[186] Hence, while these complexes can react with external ligands to catalyse 
various reactions, coordination of the ligand is retained even at high temperatures. This results in 
better performances in reactions requiring notoriously harsh conditions in which catalyst stability 
might be compromised, such as Heck couplings or alkane dehydrogenation.[187] 
 
Figure 31: Some selected phosphine-based pincer ligands[183] 
Variation of the nature of the donor atoms leads to modification of the properties of the pincer 
complex. PNP ligands, with a central amine donor, are much stronger σ-bond donors than PCP ligands, 
leading to a weaker trans influence on the free binding site of the metal.[186] The nitrogen atom can be 
neutral in the case of pyridines,[188] or anionic for dialkyl[189] and diarylamines.[190,191] The conjugated 
system in 4.1, 4.2 and 4.4 allows dearomatisation of the pincer complex by delocalisation, meaning 
these compounds can participate in redox reactions.[192] The hard amine-based donor, together with 
the soft phosphine donors, allow PNP ligands to bind both hard (early) and soft (late) transition metal 
centres.[183] Phosphine donors are not the only functionalities which can be introduced on the 
wingtips, and the catalytic properties of the metal centre can be fine-tuned by modification of these 
moieties. Design alteration of the ligand permits versatility in the modification of the electronic 
properties of the complexes and of the σ-bond donation ability of the chelating groups, as well as 
adjustment of the local steric demand.[193]  
91 
 
IV.1.1. Diarylamines as pincer ligands 
Problems arise from the use of amido ligand 4.3; the high flexibility of the scaffold allows rapid 
association/dissociation of the phosphine groups to the metal centre and exchange between a mer 
and fac arrangement, leading to poor definition of the complex.[191] Furthermore, the β-hydrogens 
makes the ligand more prone to decomposition at high temperatures. To overcome these issues, 
diarylamine PNP ligand 4.4 was independently introduced by Mayer, Kaska,[190] and Liang.[191] This 
novel scaffold confers rigidity to the planar complex, with the sp2 nitrogen π-donating electrons to the 
aromatic system.[191] 
Bisphosphines such as 4.4 were the first diarylamines reported as pincer ligands and are probably the 
most studied. Complexes of these substrates with transition metals have been observed for group 8 
(Ru[194] and Fe[195]), group 9 (Rh,[196] Ir,[197] and Co[195]), and group 10 elements (Ni,[191] Pd,[198] and Pt[199]), 
but also with main group elements such as P(III).[200] Unusual alkylidene complexes of group 4 
elements such as Hf,[201] Ti[202] or Zr[203] (Schrock carbenes) can be prepared with these ligands. The 
particular reactivity of these complexes was demonstrated by Mindiola.[202,204] In pyridine, titanium 
alkylidene 4.5 extrudes neopentane to generate a transient titanium alkylidyne which reacts with 
pyridine by ring opening metathesis (Scheme 58). Treatment of metallaazabicycle 4.6 with a silyl 
monochloride results in denitrogenation and formation of tert-butyl benzene by insertion of the 
corresponding olefin group. 
 
Scheme 58: Ring opening metathesis of pyridine by a diarylamine-based titanium alkylidyne[204] 
Despite thorough investigation of diarylamine-based PNP complexes, only a few catalytic applications 
have been described thus far. The cationic, PNP-supported iridium complex 4.8 is a precatalyst for the 
hydrosilylation of alkenes[205] and ketones[206] (Scheme 59). The addition to the alkene occurs with full 
anti-Markovnikov selectivity by direct insertion of a Si−H bond, in an analogous manner to that in 
hydroboration. The authors also suggest that the complete regioselectivity is owed to the large steric 
demand of the complex.[197] The reactivity of complex 4.8 is also unique for the hydrosilylation of 
ketones as this reaction usually require high oxidation states and coordination numbers at the iridium 
centre.[206] This can be attributed to both a Lewis acidic silylene ligand and a Lewis base amido nitrogen 




Scheme 59: Hydrosilylation of alkenes and ketones by a PNP supported iridium complex[205,206] 
The superior stability and activity of pincer ligands was demonstrated by Liang and co-workers with 
diarylamine based PNP palladium ligand 4.9 in the Heck reaction of styrene with aryl iodides and aryl 
bromides (Scheme 60).[207] The high activity of this complex allowed the use of catalyst loadings as low 
as 0.2 mol ppm in the synthesis of 1,2-diphenylethene, with catalyst turn-over number (TON) as high 
as 4,500,000 – one of the highest reported to date.[208] 
 
Scheme 60: Heck reaction using sub-ppm level of pincer complex[207] 
Nickel complexes of PNP ligands have been used in the cross-coupling of alkyl and aryl halides with 
Grignard reagents (Kumada coupling). The reaction, catalysed by nickel-pincer complexes, proceeded 
at ambient temperature, preventing decomposition of the catalyst.[209] The particular strength of the 
pincer complex is the absence of β-hydrogen elimination in the reaction conditions, which was 
kinetically allowed but thermodynamically disfavoured, allowing the coupling of saturated 
substrates.[210] However, while PNP ligands catalyse the cross coupling of aryl Grignard reagents with 
aryl iodides in excellent yield, the use of alkyl Grignard reagents leads to a significant formation of 
homocoupling by-products.[211] Investigation of the reaction mechanism suggested the existence of a 
Ni(III)/Ni(IV) redox cycle.[212] Stabilisation of the highly reactive Ni(IV) intermediate was thought to be 
improved by replacement of the phosphine wingtips with harder donors. Diarylamines are also redox 
active, non-innocent ligands, providing access to otherwise unstable oxidation states at the metal 
centre.[212] Following this concept, a NNN nickel pincer complex coined Nickamine by Hu and co-
workers, was developed and found to be particularly active for the Kumada reaction.[213,214]  
Replacing phosphine donors with dimethylamino groups proved to be beneficial for the development 
of a highly tolerant Kumada coupling, even on substrates containing β-hydrogens (Scheme 61). The 
coupling of non-activated alkyl halides with alkyl Grignard reagents occurred at low temperature and 
in short reaction time,[214] while the use of aryl Grignard reagents necessitated the use of an additive 
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and warming the reaction mixture to room temperature.[213] The reaction tolerated a large variety of 
functional groups, even those which are prone to side reaction with the highly nucleophilic and basic 
Grignard reagents. Functionalized aryl and heteroaryl Grignard reagents were also tolerated, a feature 
which previously necessitated cross coupling with organozinc, boron, or silicon compounds, most of 
which to be prepared from the related Grignard reagent.[215] 
 
Scheme 61: A NNN nickel pincer complex active for the Kumada reaction[213,214] 
The marked activity of Nickamine was also demonstrated in the coupling of alkyl halides with terminal 
alkynes[216] (Sonogashira coupling) as well as with alkynyl Grignard reagents,[217] and for the alkylation 
of heterocyclic C–H bonds with alkyl halides.[218] A diarylamine precatalyst 4.10, analogous to 
Nickamine, was also found to be active in the highly selective, anti-Markovnikov hydrosilylation of 
gem alkenes (Scheme 62).[219] 
 
Scheme 62: A NNN nickel pincer complex active for the hydrosilylation of alkenes[219] 
IV.1.2. Diarylamine pincer ligands in asymmetric catalysis 
The side arms of pincer complexes are not free to rotate.[193] This means that substituents on sp3 atoms 
in the vicinity of the wingtips will be projected into geometrically defined quadrants, offering a well-
defined conformation at the catalytic centre.[192] Many approaches have used other classes of pincer 
compounds to introduce enantiodifferentiation by incorporating chirality in the bridging units,[220] 
namely P-stereogenic compounds[221] or pendant chiral units.[222] However, only one class of 
diarylamine-based chiral pincer ligands have emerged so far, using chiral oxazoline side arms as two 
flanking lone-pair donors (BOPA).[223] Conveniently, BOPA derivatives can be easily assembled by 
Buchwald–Hartwig coupling,[224] or modular synthesis can be performed from the corresponding 
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carboxylic acid by amide coupling with an amino alcohol, followed by zinc-promoted cyclisation to 
obtain a vast collection of BOPA derivatives with various chiral groups.[225] 
Zinc complexes of BOPA ligands have been widely applied in the asymmetric Friedel–Craft alkylation 
of heterocycles with Michael acceptors such as nitroalkenes. The Du group reported the highly 
enantioselective alkylation of pyrroles,[226] indoles,[227] and 2-methoxyfurans,[222] and developed a 
reusable catalyst supported on dendrimers.[228] The Guiry group developed a highly enantioselective 
one-pot Friedel–Craft alkylation/Michael addition of functionalised indoles with nitroalkenes en route 
to ergoline derivatives (Scheme 63), obtaining heterocyclic structure 4.11 containing three contiguous 
chiral centres in perfect diastereocontrol and enantioselectivity.[229]  
 
Scheme 63: Highly enantioselective one-pot Friedel–Craft alkylation/Michael addition of indoles[229] 
BOPA ligands have been used for asymmetric catalysis using a variety of transition metal centres as 
catalysts. The enantioselective hydrosilylation of ketones was performed using either iron or cobalt 
complexes with BOPA ligands, providing enantioenriched secondary benzyl alcohol after work-up.[230] 
The Ward group used BOPA ligands in the calcium-catalysed enantioselective hydroamination of 
amino-olefins. While the enantiomeric excesses reported were moderate, BOPA ligands provided a 
significantly higher degree of selectivity compared to other reported calcium systems.[231] Guiry et al. 
disclosed a chromium(III)-catalysed homoallenylation of aldehydes (also known as the Nozaki–
Hiyama–Kishi reaction) proceeding in excellent regio- and enantioselectivity, using a diarylamine-
chromium complex.[232] Interestingly, the use of a pincer ligand improved the regioselectivity 
compared to TMEDA. 
IV.1.3. Twisted conformation in pincer ligands 
It has largely been accepted that the particular stability and activity of pincer ligands is due to the 
rigidity of their backbone, forming a tightly bound complex with the metal centre and preventing 
ligand dissociation.[185] However, the planarity associated with pincer ligands can sometimes be 
plagued with poor solubility.[233] Examples involving a twisted conformation in diarylamine-based 
pincer ligands have been scarce. In fact, to the best of our knowledge, only one C2-symmetric 
diarylamine ligand has been reported by Ozerov et al.[234] Building on the superior results of tied pincer 
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ligands 4.13 over diarylamine 4.14 in the rhodium-catalysed dimerization of alkynes,[235] the authors 
tested the effect of steric constraint over a non-fused scaffold (Table 25). 
 
Entry Catalyst T (°C) t (h) Conversion Ratio A:B:C 
1 4.13 (0.5 mol%) 100 7 98% 2:98:0 
2 4.14 (0.5 mol%) 100 120 85% 2:98:0 
3 4.15 (1.0 mol%) 80 70 74% 2:73:25 
Table 25: Influence of conformation of PNP pincer ligands on alkyne dimerization 
Unfortunately, this hypothesis did not prove to be valid. While tied ligand 4.13 provides full conversion 
to a single E alkene product in a short reaction time, 4.15 is as sluggish as 4.14. The authors showed 
that, using 4.15, a similar degree of conversion could be achieved in a shorter reaction time versus 
4.14, albeit with double the catalyst loading. But 4.15 suffers from poor selectivity, as oligomers C 
arise from the formation and further reactivity of gem alkene A. 
Crabtree et al. designed CNC ligand 4.16 which supports a methylene linker between the NHC side 
arms and the pyridine core (Scheme 64).[233] As a consequence of the fused ring/metallacycle system, 
the methylene bridges sit outside of the plane while the ligands still tightly bind palladium(II) in a 
square-planar fashion. The resulting ligand is chiral, rapidly interconverting, with a barrier to 
interconversion ΔG≠278 K = 52.9 kJ mol–1 in CDCl3.[233] The interconversion was reported to take place 
through a stepwise mechanism where no planar transition state was found.[236] As compound 4.16 
was still extremely active for the Heck coupling of aryl chlorides, achieving full conversion using only 
0.2 mol% of catalyst, the authors demonstrated that planarity is not necessary in the design of pincer 




Scheme 64: Interconversion of a fluxional pincer complex 
Compound 4.16 forms two six-membered palladacycles, more likely to be fluxional due to their higher 
flexibility, but others also described pyridine-based PNP ligands of which a twisted, chiral iridium 
complex forms two fused, rapidly interconverting puckered 5-membered metallacycles.[237] Similarly, 
compound 4.17 is a highly twisted pincer complex forming two fused 7-membered metallacycles.[238] 
Complex 4.17 was highly active for the Suzuki-Miyaura coupling of sterically hindered aryl chlorides 
under mild conditions.[238] 
Hence, this lack of prerequisite for planarity of pincer ligands supports investigation of axial chirality 
in the scaffolds. No work has been reported on stable, atropisomeric axially chiral in pincer ligands 
and their application to asymmetric catalysis.  
 
IV.2. Results and discussion 
IV.2.1. Aim 
Based on the results presented in Chapter 2, it is now known that large steric hindrance can produce 
conformationally stable, axially chiral diarylamines. Induction of enantioselectivity with diarylamine-
based pincer ligands has only been performed using pendant oxazolines as a chiral unit for 
enantiodifferentiation. Axial chirality in diarylamines has been overlooked thus far and understanding 
the conformational properties of such ligands in transition metal-complexes may provide insight into 
ligand design. As Crabtree et al. proved that twisted geometry in the ligand is not detrimental for 
activity (see section IV.1.3.), the potential for introducing a stable chirogenic axis in the core scaffold 
of pincer ligands should be addressed. Diarylamines have been used in several reactions yielding 
chiral, racemic products which have the potential to be made enantioselectively using axially chiral 
ligands. 
Hence, bulky ortho-functional groups necessary for the design of pincer ligands, such as 
diarylphosphines or tertiary amines, can be used to promote conformational stability in novel, axially 
chiral ligands. The introduction of such bulky groups can be achieved by the use of a handle for post-
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functionalisation (or before, provided the steric bulk and electronic effects do not hinder the 
reactivity), or potentially by introducing the functional groups directly in the substrates, using 
methods which are less sensitive to steric hindrance, such as SNAr reactions. 
IV.2.2. Towards axially chiral PNP ligands 
Phosphine-based PNP diarylamines ligands have been widely applied to reactions with a potential for 
asymmetric induction (see section IV.1.1.). Inspired by Tilley’s phosphines for the hydrosilylation of 
ketones[206] and alkenes,[205] we decided to focus on the synthesis of congested diarylamines bearing 
pendant phosphine groups at one ortho-position of each ring. Following the results on the 
conformational stability of diarylamine presented in Chapter 2, tetra-ortho-substituted diarylamines 
4.18 and 4.19 were chosen as model substrates for the introduction of axial chirality in diarylamines 
pincer ligands, as a para-substituent would simplify their synthesis (Figure 32). The first design 
focussed on the use of triarylphosphines ligands, but diversification of the targets was also considered.  
 
Figure 32: Targets for the preparation of axially chiral PNP ligands 
Three different routes were envisaged to prepare these targets. Di-ortho-bromination of diarylamines 
prepared by Buchwald–Hartwig coupling would allow the introduction of phosphine moieties on 4.20 
by a lithiation/electrophilic quench sequence (Scheme 65).[190]  
 
Scheme 65: Retrosynthetic routes towards axially chiral PNP ligands 
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The advantage of this route is the possibility of a late-stage addition of a wide range of phosphines on 
a specific scaffold to tune the properties of the resulting ligand, but also the relatively modest steric 
demand of the substrate prior to halogenation, simplifying the preparation of the starting materials. 
Furthermore, other reactivities of the C–Br bond can be envisaged, such as transition metal-catalysed 
reactions, to access different type of side-arm functionalities.[239] 
Nucleophilic aromatic substitution reactions were also envisaged for the synthesis of diarylamines 
4.18 and 4.19. Synthesis of ortho-fluorinated diarylamines 4.21 would allow the late-stage 
introduction of phosphine ligands by microwave-assisted SNAr with a secondary phosphine.[240] 
Alternatively, a phosphine oxide moiety can be used as an electron-withdrawing group allowing the 
formation of a C–N bond by SNAr of 4.22 on anisole 4.23.[241] 
By ortho-bromination 
The bromination of diarylamines with subsequent functionalisation by lithium–halogen exchange and 
electrophilic quench is a key strategy for the introduction of functional groups in XNX pincers.[242] 
These ortho-brominated diarylamines can then be functionalised by various groups such as 
phosphines,[190] but diversity can be obtained from the same substrate as electrophilic species allowing 
the introduction of moieties such as alcohols[243] or heteroaryls.[239] 
As tert-butyl groups showed a significant impact of the barrier to rotation of atropisomeric 
diarylamines, compound 4.25 was prepared as an intermediate in the synthesis of 4.18 (Scheme 66). 
To facilitate the synthesis, both para-positions were substituted with tert-butyl groups. 
Synthesis of bis(2,4-di-tert-butylphenyl)amine 4.25 was achieved by a convergent palladium-catalysed 
cross-coupling reaction between aryl bromide 4.24 and the previously made aniline 1.25, both 
synthesised from the same precursor according to reported procedures (Scheme 66). Pleasingly, the 
Buchwald–Hartwig coupling of sterically hindered 4.24 and 1.25 on gram scale proceeded in good 
yield with the commercially available phosphine ligand 1,1′-bis(diphenylphosphino)ferrocene (dppf). 
 
Scheme 66: Synthesis of bis(2,4-di-tert-butylphenyl)amine 4.25 
Diarylamine 4.25 was then subjected to different brominating conditions (Table 26). Although 
different sources of bromine were tested (Br2, N-bromosuccinimide, or copper(II) bromide), none of 
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the conditions yielded the desired product 4.18. Instead, carbazole 4.27 was formed by oxidative 
cyclisation in most cases.  
 
Entry Conditions Results 
1 Br2 (2.0 eq.), DCM/MeOH (1:1, 0.1 M), rt, 2 h 4.26 (18%) + 4.27 (55%) 
2 Br2 (2.0 eq.), P(O)(OMe)3 (0.1 M), 70 °C, 3 h Complex mixture 
3 CuBr2 (2.5 eq.), Oxone (6.0 eq.), MeCN (0.1 M), rt, 16 h 4.27 (60%) 
4 NBS (2.1 eq.), acetone (0.1 M), 0 °C, 3 h Complex mixture  
Table 26: Ortho-bromination of 4.25 
The use of bromine in a mixture of DCM and methanol reacted quickly to form a mixture of the product 
of mono-bromination 4.26 and carbazole 4.27. Exchanging the solvent to trimethyl phosphate made 
the reaction more sluggish and heating the mixture to 70 °C gave a complex mixture of products which 
could not be separated. While using copper(II) bromide only gave the carbazole product, reaction with 
NBS in acetone produced a mixture of inseparable by-product including the mono-brominated 
derivative. In a short communication, Polivin et al. described the oxidative cyclisation of 
diphenylamine with bromine (Scheme 67).[244] 
 
Scheme 67: Cyclisation of diphenylamine with bromine[244] 
Others have reported the formation of carbazoles from the cyclisation of N-centred radicals,[245] but 
also from radical dianions via radical-nucleophilic aromatic substitution,[246] as well as from diphenyl 
nitrenium ions through Nazarov-like cyclisation, followed by rearomatisation.[247] However, no 
example of formation of such reactive species with a halogen source has been reported to date. This 
reaction likely proceeds because of the proximity of the reactive positions due to steric repulsion of 
the two ortho-tert-butyl groups. To overcome this issue, the nature of the diarylamine nitrogen was 
altered. Reaction of diarylamine 4.26 in acetic acid with bromine was attempted in order to prevent 
the nitrogen lone pair to participate in the diarylamines π system.[248] Unfortunately, compound 4.25 
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was not soluble in the reaction conditions, and thus bromination of tertiary diarylamines was explored 
as an alternative approach. 
Installation of a third substituent on the nitrogen of compound 4.25 was tried with various groups 
(Table 27).  
 
Entry Conditions R Results 
1 
Boc2O (1.5 eq.), DMAP (0.1 eq.), THF (0.05 M), 
rt, 24 h 
Boc No conversion 
2 (4-Cl)PhNCO (3.0 eq.), DCM (0.5 M), rt, 18 h 4-chlorophenyl urea No conversion 
3 
NaH (1.1 eq.), THF (0.1 M), 0 °C, 30 min 
then AcCl (1.1 eq.), rt, 18 h 
Ac No conversion 
4 AcCl (0.1 M), reflux, 18 h Ac No conversion 
5 
NaH (4.0 eq.), THF (0.2 M), reflux, 30 min  
then MeI (3.5 eq.), reflux, 18 h 
CH3 No conversion 
6 
NaH (4.0 eq.), THF (0.2 M), reflux, 30 min  
then SO2(OMe)2 (3.5 eq.), reflux, 18 h 
CH3 No conversion 
7 
n-BuLi (1.2 eq.), THF (0.2 M), 0 °C, 15 min  
then MeI (1.5 eq.), rt, 1 h 
CH3 Complex mixture 
8 
LiHMDS (1.2 eq.), THF (0.5 M), rt, 15 min  
then MeI (1.5 eq.), rt, 1 h 
CH3 Complex mixture 
Table 27: Attempts at the N-methylation of the unprotected nitrogen of 4.25 
Highly reactive electrophiles such as anhydrides or isocyanates did not yield any reaction with 4.25 at 
room temperature (entries 1 and 2). Amide bond formation using neat acetyl chloride at high 
temperature over a prolonged time did not give any conversion, and neither did using a strong base 
to promote addition (entries 3 and 4). As diarylamine 4.25 proved to be unreactive towards highly 
electrophilic reagents, even in relatively drastic conditions, efforts were concentrated on a smaller 
electrophile by N-methylation. However, this strategy did not prove successful either. Deprotonation 
by sodium hydride, followed by methylation over extended periods of time with both methyl iodide 
and dimethyl sulfate also failed (entries 5 and 6). Only the use of stronger organometallic bases such 
as butyl lithium and lithium hexamethyldisilazide, afforded conversion, though providing complex, 
inseparable mixtures of by-products (entries 7 and 8).  
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Alternatively, the Buchwald–Hartwig coupling of protected aniline substrates was envisaged. N-
acylated and N-methylated 2,4-di-tert-butylaniline 1.25 derivatives 4.28 and 4.29 were made in 
quantitative and moderate yield, respectively (Scheme 68).  
 
Scheme 68: Functionalisation of 1.25 
These two compounds were subjected to the typical coupling conditions for the synthesis of 
diarylamines 1.28a–z with PNp3 (see Chapter 2), as well as with the commercially available ligand dppf. 
Unfortunately, both procedures failed to yield any product for the substrates tested. The total lack of 
reactivity of bis(2,4-di-tert-butylphenyl)amine 4.25 derivatives necessitated the selection of 
alternative targets. As naphthalene rings provide high barriers to rotation (see Chapter 1), the ortho-
bromination strategy was brought towards dinaphthylamine 4.19 (Scheme 69). 
 
Scheme 69: Diarylamines 5.19 by ortho-bromination of 4.30 
Aniline 4.32 was prepared in good yield by a one-pot sequence comprising the copper-catalysed 
Ullman amination of aryl bromide 4.31 with formamide and subsequent hydrolysis (Scheme 70).  
 
Scheme 70: Synthesis of aniline 4.32 
Buchwald–Hartwig coupling of aniline 4.32 with aryl bromide 4.31 using a commercially available 
phosphine ligand then afforded diarylamine 4.30 in excellent yield (Scheme 71). Bis-brominated 
diarylamine 4.19 was then obtained in excellent yield by treatment of its precursor 4.30 with bromine 
in acetic acid. Interestingly, bromination of 4.30 under oxidative conditions, using stoichiometric 
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amounts of copper(II) bromide and Oxone in acetonitrile led to decomposition, while using NBS in 
acetone afforded only the mono-brominated analogue in low yield, possibly because of the poor 
solubility of the product.  
 
Scheme 71: Synthesis of 4.19 
The insolubility of compound 4.19 turned out to be a general feature hampering further work. 
Consequently, investigation of its barrier to enantiomerisation by chiral HPLC analysis proved to be 
difficult. While enantiomerical peaks of compound 4.19 could be observed, its poor solubility in the 
mobile phase, together with poor resolution, precluded any investigation of its barrier to rotation. 
Furthermore, any attempt to functionalise diarylamine 4.19 failed, as lithium–halogen exchange led 
to decomposition and both copper- and palladium-catalysed reactions did not yield any conversion. 
By functionalisation of ortho-fluorinated diarylamines 
As the use of di-ortho-brominated diarylamines seemed to be a tedious strategy for the introduction 
of phosphines at the desired position, another approach in which a functional handle is introduced at 
the beginning of the synthesis was attempted. Due to its low steric hindrance and high reactivity 
towards SNAr, the fluorine atom seemed to be an ideal functional handle. Previous work by Seipel et 
al. demonstrated that the introduction of a phosphine group at the ortho-position of a diarylamine 
was possible in excellent yield by a microwave-assisted displacement of a fluorine atom by SNAr  
(Scheme 72).[240] Due to its substitution pattern, ligand 4.33 is not chiral but the good reactivity of this 
relatively hindered molecule was encouraging. 
 
Scheme 72: Previous work on microwave-assisted SNAr[240] 
As with earlier attempts at ortho-bromination, it was decided to attempt the functionalisation of 
bis(2,4-di-tert-butyl-6-fluorophenyl)amine 4.34 (Scheme 73). Again, for ease of synthesis of the 
substrates, the target molecule 4.34 contained tert-butyl groups at the para-positions. The coupling 




Scheme 73: Retrosynthetic analysis of compound 4.34 
The precursor to both starting materials, 1,3-di-tert-butyl-5-fluorobenzene 4.38, was prepared using 
a procedure described by Ritter et al. (Scheme 74).[249] Boronic acid 4.37 was prepared in excellent 
yield by addition of the related Grignard reagent to trimethylborate, followed by hydrolysis.[250] 
Fluorination of its silver complex with Selectfluor then allowed isolation of 4.38 in good yield, which 
was converted to aryl bromide 4.36a in excellent yield using bromine. 
 
Scheme 74: Synthesis of compound 4.36a 
The synthesis of aryl iodide 4.36b was also envisaged following reported procedures for the iodination 
of similar compounds (Table 28). Electrophilic iodination with NIS did not yield any conversion. Forcing 
conditions using a concentrated solution of iodine in DMF at high temperature for 4 days was not 
effective either. Generation of the aryl anion and quench with molecular iodine gave a mixture of 
starting material as well as multiple compounds which could not be separated. 
 
Entry Conditions Results 
1 N-Iodosuccinimide (1.0 eq.), MeCN (0.5 M), rt, 48 h No conversion 
2 I2 (1.2 eq.), K3PO4 (1.25 eq.), DMF (1 M), 130 °C, 96 h No conversion 
3 
n-BuLi (1.1 eq.), THF (0.5 M), –78°C, 1.5 h 
then I2 (1.1 eq.), rt, 16 h 
Complex mixture 
Table 28: Iodination of 4.38 
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A series of test reactions for the Buchwald–Hartwig of 4.36a were performed with 2-tert-butylaniline, 
a substrate with a similar steric demand as 4.35 (Table 29). The coupling was first attempted using the 
standard conditions used before for the synthesis of sterically hindered diarylamines, both with dppf 
and PNp3 (entries 1 and 2).  
 
Entry Ligand Concentration T (°C) t (h) Results 
1 dppf 0.65 M 80 40 No conversion 
2 PNp3 0.65 M 80 40 No conversion 
5 dppf 1 M 100 168 No conversion 
6 PNp3 1 M 100 168 No conversion 
7 DPEPhos 1 M 100 168 No conversion 
8a DPEPhos 1.6 M 100b 2.5 No conversion 
9a,c DPEPhos 1.6 M 100b 2.5 No conversion 
a Pd(OAc)2 (2mol%), DPEPhos (2.4mol%), NaOtBu (1.2 eq.), THF (1.6 M) b Reaction performed under microwave heating 
c Aniline used as ArNH2 
Table 29: Attempt at coupling fluorinated aryl bromide 4.36a with 2-tert-butylaniline 
Similar conditions were used at higher temperature and in higher concentration for up to seven days. 
DPEPhos was also screened as a potential ligand, but neither condition gave any conversion (entries 
3, 4, and 5). As these gave no conversion, the conditions reported by Seipel were tried,[240] using both 
2-tert-butylaniline and aniline (entries 8 and 9), without success. Starting material 4.36a was always 
distinguishable in the 1H NMR spectrum of the  crude mixture, indicating that oxidative addition does 
not happen. The lack of reactivity in this step prevents any subsequent coupling from occurring.  
As fluorinated aryls yielded no reaction, this strategy appeared unfeasible. Results in Chapter 1 
showed the limits of transition metal-catalysed reactions, and the synthesis of these hindered 
functionalised substrates may be not possible by this route. However, the potential for making C–N 
bonds in hindered diarylamines by nucleophilic aromatic substitution reactions was still encouraging.  
Using the phosphine oxide moiety as an activating group for SNAr  
Whilst investigating the preparation of atropisomeric ligands based on N,N-dialkylanilines, the Mino 
group prepared various congested, ortho-phosphorylated anilines by addition of lithiated amines on 
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electron-poor anisoles (Scheme 75).[13,91,251,252] The reaction, first disclosed by Hattori et al.,[241] 
ingenuously uses the inherent electron-deficiency of the phosphine oxide group to improve the 
reactivity of the substrate towards SNAr, allowing the facile formation of novel P,N-ligands.  
 
Scheme 75: Synthesis of P,N-ligand by SNAr[252]  
The authors were able to prepare configurationally stable, axially chiral ligands capable of inducing 
enantioselectivity in the palladium catalysed allylic alkylation by addition of a hindered alkyl amines 
on anisole derivatives. Considering the high steric demand of the substrates made this way, the high 
reactivity of ortho-phosphorylated anisole derivatives towards SNAr reactions was employed for the 
synthesis of atropisomeric diarylamines. Thus, formation of target diarylamine 4.40 by SNAr reaction 
of aniline 4.42 and anisole 4.41 was envisaged (Scheme 76). Conveniently, aniline 4.42 can be accessed 
from anisole 4.41 by SNAr reaction of a protected amine followed by deprotection. 
 
Scheme 76: Retrosynthetic analysis of 4.40 
First, commercially available, hindered anilines were reacted with 4.41 following the procedure 
reported by Hattori et al.[13,241] As anilines were less reactive than alkylamines, the coupling was 
performed at reflux. While the reaction was sluggish with aniline, high steric demand at the ortho-
positions was tolerated, as diarylamines 4.43b and 4.43c were synthesised in moderate yield (Scheme 
77). Interestingly, augmentation of the steric demand around the reactive atom by a second 




Scheme 77: Synthesis of ortho-phosphorylated diarylamines by SNAr 
The 13C NMR spectra of 4.43b and 4.43c showed diastereotopic signals for the phosphine phenyl 
carbons, indicating a chiral ground state slowly interconverting over the NMR timescale at room 
temperature. Enantiomers of 4.43b could be resolved by chiral HPLC and displayed an interconversion 
plateau typical of dynamic compound with a half-life to enantiomerisation of a few minutes (Figure 
33). VT-HPLC was used to calculate the barrier to rotation and compound 4.43b was atropisomer with 
a barrier to interconversion of 93.3 kJ mol–1. Unfortunately, enantiomers of 4.43c could not be 
separated. 
 
Figure 33: Portion of the HPLC chromatogram of 4.43b at 40 °C 
With these promising results, aniline 4.42 was prepared in excellent yield by addition of lithiated 
benzylamine on anisole 4.41 at room temperature, followed by hydrogenation of 4.44 (Scheme 78).
 
Scheme 78: Synthesis of aniline 4.42 
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Coupling of 4.41 and 4.42 was then attempted using the modified procedure (Table 30, entry 1). 
However, as no reaction occurred, the use of different additives and bases was explored. Following a 
report by Bappert et al.,[253] TMEDA was used as an additive, as well as DMPU. However, neither of 
these gave any conversion (Entries 2 and 3). As Hellwinkel et al.[254] suggested the chelation of a lithium 
cation between the deprotonated nitrogen and the phosphine oxide oxygen, we speculated that the 
anion was stabilised and thus less reactive. However, exchanging the counter-cation using KHMDS or 
NaHMDS as a base did not affect any change (entries 4 and 5). Using 18-crown-6 as a chelator of the 
potassium cation to increase the nucleophilicity of the aniline yielded some conversion, although a 
complex mixture of side products was obtained after work-up, mostly containing starting materials 
4.41 and 4.42 (entry 6). This lower reactivity of aniline is probably due to the electron-withdrawing 
phosphine oxide, making the nitrogen a poor nucleophile. 
 
Entry Base Additive t1 (h) t2 (h) Results 
1 n-BuLi – 1 16 No conversion 
2 n-BuLi TMEDA (1.0 eq.) 1 16 No conversion 
3 n-BuLi DMPU (1.1 eq.), 1 16 No conversion 
4 KHMDS – 1 4 No conversion 
5 NaHMDS – 1 4 No conversion 
6 KHMDS 18-crown-6 (2.0 eq.) 0.25 16 Complex mixture 
Bases: n-BuLi (1.4 M in hexanes), NaHMDS and KHMDS (1.0 M in THF). 
Table 30: Coupling of 4.41 and 4.42 
As the strategies applied to the synthesis of axially chiral, diarylamine-based PNP ligands proved 
unsuccessful, our efforts focussed on diarylamines with different functionalities at the ortho-position. 
IV.2.3. Towards an axially chiral analogue of Nickamine 
Nickamine and its analogues have been used as catalysts for reaction with potential for asymmetry, 
such as alkene hydrosilylation (see IV.1.1.). Hence, an axially chiral analogue of Nickamine was 
designed by adding bulky groups at the two free ortho-positions (Scheme 79, diarylamine 4.45). In this 
case, it was possible to design the synthesis of 4.45 so that the electronic properties of both substrates 
are optimised towards SNAr. Electron-deficient anisole 4.47, with a functional handle for the formation 
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of the desired dimethylamino group, was synthesised by methylation of the corresponding phenol 
according to reported protocols.[255] 
 
Scheme 79: An axially chiral analogue of Nickamine 
Musk 4.48, obtained in three steps from 3,5-di-tert-butylaniline,[58] was used to produce aniline 4.49 
in excellent yield by bismethylation of the aniline, followed by reduction of the nitro group  
(Scheme 80). Aniline 4.46, already containing the dimethylamino moiety as an electron-donating 
group, was thought to be activated for SNAr. 
 
Scheme 80: Synthesis of aniline 4.46 
Different coupling conditions were tested, using microwave irradiation or by stepwise deprotonation 
of aniline 4.46 followed by addition to anisole 4.47 (Table 31). Forcing conditions reaching high 
temperature by microwave irradiation, with a strong base, did not afford any conversion (entry 1). 
Treatment of the starting materials with a procedure similar to the one of Bappert et al.[253] only 
afforded decomposition of 4.46 as well as full recovery of 4.47 (entry 2). Changing the base and the 
counter-cation did not affect the reaction either, as both starting materials were recovered  
(entries 3 and 4). Thus, as SNAr reactions did not yield any encouraging results, it was decided at this 





Entry Conditions Results 
1a KOtBu (1.1 eq.), DMF (0.6 M), 170 °C, 2 h No conversion 
2 
4.46, n-BuLi (2.0 eq.), TMEDA (4.0 eq.), THF (0.5 M), –20 °C, 30 min 




4.46, KHMDS (2.0 eq.), TMEDA (4.0 eq.), THF (0.5 M), –20 °C, 30 min 
then 4.47, 60 °C, 16 h 
No conversion 
4 
4.46, NaHMDS (2.0 eq.), TMEDA (4.0 eq.), THF (0.5 M), –20 °C, 30 min 
then 4.47, 60 °C, 16 h 
No conversion 
a Reaction performed under microwave heating 
Table 31: Coupling of 4.46 and 4.47 
IV.2.4. Towards an axially chiral NNN ligand by Smiles rearrangement 
The Smiles rearrangement of anthranilamides presented in Chapter 2 is particularly tolerant of steric 
demand on the product, and the reaction yields diarylamines with a pendant amide group. While only 
N-methyl amides were investigated (as well as the ring expansion of heterocycles in Chapter 3), we 
sought to exploit the possibility of using the resulting amide moiety as a functional handle to prepare 
axially chiral diarylamine pincer ligands. Diarylamines bearing pendant oxazoline rings at their ortho-
positions had been used successfully in asymmetric catalysis, with the source of chirality coming from 
the functionalised oxazolines (see IV.1.2.). We therefore aimed at preparing diarylamine 4.50, with 
achiral oxazoline rings (Scheme 81). This compound was expected to be made from diarylamine 4.41 
by protecting group removal and cyclisation of the resulting alcohol to produce the corresponding 
oxazoline, followed by hydrogenolysis of the benzyl group. This diarylamine would be the product of 
the Smiles rearrangement of anthranilamide 4.52. While the large steric demand of the product and 
the unknown reactivity of the amide side chain were identified as key challenges to overcome, we 
thought that the inherent electron-deficiency of the migrating ring would favour rearrangement. 
Finally, building blocks 4.53 and 4.54 were expected to react to form anthranilamide 4.52 in a similar 




Scheme 81: Retrosynthetic analysis of diarylamine 4.48. PG = Protecting group. 
Isatoic anhydride 4.53 is known,[256] and alkylation of ortho-cyano naphthylamine 4.55[257] was 
attempted with 2-ethyloxy chains with various protecting groups (Table 32). 
 
Entry R Conditions Results 
1a H HOCH2CH2OTf (10 eq.), Et3N (1.5 eq.), neat, 150 °C, 24 h No conversion 
2a H 
Ethylene glycol (10 eq.), Pd/C (10mol% Pd), ZnO (3.0 eq.) 
H2O (0.15 M), 150 °C, 24 h 
No conversion 
3 Bn 
Benzyloxy acetaldehyde (1.5 eq.), THF (0.5 M), rt, 72 h then 




MOMOCH2CH2Br (1.0 eq.), Et3N (1.0 eq.),  
toluene (0.5 M), reflux, 48 h 
No conversion 
5b MOM 
MOMOCH2CH2Br (2.0 eq.), K3PO4 (2.0 eq.),  
toluene (0.5 M), 150 °C, 4 h 
No conversion 
6b MOM 
MOMOCH2CH2Br (2.0 eq.), K3PO4 (2.0 eq.),  
DMF (0.5 M), 150 °C, 4 h 
Decomposition 
7 MOM 
MOMOCH2CH2Br (2.0 eq.), NaH (1.1 eq.),  
THF (0.5 M), rt, 72 h 
No conversion 
a Reaction performed in a sealed vial b Reaction performed under microwave irradiation b Diethyl 1,4-dihydro-2,6-dimethyl-
3,5-pyridinedicarboxylate 
Table 32: Alkylation of naphthylamine 4.55 
111 
 
Attempted substitution of an alkyl triflate,[258] neat, at high temperature did not yield any conversion 
(entry 1). A hydrogen borrowing reaction was tried with ethylene glycol and a heterogenous catalyst 
mixture of palladium on charcoal and ZnO2 in water[259] left the substrate untouched (entry 2). 
Reductive amination using a mild reducing agent[260] led to the formation of multiple compounds by 
reaction of the nitrile group (entry 3). While substitution of a protected alkyl bromide using a weak 
base and high temperature did not yield any product in toluene (entries 4 and 5), the use of DMF as a 
solvent led to a side reaction on the substrate, presumably by reaction with the solvent at high 
temperature (entry 6). Upon exchanging solvent to THF and using a strong organometallic base, no 
reaction was observed either (entry 7). 
The nitrile group ortho to the reactive nitrogen likely decreases its nucleophilicity. To overcome this, 
oxazoline-substituted naphthylamine 4.56 was made in good yield by treating naphthylamine 4.55 
with ethanolamine and zinc(II) chloride in chlorobenzene. Its N-alkylation was expected to be easier 
due to the lower electron-withdrawing character of the oxazoline group compared to that of the nitrile 
moiety (Table 33).[261] 
 
Entry Conditions Results 
1 
BnOCH2CHO (2.0 eq.), AcOH (2.0 eq.),  
NaHB(OAc)3 (2.0 eq.), DCE (0.5 M), rt, 3 h 
No conversion 
2a 
BnOCH2CH2I (2.0 eq.), KOtBu (1.5 eq.),  
THF (0.3 M), 150 °C, 18 h 
Decomposition 
3a 
BnOCH2CH2I (2.0 eq.), n-BuLib (1.1 eq.),  
THF (0.3 M), 150 °C, 18 h 
No conversion 
4a 
BnOCH2CH2I (2.0 eq.), NaHMDSc (1.1 eq.),  
THF (0.3 M), 150 °C, 18 h 
No conversion 
5a 
BnOCH2CH2I (2.0 eq.), DIPEA (1.5 eq.),  
toluene (0.5 M), 150 °C, 18 h 
No conversion 
6a 
BnOCH2CH2I (2.0 eq.), DIPEA (1.5 eq.),  
DMF (0.5 M), 150 °C, 4 h 
20 % 
7a 
BnOCH2CH2I (2.0 eq.), DIPEA (1.5 eq.),  
DMAc (0.5 M), 150 °C, 4 h 
14 % 
a Reaction performed under microwave irradiation b n-BuLi (1.4 M in hexanes) c NaHMDS (1.0 M in THF) 
Table 33: Alkylation of naphthylamine 4.56 
112 
 
Reductive amination using sodium borohydride led to the reduction of the oxazoline ring. Decreasing 
the reactivity of the reducing agent, using sodium triacetoxyborohydride, though, did not give any 
conversion (entry 1). As using alkyl bromides gave no alkylation, benzyloxyethyl iodide was prepared 
from benzyl-protected ethylene glycol using the imidazole-triphenylphosphine-iodine reagent.[262,263] 
Screening of strong bases in THF under microwave heating was not successful, as potassium tert-
butoxide gave decomposition of the substrates (entry 2) and n-butyl lithium and sodium 
hexamethyldisilazide did not yield any conversion (entries 3 and 4). When using a weaker base, no 
reaction was observed in toluene, but N-alkylated aniline 4.57 was isolated in poor yield after reaction 
in DMF (entries 5 and 6). In order to avoid side reaction with DMF, dimethyl acetamide was used as a 
solvent, although the product was isolated in lower yield (entry 7). As this yield could not be improved, 
the project was halted. 
IV.3. Conclusion 
The synthesis of sterically congested diarylamines containing functional group at the ortho-positions 
was attempted in order to study the impact of axial chirality in pincer ligands. Unfortunately, attempts 
to introduce steric demand large enough to obtain atropisomerism in the desired diarylamines were 
hampered by a lack of reactivity. 
Introduction of ortho-functional groups by reaction on ortho-halogenated diarylamines was 
unsuccessful due to either side reaction preventing the bromination step or because of the poor 
solubility of the brominated diarylamines. When ortho-tert-butyl groups were present, an unexpected 
intramolecular cyclisation to the corresponding carbazole proceeded cleanly. 
Attempts to introduce fluorine atoms at the ortho-positions were hampered by the lack of reactivity 
of the substrate towards Buchwald–Hartwig coupling. Further attempts to increase reactivity by 
iodination failed. While the SNAr reaction of anilines on ortho-phosphorylated anisole derivative 4.41 
proceeded with good tolerance towards steric hindrance, the lack of reactivity of the electron-
deficient phosphorylated aniline 4.42 prevented the synthesis of axially chiral PNP ligands. 
Attempts to synthesise NNN ligands were not successful either. The synthesis of a Nickamine analogue 
4.45 by SNAr reaction of substrates seemingly matched the right electronic properties yet did not 
provide any observable reaction. Finally, the strategic use of the newly discovered Smiles 
rearrangement of anthranilamides could not be applied in this case as the synthesis of the required 















The ‘rise of the molecular machines’ over the past decades has demonstrated the fundamental role 
of dynamic stereochemistry in the recent applications of chemical sciences.[264] The “original” 
molecular machines, namely biomacromolecules, have implications in a large number of biological 
processes – from carrying substrates around cells to synthesising or replicating proteins – and have 
inspired chemists to design synthetic, functional compounds.[265] The use of chirality to control 
molecular motion in technomimetic systems such as molecular gears,[266] propellers,[267] or motors[268] 
results in translocation of the classical, Euclidean chirality to topological chirality.[269] These advances 
are further eased by the advances of analytical techniques such as dynamic NMR analysis or dynamic 
chromatography (see Chapter 1). 
Molecules hold information in their stereochemistry.[270] For example, the stereochemical 
environment of a chiral catalyst defines the asymmetric induction in a reaction.[271] Organic molecules 
rarely have a single, fixed topology, as they usually fluctuate into stereoisomeric structures, depending 
on the relative stability of the resulting conformers.[269] Many non-covalent interactions define the 
distribution of conformations in a given compound due to adjacent functionalities. The steric and 
electronic interactions between these functionalities can be exploited to reduce the conformational 
space available, thus controlling the overall topology of a molecule.[270] To this end, stereochemical 
relays and thermodynamic control can permit the remote control of conformation over nanometre 
distances.[272] 
V.1.1. Effect of dipolar interactions on conformation 
Non-covalent interactions form the basis of conformational preferences from natural peptides to 
synthetic foldamers.[273] Hydrogen bonding, dipolar and electrostatic interactions are used to generate 
a conformational bias in foldamers, producing structural complexity through weak interactions.[274] 
The rigidity and large dipole moment of carbonyl groups make them attractive for conformation-
imparting interactions.[274] 
Electrostatic and dipolar interactions are commonly found in the solid-state structure of organic 
molecules, particularly planar, aromatic compounds.[275] In crystallographic databases, three types of 
dipole-dipole interactions have been observed: the antiparallel arrangement of carbonyls is the most 
prevalent, but parallel orientations and orthogonal relationships also exist.[275] In solution, provided a 
scaffold offers enough flexibility to give rise to multiple conformations, dipole-dipole interactions of 
carbonyl groups result in a parallel, coplanar, ‘head-to-tail’ orientation, or an antiparallel, stacked 
arrangement of the carbonyls, termed ‘side-by-side’.[276,277] This feature was used by various groups 
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to bias the conformational equilibrium of organic molecules, allowing the use of dipolar repulsion for 
conformational control,[278] ligand sensing[279] or remotely relaying chiral information.[272] 
Coplanar alignment of the dipoles 
In an effort to address the challenge of targeting protein-protein interactions, the Hamilton group 
developed non-peptidic molecules mimicking protein β-strands.[278,280,281] β-sheets are an extended 
secondary structure of proteins where hydrogen bonding aligns the amide groups in a plane  
(Scheme 82, top left corner).[282] Each amino acid residue is projected perpendicularly to the amide 
backbone, alternating between protruding upwards and downwards. The synthetic design of Hamilton 
and co-workers alternates meta-substituted (hetero)aryl rings with imidazolidinones mimicking only 
one side of the strand (i.e. the i, i+2, i+4… residues).[278,280,281] First-generation compound 5.1, 
connected through meta-substituted phenyl group, exist as a mixture of conformers that rapidly 
interconverted at room temperature because of unrestricted rotation around the C–N bond, giving 
rise to different relative arrangements of the imidazolidinone carbonyls.[280] While conformer C was 
highly unfavourable due to dipolar repulsion, conformers A and B were energetically equivalent. 
However, only conformer A is reminiscent of the geometry of β-strands, and foldamer 5.1 would 
presumably bind protein targets in an energy-demanding, induced-fit manner. 
 
Scheme 82: Using dipoles repulsion to control the conformation of a β-strand mimic 
Conformational homogeneity was achieved by linking the imidazolidinone rings through a  
2,6-disubstituted pyridine in compound 5.2. Dipolar repulsion between the carbonyl groups and the 
pyridine linkers was found to be the determinant for attaining a single conformation of oligomer 5.2 
in solution (Scheme 82).[278] This dipole obviates the existence of conformer B, as conformer A 
accounted for 98% of the populated conformations in 5.2. The solid-state structure of 5.2 was 
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approximately planar, with side-chains projecting on one face, and with inter-residue distances similar 
to those in peptidic β-strands. The conformation in solution was confirmed by NOESY analysis. 
Stacked alignment of the dipoles 
The work by Hamilton and co-workers on β-strand mimetic 5.1 demonstrated that dipolar repulsion 
across an arene rapidly decreases with distance if the dipoles are coplanar. Bulky tertiary benzamides 
are known to adopt an approximately perpendicular arrangement with regards to the arene.[113] 
Clayden et al. have found that meta-related bis-benzamides such as 5.3 existed almost exclusively as 
the anti conformer in CDCl3, where both amides pointed in opposite directions, perpendicular to the 
plane of the aryl ring, because of dipolar repulsion (Figure 34).[283] When a third dipole was introduced 
as in ester 5.4, predomination of the syn conformer (relative the two amido carbonyls) was observed 
as a result of the relay of the relative anti orientation of the adjacent dipoles. 
 
Figure 34: The influence of steric and electronic parameters on the conformation of meta-related amides in CDCl3 
When steric hindrance between the two dipoles was introduced as in compound 5.5, the syn 
conformation was favoured, albeit with poorer control than in 5.3, indicating that dipolar repulsion 
played a major role in the conformer distribution.  
Kawai et al. built on this phenomenon to design a sensor for catecholamines such as adrenaline.[279] 
Hydrindacene 5.6 possessed a pair of chiral axes due to the perpendicular arrangement of the 
benzamide groups (Scheme 83). Following a similar trend to compound 5.3, bis-benzamide 5.6 existed 
as a pair of syn and anti conformers, slowly interconverting relative to the NMR timescale. In CDCl3, 
dipolar repulsion induced a conformational bias towards the anti conformer, as observed by 1H NMR 
analysis. However, portion-wise addition of an excess of adrenaline resulted in the progressive 
disappearance of the peaks corresponding to the anti conformer in the 1H NMR spectrum of 5.6 to 
achieve full conversion to the syn conformer. In this orientation, compound 5.6 adopted an ideal 
conformation for binding adrenaline by forming hydrogen bonds between the amide carbonyls and 
the phenol and ammonium cation. The esters also augmented the interaction by providing additional 




Scheme 83: Adrenaline-induced conformational change in a bis-benzamide 
Signal transduction was created by modulation of the conformation of the receptor by an external 
effector molecule, making this compound mimetic of adrenergic receptors. However, 1H NMR analysis 
of this compound can become difficult due to the complexity of the spectra and/or partial overlap of 
the conformers signals, which results in the output being difficult to decipher. Furthermore, this 
design only gave an “on/off” signal for the presence or absence of a given analyte, and chirality was 
not sensed. These problems were addressed by the same group, using circular dichroism as a reporter 
of the guest chirality (Scheme 84).[284] The two chiral axes of compound 5.7 rapidly interconverted to 
form a mixture of anti and syn conformers, with a preference for the former. Upon complexation with 
the chiral diammonium salt, the syn conformation of 5.7 was favoured. Steric hindrance of the two 
stiff diphenylacetylene units rendered the molecule helical – and therefore chiral – with arms serving 
as a chromophore for the dynamic recognition of the absolute chirality of the analyte by circular 
dichroism. 
 
Scheme 84: Conformational changes for the determination of absolute confirguration of an ammonium salt 
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V.1.2. Remote control of conformation by dipolar repulsion 
Clayden et al. observed that the relative conformation of amides installed on a scaffold made of non-
rigidly interconnected aromatic rings such as 2,2’-disubstituted biphenyl 5.8 was biased. While the 
synthesis of 5.8 by introduction of the benzylic methyl groups by double ortho-lithiation solely 
produced the centrosymmetric syn conformer, thermal equilibration in toluene led to a mixture of 
stereoisomers in which the C2-symmetric anti compound predominated.[285] Despite the fast rotation 
of the CAr–CAr bond, the two dipoles interacted with each other, resulting in a preferred conformer due 
to dipolar repulsion. This communication could be extended to longer distances as in terphenyl 5.9. 
Chiral HPLC analysis showed that the single compound obtained after thermal equilibration was chiral 
and racemic, therefore adopting the conformation depicted in Figure 35 in which a C2 axis features in 
the central aromatic ring, perpendicular to its plane.  
 
Figure 35: Relay of conformation by dipolar repulsion in biphenyls and terphenyls (the red arrows denote the relative 
relationships used to describe the conformation) 
The same group demonstrated that the orientation of an axially chiral amide was sensitive to the local 
chiral environment.[286] By introduction of a chiral centre in the vicinity of one of the terminal amides, 
steric and electronic interactions reorientated the proximal dipole and set the absolute configuration 
of the related chiral axis (Scheme 85).[270] Consequently, the overall absolute configuration of a 
dynamic compound can be set by a single chiral centre. After formation of the enantiopure oxazolidine 
5.10 from (–)-ephedrine, one diastereoisomeric form was relayed along the scaffold to the terminal 
amide to form exclusively one enantiomer.[287] Upon treatment with phenylmagnesium bromide, 
formation of alcohol 5.11 occurred with excellent diastereoselectivity as governed by the orientation 
of the adjacent amide.[271] The stereoselective outcome of the Grignard addition hence came from the 





Scheme 85: 1,11-Relay of chirality in a terphenyl 
1,8-Xanthene dicarboxamides (Scheme 86, highlighted in blue) arrange their amide groups outside of 
the xanthene plane, creating two chiral axes.[288] The relative orientation of the amide groups 
originates from the steric demand of the nitrogen substituents, and a single C2-symmetric anti 
diastereomer was observed by 1H NMR analysis with diisopropyl amides.[288] Combining this 
conformational bias with their biphenyl relay, Clayden et al. were able to control the stereoselective 
outcome of the Grignard addition on the aldehyde moiety of 5.12, achieving full diastereocontrol by 
the remote relay of the configuration by a (–)-ephedrine-derived oxazolidine.[272] This “ultra-remote” 
control allowed the formation of a chiral centre by relaying chiral information along 22 bonds. This 
corresponded to a distance of approximately 2.5 nm, the order of thickness of a cell membrane. 
 
Scheme 86: 1,22-Relay of chirality in 1,8-xanthene dicarboxamides 
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V.1.3. C–N atropisomerism in anilides 
Various C–N atropisomers were presented in Chapter 1. While secondary amides usually exist 
predominantly as the less hindered E isomer, N,N-disubstituted amides exist as a mixture in a ratio 
greatly dependent on factors such as steric demand.[289,290] Steric demand forces the aryl ring to twist 
out of the plane of the amide, breaking conjugation. The E isomer is then favoured as it prevents 
unfavourable interactions between the lone pair of electrons of the oxygen lone pair and the aryl ring 
π-electrons.[26] Axial chirality arises at the CAr–N bond as a consequence of this twisting. Curran and 
co-workers have described atropisomeric anilides with a single ortho-tert-butyl group, such as in 
compound 5.14 (Figure 36).[26] N-aryl lactams such as 5.16 retained their conformation at room 
temperature, with a fixed amide bond geometry.[291] 5-Membered N-aryl lactams such as 5.17  were 
also found to be axially chiral at room temperature, albeit with a significantly lower barrier to 
rotation.[292] 
 
Figure 36: Selected atropisomeric anilides and their barrier to enantiomerisation 
Dipolar repulsion in 2,2’-bis-anilides 
Mazzanti et al. thoroughly studied the conformation of 2,2’-bis-anilides such as 5.18 (Scheme 87).[293] 
Although facile bond rotation allowed for the rapid interconversion of different stereoisomers at room 
temperature, apolar mixtures of chlorofluorocarbons gave a major conformer by 1H NMR analysis at 
cryogenic temperatures. This conformer was attributed to the formation of an intramolecular 
hydrogen bond (5.18A) and was also observed in the solid-state. However, above these temperatures, 
bis-anilide 5.18 exists as a mixture of two conformers in fast exchange, of which the major compound 
was C2-symmetric. Further computational work highlighted the existence of conformer 5.18B in which 
the amide groups were in conjugation with the aryl rings, allowing dipolar repulsion to dictate the 
conformation. When the steric demand around the CAr–CAr bond was increased, conformational 
flexibility was decreased and so compound 5.19 was observed as a single conformer resulting from 




Scheme 87: Dipolar repulsion in 2,2'-bis-anilides 
To gain insight into the influence of this intramolecular hydrogen bond on conformation, the authors 
prepared a tertiary analogue of 5.18 by methylation of the amide groups. However, the 1H NMR 
spectrum of the resulting compound became particularly complex. The hindered amides were 
expected to be disposed perpendicularly to the aryl rings, creating two stereogenic axes, in addition 
to E/Z isomerisation. Dynamic exchange between several conformers hence precluded detailed 
analysis. 
V.2. Results and Discussion 
V.2.1. Aim 
The use of dynamic molecules in relaying information over long distances has led to communication 
of chirality over nanometre distances in rigid, aromatic scaffolds. A major limitation for the 
development of a longer structures for the remote communication of chirality comes from problems 
arising from the tedious, work-intensive synthesis of the substrates and their poor solubility.[272,288,294] 
Furthermore, while dipolar interactions clearly play a major role in the relative orientation of the 
amides of compound 5.12, the great steric bulk of these groups is also critical in the high selectivity. 
New scaffolds purely based on dipolar repulsion are needed to gain a greater understanding of the 
requisites to develop efficient conformational relays with a high stereocontrol. 
Mazzanti et al. determined the various conformations of 2,2’-bis-anilides in solution, showing the 
potential for axially chiral amides to create conformational control by dipolar repulsion. The 
diphenylacetylene scaffold (Figure 37, in blue), offering a rigid structure over extended distances, is 
easily assembled by Sonogashira coupling.[295] In the design of functional groups for dipolar 
interactions, isoindolinones (Figure 37, in red) offer advantages such as planarity and rigidity, limiting 
the number of interconverting ground state conformations, while the inclusion of the amide nitrogen 
in a ring eliminates E/Z isomerisation. Bates et al. showed that N-aryl isoindolinones with a single 
functionality at the ortho-position adopt a chiral ground state at room temperature with barriers to 




Figure 37: Model for the long-distance dipolar repulsion of isoindolinones 
V.2.2. Dipoles repulsion in a meta-oligo(phenylacetylene) scaffold 
Conformational control by isoindolinones 
To probe the influence of dipolar repulsion in isoindolinones through a diphenyl acetylene scaffold, 
dimer 5.20 was designed (Scheme 88). The only two chiral axes reduces the number of possible 
conformations. While the ground state of the diphenyl acetylene core is expected to be planar and 
rapidly rotating, it was anticipated that dipolar repulsion and steric hindrance would force the amide 
ground out of the plane of the aryl ring, creating a bias towards one conformer (presumably with an 
anti relationship). 
 
Scheme 88: Model dimer 5.20 
To access isoindolinone 5.20, a two-step, one-pot procedure for the synthesis of N-aryl isoindolinones 
from the corresponding aniline with acyl chloride 5.21 (Scheme 89) was devised as a key step. 
Compound 5.21 was prepared in high yield on multigram scale according to a reported protocol.[296]  
 
Scheme 89: Preparation of 5.21 
Dianiline 5.22 was made in good yield by Sonogashira coupling of commercially available 2-iodoaniline 
and 2-ethylnyl aniline (Scheme 90). Model dimer 5.20 was then made in poor yield by amide bond 
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formation, followed by DBU-promoted intramolecular cyclisation to form the corresponding  
N-arylisoindolinone. 
 
Scheme 90: Synthesis of dimer 5.20 
Dimer 5.20 displayed a sharp singlet in its 1H NMR spectrum for the benzylic proton, implying that at 
room temperature, the ground state conformation of 5.20 adopts a planar, achiral conformation 
interconverting too rapidly to be observed on the NMR timescale. To slow down C–N bond rotation 
and enforce a chiral, three-dimensional geometry of the amide group at room temperature, additional 
steric hindrance near the C–N bond was necessary, and dimer 5.26 was designed (Scheme 91). Due to 
the low yield of the isoindolinone formation, compound 5.26 was made through a step-intensive route 
from 2-iodo-4,6-dimethyl aniline. Isoindolinone ring formation on this substrate allowed the 
preparation of anilide 5.23 in good yield and on large scale. Sonogashira coupling with trimethylsilyl 
(TMS) acetylene, followed by desilylation using potassium carbonate in methanol produced terminal 
alkyne 5.25 in excellent yield. Finally, cross-coupling with 5.23 afforded dimer 5.26. Although longer, 
this sequence was found to be more robust than the previous strategy used for 5.20. 
 
Scheme 91: Synthesis of dimer 5.26 
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The isoindolinone benzylic protons of 5.26 displayed sharp signals corresponding to AB systems in the 
1H NMR spectrum, characteristic of a chiral compound slowly interconverting on the NMR timescale 
(Figure 38). In CDCl3, splitting of most signals suggested the existence of a minor conformer. Crystals 
of 5.26 suitable for X-ray diffraction were grown by slow evaporation of a saturated solution of 5.26 
in toluene. The solid-state structure showed a near-perpendicular arrangement of the amide moiety 
with a torsion angle of 89.1°, while the diphenylacetylene core was approximately planar, as the 
average torsion angle was 4.7°. 
 
Figure 38: 1H NMR spectrum of 5.26 and zoom of the isoindolinone benzylic methylene region 
The conformer distribution was solvent-dependent (Table 34), as determined by the relative 
integration of well-resolved signals of each stereoisomer. From earlier work using bis-benzamides (see 
section V.1.2.), and from the solid-state structure of 5.26, it was assumed that the anti conformer was 
the major stereoisomer. In polar solvents such as DMSO-d6 and CD3CN, the proportion of minor 
conformer increased, with the major conformer being present only in a slight excess in DMSO-d6. The 
trend was similar, although less significant in CD3OD. Dipolar interactions with the solvent presumably 
decreased the intramolecular repulsion, stabilising the syn conformer. The largest ratio was in 
toluene-d8, where the amount of major conformer was fivefold larger than the minor.  
Solvent toluene-d8 CDCl3 DMSO-d6 CD3OD CD3CN 
Ratio (anti:syn)a 1:0.20 1:0.30 1:0.75 1:0.55 1:0.67 
a Determined by integration of the 1H NMR signals.  
Table 34: Conformer distribution of 5.26 in various solvents 
Dimer 5.26 exists as a pair of racemic, inequivalent stereoisomers. To gain insight into the kinetic 
parameters of conformer interconversion in 5.26, enantiomers of its starting material 5.24, bearing 




Figure 39: HPLC trace of 5.24 at 40 °C 
Above room temperature, substrate 5.24 displayed a plateau typical of an atropisomer with a low 
barrier to enantiomerisation. VT-HPLC, followed by Eyring analysis allowed the calculation of the 
barrier to rotation about the CAr–N bond of 5.24 (See Chapter 1). Anilide 5.24 was found to be an 
atropisomer with a barrier to enantiomerisation of 93.0 kJ mol–1 at room temperature, corresponding 
to a half-life of 19 minutes under these conditions. Hence, enough time had to be left for samples of 
compounds derived from 5.26 to allow them to thermally equilibrate. 
Towards stimuli-responsive dipolar repulsion 
Modification of the electron density of the N-aryl ring of dimer 5.26 was thought to have an impact 
on the electronic properties of the amide electronic properties, and hence lead to a change of the 
conformational bias. Furthermore, direct modification of the electronic properties of the scaffold 
would offer the possibility to switch conformer preference with an external stimulus. Para-substituted 
pyridines were thought to bring electronic modification and potential for a property switch by 
treatment with an appropriate acid. Model compound 5.30 was synthesised to test this hypothesis 
(Scheme 92). Isoindolinone formation on the iodinated DMAP derivative 5.27, though, performed in 
poor yield. While Sonogashira coupling with trimethylsilyl acetylene proceeded in good yield, the two 
steps deprotection/cross-coupling to form dimer 5.30 only provided trace amounts of products. 
Presumably, poor solubility of both the substrates and the product in the reaction solvents, together 





Scheme 92: Synthesis of dimer 5.30 
Nevertheless, sufficient material was isolated to observe the two conformers by 1H NMR, in a similar 
ratio to that of dimer 5.26. Treatment of pyridine 5.30 with five equivalents of trifluoroacetic acid and 
overnight equilibration of the sample at room temperature resulted in a modification of the conformer 
distribution (Table 35), with almost no preference for one stereoisomer over the other.  
Compound 5.26 5.30 [5.30·TFA2]2+ 
Ratio (anti/syn)a 1:0.30 1:0.40 1:0.90b 
a Determined by integration of the 1H signals in CDCl3 b After treatment of 5.30 with 5 equivalents of TFA 
Table 35 : Conformer ratio of 5.30 
Addition of trifluoroacetic acid to the solution to protonate the pyridine rings possibly changes the 
medium polarity. Furthermore, the various ionic species formed can interact with the amido carbonyl 
groups to disrupt intramolecular interactions and lead to no conformational preference. 
Conformational relay through a meta-oligo(phenylacetylene) scaffold 
While dimer 5.26 did not display exclusive conformational control, we focused our efforts on 
understanding the strength of the repulsive interaction between the amide dipoles over longer 
distances with trimer 5.35 (Scheme 93). Initial attempts to directly form the isoindolinone ring on 
aniline 5.31 did not yield any product, while using the same conditions to its dibrominated derivative 
led to decomposition of the amide intermediate after addition of DBU. As steric hindrance seemed to 
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impart reactivity for the synthesis of the starting materials, a step-intensive, iterative approach was 
attempted. 
 
Scheme 93 : Synthesis of trimer 5.35 
An isopropyl group was introduced at the para-position of 5.32 in the hope it would provide 
information on the compound symmetry, and hence be used to deduce its relative conformation. 
Mono-alkynylation of aniline 5.31 was performed following standard conditions forming aniline 5.32 
in poor yield. Isoindolinone formation was then used to obtain 5.33 in moderate yield. The use of a 
triisopropylsilyl (TIPS) protecting group was necessary, as formation of the isoindolinone ring on the 
TMS-protected analogue of 5.32 led to decomposition, with disappearance of the alkynyl peaks by  
13C NMR. Silyl-protected compound 5.33 was then coupled to terminal alkyne 5.25 in good yield, and 
a two steps deprotection/coupling allowed the isolation of trimer 5.35 in excellent yield. 
Analysis of trimer 5.35 proved to be difficult. The existence of three stereogenic axes gave rise to three 
diastereomeric compounds A, B and C, with a (syn, syn), (anti, anti), and (syn, anti) relative orientation 
respectively, as illustrated by the portion of the 1H NMR spectrum corresponding to the isoindolinone 




Figure 40: Portion of the 1H NMR spectrum of 5.35 used to determine the conformer distribution 
The conformer distribution of trimer 5.35 varied in different solvents, although with a general trend 
(Table 36). The relative conformation was deduced from the signal multiplicity of the 1H NMR signals 
for the benzylic protons as well as the number of signals for the carbonyl and the alkyne groups by  
13C NMR analysis. The 13C NMR spectrum of the minor conformer A displayed two carbonyl resonances 
in a 2:1 ratio and two alkynic resonances, showing a plane of symmetry. The same features were 
observed in the 13C NMR spectrum of conformer B, the major isomer in CDCl3 and toluene-d8. Its 1H 
NMR spectrum also unambiguously displayed one AB system and one singlet in a 2:1 ratio for the 
benzylic protons of the isoindolinone rings, also due to a plane of symmetry. Eventually, neither the 
1H nor 13C NMR spectra of isomer C displayed characteristics of a symmetrical molecule. Based on 
these pieces of evidence, and on the crystal structure of dimer 5.26, isomer C was assigned as the 
(anti, syn) conformer, while A and B were assigned as (syn, syn) and (anti, anti), respectively (Table 
36).  
  
Ratioa toluene-d8 CDCl3 CD3OD 
A (syn, syn) 4% 8% 16% 
B (anti, anti) 55% 49% 35% 
C (syn, anti) 41% 43% 49% 
a Determined by averaged integration of the carbonyl and alkyne 13C signals  
Table 36: Schematic representation of the conformer of 5.35 and their distribution in various solvents 
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The conformer distribution of trimer 5.35 showed the same trend in its solvent-dependence as for 
dimer 5.26, with a marginal amount of conformer A in toluene-d8 gradually increasing in CDCl3 and 
CD3OD, respectively. The stability of the preferred (anti, anti) conformer was also imparted by the 
change of solvent as it became minor compared to the doubly degenerate (syn, anti) conformer in 
CD3OD. This mixture of conformers resulted in a heterogeneously-defined scaffold, making it a poor 
candidate for relaying conformational changes over long distances.  
Influence of dipole moment on dipolar repulsion  
The ability of other dipoles to provide conformational control on a diphenylacetylene scaffold was 
investigated. Oxazolidinone 5.37, sulfonamide 5.38 and imidazolone 5.39 were selected as dipolar 
groups because of their potential access from the same aniline substrates. Their respective dipole 
moments were calculated using the software Spartan, after optimisation of their ground state 
geometry using the 6-31G* basis in a vacuum (Table 37).  
 
Compound 5.36 5.37 5.38 5.39 
Dipole moment (D) 4.26 5.71 6.19 3.93 
Table 37: Calculated dipole moment of selected molecules 
Oxazolidinone 5.37 and sulfonamide 5.38 were found to have the largest dipoles, and thus were 
expected to provide more control of the topology of the diphenylacetylene scaffold, while imidazolone 
5.39 had a slightly lower dipole than isoindolinone 5.36. These three moieties were deemed to be 
easily amenable to the synthesis of derivatives of dimer 5.26. Dianiline 5.42 was made in moderate 
yield by cross-coupling of the respective ortho-iodoaniline and ortho-ethynylaniline (Scheme 94). 
However, treatment of this compound with the substrates used for the formation of the sulfonamide, 





Scheme 94 : Synthesis of substrate 5.42 
Synthesis of imidazolone 5.44a was initially attempted by coupling 2-iodo-4,6-dimethylaniline with 
the carbamoyl chloride derived from 5.43, but gave no reaction. 2-Iodo-4,6-dimethyl aniline was then 
transformed into the corresponding isocyanate by treatment with triphosgene, followed by coupling 
with secondary amine 5.43 (Scheme 95). Eventually, deprotection of the acetal group under acidic 
conditions[297] yielded the cyclised product in excellent yield over three steps. 
 
Scheme 95: Synthesis of imidazolone substrate 5.44a 
Preparation of sulfonamide 5.44b was undertaken following a procedure by Ulven et al.  
(Scheme 96).[298] Condensation of 2-iodo-4,6-dimethylaniline with the corresponding sulfonyl chloride 
gave sulfonamide 5.45 in moderate yield. Cyclic compound 5.44b was obtained in good yield over two 
steps by reduction of the ester group of 5.45, followed by displacement of the resulting alcohol using 
phosphorus tribromide and spontaneous cyclisation. 
 
Scheme 96: Synthesis of sulfonamide substrate 5.44c 
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With a similar strategy to that employed for the formation of the isoindolinone ring, oxazolidinone 
5.44c was prepared by a one-pot sequence from 2-chloroethyl chloroformate involving carbamate 
formation followed by cyclisation to the corresponding oxazolidinone upon treatment with DBU to 
afford 5.44c in excellent yield (Scheme 97). 
 
Scheme 97: Synthesis of carbamate substrate 5.44c 
These three derivatives were then subjected to Sonogashira coupling with TMS-acetylene following 
the procedure previously described (Scheme 98). While imidazolone 5.44a and oxazolidinone 5.44c 
readily reacted to form the corresponding phenyl acetylene product, decomposition of sulfonamide 
5.44b occurred under the reaction conditions. 
 
Scheme 98: Synthesis of dimers with various dipoles 
Removal of the silyl protecting group followed by Sonogashira coupling with the corresponding aryl 
iodide did not yield any oxazolidinone dimer, and imidazolone 5.47a was only formed in poor yield. 
The 1H and 13C NMR spectra of dimer 5.47a displayed two stereoisomers, as demonstrated in the 
change of their distribution in various solvents. Unfortunately, compound 5.47a was poorly soluble in 
most organic solvents, limiting its applicability. Nonetheless, a similar trend to that of dimer 5.26 was 
observed relative to the solvent polarity (Table 38). While the major conformer of 5.47a was present 
in more than a twofold ratio in CDCl3 and toluene-d8, the distribution dropped significantly in CD3OD. 
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Solvent toluene-d8 CDCl3 CD3OD 
Ratio (anti/syn)a 1:0.40 1:0.45 1:0.70 
a Determined by integration of the 1H signals 
Table 38: Conformers distribution of 5.47a in various solvents 
Imidazolone dimer 5.47a offered poorer conformational control than its analogous compound 5.26, 
as expected from its lower dipole moment. This, together with the poor yields obtained during its 
synthesis and the poor solubility of compound 5.47a, shows that the N-aryl isoindolinone scaffold is 
the most versatile and easily amenable to a variety of conformational relays.  
V.2.2. Influence of distance on dipolar repulsion 
While dimer 5.26 does not exist as a single conformer, it is still remarkable, considering the distance 
by which these dipoles are separated, that conformation is remotely influenced solely by dipolar 
repulsion. We sought to gain more insight into the distance at which dipoles can be separated and still 
be ‘in communication’ by modification of the core scaffold. 
Biphenyl 5.50 did not bear an acetylene spacer, bringing the two dipoles in closer proximity (Scheme 
99). Symmetrical biphenyl 5.48 was prepared by palladium-catalysed decarboxylative homocoupling 
of the corresponding benzoic acid.[299] Reduction of the nitro groups followed by the key isoindolinone 
formation allowed the preparation of biphenyl 5.50 in good yield. 
 
Scheme 99: Synthesis of 2,2'-substituted biphenyl 5.50 
Despite the proximity of the two dipoles, two conformers were in an approximately 1:1 ratio in CD2Cl2 
as well as in toluene-d8 (Figure 41). Upon cooling to –80 °C in both solvents, line-broadening was 
followed by appearance of more resonances. The ratio of conformers reached 2:1 in both solvents at 
this temperature, and complexity arose from the isoindolinone benzylic protons signal. The splitting 
of each methyl signal into two resonances upon cooling suggested that the conformer did not hold a 
plane or centre of symmetry. Possibly, the CAr–CAr bond sits in a skewed arrangement of the two aryl 
rings of the biphenyl moiety, leading to asymmetry of the molecule regardless of the relative 
orientation of the amide groups. 
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Figure 41: VT 1H NMR spectrum (300 MHz) of 5.50 in CD2Cl2 (left) and toluene-d8 (right). 
Upon warming a sample of 5.50 in toluene-d8 up to 100 °C, one of the benzylic AB systems coalesced, 
together with line broadening of some aromatic signals (Figure 42). Interestingly, the two singlets of 
the methyl groups merged into one signal. 
 
Figure 42: VT 1H NMR spectrum (500 MHz) of 5.50 toluene-d8. 
Bringing the dipoles to close proximity did not result in the formation of a single conformer at room 
temperature. Instead, the complexity of the NMR spectra of biphenyl 5.50 arising from another slowly 






















slowly in solution. Snieckus et al. found the barrier to rotation around the CAr–CAr bond in similar 
biphenyls to be high enough to observe slow rotation on the NMR timescale at low temperature.[300] 
Hence, at cryogenic and room temperatures, multiple atropdiastereomers of different ground state 
energies arose from this third chiral axis. Upon warming to high temperature, coalescence of the 
benzylic proton resonances suggested that rapid rotation around the CAr–CAr bond revealed the 
existence of only one relative arrangement of the dipoles due to their close proximity. 
While shorter dipole-dipole distances lead to complete control of the relative orientation of the amide 
groups, the effect of separating dipoles to longer distances was investigated to gain insight into the 
maximum distance at which dipoles can still be in communication. Diyne 5.51 was made in 
quantitative yield by oxidative homocoupling of monomer 5.25 (Scheme 100). Crystals of 5.51 suitable 
for X-ray diffraction were grown by slow evaporation of a saturated solution of 5.51 in methanol. 
While no preferred relative orientation of the dipoles was observed in the solid-state, the amide 
groups still lay perpendicular to the central core, with torsion angles of 98.0 and 95.8°. Remarkably, 
despite the high degree of flexibility offered by the diyne moiety, the diphenylacetylene scaffold was 
still planar, with an average torsion angle of 1.2°. 
 
Scheme 100: Synthesis of diyne 5.51 
The 1H NMR spectrum of diyne 5.51 in CDCl3 showed a mixture of conformers in a 1:0.7 ratio. While 
this ratio showed that the difference in energy between the anti and syn stereoisomers was low, it 
was remarkable that despite the increased distance between the dipole (dN-N’ = 8.62 Å in the crystal 
structure), dipolar repulsion was still strong enough to impart a conformational bias. Larger distances 
were then covered by (hetero)aromatic groups connecting both monomer through an alkyne bond 
(Scheme 101). While compound 5.52 did not contain a polarised linker, carbazoles 5.54a–c and 
pyridine 5.53 would potentially contribute to the overall dipole moment of the molecule, and bias one 




Scheme 101: Introduction of various linkers between the dipoles 
In CDCl3, the aryl spacer in 5.52 yielded a 1:1 mixture of conformers (Table 39). Consequently, 
communication of information was prevented by the particularly long linker bridging the two dipoles, 
as the distance between both nitrogen atoms was calculated to be dN-N’ = 10.5 Å in the optimised 
geometry of 5.52 using semi-empirical methods in a vacuum (PM3). While only poor, the influence of 
the pyridine dipole 5.53 on conformer distribution was apparent in the 1H NMR spectrum. Despite the 
similar distance separating the dipoles compared to 5.52, one conformer was in slight excess. 
However, should the oligo(phenylacetylene) scaffold be planar, the pyridine and isoindolinone dipoles 
would be orthogonal. Possibly, the ground state conformation of the core scaffold is twisted, allowing 
alignment of the various dipoles to a certain extent. Unfortunately, attempts to optimise the geometry 
of 5.53 using computational methods did not provide any clear major conformer. Upon protonation 
of the pyridine using trifluoroacetic acid, a 1:1 mixture of conformers was obtained after equilibration. 
No significant change on the chemical shift and resonance of the signals in the 1H NMR spectrum of 
[5.53·TFA]+ supported the hypothesis of a similar overall conformation of the core scaffold. In water, 
the dipole moment of pyridinium ion is lower than that of pyridine,[301] and probably is not strong 
enough to participate in long-distance communication in [5.53·TFA]+. As with dimer 5.30, the equal 
energy of the two conformers might also be due to the change in solvent polarity, or to intermolecular 
interactions with the resulting ion pair. 
Compound 5.52 5.53 [5.53·TFA]+ a 5.54a 5.54b 5.54c 
Ratiob (anti/syn) 1:1c 1:0.85c 1:1c 1:0.35c 1:0.80c 1:0.90d 
a After treatment of 5.53 with 5 eq. of TFA. b In CDCl3. c Determined by 1H NMR analysis. d Determined by 13C NMR analysis.  
Table 39: Influence of the linker on conformer ratio 
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Although unsubstituted pyridine and carbazole have a similar dipole moment (respectively 2.15[302] 
and 2.09 D[303]), the proportion of the major conformer of dimer 5.54a was greater than that of 5.53. 
In fact, this ratio was close to the one for the shorter isoindolinone dimer 5.26, despite the longer 
linker between the two dipoles. However, N-substitution significantly changed the conformer 
distribution. N-alkylated carbazoles have a smaller dipole moment compared to carbazole itself (the 
dipole moment of N-ethyl carbazole, for example, is 1.74 D[303]), which led to a drop in the conformer 
ratio to reach a near-equivalent mixture. The effect was even more dramatic when a benzyl group was 
introduced on the carbazole nitrogen as in 5.54c. However, while the 1H NMR spectra of 5.54a and 
5.54b displayed sharp signals, significant line broadening was observed for 5.54c (Figure 43). 
               
Figure 43: The 1H NMR signals of the isoindolinone benzylic protons in carbazoles 5.54a, 5.54b and 5.54c respectively 
Upon cooling in CD2Cl2, the broad isoindolinone benzylic signals de-coalesced into two sets of peaks, 
in the same ratio as observed by 13C NMR at room temperature, indicating two conformers  
(Figure 44). One conformer possesses a plane of symmetry, as revealed by the existence of a single AB 
system for its isoindolinone benzylic protons, while the other pair of AB systems showed that the 
second conformer does not hold any element of symmetry. 
 
Figure 44: VT 1H NMR (300 MHz) of 5.54c in CD2Cl2, isoindolinone benzylic protons. 
Oligo(phenylacetylene)s linked by carbazole derivatives are known to form helices by π-stacking.[304] 
While the geometry of the amide group, forced out of the plane of the aryl group by the adjacent 







carbazole derivatives 5.54a–c were modelled using semi-empirical methods in a vacuum (PM3) with 
the software Spartan (Figure 45). While this level of theory was too basic to elucidate the energy 
difference of conformers arising from dipolar repulsion, this method gave insight towards the change 
in ground state conformation brought about by steric hindrance around the carbazole nitrogen atom.  
In carbazole dimer 5.54a, the core scaffold sits in an approximately planar, extended fashion, with the 
two aryl rings lying at 10.6° and 14.0° with respect to the carbazole group. The isoindolinones rings 
sat on the outer side of the carbazole moiety, perpendicular to the rest of the scaffold at 73.9°, with 
planar nitrogen atoms. Due to the long distance between the isoindolinone rings (dN–N’ = 11.6 Å), the 
dipole of the carbazole group must play a role in the communication of information as dN-–N’H = 6.5 Å 
on average, similar to that in the crystal of dimer 5.26. A similar structure was found after methylation 
of the carbazole, although twisting of the aryl rings through the alkyne bonds in 5.54b was more 
pronounced at 9.5° and 33.5°, resulting in longer inter-dipolar distances dN–N’ = 12.4 Å and  
dN–N’Me = 6.7 Å. Hence, an alkyl substituent not only reduced the dipole moment of the carbazole ring, 
disrupting the dipolar repulsion, but the added steric hindrance presumably hampered bond rotation 
and prevented the optimisation of an ideal conformation for dipolar interaction. 
   
Figure 45: Ground state conformations of 5.54a, 5.54b¸and 5.54c¸respectively, at the PM3 level of theory, in vacuum 
A more significant change in the ground state conformation was observed for 5.54c. Benzylation of 
the carbazole provided too much steric encumbrance about the side arms to allow coplanarity and 
conjugation through the alkyne. In this case, the aryl rings sit perpendicularly to the carbazole, at 
angles of 57.5° and 84.2°, giving rise to an anti arrangement of the N-aryl rings relative to the plane of 
the carbazole, slowly interconverting at the NMR timescale. The distance between the dipole and the 
carbazole was shortened, dN–N’Bn = 5.9 Å, but the substrate was not able to arrange for dipole alignment 
because of steric bulk. Furthermore, the inter-dipolar distance was too large (dN–N’ = 10.0 Å) to give 





Remote control of conformation was previously achieved by using both steric and electronic 
interactions to bias the relative conformation of dipoles along a rigid scaffold. We found that 
conformational control can be attained in a rigid, rapidly rotating diphenylacetylene scaffold. 
Isoindolinones can serve as non-sterically demanding dipoles, and dipolar interactions alone impact 
the relative conformation of molecules at distances of up to 8.6 Å. However, dipolar interactions alone 
do not seem to be sufficient to relay a major relative conformation over multiple dipoles, as the 
conformational analysis of trimer 5.35 suggested. 
While other dipoles were expected to act similarly, only imidazolone containing models could be 
synthesised. The poorer control over the relative orientation correlated with the lower calculated 
dipole moment of this scaffold. 
The use of longer linking units to study the impact of long distance on dipolar repulsion showed that 
at distances higher than 10.5 Å, no intramolecular interactions were observed. Compound 5.52 also 
demonstrated the intramolecular nature of the conformational bias in shorter substrates. Eventually, 
introducing additional dipoles within the rigid scaffold have an impact on the peripheral dipoles 
relative conformation, as demonstrated by pyridine 5.53 and carbazoles 5.54a–c. Insight into the 
conformation of the various carbazole scaffolds suggested that freedom of rotation was required for 





Reactions requiring anhydrous conditions were performed under nitrogen atmosphere in glassware 
which was flame-dried. Air- and moisture-sensitive liquids and solutions were transferred by syringe 
or cannula into the reaction vessels through rubber septa. Reactions run in a microwave oven were 
completed on a Biotage Initiator+. All reagents were purchased at highest commercial quality and 
used as received. Non-anhydrous solvents were purchased (unless specified) at the highest 
commercial quality and used as received. All solvents were removed in vacuo using a rotary 
evaporator. Petroleum ether indicates fractions of PE boiling at 40-60 °C. Acetone/dry ice cooling 
baths were used to obtain -78 °C. Anhydrous THF, Et2O, CH2Cl2, and toluene were purified by filtration 
over a column of activated alumina (A-2). 
Nuclear Magnetic Resonance (NMR) spectra (1H and 13C) were recorded on either Bruker Avance III 
400 or 500 MHz, Jeol ECS 300 or 400 MHz or Varian VNMRS 400 or 500 MHz spectrometers. The 
residual solvent peak was used as internal standards when assigning NMR spectra.[305] Chemical shifts 
(δ) are quoted in Parts per million (ppm) downfield of trimethylsilane. Coupling constants (J) are 
reported to the nearest 0.1 Hz. The splitting patterns for the spectra assignment are abbreviated to 
singlet (s), doublet (d), triplet (t), quartet (q), septet (sept.), multiplet (m), broad (br.) and some as a 
combination of these. When possible, each signal was assigned to the corresponding atom.  
IR spectra were recorded on neat compounds using a Perkin Elmer (Spectrum One) FT-IR 
spectrometer. Only strong and selected absorbance’s (νmax expressed in cm−1) are reported. 
High resolution mass spectra were recorded on a Bruker Daltronics MicroTOF 2 (ESI), a Bruker 
Daltronics ultrafleXtreme (MALDI) or a Thermo ORBITRAP Exactive Plus (APCI) mass spectromers. 
Capillary melting points were determined on a Stuart Scientific melting point SMP 10 apparatus. 
Thin layer chromatography (TLC) was performed using commercially available pre-coated plates 
(Macherey-Nagel alugram SIL G/UV254). Visualisation was by UV light (at 254 nm) or by staining with 
phosphomolybdic acid or ‘Seebach’ dip (2.50 g phosphomolybdic acid hydrate, 1.00 g Cerium (IV) 
sulfate tetrahydrate, 3.2 mL conc. H2SO4, 90 mL H2O) then heating. Flash column chromatography used 
chromatography grade silica, 60 Å particle size from Aldrich or was performed on an automated 
Biotage IsoleraTM Spektra Four using gradient elution on pre-packed silica gel Biotage® SNAP Ultra 





General Procedure 1.1 (GP1.1), Buchwald–Hartwig coupling: A flame-dried microwave vial was 
allowed to cool to rt in vacuo and refilled with nitrogen. To this was added the required aniline (1.2 
eq.), aryl bromide (1.0 eq.), NaOtBu (1.25 eq.), Pd2dba3 (1 mol%), PNp3 (2 mol%) and distilled toluene 
(1.0 M). The reaction was allowed to stir at 80 °C for 16 h, cooled down to rt, filtered over Celite and 
concentrated in vacuo to yield the crude diarylamine. Purification by column chromatography yielded 
the desired product.  
Tert-butyl (2-isopropylphenyl)carbamate – 1.21a 
To a solution of 2-isopropylaniline (4.6 mL, 32.8 mmol, 1.0 eq.) in DCE (40 mL) 
was added di-tert-butylcarbonate (9.0 g, 41.0 mmol, 1.25 eq.). The reaction 
mixture was stirred for 16 h at 40 °C, concentrated in vacuo, and dissolved in 
CH2Cl2. The solution was washed with an aqueous solution of 1M HCl, a 
saturated aqueous solution of NaHCO3, brine, dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, petroleum ether /EtOAc, 99:1) yielded the title 
compound as a red oil (8.6 g, 29.9 mmol, 91%). Mixture of conformers in a 1:0.25 ratio.  
δ1H (400 MHz, CDCl3) 7.70 (1 H, d, J = 5.5 Hz, H-1), 7.25 (1 H, d, J = 7.8 Hz, H-4), 7.18 (1 H, t, J = 7.6 Hz, 
H-2), 7.10 (1 H, t, J = 7.5 Hz, H-3), 6.31 (1 H, s, NH), 3.03 (1 H, sept., J = 5.8 Hz, H-7), 1.53 (9 Hmin, s,  
H-11), 1.52 (9 Hmaj, s, H-11), 1.25 (6 H, d, J = 5.8 Hz, H-8). δ13C (101 MHz, CDCl3) 153.7 (C-9maj),  
146.9 (C-9min), 139.0 (broad, C-6), 134.8 (C-5), 126.4 (C-2), 125.5 (C-4), 124.8 (C-3), 123.0 (C-1),  
85.3 (C-10min), 80.4 (C-10maj), 28.5 (C-11maj), 27.8 (C-7), 27.5 (C-11min), 23.1 (C-8). Data consistent with 
that reported.[306] 
Tert-butyl (2-(tert-butyl)phenyl)carbamate – 1.21b 
To a solution of 2-tert-butylaniline (3.1 mL, 19.9 mmol, 1.0 eq.) in DCE (25 mL) 
was added di-tert-butylcarbonate (5.7 g, 26.0 mmol, 1.3 eq.). The reaction 
mixture was stirred for 16 h at 60 °C. As the reaction did not go to full 
conversion, extra di-tert-butylcarbonate (2.5 g, 11.4 mmol, 0.6 eq.) was added 
and the reaction mixture was heated for 96 h at 70 °C. The solution was concentrated in vacuo, taken 
up in CH2Cl2, washed with an aqueous solution of 1M HCl, a saturated aqueous solution of NaHCO3, 
brine, dried over Na2SO4 and concentrated in vacuo. Purification by flash column chromatography 
(SiO2, petroleum ether /EtOAc, 99:1) yielded the title compound as a white solid (4.5 g, 14.9 mmol, 
75%). δ1H (400 MHz, CDCl3) 7.56 (1 H, d, J = 7.0 Hz, H-1), 7.36 (1 H, d, J = 7.9 Hz, H-4),  
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7.21 (1 H, t, J = 7.6 Hz, H-2), 7.11 (1 H, t, J = 7.6 Hz, H-3), 6.35 (1 H, s, NH), 1.51 (9 H, s, H-8),  
1.41 (9 H, s, H-10). δ13C (101 MHz, CDCl3) 153.8 (C-11), 141.9 (C-5), 135.8 (C-6), 127.0 (C-1),  
126.9 (C-2), 126.5 (C-4), 125.3 (C-3), 80.3 (C-9), 34.6 (C-7), 30.8 (C-10), 28.6 (C-8). Data consistent with 
that reported.[307] 
2,4-Di-tert-butyl-1-nitrobenzene – 1.24 
To a solution of 1,3-di-tert-butylbenzene (7.9 g, 41.8 mmol, 1.0 eq.) in 
trifluoroacetic acid (32 mL) was added NH4NO3 (3.43 g, 42.8 mmol, 1.02 eq.). 
The reaction mixture was stirred for 2 h, poured in water and extracted with 
CH2Cl2. The organic phases were combined, washed with brine, dried over 
MgSO4 and concentrated in vacuo. Recrystallization in isopropanol yielded the title compound as an 
off-white solid (6.4 g, 27.2 mmol, 65%). δ1H (400 MHz, CDCl3) 7.55 (1 H, d, J = 1.5 Hz, H-4),  
7.29 (1 H, dd, J = 8.4, 1.7 Hz, H-2), 7.26 (1 H, d, J = 8.2 Hz, H-1), 1.41 (9 H, s, H-9), 1.33 (9 H, s, H-10).  
δ13C (101 MHz, CDCl3) 154.1 (C-3), 149.1 (C-6), 140.9 (C-5), 125.5 (C-4), 123.9 (C-1), 123.8 (C-2),  
35.9 (C-7), 35.3 (C-8), 31.3 (C-10), 30.8 (C-9). Data consistent with that reported.[44] 
2,4-Di-tert-butyl-aniline – 1.25 
2,4-di-tert-butyl-1-nitrobenzene 1.24 (4.1 g, 17.6 mmol, 1.0 eq.) and palladium 
on activated charcoal (10%, 0.5 g, 0.5 mmol, 3 mol%) were suspended in a 
mixture of ethanol (35 mL) and hydrazine hydrate (25 mL). The reaction 
mixture was heated under reflux for 16 h, concentrated in vacuo, taken up in a 
solution of 5M NaOH and extracted with ethyl acetate. The organic phases were combined, washed 
with brine, dried over Na2SO4, filtered and concentrated in vacuo to yield the title compound as a 
yellow oil (3.4 g, 16.7 mmol, 95%) δ1H (400 MHz, CDCl3) 7.28 (1 H, d, J = 2.3 Hz, H-4),  
7.06 (1 H, dd, J = 8.2, 2.3 Hz, H-2), 6.61 (1 H, d, J = 8.2 Hz, H-1), 3.72 (2 H, br. s, NH), 1.43 (9 H, s, H-9), 
1.28 (9 H, s, H-10). δ13C (101 MHz, CDCl3) 142.1 (C-3), 141.2 (C-6), 133.3 (C-5), 123.8 (C-2), 123.7 (C-4), 
117.6 (C-1), 34.7 (C-7), 34.3 (C-8), 31.7 (C-10), 29.8 (C-9). IR (film, cm-1) νmax 3502 (N–H), 3407 (N–H), 
2956 (C–H), 1621 (N–H), 1484 (C–C), 874 (N–H); HRMS (ESI+) m/z calcd for C15H26N [M+H]+ 220.2065, 
found 220.6068. 
1,5-Di-tert-butyl-3-methyl-2-nitrobenzene – 1.26 
To a solution of 3,5-di-tert-butyltoluene (5.2 g, 25.4 mmol, 1.0 eq.) in acetic 
anhydride (4.3 mL) was added dropwise a mixture of aq. HNO3 (70%, 1.6 mL, 
101 mmol, 4 eq.), AcOH (1.5 mL) and acetic anhydride (1.5 mL) while keeping 
the internal temperature below 20 °C. The solution was stirred at rt for 3 h and 
at 55 °C for 10 min. The reaction mixture was poured on ice, filtered and recrystallized in ethanol, 
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yielding the title compound as a pale yellow solid (3.1 g, 12.2 mmol, 49%). δ1H (400 MHz, CDCl3)  
7.37 (1 H, d, J = 1.9 Hz, H-4), 7.13 (1 H, d, J = 1.7 Hz, H-2), 2.23 (3 H, s, H-7), 1.38 (9 H, s, H-10),  
1.31 (9 H, s, J = 1.8, H-11). δ13C (101 MHz, CDCl3) 152.3 (C-3), 149.1 (C-6), 139.6 (C-5), 129.2 (C-1),  
126.1 (C-2), 122.9 (C-4), 36.0 (C-8), 35.0 (C-9), 31.3 (C-11), 31.1 (C-10), 17.8 (C-7). Data consistent with 
that reported in the literature.[308] 
2,4-Di-tert-butyl-6-methylaniline – 1.27 
To a solution of 1.26 (1.0 g, 4.05 mmol, 1.0 eq.) in THF (50 mL) was added 
portionwise LiAlH4 (1.5 g, 40.5 mmol, 10.0 eq.). The reaction mixture was 
cautiously heated to reflux and stirred for 16 h, then quenched with a saturated 
aqueous solution of Na2S2O3. After filtration, the reaction mixture was 
extracted with Et2O and concentrated in vacuo. The resulting oil was dissolved in a solution of HCl in 
MeOH, concentrated in vacuo and triturated in Et2O. The pink solid was suspended in an aqueous 
solution of 2M NaOH and extracted with Et2O. Organic phases were combined, dried over Na2SO4, 
filtered and concentrated in vacuo, and filtration over a small plug of silica (petroleum ether/ CH2Cl2 
60:40) yielded the title compound as a colourless oil (660 mg, 3.0 mmol, 75%). δ1H (400 MHz, CDCl3)  
7.19 (1 H, d, J = 1.6 Hz, H-4), 7.01 (1 H, d, J = 1.6 Hz, H-2), 3.75 (2 H, br. s,), 2.20 (3 H, s, H-7),  
1.45 (9 H, s, H-11), 1.29 (9 H, s, H-10). δ13C (101 MHz, CDCl3) 140.36 (C-6), 140.23 (C-5), 132.7 (C-3), 
125.5 (C-2), 122.9 (C-1), 121.7 (C-4), 34.6 (C-9), 34.2 (C-8), 31.8 (C-10), 30.0 (C-11), 18.8 (C-7). Data 
consistent with that reported in the literature.[308] 
Trineopentyl phosphine – PNp3 
To a solution of neopentyl magnesium chloride in THF (1.0 M, 24 mL, 24 mmol,  
4.5 eq.) at 0 °C was added phosphorus trichloride (0.46 mL, 5.27 mmol, 1.0 eq.) 
dropwise. The solution was heated under reflux for 5 h, allowed to cool to rt and 
stirred for 14 h. The reaction mixture was concentrated in vacuo, and degassed Et2O 
was added, as well as a saturated aqueous solution of NH4Cl. The aqueous phase was extracted with 
Et2O. The organic phases were combined, dried over MgSO4 and concentrated in vacuo. The resulting 
brown oil was distilled in vacuo (15 mbar, 150 °C) and recrystallized in ethanol to yield PNp3 as white 
crystalline needles (222 mg, 0.91 mmol, 17%), m.p.: 59 °C. δ1H (400 MHz, CDCl3)  
1.35 (6 H, d, J = 3.7 Hz, H-1), 0.98 (27 H, s, H-3). δ13C (101 MHz, CDCl3) 47.7 (d, J = 14.8 Hz, C-1),  
32.0 (d, J = 13.8 Hz, C-2), 31.1 (d, J = 8.3 Hz, C-3). Data consistent with that reported.[48] 
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2-Isopropyl-N-(o-tolyl)aniline – 1.28a 
Following GP1.1 with 2-bromotoluene (180 µL, 1.5 mmol, 1.0 eq.), 2-isopropyl 
aniline (263µL, 1.87 mmol, 1.25 eq), NaOtBu (159 mg, 1.65 mmol, 1.5 eq.), 
Pd2(dba)3 (13.7 mg, 0.015 mmol, 1 mol%), PNp3 (7.3 mg, 0.03 mmol, 2 mol%) 
and toluene (3 mL). Filtration over a plug of silica (SiO2, petroleum ether) 
yielded the title compound as a yellow oil (341 mg, 1.5 mmol, quant.). δ1H (400 MHz, CDCl3)  
7.33 (1 H, dd, J = 7.5, 1.5 Hz, H-4), 7.21 (1 H, d, J = 7.4 Hz, H-11), 7.14 (2 H, m, H-6 + H-9), 7.08 (1 H, m, 
H-7), 7.05 (1 H, m, H-5), 6.93 (1 H, d, J = 8.0 Hz, H-8), 6.88 (1 H, td, J = 7.4, 1.1 Hz, H-10), 5.25 (1 H, s, 
NH), 3.16 (1 H, sept, J = 5.8 Hz, H-13), 2.30 (3 H, s, H-14), 1.29 (6 H, d, J = 5.9 Hz, H-15).  
δ13C (101 MHz, CDCl3) 143.2 (C-2), 140.4 (C-3), 139.5 (C-1), 130.8 (C-11), 127.0 (C-7), 126.6 (C-6),  
126.5 (C-12), 126.1 (C-4), 122.8 (C-9), 121.0 (C-5), 120.7 (C-10), 117.0 (C-8), 27.9 (C-13), 23.1 (C-15), 
18.0 (C-14). IR (film, cm-1) νmax 3405 (N–H), 3033 (C–H), 2960 (C–H), 1584 (N–H), 1491; HRMS (APCI+) 
m/z calcd for C16H20N [M+H]+ 226.1596, found 226.1599. 
Bis(2-isopropylphenyl)amine – 1.28b 
Following GP1.1 with 1-bromo-2-isopropylbenzene (230 µL, 1.5 mmol, 1.0 eq.), 
2-isopropylaniline (263µL, 1.87 mmol, 1.25 eq), NaOtBu (159 mg, 1.65 mmol,  
1.5 eq.), Pd2(dba)3 (13.7 mg, 0.015 mmol, 1 mol%), PNp3 (7.3 mg, 0.03 mmol,  
2 mol%) in distilled toluene (3 mL). Filtration over a plug of silica (SiO2, petroleum 
ether) yielded the title compound as a yellow oil (312 mg, 1.2 mmol, 82%). δ1H (400 MHz, CDCl3)  
7.32 (2 H, d, J = 7.9 Hz, H-3), 7.13 (2 H, td, J = 7.6, 1.4 Hz, H-5), 7.01 (2 H, t, J = 7.8 Hz, H-4),  
7.00 (2 H, d, J = 7.9 Hz, H-6), 5.36 (1 H, s, NH), 3.15 (2 H, sept., J = 5.8 Hz, H-7), 1.32 (12 H, d, J = 5.8 Hz, 
H-8). δ13C (101 MHz, CDCl3) 141.5 (C-2), 138.3 (C-1), 126.6 (C-5), 125.9 (C-3), 121.9 (C-4), 119.5 (C-6), 
27.9 (C-7), 22.9 (C-8). IR (film, cm-1) νmax 3412 (N–H), 3034 (C–H), 2960 (C–H), 1583 (N–H), 1502, 1489, 
1449; HRMS (APCI +) m/z calcd for C18H24N [M+H]+ 254.1909, found 253.1897. 
2-(Tert-butyl)-N-(2-isopropylphenyl)aniline – 1.28c 
Following GP1.1 with 1-bromo-2-tert-butylbenzene[309] (180 µL, 1.5 mmol,  
1.0 eq.), 2-isopropylaniline (263µL, 1.87 mmol, 1.25 eq), NaOtBu (159 mg, 
1.65 mmol, 1.5 eq.), Pd2(dba)3 (13.7 mg, 0.015 mmol, 1 mol%), PNp3 (7.3 mg, 
0.03 mmol, 2 mol%) in distilled toluene (3 mL). Filtration over a plug of silica 
(SiO2, petroleum ether) yielded the title compound as an orange oil (388 mg, 1.4 mmol, 96%).  
δ1H (400 MHz, CDCl3) 7.43 (1 H, dd, J = 7.9, 1.2 Hz, H-11), 7.32 (1 H, dd, J = 7.6, 1.0 Hz, H-4),  
7.15 (1 H, m, H-9), 7.11 (1 H, m, H-6), 7.08 (1 H, d, J = 5.8 Hz, H-8), 7.01 (1 H, m, H-10), 6.99 (1 H, m,  
H-5), 6.96 (1 H, d, J = 7.9 Hz, H-7), 5.47 (1 H, br. s, NH), 3.12 (1 H, sept, J = 5.8 Hz, H-13), 1.50 (9 H, s, 
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H-16), 1.33 (6 H, d, J = 5.8 Hz, H-15). δ13C (101 MHz, CDCl3) 142.9 (C-2), 141.9 (C-1), 140.4 (C-12),  
137.6 (C-3), 127.02 (C-11), 126.99 (C-9), 126.6 (C-6), 125.8 (C-4), 122.7 (C-8), 122.1 (C-10), 121.3 (C-5), 
119.0 (C-7), 34.8 (C-14), 30.5 (C-16), 27.8 (C-13), 23.0 (C-15). IR (film, cm-1) νmax 3479 (N–H),  
2959 (C–H), 1580 (N–H), 1499, 1443; HRMS (APCI +) m/z calcd for C19H26N [M+H]+ 268.2065, found 
268.2061. 
N-(2-Isopropylphenyl)-2,6-dimethylaniline – 1.28d 
Following GP1.1 with 2-bromo-1,3-dimethylbenzene (200 µL, 1.5 mmol,  
1.0 eq.), 2-isopropylaniline (263 µL, 1.87 mmol, 1.25 eq), NaOtBu (159 mg, 
1.65 mmol, 1.5 eq.), Pd2(dba)3 (13.7 mg, 0.015 mmol, 1 mol%), PNp3  
(7.3 mg, 0.03 mmol, 2 mol%) in distilled toluene (3 mL). Filtration over a plug 
of silica (SiO2, petroleum ether) yielded the title compound as an off-white solid (274 mg, 1.1 mmol, 
76%), m.p.: 116 – 119 °C (degradation). δ1H (400 MHz, CDCl3) 7.25 (1 H, d, J = 7.2 Hz, H-9),  
7.14 (2 H, d, J = 7.2 Hz, H-4), 7.09 (1 H, dd, J = 8.5, 6.2 Hz, H-3), 6.97 (1 H, t, J = 7.6 Hz, H-7),  
6.81 (1 H, t, J = 7.2 Hz, H-8), 6.20 (1 H, d, J = 8.0 Hz, H-6), 5.14 (1 H, br. s, NH),  
3.17 (1 H, sept, J = 5.8 Hz, H-12), 2.20 (6 H, s, H-11), 1.40 (6 H, d, J = 5.8 Hz, H-13) δ13C (101 MHz, CDCl3) 
142.9 (C-2), 139.0 (C-1), 135.5 (C-5), 133.0 (C-10), 128.7 (C-4), 126.6 (C-7), 125.43 (C-3), 125.34 (C-9), 
118.7 (C-8), 112.7 (C-6), 27.8 (C-8), 22.5 (C-13), 18.5 (C-11). IR (film, cm-1) νmax 3407 (N–H),  
3033 (C–H), 2956 (C–H), 1604 (N–H), 1581 (N–H), 1498, 1453; HRMS (APCI +) m/z calcd for C17H22N 
[M+H]+ 240.1752, found 240.1753. Supplementary crystallographic data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre (CCDC 1842708). 
2-Ethyl-N-(2-isopropylphenyl)-6-methylaniline – 1.28e 
Following GP1.1 with 1-bromo-2-isopropylbenzene (230 µL, 1.5 mmol,  
1.0 eq.), 2-ethyl-6-methylaniline (260 µL, 1.87 mmol, 1.25 eq), NaOtBu (159 
mg, 1.65 mmol, 1.5 eq.), Pd2(dba)3 (13.7 mg, 0.015 mmol, 1 mol%), PNp3  
(7.3 mg, 0.03 mmol, 2 mol%) in distilled toluene (3 mL). Filtration over a plug 
of silica (SiO2, petroleum ether) yielded the title compound as a yellow oil (348 mg, 1.4 mmol, 91%).  
δ1H (400 MHz, CDCl3) 7.25 (1 H, d, J = 7.5 Hz, H-4), 7.18 (3 H, m, H-9 + H-10 + H-11),  
6.97 (1 H, t, J = 7.7 Hz, H-6), 6.80 (1 H, t, J = 7.4 Hz, H-5), 6.18 (1 H, dd, J = 8.0, 0.9 Hz, H-1),  
5.17 (1 H, s, NH), 3.15 (1 H, sept., J = 5.7 Hz, H-13), 2.58 (2 H, m, H-14), 2.18 (3 H, s, H-17),  
1.40 (6 H, d, J = 5.8 Hz, H-15), 1.17 (3 H, t, J = 7.6 Hz, H-16). δ13C (101 MHz, CDCl3) 143.3 (C-3),  
141.5 (C-12), 138.2 (C-2), 136.0 (C-8), 132.6 (C-1), 128.7 (C-9), 126.9 (C-10), 126.6 (C-6), 125.8 (C-11), 
125.3 (C-4), 118.5 (C-5), 112.5 (C-7), 27.7 (C-13), 24.9, (C-14) 22.5 (C-15), 22.5 (C-15), 18.6 (C-17),  
14.9 (C-16). IR (film, cm-1)νmax 3420 (N–H), 2961 (C–H), 2871 (C–H), 1604 (N–H), 1581 (N–H), 1498, 
1454; HRMS (APCI +) m/z calcd for C18H24N [M+H]+ 254.1909, found 254.1910. 
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N-(2-(Tert-butyl)phenyl)-2-ethyl-6-methylaniline – 1.28f 
Following GP1.1 with 1-bromo-2-tert-butylbenzene[309] (476 mg, 2.2 mmol,  
1.0 eq.), 2-ethyl-6-methylaniline (0.39 mL, 2.8 mmol, 1.25 eq), NaOtBu  
(0.24 g, 2.5 mmol, 1.1 eq.), Pd2(dba)3 (20.6 mg, 0.022 mmol, 1 mol%), PNp3 
(11.0 mg, 0.045 mmol, 2 mol%) in distilled toluene (4.5 mL). Filtration over a 
plug of silica (SiO2, petroleum ether) yielded the title compound as an off-white solid (425 mg,  
1.6 mmol, 72%), m.p.: 67 – 68 °C. δ1H (400 MHz, CDCl3) 7.34 (1 H, dd, J = 7.8, 1.2 Hz, H-4),  
7.17 (1 H, dd, J = 8.9, 4.7 Hz, H-10), 7.14 (2 H, m, H-9 + H-11), 6.96 (1 H, t, J = 7.6 Hz, H-6),  
6.75 (1 H, t, J = 7.5 Hz, H-5), 6.20 (1 H, dd, J = 8.0, 0.8 Hz, H-7), 5.36 (1 H, s, br.s, NH),  
2.60 (CHAHB, 1 H, sept., J = 7.6 Hz, H-14), 2.57 (CHAHB, 1 H, sept., J = 7.6 Hz, H-14),  
2.16 (3 H, s, H-17), 1.56 (9 H, s, H-15), 1.16 (3 H, t, J = 7.6 Hz, H-16). δ13C (101 MHz, CDCl3) 144.5 (C-3),  
141.3 (C-12), 138.4 (C-2), 135.9 (C-6), 133.9 (C-1), 128.8 (C-9), 127.1 (C-6), 126.9 (C-10), 126.5 (C-4), 
125.7 (C-11), 118.3 (C-5), 113.8 (C-7), 34.6 (C-13), 30.0 (C-15), 25.0 (C-14), 18.8 (C-17), 15.0 (C-16).  
IR (film, cm-1) νmax 3458 (N–H), 2963, (C–H), 1600 (N–H), 1591 (N–H), 1576; HRMS (APCI +) m/z calcd 
for C19H26N [M+H]+ 268.2065, found 268.2053.  
2-Isopropyl-6-methyl-N-(o-tolyl)aniline – 1.28g 
Following GP1.1 with 2-bromotoluene (42 µL, 0.35 mmol, 1.0 eq.), 2-isopro- 
pyl-6-methylaniline (68 µL, 0.44 mmol, 1.25 eq), NaOtBu (50 mg, 0.52 mmol, 
1.5 eq.), Pd2(dba)3 (3.2 mg, 3.5 μmol, 1 mol%), PNp3 (1.7 mg, 7 μmol, 2 mol%) 
in distilled toluene (0.7 mL). Filtration over a plug of silica (SiO2, petroleum 
ether) yielded the title compound as a colourless oil (82 mg, 0.34 mmol, 98%). δ1H (400 MHz, CDCl3) 
7.34 (1 H, d, J = 7.2 Hz, H-4), 7.29 (1 H, t, J = 7.5 Hz, H-5), 7.23 (2 H, d, J = 7.0 Hz, H-6 + H-8),  
7.06 (1 H, t, J = 7.6 Hz, H-10), 6.79 (1 H, t, J = 7.3 Hz, H-9), 6.23 (1 H, d, J = 8.0 Hz, H-11),  
5.05 (1 H, br. s, NH), 3.26 (1 H, sept., J = 5.8 Hz, H-13), 2.44 (3 H, s, H-14), 2.26 (3 H, s, H-16),  
1.27 (6 H, br. s, H-15). δ13C (101 MHz, CDCl3) 146.7 (C-3), 145.1 (C-7), 137.3 (C-1), 136.5 (C-2),  
130.3 (C-8), 128.4 (C-6), 127.1 (C-10), 126.5 (C-5), 124.0 (C-4), 122.0 (C-12), 117.8 (C-9), 111.5 (C-11), 
28.2 (C-13), 24.6 (C-15), 23.2 (C-15), 18.6 (C-16), 17.8 (C-14). IR (film, cm-1) νmax 3412 (N–H),  
3034 (C–H), 2961 (C–H), 2867 (C–H), 1606 (N–H), 1584 (N–H), 1500, 1462; HRMS (APCI +) m/z calcd for 




2-Isopropyl-N-(2-isopropylphenyl)-6-methylaniline – 1.28h 
Following GP1.1 with 2-bromotoluene (230 µL, 1.5 mmol, 1.0 eq.), 2-isopro-
pyl-6-methylaniline (0.29 mL, 1.87 mmol, 1.25 eq), NaOtBu (159 mg, 1.65 
mmol, 1.5 eq.), Pd2(dba)3 (13.7 mg, 0.015 mmol, 1 mol%), PNp3 (7.3 mg, 0.03 
mmol, 2 mol%) in distilled toluene (3 mL). Filtration over a plug of silica (SiO2, 
petroleum ether) yielded the title compound as a yellow oil (334 mg, 1.2 mmol, 83%). 
δ1H (400 MHz, CDCl3) 7.26 (2 H, d, J = 7.5 Hz, H-4 + H-11), 7.21 (1 H, t, J = 7.5 Hz, H-10),  
7.16 (1 H, d, J = 7.2 Hz, H-9), 6.97 (1 H, t, J = 7.7 Hz, H-6), 6.80 (1 H, t, J = 7.4 Hz, H-5),  
6.18 (1 H, dd, J = 8.0, 0.8 Hz, H-7), 5.17 (1 H, s, NH), 3.16 (1 H, m, H-14), 3.15 (1 H, m, H-13),  
2.19 (3 H, s, H-17), 1.41 (6 H, d, J = 5.8 Hz, H-15), 1.20 (CHAHB, 3 H, d, J = 5.8 Hz, H-16),  
1.18 (CHAHB, 3 H, d, J = 5.9 Hz, H-16). δ13C (101 MHz, CDCl3) 146.5 (C-12), 143.7 (C-2), 137.4 (C-3),  
136.3 (C-8), 132.3 (C-1), 128.5 (C-5), 126.7 (C-6), 126.3 (C-10), 125.2 (C-4), 124.0 (C-11), 118.3 (C-5), 
112.2 (C-7), 28.2 (C-14), 27.8 (C-13), 24.6 (C-16), 23.1 (C-16), 22.48 (C-15), 22.43 (C-15), 18.8 (C-17).  
IR (film, cm-1) νmax 3423 (N–H), 3035 (C–H), 2960 (C–H), 2868 (C–H), 1604 (N–H), 1581 (N–H), 1497, 
1454; HRMS (APCI +) m/z calcd for C19H26N [M+H]+ 268.2065 found 268.2056. 
N-(2-(Tert-butyl)phenyl)-2-isopropyl-6-methylaniline – 1.28i 
Following GP1.1 with 1-bromo-2-tert-butylbenzene[309] (73 mg, 0.35 mmol,  
1.0 eq.), 2-isopropyl-6-methylaniline (68 µL, 0.44 mmol, 1.25 eq), NaOtBu  
(50 mg, 0.52 mmol, 1.5 eq.), Pd2(dba)3 (3.2 mg, 3.5 μmol, 1 mol%), PNp3  
(1.7 mg, 7 μmol, 2 mol%) in distilled toluene (0.7 mL). The reaction time was 
48 h, after which filtration over a plug of silica (SiO2, petroleum ether) yielded the title compound as 
a yellow oil (34 mg, 0.12 mmol, 34%). δ1H (400 MHz, CDCl3) 7.38 (1 H, dd, J = 7.8, 1.0, H-8),  
7.28 (1 H, d, J = 7.4 Hz, H-4), 7.22 (1 H, t, J = 7.5 Hz, H-5), 7.18 (1 H, d, J = 7.0 Hz, H-6),  
6.99 (1 H, t, J = 7.2 Hz, H-9), 6.78 (1 H, t, J = 7.4 Hz, H-10), 6.24 (1 H, d, J = 8.0 Hz, H-11), 5.39 (1 H, s, 
NH), 3.15 (1 H, sept, J = 5.8 Hz, H-13), 2.20 (3 H, s, H-16), 1.60 (9 H, s, H-17), 1.23 (3 H, d, J = 5.9 Hz,  
H-15), 1.19 (3 H, d, J = 5.9 Hz, H-15). δ13C (101 MHz, CDCl3) 146.3 (C-1), 144.9 (C-2), 137.6 (C-3),  
136.1 (C-7), 133.5 (C-12), 128.6 (C-6), 127.1 (C-2), 126.5 (C-8), 126.1 (C-5), 124.0 (C-4), 118.1 (C-3), 
113.6 (C-11), 34.5 (C-14), 30.0 (C-17), 28.3 (C-13), 24.7 (C-15), 22.9 (C-15), 19.0 (C-16).  
IR (film, cm-1) νmax 3463 (N–H), 3049 (C–H), 2963 (C–H), 2871 (C–H), 1600 (N–H), 1576 (N–H), 1497, 
1443; HRMS (APCI +) m/z calcd for C20H28N [M+H]+ 282.2222, found 282.2236. 
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2,6-Diisopropyl-N-(o-tolyl)aniline – 1.28j 
Following GP1.1 with 2-bromotoluene (230 µL, 1.5 mmol, 1.0 eq.), 2,6-
diisopropyl aniline (260 µL, 1.87 mmol, 1.25 eq), NaOtBu (159 mg, 1.65 mmol, 
1.5 eq.), Pd2(dba)3 (13.7 mg, 0.015 mmol, 1 mol%), PNp3 (7.3 mg, 0.03 mmol, 
2 mol%) in distilled toluene (3 mL). Filtration over a plug of silica (SiO2, 
petroleum ether) yielded the title compound as a colourless oil (348 mg,  
1.3 mmol, 87%). δ1H (500 MHz, CDCl3) 7.31 (1 H, m, H-3), 7.25 (2 H, m, H-4), 7.16 (1 H, d, J = 7.3 Hz,  
H-13), 6.97 (1 H, t, J = 7.7 Hz, H-7), 6.69 (1 H, t, J = 7.3 Hz, H-8), 6.14 (1 H, d, J = 8.0 Hz, H-9),  
4.93 (1 H, br. s, NH), 3.13 (2 H, sept, J = 5.8 Hz, H-11), 2.37 (3 H, s, H-12),  
1.18 (CHAHB, 6 H, t, J = 7.5 Hz, H-6), 1.14 (CHAHB, 6 H, d, J = 5., H-6). δ13C (126 MHz, CDCl3)  
147.4 (C-1), 146.2 (C-2), 135.9 (C-5), 130.2 (C-9), 127.2 (C-3), 127.1 (C-7), 123.9 (C-4), 121.4 (C-10), 
117.6 (C-8), 111.6 (C-13), 28.4 (C-11), 24.9 (C-6), 23.1 (C-6), 17.8 (C-12). IR (film, cm-1) νmax  
3425 (N–H), 2961 (C–H), 1606 (N–H), 1585 (N–H), 1500; HRMS (APCI+) m/z calcd for C19H26N [M+H]+ 
268.2065, found 268.2066. 
2,6-Diisopropyl-N-(2-isopropylphenyl)aniline – 1.28k 
Following GP1.1 with 1-bromo-2-isopropylbenzene (54 µL, 0.35 mmol,  
1.0 eq.), 2,6-diisopropylaniline (83 µL, 0.44 mmol, 1.25 eq), NaOtBu (50 mg, 
0.52 mmol, 1.5 eq.), Pd2(dba)3 (3.2 mg, 3.5 μmol, 1 mol%), PNp3 (1.7 mg,  
7 μmol, 2 mol%) in distilled toluene (0.7 mL). Filtration over a plug of silica 
(SiO2, petroleum ether) yielded the title compound as a yellow oil (90 mg, 0.23 mmol, 65%).  
δ1H (400 MHz, CDCl3) 7.31 (1 H, dd, J = 8.6, 6.4 Hz, H-3), 7.26 (2 H, m, H-4), 7.24 (1 H, br. d, H-6),  
6.95 (1 H, t, J = 7.3 Hz, H-8), 6.77 (1 H, t, J = 7.4 Hz, H-7), 6.16 (1 H, d, J = 8.0 Hz, H-9), 5.11 (1 H, s, NH),  
3.12 (3 H, m, H-12 + H-11), 1.41 (6 H, d, J = 5.8 Hz, H-14), 1.18 (CHAHB, 6 H, d, J = 5.9 Hz, H-13),  
1.13 (CHAHB, 6 H, d, J = 5.9 Hz, H-13). δ13C (101 MHz, CDCl3) 147.2 (C-5), 144.7 (C-2), 135.8 (C-1),  
131.6 (C-10), 127.0 (C-3), 126.6 (C-8), 125.1 (C-6), 124.0 (C-4), 117.9 (C-7), 112.1 (C-9), 28.3 (C-11), 
27.8 (C-12), 24.9 (C-13), 23.0 (C-13), 22.4 (C-14). IR (film, cm-1) νmax 3432 (N–H), 3034 (C–H),  
2961 (C–H), 1605 (N–H), 1581 (N–H), 1498, 1445; HRMS (APCI+) m/z calcd for C21H30N [M+H]+ 




N-(2-(Tert-butyl)phenyl)-2,6-diisopropylaniline – 1.28l 
Following GP1.1 with 1-bromo-2-tert-butylbenzene[309] (75 mg, 0.35 mmol,  
1.0 eq.), 2,6-diisopropylaniline (83 µL, 0.44 mmol, 1.25 eq), NaOtBu (50 mg, 
0.52 mmol, 1.5 eq.), Pd2(dba)3 (3.2 mg, 3.5 μmol, 1 mol%), PNp3 (1.7 mg,  
7 μmol, 2 mol%) in distilled toluene (0.7 mL). Filtration over a plug of silica 
(SiO2, petroleum ether) yielded the title compound as a yellow oil (80 mg, 
0.26 mmol, 76%). δ1H (400 MHz, CDCl3) 7.34 (1 H, dd, J = 7.9, 1.0 Hz, H-9), 7.30 (1 H, m, H-3),  
7.25 (2 H, m, H-4), 6.95 (1 H, t, J = 7.6 Hz, H-7), 6.73 (1 H, t, J = 7.5 Hz, H-8), 6.19 (1 H, d, J = 8.0 Hz,  
H-6), 5.28 (1 H, s, NH), 3.09 (2 H, sept, J = 5.8 Hz, H-11), 1.57 (9 H, s, H-14),  
1.18 (CHAHB, 6 H, d, J = 5.9 Hz, H-13), 1.12 (CHAHB, 6 H, d, J = 5.9 Hz, H-13). δ13C (101 MHz, CDCl3)  
147.1 (C-5), 146.0 (C-2), 136.0 (C-1), 132.9 (C-10), 127.1 (C-7), 126.9 (C-3), 126.4 (C-9), 124.1 (C-4), 
117.8 (C-8), 113.6 (C-6), 34.4 (C-12), 29.9 (C-14), 28.4 (C-11), 25.0 (C-13), 22.9 (C-13).  
IR (film, cm-1) νmax 3468 (N–H), 2961 (C–H), 2869 (C–H), 1601 (N–H), 1576 (N–H), 1497, 1443;  
HRMS (APCI+) m/z calcd for C22H32N [M+H]+ 310.2535, found 310.2520. 
N-(2,4-Di-tert-butylphenyl)-2-methylnaphthalen-1-amine – 1.28m 
Following GP1.1 with 1-bromo-2-methylnaphthalene (63 µL,  
0.41 mmol, 1.0 eq.), aniline 1.25 (104 mg, 0.51 mmol, 1.25 eq), 
NaOtBu (58 mg, 0.61 mmol, 1.5 eq.), Pd2(dba)3 (3.7 mg, 4.1 μmol,  
1 mol%), PNp3 (2.0 mg, 8.2 μmol, 2 mol%) in distilled toluene  
(0.8 mL). Filtration over a plug of silica (SiO2, petroleum ether) yielded the title compound as a yellow 
oil (93 mg, 0.27 mmol, 66%). δ1H (400 MHz, CDCl3) 7.91 (1 H, d, J = 8.1 Hz, H-14),  
7.85 (1 H, d, J = 7.5 Hz, H-19), 7.68 (1 H, d, J = 8.4 Hz, H-9), 7.41 (4 H, m, H-4 + H-10 + H-18 + H-20),  
6.88 (1 H, dd, J = 8.4, 2.3 Hz, H-6), 6.09 (1 H, d, J = 8.4 Hz, H-7), 5.63 (1 H, br. s, NH), 2.38 (3 H, s, H-21), 
1.68 (9 H, s, H-15), 1.29 (9 H, s, H-17). δ13C (101 MHz, CDCl3) 142.2 (C-5), 140.9 (C-3), 135.9 (C-2),  
133.6 (ArC), 133.5 (ArC), 131.4 (ArC), 131.2 (ArC), 129.5 (C-4), 128.3 (C-19), 126.2 (C-18 or C-20), 
125.24 (C-18 or C-20), 125.21 (C-9), 123.7 (C-14), 123.6 (C-6 + C-10), 114.8 (C-7), 35.0 (C-13),  
34.3 (C-16), 31.7 (C-17), 30.3 (C-15), 19.0 (C-21). IR (film, cm-1) νmax 3450 (N–H), 3052 (C–H),  
2959 (C–H), 2868 (C–H), 1608 (N–H), 1571 (N–H), 1491, 1391; HRMS (APCI+) m/z calcd for C25H32N 
[M+H]+ 346.2535, found 346.2541. 
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2,4-Di-tert-butyl-6-methyl-N-(o-tolyl)aniline – 1.28n 
Following GP1.1 with 2-bromotoluene (49 µL, 0.41 mmol, 1.0 eq.), 
aniline 1.27 (111 mg, 0.51 mmol, 1.25 eq), NaOtBu (58 mg, 0.61 mmol, 
1.5 eq.), Pd2(dba)3 (3.7 mg, 4.1 μmol, 1 mol%), PNp3 (2.0 mg, 8.2 μmol, 
2 mol%) in distilled toluene (0.8 mL). Filtration over a plug of silica (SiO2, 
petroleum ether) yielded the title compound as a colourless oil (123 mg, 0.40 mmol, 97%).  
δ1H (400 MHz, CDCl3) 7.36 (1 H, d, J = 2.1 Hz, H-4), 7.16 (1 H, d, J = 2.0 Hz, H-6), 7.13 (1 H, d, J = 7.3 Hz, 
H-11), 6.97 (1 H, t, J = 7.6 Hz, H-9), 6.66 (1 H, t, J = 7.1 Hz, H-10), 6.09 (1 H, d, J = 8.0 Hz, H-8),  
5.06 (1 H, br. s, NH), 2.31 (3 H, s, H-14), 2.06 (3 H, s, H-18), 1.38 (9 H, s, H-15), 1.35 (9 H, s, H-17).  
δ13C (101 MHz, CDCl3) 148.4 (C-5), 147.0 (C-3), 145.2 (C-2), 137.6 (C-1), 135.9 (C-7), 130.2 (C-11),  
127.0 (C-9), 126.3 (C-6), 122.0 (C-4), 121.4 (C-12), 117.3 (C-6), 112.1 (C-8), 35.7 (C-13), 34.7 (C-16), 
31.6 (C-17), 31.4 (C-15), 19.3 (C-18), 17.9 (C-14). IR (film, cm-1) νmax 3457 (N–H), 2961 (C–H),  
2867 (C–H), 1607 (N–H), 1586 (N–H), 1492, 1471; HRMS (APCI+) m/z calcd for C22H32N [M+H]+ 
310.2535, found 310.2531.  
2,4-Di-tert-butyl-N-(2-isopropylphenyl)-6-methylaniline – 1.28o 
Following GP1.1 with 1-bromo-2-isopropylbenzene (62 µL, 0.41 mmol, 
1.0 eq.), aniline 1.27 (111 mg, 0.51 mmol, 1.25 eq), NaOtBu (58 mg,  
0.61 mmol, 1.5 eq.), Pd2(dba)3 (3.7 mg, 4.1 μmol, 1 mol%), PNp3 (2.0 mg, 
8.2 μmol, 2 mol%) in distilled toluene (0.8 mL). Filtration over a plug of 
silica (SiO2, petroleum ether) yielded the title compound as a colourless oil (20 mg, 0.06 mmol, 14%). 
δ1H (400 MHz, CDCl3) 7.37 (1 H, d, J = 2.0 Hz, H-4), 7.23 (1 H, d, J = 7.6 Hz, H-11),  
7.16 (1 H, d, J = 1.8 Hz, H-6), 6.95 (1 H, t, J = 7.6 Hz, H-9), 6.75 (1 H, t, J = 7.4 Hz, H-10),  
6.12 (1 H, d, J = 8.0 Hz, H-8), 5.25 (1 H, s, NH), 3.07 (1 H, sept., J = 5.7 Hz, H-14), 2.06 (3 H, s, H-19), 
1.39 (9 H, s, H-17), 1.37 (6 H, m, C-18), 1.35 (9 H, s, H-15). δ13C (101 MHz, CDCl3) 148.2 (C-3),  
146.9 (C-5), 143.9 (C-12), 137.4 (C-1), 136.1 (C-7), 132.0 (C-12), 126.5 (C-9), 126.5 (C-4), 125.1 (C-8), 
122.0 (C-6), 117.8 (C-10), 113.1 (C-8), 35.7 (C-13), 34.7 (C-16), 31.7 (C-17), 31.4 (C-15), 27.7 (C-14), 
22.8 (C-18), 22.4 (C-18), 19.5 (C-19). IR (film, cm-1) νmax 2961 (C–H), 2869 (C–H), 1605 (N–H),  
1582 (N–H), 1498, 1456, 1362; HRMS (APCI+) m/z calcd for C24H36N [M+H]+ 338.2848, found 338.2833.  
2,4-Di-tert-butyl-N-(2,4-di-tert-butylphenyl)-6-methylaniline – 1.28p 
Following GP1.1 with aniline 1.25 (109 mg, 0.41 mmol, 1.0 eq.), 
2,4-di-tert-butyl-1-bromobenzene[310] (111 mg, 0.51 mmol,  
1.25 eq), NaOtBu (58 mg, 0.61 mmol, 1.5 eq.), Pd2(dba)3 (3.7 mg, 
4.1 μmol, 1 mol%), PNp3 (2.0 mg, 8.2 μmol, 2 mol%) in distilled 
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toluene (0.8 mL). Filtration over a plug of silica (SiO2, petroleum ether) yielded the title compound as 
a colourless oil (3 mg, 0.0074 mmol, 2%). δ1H (400 MHz, CDCl3) 7.35 (1 H, d, J = 2.1 Hz, H-4),  
7.30 (1 H, d, J = 2.2 Hz, H-8), 7.12 (1 H, d, J = 1.8 Hz, H-6), 6.91 (1 H, dd, J = 8.4, 2.1 Hz, H-9),  
6.08 (1 H, d, J = 8.4 Hz, H-8), 5.30 (1 H, br. s, NH), 2.00 (3 H, s, H-18), 1.54 (9 H, s, C(CH3)3), 1.39 (9 H, s, 
C(CH3)3), 1.33 (9 H, s, C(CH3)3), 1.26 (9 H, s, C(CH3)3). IR (film, cm-1) νmax 2958 (C–H), 2855 (C–H),  
1610 (N–H), 1500, 1480, 1393; HRMS (APCI+) m/z calcd for C29H6N [M+H]+ 408.3630, found 408.3646. 
Too little material was isolated for the measurement of a 13C NMR spectrum. 
N-(2,4-Di-tert-butyl-6-methylphenyl)-[1,1'-biphenyl]-2-amine – 1.28q 
Following GP1.1 with 2-bromo-1,1'-biphenyl (70 µL, 0.41 mmol,  
1.0 eq.), aniline 1.27 (111 mg, 0.51 mmol, 1.25 eq), NaOtBu (58 mg,  
0.61 mmol, 1.5 eq.), Pd2(dba)3 (3.7 mg, 4.1 μmol, 1 mol%), PNp3 (2.0 mg, 
8.2 μmol, 2 mol%) in distilled toluene (0.8 mL). Filtration over a plug of 
silica (SiO2, petroleum ether) yielded the title compound as a colourless 
oil (9 mg, 0.024 mmol, 6%). δ1H (400 MHz, CDCl3) 7.52 (2 H, d, J = 7.1 Hz, H-19), 7.46 (2 H, t, J = 7.6 Hz, 
H-21), 7.36 (1 H, t, J = 7.3 Hz, H-20), 7.30 (1 H, d, J = 1.9 Hz, H-4), 7.17 (1 H, d, J = 7.4 , H-11),  
7.13 (1 H, d, J = 1.8 Hz, H-6), 7.09 (1 H, t, J = 7.7 Hz, H-9), 6.76 (1 H, t, J = 7.3 Hz, H-10),  
6.18 (1 H, d, J = 8.1 Hz, H-8), 5.32 (1 H, br. s, NH), 2.09 (3 H, s, H-18), 1.32 (9 H, s, H-17), 1.28 (9 H, s,  
H-15). δ13C (101 MHz, CDCl3) 148.6 (C-5), 147.5 (C-3), 144.3 (C-2), 139.6 (C-14), 137.7 (C-1),  
135.6 (C-7), 130.0 (C-11), 129.7 (C-19), 129.0 (C-21), 128.6 (C-9), 127.5 (C-20), 127.4 (C-12),  
126.4 (C-6), 122.0 (C-4), 117.1 (C-10), 112.3 (C-8), 35.7 (C-13), 34.7 (C-16), 31.6 (C-17), 31.2 (C-15), 
19.6 (C-18). IR (film, cm-1) νmax 3480 (N–H), 2959 (C–H), 2867 (C–H), 1592 (N–H), 1466; HRMS (APCI+) 
m/z calcd for C27H34N [M+H]+ 372.2691, found 372.2692.  
N-(2-Ethyl-6-methylphenyl)-2-methylnaphthalen-1-amine – 1.28r 
Following GP1.1 with 1-bromo-2-methylnaphthalene (0.31 mL,  
2.0 mmol, 1.0 eq.), 2-ethyl-6-methylaniline (0.36 mL, 2.5 mmol, 1.25 eq), 
NaOtBu (0.24 g, 2.5 mmol, 1.25 eq.), Pd2(dba)3 (9.1 mg, 0.01 mmol,  
0.5 mol%), PNp3 (4.9 mg, 0.02 mmol, 1 mol%) in distilled toluene (4 mL). 
The reaction time was 48 h, after which filtration over a plug of silica (SiO2, petroleum ether) yielded 
the title compound as a green oil (548 mg, 2.0 mmol, quant.). δ1H (400 MHz, CDCl3)  
7.95 (1 H, d, J = 8.2 Hz, H-14), 7.80 (1 H, d, J = 7.7 Hz, H-19), 7.48 (1 H, d, J = 8.3 Hz, H-10),  
7.39 (2 H, m, H-16 + H-20), 7.24 (1 H, d, J = 8.3 Hz, H-9), 7.10 (1 H, d, J = 7.4 Hz, H-6),  
6.98 (1 H, d, J = 7.4 Hz, H-4), 6.93 (1 H, t, J = 7.4 Hz, H-5), 2.54 (2 H, q, J = 7.5 Hz, H-13), 2.07 (3 H, s,  
H-18), 1.86 (3 H, s, H-17), 1.17 (3 H, t, J = 7.5 Hz, H-15). δ13C (101 MHz, CDCl3) 141.9 (C-13),  
137.7 (C-2), 134.5 (C-1), 133.4 (C-11), 129.9 (C-9), 129.3 (C-7), 129.2 (C-4), 128.9 (C-12), 128.3 (C-19), 
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126.7 (C-6), 125.7 (C-8), 125.6 (C-16 or C-20), 125.1 (C-16 or C-20), 122.6 (C-14), 122.4 (C-10),  
121.9 (C-5), 25.1 (C-13), 19.44 (C-17 or C-18), 19.39 (C-17 or C-18), 14.0 (C-15). IR (film, cm-1) νmax  
3416 (N–H), 3049 (C–H), 2965 (C–H), 1593 (N–H), 1569, 1468. HRMS (APCI+) m/z calcd for C20H22N 
[M+H]+ 276.1747, found 276.1767. 
N-(2-Ethyl-6-methylphenyl)-2,4-methylnaphthalen-1-amine – 1.28s 
Following GP1.1 with 1-bromo-2,4-di-methylnaphthalene (0.80 g,  
3.4 mmol, 1.2 eq.), 2-ethyl-6-methylaniline (0.39 mL, 2.8 mmol, 1.0 eq), 
NaOtBu (0.34 g, 0.52 mmol, 1.25 eq.), Pd2(dba)3 (51 mg, 0.056 mmol, 2 
mol%), PNp3 (47 mg, 0.084 mmol, 3 mol%) in distilled toluene (0.7 mL). 
Filtration over a plug of silica (SiO2, petroleum ether) yielded the title compound as a yellow oil  
(0.74 mg, 92%). δ1H (400 MHz, CDCl3) 8.24 – 8.07 (1 H, dd, J = 8.6, 1.3 Hz, H-14),  
8.08 – 7.93 (1 H, dd, J = 8.6, 1.3 Hz, H-19), 7.50 (1 H, ddd, J = 8.3, 6.7, 1.5 Hz, H-20),  
7.45 (1 H, ddd, J = 8.2, 6.7, 1.5 Hz, H-16), 7.12 (2 H, dd, J = 7.4, 1.5 Hz, H-4 + H-9),  
7.01 (1 H, dd, J = 7.6, 1.7 Hz, H-6), 6.92 (1 H, t, J = 7.5 Hz, H-5), 5.38 (1 H, br. s, NH), 2.68 (3 H, s, H-21), 
2.57 (2 H, q, J = 7.5 Hz, H-13), 2.08 (3 H, s, H-18), 1.89 (3 H, s, H-17), 1.22 (3 H< t, J = 7.5 Hz, H-15).  
δ13C (101 MHz, CDCl3) 142.4 (C-1), 135.9 (C-2), 133.5 (C-3), 132.2 (C-11), 130.6 (C-9), 129.9 (C-12),  
129.3 (C-6), 129.0 (C-10), 128.3 (C-7), 126.7 (C-4), 126.6 (C-8), 125.4 (C-16), 124.9 (C-20), 124.6 (C-19), 
123.3 (C-14), 121.2 (C-5), 25.1 (C-13), 19.4 (C-17), 19.2 (C-18 + C-21), 13.9 (C-15). IR (film, cm-1) νmax 
3465 (N–H), 2865 (C–H), 1583 (N–H), 1569, 1463. 
2,4-Di-tert-butyl-N-(2-isopropyl-6-methylphenyl)-6-methylaniline – 1.28t 
Following GP1.1 with 2-bromo-1,5-di-tert-butyl-3-methylbenzene[14] 
(115 mg, 0.41 mmol, 1.0 eq.), 2-isopropyl-6-methylaniline (79 µL,  
0.51 mmol, 1.25 eq), NaOtBu (58 mg, 0.61 mmol, 1.5 eq.), Pd2(dba)3 
(3.7 mg, 4.1 μmol, 1 mol%), PNp3 (2.0 mg, 8.2 μmol, 2 mol%) in distilled 
toluene (0.8 mL). Filtration over a plug of silica (SiO2, petroleum ether) yielded the title compound as 
a colourless oil (11 mg, 0.03 mmol, 7%). δ1H (400 MHz, CDCl3) 7.28 (1 H, d, J = 2.1 Hz, H-4),  
7.11 (1 H, d, J = 7.5 Hz, H-11), 6.95 (1 H, d, J = 1.9 Hz, H-6), 6.92 (1 H, d, J = 5.7 Hz, H-9),  
6.85 (1 H, t, J = 7.5 Hz, H-10), 5.34 (1 H, br. s, NH), 3.02 (1 H, dt, J = 13.6, 6.8 Hz, H-14), 1.86 (3 H, s,  
H-19), 1.72 (3 H, s, H-20), 1.51 (9 H, s, H-15), 1.31 (9 H, s, H-17), 1.18 (CHAHB, 3 H, d, J = 5.8 Hz, H-18), 
1.14 (CHAHB, 3 H, d, J = 5.8, H-18). δ13C (101 MHz, CDCl3) 144.8 (C-5), 140.7 (C-2), 139.8 (C-3),  
139.3 (C-1), 137.6 (C-12), 131.5 (C-7), 129.1 (C-9), 127.5 (C-8), 126.5 (C-6), 124.1 (C-11), 121.7 (C-4), 
120.6 (C-10), 35.6 (C-13), 34.5 (C-16), 31.7 (C-17), 31.0 (C-15), 27.8 (C-14), 24.7 (C-18), 22.3 (C-18), 
20.4 (C-20), 19.9 (C-19). IR (film, cm-1) νmax 3439 (N–H), 2955 (C–H), 2925 (C–H), 2867 (C–H),  
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1605 (N–H), 1580 (N–H), 1503, 1486, 1458; HRMS (APCI+) m/z calcd for C25H38N [M+H]+ 352.3004, 
found 352.3021.  
N-(2-Isopropyl-6-methylphenyl)-2-methylnaphthalen-1-amine – 1.28u 
Following GP1.1 with 1-bromo-2-methylnaphthalene (55 µL, 0.35 mmol, 
1.0 eq.), 2-isopropyl-6-methylaniline (68 µL, 0.44 mmol, 1.25 eq), NaOtBu 
(50 mg, 0.52 mmol, 1.5 eq.), Pd2(dba)3 (3.2 mg, 3.5 μmol, 1 mol%), PNp3 
(1.7 mg, 7 μmol, 2 mol%) in distilled toluene (0.7 mL). Filtration over a 
plug of silica (SiO2, petroleum ether) yielded the title compound as a pink oil (86 mg, 0.30 mmol, 85%). 
δ1H (400 MHz, CDCl3) 7.94 (1 H, d, J = 8.3 Hz, H-14), 7.82 (1 H, d, J = 8.2 Hz, H-16),  
7.47 (1 H, d, J = 8.3 Hz, H-10), 7.42 (1 H, t, J = 7.9 Hz, H-17), 7.37 (1 H, m, H-18), 7.25 (1 H, d, J = 8.2 Hz, 
H-9), 7.21 (1 H, d, J = 7.4 Hz, H-4), 7.02 (1 H, , t, J = 7.4 Hz, H-5), 6.99 (1 H, d, J = 7.3 Hz, H-6),  
5.49 (1 H, s, NH), 3.27 (1 H, sept, J = 5.8 Hz, H-13), 2.10 (3 H, s, H-19), 1.85 (3 H, s, H-20),  
1.24 (CHAHB, 3 H, d, J = 5.8 Hz, H-15), 1.20 (CHAHB, 3 H, d, J = 5.8 Hz, H-15). δ13C (101 MHz, CDCl3)  
141.0 (C-7), 140.0 (C-3), 138.1 (C-2), 133.5 (C-12), 130.5 (C-1), 130.1 (C-9), 128.9 (C-6), 128.4 (C-16), 
128.3 (C-12), 125.4 (C-18), 125.1 (C-17), 124.6 (C-8), 123.9 (C-4), 122.7 (C-5), 122.5 (C-14),  
121.9 (C-10), 28.1 (C-13), 23.8 (C-15), 23.0 (C-15), 19.63 (C-20), 19.46 (C-19). IR (film, cm-1) νmax  
3423 (N–H), 3051 (C–H), 2960 (C–H), 2866 (C–H), 1593 (N–H), 1568, 1465; HRMS (APCI+) m/z calcd for 
C21H24N [M+H]+ 290.1909, found 290.1895. Supplementary crystallographic data can be obtained free 
of charge from The Cambridge Crystallographic Data Centre (CCDC 1842707). 
N-(2,6-Diisopropylphenyl)-2-methylnaphthalen-1-amine – 1.28v 
Following GP1.1 with 1-bromo-2-methylnaphthalene (55 µL,  
0.35 mmol, 1.0 eq.), 2,6-diisopropylaniline (83 µL, 0.44 mmol, 1.25 eq), 
NaOtBu (50 mg, 0.52 mmol, 1.5 eq.), Pd2(dba)3 (3.2 mg, 3.5 μmol, 1 
mol%), PNp3 (1.7 mg, 7 μmol, 2 mol%) in distilled toluene (0.7 mL). 
Filtration over a plug of silica (SiO2, petroleum ether) yielded the title compound as a yellow oil  
(72 mg, 0.23 mmol, 65%). δ1H (400 MHz, CDCl3) 7.86 (1 H, d, J = 8.5 Hz, H-12), 7.80 (1 H, d, J = 8.1 Hz, 
H-13), 7.41 (1 H, d, J = 8.0 Hz, H-8), 7.39 (1 H, d, J = 7.9 Hz, H-14), 7.32 (1 H, t, J = 7.6 Hz, H-15),  
7.24 (1 H, d, J = 8.3 Hz, H-7), 7.18 (3 H, s, H-3 + H-4), 5.41 (1 H, s, NH), 3.15 (2 H, sept., J = 5.8 Hz,  
H-11), 2.13 (3 H, s, H-16), 1.14 (CHAHB, 6 H, d, J = 5.8 Hz, H-17), 1.04 (CHAHB, 6 H, d, J = 5.8 Hz, H-17). 
δ13C (101 MHz, CDCl3) 142.8 (C-5), 139.5 (C-1), 139.2 (C-2), 133.8 (C-9), 130.5 (C-7), 128.4 (C-13),  
127.0 (C-10), 125.04 (C-15), 124.96 (C-14), 124.4 (C-3), 123.8 (C-4), 122.5 (C-12), 122.1 (C-6),  
120.7 (C-8), 28.2 (C-11), 23.9 (C-17), 23.2 (C-17), 19.6 (C-16). IR (film, cm-1) νmax 3430 (N–H),  
3054 (C–H), 2960 (C–H), 2867 (C–H), 1567, 1465, 1384; HRMS (APCI+) m/z calcd for C23H28N [M+H]+ 
318.2222, found 318.2208. 
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N-(2-(Tert-butyl)-6-methylphenyl)-2-methylnaphthalen-1-amine – 1.28x 
Following GP1.1 with 1-bromo-2-methylnaphthalene (55 µL,  
0.35 mmol, 1.0 eq.), aniline 1.27 (96 mg, 0.44 mmol, 1.25 eq), 
NaOtBu (50 mg, 0.52 mmol, 1.5 eq.), Pd2(dba)3 (3.2 mg, 3.5 μmol,  
1 mol%), PNp3 (1.7 mg, 7 μmol, 2 mol%) in distilled toluene (0.7 mL). 
Filtration over a plug of silica (SiO2, petroleum ether) yielded the title compound as a yellow oil  
(38 mg, 0.11 mmol, 30%). δ1H (500 MHz, CDCl3) 7.80 (1 H, d, J = 8.1 Hz, H-14), 7.76 (1 H, d, J = 8.6 Hz, 
H-16), 7.40 (1 H, d, J = 2.2 Hz, H-4), 7.39 (2 H, m, H-18 + H-10), 7.27 (2 H, m, H-17 + H-9), 7.02 (1 H, d, 
J = 2.1 Hz, H-6), 5.82 (1 H, s, NH), 2.14 (3 H, s, H-19), 1.69 (3 H, s, H-20), 1.58 (9 H, s, H-15),  
1.38 (9 H, s, H-22). δ13C (126 MHz, CDCl3) 145.6 (C-5), 140.6 (C-3), 139.3 (C-1), 138.1 (C-2),  
133.7 (C-11), 132.5 (C-12), 130.4 (C-9), 128.5 (C-14), 126.7 (C-7), 126.5 (C-6), 124.9 (C-18),  
124.8 (C-17), 122.4 (C-14), 121.8 (C-4), 121.1 (C-8), 120.2 (C-10), 35.5 (C-15), 34.6 (C-21), 31.7 (C-22), 
31.2 (C-15), 20.0 (C-20), 19.5 (C-19). IR (film, cm-1) νmax 3465 (N–H), 2953 (C–H), 2867 (C–H), 1567, 
1481; HRMS (APCI+) m/z calcd for C26H34N [M+H]+ 360.2691, found 360.2682. 
2,6-Diisopropyl-N-methyl-N-(o-tolyl)aniline – 1.29 
To a solution of compound 1.28j (53 mg, 0.20 mmol, 1.0 eq.) in DMF (2.0 mL, 
0.1 M) at 0 °C was added NaH (60% suspension in mineral oil, 16 mg,  
0.40 mmol, 2.0 eq.) followed by iodomethane (33 μL, 0.40 mmol, 2.0 eq.). 
The reaction mixture was allowed to warm up to rt, stirred for 18h, then 
quenched with an aqueous solution of saturated NaHCO3 and extracted with ethyl acetate. The 
organic phases were combined, washed with brine, dried over MgSO4 and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, petroleum ether) yielded the title compound as a 
colourless oil (28 mg, 50%). δ1H (400 MHz, DMSO-d6) 7.28 – 7.20 (1 H, m, ArCH),  
7.20 – 7.06 (3 H, m, ArCH), 7.02 – 6.76 (2 H, m, ArCH), 6.67 (1 H, td, J = 7.3, 1.2 Hz, ArCH), 3.16 (3 H, s, 
NCH3), 3.08 (2 H, hept, J = 5.9 Hz, CH(CH3)2), 1.47 (3 H, br. s, CCH3), 1.14 (CHAHB, 6 H, d, J = 5.9 Hz, 
CH(CH3)2), 0.93 (CHAHB, 6 H, d, J = 5.8 Hz, CH(CH3)2).δ13C (126 MHz, CDCl3) 147.2 (C-1), 144.6 (C-2), 
132.5 (C-5 + C-9), 126.9 (C-3), 126.7 (C-7), 125.5 (C-4), 124.3 (C-10), 118.6 (C-8), 111.4 (C-13),  
42.9 (C-14), 27.9 (C-11), 25.4 (C-6), 22.8 (C-6), 21.2 (C-12). IR (film, cm-1) νmax 2966 (C–H), 1697, 1514, 






General Procedure 2.1 (GP2.1), formation of N,N’-diarylureas: Part 1: A flame-dried round 
bottom flask was allowed to cool to rt in vacuo and refilled with nitrogen. To this was added the 
required 2-bromoaniline (1.0 eq.) and anhydrous CH2Cl2 (0.55 M). The required isocyanate (1.2 eq.) 
was added dropwise and the reaction allowed to stir at rt until consumption of the urea was observed 
by TLC. The reaction mixture was filtered, and the residue was rinsed with a small amount of cold 
CH2Cl2 to give the desired urea which was directly used in the next step without further purification.  
Part 2: A flame-dried round bottom flask was allowed to cool to rt in vacuo and refilled with nitrogen. 
To this was added the required urea (1.0 eq.) and anhydrous THF (0.5 M) and the reaction mixture was 
cooled to 0 °C. NaH (4.0 eq.) was added portion wise, followed by dropwise addition of methyl iodide 
(6.0 eq.). The reaction mixture was allowed to stir at rt until consumption of the urea was observed 
by TLC. The reaction mixture was quenched with sat. Na2S2O3 (aq.) and extracted with Et2O. The 
combined organic phases were washed with brine, dried over MgSO4, filtered and concentrated in 
vacuo to yield the crude methylated urea. Purification by flash column chromatography yielded the 
desired product. 
General Procedure 2.2 (GP2.2), anionic ortho-Fries rearrangement of ureas: A flame-dried 
round bottom flask was allowed to cool to rt in vacuo and refilled with nitrogen. To this was added 
the required methylated urea (1.0 eq.) and anhydrous THF (0.2 M) and the reaction mixture was cooled 
to −78 °C. n-BuLi (1.44 M in hexanes, 1.1 eq.) was added dropwise and the reaction was left to stir at 
−78 °C for 2 h. The reaction mixture was quenched with MeOH and concentrated in vacuo to yield the 
crude benzamide. Purification by flash column chromatography yielded the desired product. 
General Procedure 2.3 (GP2.3), Diarylamine formation by Smiles Rearrangement: A flame-dried 
round bottom flask was allowed to cool to rt in vacuo. To this was added the required aniline  
(1.0 eq.) and anhydrous THF (0.2 M) and the reaction mixture was cooled to 0 °C. NaHMDS  
(1.0 M in THF, 1.1 eq.) was added dropwise and the reaction was allowed to stir at rt for 4 h. The 
reaction mixture was quenched with MeOH and concentrated in vacuo to yield the crude diarylamine. 
Purification by column chromatography yielded the desired product. (N.B. reactions heated under 
reflux (66 °C) were performed in flame-dried sealed Biotage microwave vials) 
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1-(2-Iodophenyl)-1,3-dimethyl-3-phenylurea – 2.34  
Following GP2.1 (Part 1) 2-iodoaniline (5.0 g, 23 mmol, 1 eq.), phenyl 
isocyanate (3.0 mL, 27 mmol, 1.2 eq.) in CH2Cl2 (40 mL, 0.55 M) were 
stirred at rt for 3 h. Filtration yielded the urea as a white solid (6.1 g, 79%) 
which was used directly in the next step. Following GP2.1 (Part 2)  
The required urea (6.0 g, 18 mmol, 1 eq.), NaH (1.7 g, 72 mmol, 4.0 eq., 60% in mineral oil), MeI  
(6.6 mL, 107 mmol, 6.0 eq.) in THF (36 mL, 0.5 M) were stirred at rt overnight. Purification by flash 
column chromatography eluting with (10% to 60% EtOAc/Petrol) yielded the title compound as an off-
white solid (5.4 g, 83%). Rf 0.12 (40% Et2O/Petrol). m.p.: 74 – 77 °C. δ1H (400 MHz, CDCl3)  
7.59 (1 H, dd, J = 8.3, 1.4 Hz, H-8), 7.03 (2 H, t, J = 7.5 Hz, H-2), 6.98 – 6.90 (2 H, m, H-1 + H-9),  
6.76 (2 H, d, J = 9.4 Hz, H-2), 6.66 (2 H, d, J = 7.9 Hz, H-10 + H-11), 3.19 (3 H, s, H-12), 3.15 (3 H, s,  
H-13). δ13C (101 MHz, CDCl3) 160.4 (C-5), 147.2 (C-6), 145.4 (C-4), 139.7 (C-8), 129.6 (C-11),  
129.0 (C-2), 128.8 (C-1), 127.4 (C-10), 126.3 (C-3), 125.5 (C-9), 98.5 (C-7), 40.4 (C-12), 39.0 (C-13).  
IR (film, cm-1) νmax 1655 (C=O), 749 (C–I). HRMS (ESI+) m/z calcd for C15H16IN2O [M+H]+ 367.0302; 
found: 367.0310. 
1-(2-Iodophenyl)-1,3-dimethyl-3-phenylurea – 2.35 
Following GP2.1 (Part 1) 2-bromoaniline (1.2 mL g, 11 mmol, 1 eq.), 
phenyl isocyanate (1.4 mL, 13 mmol, 1.2 eq.) in CH2Cl2 (22 mL, 0.55 M) 
were stirred at rt overnight. Filtration yielded the urea as a white solid  
(2.7 g, 84%) which was used directly in the next step. Following GP2.1  
(Part 2) The required urea (2.7 g, 9.2 mmol, 1 eq.), NaH (1.5 g, 37 mmol, 4.0 eq., 60% in mineral oil), 
MeI (3.5 mL, 55 mmol, 6.0 eq.) in THF (18 mL, 0.5 M) were stirred at rt for 2 h. Purification by flash 
column chromatography eluting with (10% to 60% EtOAc/Petrol) yielded the title compound as an off-
white solid (2.8 g, 95%). Rf 0.32 (25% EtOAc/Petrol). m.p.: 100 – 101 °C. δ1H (400 MHz, CDCl3)  
7.30 (1 H, dd, J = 7.9, 1.4 Hz, H-8), 7.02 (2 H, t, J = 7.5 Hz, H-2), 6.94 (1 H, br. t, J = 7.5 Hz, H-1),  
6.92 (1 H, td, J = 7.9, 1.4 Hz, H-10), 6.82 (1 H, td, J = 7.9, 1.7 Hz, H-9), 6.77 (2 H, dd, J = 7.5, 1.7 Hz,  
H-3), 6.71 (1 H, dd, J = 7.9, 1.7 Hz, H-11), 3.19 (3 H, s, H-13), 3.15 (3 H, s, H-12). δ13C (101 MHz, CDCl3) 
160.7 (C-5), 145.3 (C-4), 144.0 (C-6), 133.3 (C-8), 130.1 (C-11), 128.9 (C-2), 128.0 (C-10), 127.4 (C-9), 
126.1 (C-3), 125.4 (C-1), 122.8 (C-7), 40.1 (C-13), 38.6 (C-12). IR (film, cm-1) νmax 1645 (C=O),  
723 (C–Br). HRMS (ESI+) m/z calcd for C17H19N2O+ [M+H]+ 267.1492; found: 267.1491. 
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1-(2-Bromophenyl)-3-(4-fluorophenyl)-1,3-dimethylurea – 2.41b  
Following GP2.1 (Part 1) 2-bromoaniline (0.50 mL, 4.4 mmol, 1 eq.),  
4-fluorophenyl isocyanate (0.60 mL, 5.3 mmol, 1.2 eq.) in CH2Cl2  
(8.0 mL, 0.55 M) were stirred at rt overnight. Filtration yielded the urea 
as a white solid (1.26 g, 93%) which was used directly in the next step. 
Following GP2.1 (Part 2) the required urea (1.25 g, 4.05 mmol, 1 eq.), NaH (0.64 g, 16.1 mmol, 4.0 eq., 
60% in mineral oil), MeI (1.5 mL, 24 mmol, 6.0 eq.) in THF (8.1 mL, 0.5 M) were stirred at rt overnight. 
Purification by flash column chromatography eluting with (5% to 50% EtOAc/Petrol) yielded the title 
compound as a colourless oil (1.44 g, 95%). Rf 0.15 (25% EtOAc/Petrol). δ1H (400 MHz, CDCl3)  
7.33 (1 H, dd, J = 7.8, 1.6 Hz, H-7), 6.98 (1 H, td, J = 7.8, 1.6 Hz, H-9), 6.87 (1 H, td, J = 7.8, 1.6 Hz, H-8), 
6.72 (1 H, dd, J = 7.8, 1.6 Hz, H-10), 6.73 ‒ 6.69 (4 H, m, H-1 + H-2), 3.15 (3 H, s, H-11), 3.14 (3 H, s,  
H-12). δ13C (101 MHz, CDCl3) 160.6 (C-4), 160.3 (d, J = 245 Hz, C-13), 144.0 (C-5),  
141.3 (d, J = 3.1 Hz, C-3), 133.4 (C-7), 130.0 (C-10), 128.1 (C-9), 127.9 (d, J = 8.5 Hz, C-2), 127.6 (C-8), 
122.8 (C-6), 115.7 (d, J = 22.5 Hz, C-1), 40.3 (C-11), 38.7 (C-12). δ19F NMR (376 MHz, CDCl3)  
-116.5 (p, J = 5.7 Hz, C–F). IR (film, cm-1) νmax 1658 (C=O), 1508, 1351 (C–N). HRMS (ESI+) m/z calcd for 
C15H14BrFN2ONa+ [M+Na]+ 359.0166; found: 359.0179. 
1-(2-Bromophenyl)-1,3-dimethyl-3-(4-(trifluoromethyl)phenyl)urea 2.41c 
Following GP2.1 (Part 1) 2-bromoaniline (0.50 mL, 4.4 mmol, 1.4 eq.), 
4-trifluoromethylphenyl isocyanate (0.46 mL, 3.2 mmol, 1.0 eq.) in 
CH2Cl2 (8.0 mL, 0.55 M) were stirred at rt for 3 h. Filtration yielded the 
urea as a white solid (1.15 g, quant.) which was used directly in the 
next step. Following GP2.1 (Part 2) the required urea (1.15 g, 3.2 mmol, 1 eq.), NaH (0.51 g,  
13 mmol, 4.0 eq., 60% in mineral oil), MeI (1.2 mL, 19 mmol, 6.0 eq.) in THF (6.4 mL, 0.5 M) were stirred 
at rt overnight. Purification by flash column chromatography eluting with (5% to 50% EtOAc/Petrol) 
yielded the title compound as a white solid (1.19 g, 96%). Rf 0.31 (25% EtOAc/Petrol). m.p.: 94 ‒ 95 °C. 
δ1H (400 MHz, CDCl3) 7.27 (1 H, dd, J = 8.1, 1.5 Hz, H-8), 7.25 (2 H, d, J = 8.1 Hz, H-2),  
6.90 (1 H, td, J = 7.6, 1.5 Hz, H-10), 6.86 (2 H, d, J = 8.3 Hz, H-3), 6.81 (1 H, td, J = 7.7, 1.7 Hz, H-9),  
6.68 (1 H, dd, J = 7.9, 1.7 Hz, H-11), 3.17 (3 H, s, H-12), 3.13 (3 H, s, H-13). δ13C (101 MHz, CDCl3)  
160.2 (C-5), 148.4 (q, J = 1.5 Hz, C-4), 143.5 (C-6), 133.4 (C-7), 129.9 (C-11), 128.1 (C-10), 127.8 (C-9), 
127.1 (q, J = 32.7 Hz, C-1), 126.0 (q, J = 3.8 Hz, C-2), 125.7 (C-3), 124.0 (q, J = 271.8 Hz, C-14),  
122.7 (C-7), 39.5 (C-12), 38.6 (C-13). δ19F (376 MHz, CDCl3) -62.40 (s, CF3). IR (film, cm-1) νmax  





Following GP2.1 (Part 1) 2-bromoaniline (0.50 mL, 4.4 mmol, 1 eq.),  
4-methoxyphenyl isocyanate (0.69 mL, 5.3 mmol, 1.2 eq.) in CH2Cl2 
(8.0 mL, 0.55 M) were stirred at rt overnight. Filtration yielded the 
title compound as a white solid (1.15 g, 81%) which was used 
directly in the next step. Following GP2.1 (Part 2), the required urea (1.14 mg, 3.55 mmol, 1 eq.), NaH 
(567 mg, 14.2 mmol, 4.0 eq., 60% in mineral oil), MeI (1.3 mL, 21.3 mmol, 6.0 eq) in THF (10.1 mL,  
0.35 M) were stirred at rt overnight. Purification by flash column chromatography eluting with (5% to 
50% EtOAc/Petrol) yielded the title compound as colourless oil (1.22 g, 98%). Rf 0.15  
(25% EtOAc/Petrol); δ1H (400 MHz, CDCl3) 7.32 (1 H, dd, J = 8.0, 1.5 Hz, H-8),  
6.96 (1 H, td, J = 7.6, 1.5 Hz, H-10), 6.84 (1 H, td, J = 7.7, 1.6 Hz, H-9), 6.72 (1 H, dd, J = 7.9, 1.7 Hz,  
H-11), 6.66 (2 H, d, J = 8.7 Hz, H-3), 6.54 (2 H, d, J = 8.9 Hz, H-2), 3.70 (3 H, s,, H-14), 3.14 (3 H, s, H-12),  
3.13 (3 H, s, H-13). δ13C (101 MHz, CDCl3) 160.8 (C-5), 157.3 (C-1), 144.2 (C-6), 138.4 (C-4),  
133.3 (C-8), 130.00 (C-11), 127.96 (C-10), 127.5 (C-3), 127.4 (C-9), 122.8 (C-7), 114.2 (C-2), 55.6 (C-14), 
40.3 (C-12), 38.7 (C-13). IR (film, cm-1) νmax 1654 (C=O), 1510, 1354 (C–N), 1245 (C–O).  
HRMS (ESI+) m/z calcd for C16H17BrN2ONa+ [M+Na]+ 37.0366; found 371.0377. 
1-(2-Bromophenyl)-3-(3-nitrophenyl)-1,3-dimethylurea 2.41f 
 Following GP2.1 (Part 1) 2-bromoaniline (0.50 mL, 4.4 mmol, 1 eq.),  
3-nitrophenyl isocyanate (0.87 g, 5.3 mmol, 1.2 eq.) in CH2Cl2 (8.0 mL, 
0.55 M) were stirred at rt overnight. Filtration yielded the title 
compound as a yellow solid (1.48 g, quant.) which was used directly 
in the next step. Following GP2.1 (Part 2) the required urea (1.52 g, 4.4 mmol, 1 eq.), NaH (0.70 g,  
17.6 mmol, 4.0 eq. 60% in mineral oil), MeI (1.6 mL, 26.4 mmol, 6.0 eq) in THF (13.8 mL, 0.32 M) were 
stirred at rt overnight. Purification by flash column chromatography eluting with (5% to 55% 
EtOAc/Petrol) yielded the title compound as a yellow solid (1.45 g, 98%). Rf 0.21 (25% EtOAc/Petrol). 
m.p.: 106 °C. δ1H (400 MHz, CDCl3) 7.80 (1 H, ddd, J = 8.1, 2.2, 1.1 Hz, H-3), 7.62 (1 H, t, J = 2.2 Hz,  
H-5), 7.29 (1 H, ddd, J = 7.9, 1.6, 0.6 Hz, H-10), 7.23 (1 H, t, J = 8.0 Hz, H-2),  
7.15 (1 H, ddd, J = 8.0, 2.1, 1.1 Hz, H-1), 7.00 (1 H, td, J = 7.6, 1.5 Hz, H-12), 6.84 (2 H, m, H-11 + H-13),  
3.22 (3 H, s, H-14), 3.19 (3 H, s, H-15). δ13C (101 MHz, CDCl3) 159.9 (C-7), 148.5 (C-4), 146.2 (C-6),  
142.4 (C-8), 133.6 (C-10), 131.8 (C-1) , 129.7 (C-2 + C-13), 128.2 (C-12), 128.0 (C-11), 122.6 (C-9),  
120.9 (C-5), 120.1 (C-3), 39.7 (C-14), 38.6 (C-15). IR (film, cm-1) νmax 1665 (C=O), 1527 (N–O),  




 Following GP2.1 (Part 1) 2-bromoaniline (0.50 mL, 4.4 mmol, 1 eq.),  
3-methoxyphenyl isocyanate (0.69 mL, 5.3 mmol, 1.2 eq.) in CH2Cl2  
(8.0 mL, 0.55 M) were stirred at rt overnight. Filtration yielded the urea 
as a white solid (1.21 g, 86%) which was used directly in the next step. Following GP2.1 (Part 2) the 
required urea (1.21 g, 3.76 mmol, 1 eq.), NaH (0.60 g, 15 mmol, 4.0 eq., 60% in mineral oil), MeI  
(1.4 mL, 23 mmol, 6.0 eq.) in THF (6.9 mL, 0.5 M) were stirred at rt for 2 h. Purification by flash column 
chromatography eluting with (5% to 60% EtOAc/Petrol) yielded the title compound as colourless oil 
(1.12 g, 85%). Rf 0.17 (25% EtOAc/Petrol). δ1H (400 MHz, CDCl3) 7.31 (1 H, dd, J = 8.0, 1.5 Hz, H-4),  
6.98 – 6.89 (2 H, m, H-6 + H-9), 6.85 (1 H, ddd, J = 8.0, 7.4, 1.7 Hz, H-5), 6.75 (1 H, dd, J = 7.8, 1.7 Hz, 
H-7), 6.50 (1 H, ddd, J = 8.3, 2.5, 0.9 Hz, H-12), 6.37 (1 H, ddd, J = 7.8, 2.0, 0.9 Hz, H-11),  
6.27 (1 H, t, J = 2.2 Hz, H-13), 3.64 (3 H, s, H-16), 3.17 (3 H, s, H-10), 3.14 (3 H, s, H-15).  
δ13C (101 MHz, CDCl3) 160.6 (C-1), 159.9 (C-14), 146.4 (C-8), 143.9 (C-2), 133.2 (C-4), 130.1 (C-7),  
129.5 (C-9), 127.9 (C-6), 127.4 (C-5), 122.8 (C-3), 118.6 (C-11), 111.64 (C-12 or C-13),  
111.59 (C-12 or C-13), 55.3 (d, J = 5.3 Hz, C-16), 40.0 (C-10), 38.6 (C-15). IR (film, cm-1) νmax 1655 (C=O), 
1597, 1352 (C–N), 1043 (O-CH3), 755 (C–Br). HRMS (ESI+) m/z calcd for C16H17N2OBrNa+ [M+Na]+ 
371.0366; found: 371.0367. 
1-(2-Bromophenyl)-1,3-dimethyl-3-(naphthalen-1-yl)urea – 2.41j 
 Following GP2.1 (Part 1) 2-bromoaniline (0.50 mL, 4.4 mmol, 1 eq.), 
1-isocyanatonaphthalene (0.76 mL, 5.3 mmol, 1.2 eq.) in CH2Cl2  
(8.0 mL, 0.55 M) were stirred at rt overnight. Filtration yielded the 
urea as a white solid (0.79 g, 49%) which was used directly in the next 
step. Following GP2.1 (Part 2) the required urea (0.74 g, 2.2 mmol, 1 eq.), NaH (0.34 g, 8.6 mmol,  
4.0 eq., 60% in mineral oil), MeI (0.80 mL, 12.9 mmol, 6.0 eq.) in THF (8.3 mL, 0.26 M) were stirred at 
rt for 3 h. Purification by flash column chromatography eluting with (5% to 50% EtOAc/Petrol) yielded 
the title compound as an off-white solid (0.70 g, 87%). Rf 0.30 (25% EtOAc/Petrol). m.p.: 109 ‒ 110 °C. 
δ1H (400 MHz, CDCl3) 7.73 – 7.68 (1 H, m, H-19), 7.68 – 7.65 (1 H, m, H-16), 7.51 (1 H, d, J = 8.2 Hz,  
H-3), 7.40 – 7.31 (2 H, m, H-17 + H-18), 7.16 (1 H, t J = 7.7 Hz, H-2), 7.06 (1 H, d, J = 7.7 Hz, H-10),  
6.99 (1 H, d, J = 7.3 Hz, H-1), 6.51 (1 H, td, J = 7.5, 1.7 Hz, H-12), 6.46 (1 H, td, J = 7.7, 1.8 Hz, H-11), 
6.26 (1 H, d, J = 7.8 Hz, H-13), 3.31 (3 H, s, H-14), 3.11 (3 H, s, H-15). δ13C (101 MHz, CDCl3)  
161.3 (C-7), 143.2 (C-8), 141.7 (C-6), 134.4 (C-4), 133.1 (C-10), 129.8 (C-13), 129.7 (C-5), 128.1 (C-16), 
127.6 (C-12), 126.93 (C-11), 126.88 (C-3), 126.1 (C-17 or C-18), 126.0 (C-17 or C-18), 125.7 (C-2),  
124.8 (C-1), 123.1 (C-19), 122.9 (C-9), 40.1 (C-14), 38.8 (C-15). IR (film, cm-1) νmax 1653 (C=O),  
1356 (C–N). HRMS (ESI+) m/z calcd for C19H17BrN2ONa+ [M+Na]+ 391.0416; found: 391.0415. 
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1,1'-(1,3-Phenylene)bis(3-(2-bromophenyl)-1,3-dimethylurea) – 2.41k 
Following the procedure reported by Clayden et al.[2]  
2-bromoaniline (0.82 mL, 7.2 mmol, 2.3 eq.), 1,3-phenyl-
ene diisocyanate (0.50 g, 3.1 mmol, 1.0 eq.) in THF  
(15.0 mL, 0.2 M) were stirred at rt for 3 h. Volatiles were 
evaporated in vacuo and the residue was suspended in Et2O. Filtration yielded the urea as a white 
solid (1.3 g, 86%) which was used directly in the next step. The required urea (1.3 g, 2.6 mmol, 1 eq.), 
NaOH (0.51 g, 12 mmol, 4.8 eq.), MeI (0.81 mL, 13 mmol, 5.0 eq) in THF (43 mL, 0.06 M) were stirred 
at rt overnight. Purification by flash column chromatography eluting with (10% to 60% EtOAc/Petrol) 
yielded the title compound as an off-white solid (0.50 g, 34%). δ1H (400 MHz, CDCl3)  
7.28 (2 H, dd, J = 8.0, 1.5 Hz, H-8), 6.89 (2 H, td, J = 7.6, 1.5 Hz, H-10), 6.80 (2 H, td, J = 8.0, 1.6 Hz,  
H-9), 6.75 (1 H, t, J = 8.0 Hz, H-2), 6.65 (2 H, dd, J = 7.9, 1.6 Hz, H-11), 6.45 (2 H, dd, J = 8.0, 2.0 Hz,  
H-1), 6.10 (1 H, t, J = 2.0 Hz, H-3), 3.09 (6 H, s, H-12), 2.98 (6 H, s, H-13). δ13C (101 MHz, CDCl3)  
160.3 (C-5), 145.7 (C-4), 143.8 (C-6), 133.2 (C-8), 130.0 (C-11), 129.2 (C-2), 127.9 (C-10), 127.5 (C-9), 
123.0 (C-2), 123.0 (C-3), 122.7 (C-7), 39.8 (C-13), 38.7 (C-12). Spectroscopic data were consistent with 
those reported in the literature.[2] 
1-(2-Bromophenyl)-3-(2,6-diisopropylphenyl)-1,3-dimethylurea 2.41l 
 Following GP2.1 (Part 1) 2-bromoaniline (0.50 mL, 4.4 mmol, 1 eq.),  
2,6-diisopropylphenyl isocyanate (1.1 mL, 5.3 mmol, 1.2 eq.) in CH2Cl2 
(8.0 mL, 0.55 M) were heated to reflux for 72h. Volatiles were 
evaporated in vacuo, and the residue was suspended in Et2O. Filtration 
yielded the urea as a white solid (1.6 g, 97%) which was used directly in the next step. Following GP2.1 
(Part 2) the required urea (1.55 g, 4.1 mmol, 1 eq.), NaH (0.66 g, 16 mmol, 4.0 eq., 60% in mineral oil), 
MeI (1.5 mL, 25 mmol, 6.0 eq) in THF (8.2 mL, 0.5 M) were stirred at rt overnight. Purification by flash 
column chromatography eluting with (10% to 50% Et2O/Petrol) yielded the title compound as a white 
solid (1.56 g, 94%). Rf 0.58 (25% EtOAc/Petrol). m.p.: 94 ‒ 95 °C. Mixture of conformers in a 1.0:0.3 
ratio. δ1H (400 MHz, CDCl3) 7.71 (1 Hmin, br. s), 7.44 (1 Hmaj, d, J = 7.8 Hz, H-8maj), 7.35 (1 Hmin, br. s),  
7.21 – 7.05 (2 Hmaj, m, H-1 + H-11), 7.01 – 6.78 (4 Hmaj, m, H-9 + H-10 + H-2), 6.35 (1 Hmaj, d, J = 7.7 Hz, 
H-11), 3.17 (3 Hmaj, s, H-12), 3.09 (3 Hmin, br. s, H-12), 2.96 (3 Hmaj, s, H-13),  
2.91 (2 Hmaj + 2 Hmin, sept., J = 7.1 Hz, H-14), 2.64 (3 Hmin, br. s, H-13), 1.36 – 0.86 (12 Hmin + maj, m,  
H-15). δ13C (101 MHz, CDCl3) 162.0 (C-5maj), 146.8 (C-3maj), 144.3 (C-6maj), 140.0 (C-4maj), 133.9 (C-8maj), 
130.2 (C-11maj), 128.3 (C-9maj), 127.9 (C-10maj), 127.8 (C-1maj), 124.1 (C-2maj), 123.5 (C-7maj),  
40.2 (C-13maj), 40.0 (C-12maj), 27.9 (C-14maj), 26.5 (C-15maj), 22.9 (C-15maj). IR (film, cm-1) νmax  
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2963 (C–H), 1649 (C=O), 1351 (C–N). HRMS (ESI+) m/z calcd for C21H27N2OBrNa+ [M+Na]+ 425.1199; 
found: 425.1191. 
1-(2-Bromophenyl)-3-(2-(tert-butyl)-6-methylphenyl)-1,3-dimethylurea – 2.41m 
 Following GP2.1 (Part 1) 2-bromoaniline (0.50 mL, 4.4 mmol, 1 eq.), 1-(tert-
butyl)-2-isocyanato-3-methylbenzene (1.0 g, 5.3 mmol, 1.2 eq.) in CH2Cl2  
(8.0 mL, 0.55 M) were heated to reflux for 72 h. Volatiles were evaporated in 
vacuo, and the residue was suspended in Et2O. Filtration yielded the urea as a white solid (1.41 g, 89%) 
which was used directly in the next step. Following GP2.1 (Part 2) the required urea (1.35 g, 3.73 
mmol, 1 eq.), NaH (0.60 g, 15 mmol, 4.0 eq., 60% in mineral oil), MeI (1.4 mL, 22 mmol, 6.0 eq) in THF 
(7.4 mL, 0.5 M) were stirred at rt overnight. Purification by flash column chromatography eluting with 
(10% to 75% Et2O/Petrol) yielded the title compound as a colourless oil (1.22 g, 84%). Rf 0.46 (25% 
EtOAc/Petrol). Mixture of conformers in a 1.0:1.0 ratio. Integration are given relative to one 
conformer. δ1H (400 MHz, CDCl3) 7.71 (1 H, dd, J = 8.0, 1.4 Hz, ArH), 7.49 – 7.34 (3 H, m, ArH),  
7.27 (2 H, d, J = 7.1 Hz, ArH), 7.19 (1 H, td, J = 7.6, 1.8 Hz, ArH), 7.15 – 7.08 (2 H, m, ArH),  
6.89 (2 H, br. s, ArH), 6.73 (1 H, br. s, ArH), 6.50 (1 H, br. s, ArH), 6.28 (1 H, br. s, ArH), 3.16 (3 H, s, 
NCH3), 3.15 (3 H, s, NCH3), 3.05 – 2.80 (3 H, m, NCH3), 2.60 (3 H, s, NCH3), 2.13 – 1.85 (3 H, s, CCH3), 
1.96 (3 H, m, CCH3) 1.44 (9 H, br. s, C(CH3)3), 1.35 (9 H, s, C(CH3)3). δ13C (101 MHz, CDCl3) 160.3 (C=O), 
159.7 (C=O), 147.4 (ArC), 146.4 (ArC), 144.6 (ArC), 143.8 (ArC), 140.5 (ArC), 138.8 (ArC), 137.9 (ArC), 
134.3 (ArCH), 133.1 (ArCH), 130.4 (ArCH), 130.4 (ArC), 129.9 (ArCH), 129.7 (ArCH), 128.7 (ArCH), 
128.62 (ArCH), 128.60 (ArCH), 128.2 (ArCH), 127.6 (ArCH), 127.4 (ArCH), 127.1 (ArCH), 126.9 (ArCH), 
125.5 (ArCH), 124.0 (ArC), 123.6 (ArC), 40.5 (NCH3), 39.9 (NCH3), 39.8 NCH3), 39.6 (NCH3),  
36.7 (C(CH3)3), 35.6 (C(CH3)3), 32.8 (C(CH3)3), 31.8 (C(CH3)3), 19.2 (CCH3), 18.8 (CCH3). IR (film, cm-1) νmax 
2961 (C–H), 1648 (C=O), 1476, 1350 (C–N). HRMS (ESI+) m/z calcd for C20H25N2OBrNa+ [M+Na]+ 
411.1042; found: 411.1052. 
1-(2-Bromo-6-methylphenyl)-1,3-dimethyl-3-(2-methylnaphthalen-1-yl)urea – 2.41n 
 Following GP2.1 (Part 1) 2-methyl-1-naphthylamine (0.30 mL, 2.1 mmol, 
1 eq.), 2-bromo-6-methylphenyl isocyanate (2.5 mmol, 1.2 eq.) in CH2Cl2 
(3.9 mL, 0.55 M) were stirred at rt overnight. Filtration yielded the title 
compound as a white solid which was used directly in the next step. Following GP2.1 (Part 2) the 
required urea (2.1 mmol, 1 eq.), NaH (0.43 g, 8.5 mmol, 4.0 eq., 60% in mineral oil), MeI (0.79 mL,  
13 mmol, 6.0 eq.) in THF (8.0 mL, 0.27 M reaction run more dilute because of solubility) were stirred 
at rt for 2.5 h. Purification by flash column chromatography eluting with (5% to 60% EtOAc/Petrol) 
yielded the title compound as a colourless oil (0.77 g, 91%). Rf 0.24 (25% EtOAc/Petrol). Mixture of 
conformers in a 1.0:1.0 ratio. δ1H (400 MHz, CDCl3) 7.72 (1 H, d, J = 7.6 Hz, ArH), 7.69 – 7.60 (2 H, m, 
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ArH), 7.55 (1 H, d, J = 5.9 Hz, ArH), 7.47 (2 H, dd, J = 8.4, 5.7 Hz, ArH), 7.36 – 7.29 (2 H, m, ArH),  
7.28 – 7.16 (2 H, m, ArH), 7.11 (1 H, d, J = 8.4 Hz, ArH), 7.02 (1 H, d, J = 8.4 Hz, ArH),  
6.95 (1 H, dd, J = 7.1, 2.3 Hz, ArH), 6.84 (1 H, d, J = 7.8 Hz, ArH), 6.56 – 6.45 (2 H, m, ArH),  
6.34 (1 H, d, J = 7.5 Hz, ArH), 6.26 (1 H, t, J = 7.7 Hz, ArH), 3.25 (3 H, s, NCH3), 3.24 (3 H, s, NCH3),  
3.06 (3 H, s, NCH3), 3.04 (3 H, s, NCH3), 2.32 (3 H, s, ArCH3), 2.17 (3 H, s, ArCH3), 1.70 (3 H, s, ArCH3), 
1.41 (3 H, s, ArCH3). δ13C (101 MHz, CDCl3) 162.3 (C=O), 162.3 (C=O), 141.5 (ArC), 141.3 (ArC),  
138.48 (ArC), 138.46 (ArC), 138.4 (ArC), 137.9 (ArC), 134.3 (ArC), 133.2 (ArC), 133.11 (ArC),  
133.08 (ArC), 131.7 (ArCH), 130.8 (ArCH), 130.7 (ArC), 130.4 (ArC), 130.3 (ArCH), 129.6 (ArCH),  
129.2 (ArCH), 129.1 (ArCH), 128.0 (ArCH), 127.4 (ArCH), 127.0 (ArCH), 126.92 (ArCH), 126.88 (ArCH), 
126.6 (ArCH), 126.3 (ArCH), 126.0 (ArCH), 125.10 (ArCH), 125.05 (ArCH), 124.0 (ArC), 123.9 (ArC),  
123.5 (ArCH), 122.7 (ArCH), 38.4 (NCH3), 38.1 (NCH3), 37.1 (NCH3), 37.0 (NCH3), 18.50 (CCH3),  
18.48 (CCH3), 18.2 (CCH3), 17.6 (CCH3). IR (film, cm-1) νmax 1652 (C=O), 1347 (C–N). HRMS (ESI+) m/z 
calcd for C21H21N2OBrNa+ [M+Na]+ 419.0729; found 419.0732. 
1-(2-Bromo-6-methylphenyl)-3-(2-(tert-butyl)-6-methylphenyl)-1,3-dimethylurea– 2.41o 
 Following GP2.1 (Part 1) 2-bromo-6-methylaniline (1.0 g, 5.3 mmol, 1 eq.), 
1-(tert-butyl)-2-isocyanato-3-methylbenzene (1.0 g, 5.7 mmol, 1.1 eq.) in  
1,4-dioxane (5.5 mL, 1.0 M) were heated in a microwave to 200 °C for 2 h. 
Volatiles were removed in vacuo and the crude mixture was used directly in the next step. Following 
GP2.1 (Part 2) the required urea (5.3 mmol, 1 eq.), NaH (0.85 g, 21 mmol, 4.0 eq., 60% in mineral oil), 
MeI (2.0 mL, 32 mmol, 6.0 eq.) in THF (10.6 mL, 0.5 M) were stirred at rt for 24 h. Purification by flash 
column chromatography eluting with (5% to 30% EtOAc/Petrol) yielded the title compound as a 
colourless oil (0.79 g, 37%). Rf 0.39 (25% EtOAc/Petrol). Mixture of conformers slowly interconverting 
giving rise to broad peaks. Peaks of the 13C NMR spectrum could not be assigned. δ1H (400 MHz, CDCl3) 
7.66 – 6.62 (6 H, m, ArH), 3.36 – 3.06 (3 H, m, NCH3), 2.93 – 2.11 (6 H, m, CCH3 + NCH3),  
1.87 – 1.13 (12 H, m, CCH3 + C(CH3)3). δ13C (101 MHz, CDCl3) 159.1 (C=O), 147.1, 146.8, 143.0, 137.8, 
131.44, 131.42, 131.2, 130.8, 130.5, 130.3, 129.9, 129.2, 128.9, 128.6, 128.03, 128.00, 127.0, 126.9, 
126.8, 125.6, 40.5, 38.9, 38.4, 38.3, 37.7, 36.9, 36.7, 35.8, 32.9, 32.8, 32.1, 32.0, 29.9, 19.30, 19.26, 
19.21, 19.0, 18.1. IR (film, cm-1) νmax 2958, 2924 (C–H), 1644 (C=O), 1453, 1348 (C–N). HRMS (ESI+) m/z 
calcd for C21H28N2OBr+ [M+H]+ 403.1380; found: 403.1382. 
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N-Methyl-2-(methylamino)-N-phenylbenzamide - 2.42a 
 Following GP2.2 on a 5.5 mmol scale, the title compound was obtained as a 
colourless oil (1.20 g, 91%). Rf 0.31 (25% EtOAc/Petrol). δ1H (400 MHz, CDCl3)  
7.21 (2 H, t, J = 7.5 Hz, H-2), 7.14 – 7.05 (2 H, m, H-1 + H-10),  
7.04 (2 H, d, J = 7.5 Hz, H-3), 6.73 (1 H, dd, J = 7.6, 1.6 Hz, H-8),  
6.59 (1 H, d, J = 8.3 Hz, H-11), 6.26 (1 H, td, J = 7.6, 1.1, H-9), 5.76 (1 H, br. s, NH), 
3.47 (3 H, s, H-7), 2.85 (3 H, s, H-13). δ13C (101 MHz, CDCl3) 171.7 (C-5), 149.2 (C-12), 145.3 (C-4),  
131.0 (C-10), 130.0 (C-8), 129.2 (C-2), 126.4 (C-1), 126.3 (C-3), 119.0 (C-6), 114.9 (C-9), 110.6 (C-11), 
38.1 (C-7), 30.3 (C-13). IR (film, cm-1) νmax 3393 (N–H), 1631 (C=O). HRMS (ESI+) m/z calcd for 
C15H17N2O+ [M+H]+ 241.1335; found: 241.1330. 
N-(4-Fluorophenyl)-N-methyl-2-(methylamino)benzamide – 2.42b  
 Following GP2.2 on a 1.5 mmol scale, the title compound was obtained as a 
yellow solid (320 mg, 84%). Rf 0.30 (25% EtOAc/Petrol). m.p.: 81 ‒ 82 °C.  
δ1H (400 MHz, CDCl3) 7.09 (1 H, ddd, J = 8.3, 7.5, 1.6 Hz, H-9), 7.06 – 6.96 (2 H, m, 
H-1), 6.93 – 6.86 (2 H, m, H-2), 6.71 (1 H, dd, J = 7.5, 1.6 Hz, H-7),  
6.59 (1 H, dd, J = 8.3, 1.1, H-10), 6.30 (1 H, td, J = 7.5, 1.1 Hz, H-8),  
5.68 (1 H, br. s NH), 3.44 (3 H, s, H-6), 2.84 (3 H, s, H-12). δ13C (101 MHz, CDCl3) 171.7 (C-4),  
160.8 (d, J = 246 Hz, C-13), 149.1 (C-11), 141.3 (d, J = 3.2 Hz, C-1), 131.1 (C-9), 129.8 (C-10),  
127.9 (d, J = 8.4 Hz, C-2), 118.8 (C-5), 116.1 (d, J = 23 Hz, C-1), 115.1 (C-8), 110.7 (C-10),  
38.3 (d, J = 2.7 Hz, C-6), 30.3 (C-12). δ19F NMR (376 MHz, CDCl3) -116.44 (dq, J = 13.6, 5.4 Hz, C–F).  
IR (film, cm-1) νmax 3388 (N–H), 1633 (C=O), 1507. HRMS (ESI+) C15H15FN2ONa+ 281.1061; found: 
281.1050. 
N-Methyl-2-(methylamino)-N-(4-(trifluoromethyl)phenyl)benzamide – 2.42c  
 Following GP2.2 on a 0.3 mmol scale, the title compound was obtained as a 
yellow solid (71 mg, 77%). Rf 0.34 (25% EtOAc/Petrol). m.p.: 76 ‒ 77 °C.  
δ1H (400 MHz, CDCl3) 7.46 (2 H, dt, J = 8.4, 0.7 Hz, H-2), 7.18 – 7.08 (3 H, m,  
H-3 + H-10), 6.71 (1 H, dd, J = 7.6, 1.6 Hz, H-8), 6.61 (1 H, br. d, J = 8.4 Hz, H-11),  
6.29 (1 H, td, J = 7.6, 1.1 Hz, H-9), 5.81 (1 H, br. s, NH), 2.48 (3 H, s, H-7),  
2.85 (3 H, s, H-13). δ13C (101 MHz, CDCl3) 171.8 (C-5), 149.4 (C-12), 148.5 (q, J = 1.5 Hz, C-4),  
131.6 (C-10), 130.0 (C-8), 128.0 (q, J = 33 Hz, C-1), 126.3 (q, J = 3.8 Hz, C-2), 126.2 (C-3),  
123.9 (q, J = 272 Hz, C-14), 118.1 (C-6), 115.1 (C-9), 110.8 (C-11), 37.9 (C-7), 30.2 (C-13).  
δ19F NMR (376 MHz, CDCl3) -62.5 (s, CF3). IR (film, cm-1) νmax 3404 (N–H), 1639 (C=O), 1325 (C–F).  
HRMS (ESI+) C16H15F3N2ONa+ 331.1029; found: 331.1028. 
163 
 
N-Methyl-2-(methylamino)-N-(4-(methoxy)phenyl)benzamide – 2.42e 
Following GP2.2 on a 1.2 mmol scale, the title compound was obtained as a 
yellow oil (275 mg, 88%). Rf 0.61 (40% EtOAc/Petrol). δ1H (400 MHz, CDCl3)  
7.07 (1 H, ddd, J = 8.3, 7.3, 1.6 Hz, H-10), 6.96 (2 H, m, H-3), 6.74 (3 H, m,  
H-2 + H-8), 6.58 (1 H, d, J = 8.3 Hz, H-11), 6.29 (1 H, td, J = 7.5, 1.1 Hz, H-9),  
5.69 (1 H, br. s, NH), 3.73 (3 H, s, H-14), 3.43 (3 H, s, H-13), 2.84 (3 H, s, H-13).  
δ13C (101 MHz, CDCl3) 171.6 (C-5), 157.9 (C-1), 149.0 (C-12), 138.2 (C-4), 130.8 (C-10), 129.8 (C-8),  
127.4 (C-3), 119.2 (C-6), 115.0 (C-9), 114.3 (C-2), 110.6 (C-11), 55.5 (d, J = 2.6 Hz, C-14), 38.4 (C-7),  
30.3 (C-13). IR (film, cm-1) νmax 3390 (N–H), 1627 (C=O), 1507, 1245 (C–O). HRMS (ESI+) C16H19N2O2+ 
271.1441; found: 271.1430. 
N-(3-Methoxyphenyl)-N-methyl-2-(methylamino)benzamide – 2.42g 
Following GP2.2 on a 1.5 mmol scale, the title compound was obtained as 
a colourless oil (0.25 g, 62%). Rf 0.22 (25% EtOAc/Petrol).  
δ1H (400 MHz, CDCl3) 7.10 (1 H, t, J = 8.1 Hz, H-2), 7.13 – 7.04 (1 H, m,  
H-12), 6.77 (1 H, dd, J = 7.7, 1.6 Hz, H-10), 6.68 – 6.64 (1 H, m, H-1),  
6.64 – 6.61 (1 H, m, H-13), 6.60 – 6.56 (2 H, m, H-3 + H-5),  
6.29 (1 H, td, J = 7.5, 1.0 Hz, H-11), 5.71 (1 H, br. s, NH), 3.66 (3 H, s, H-16), 3.46 (3 H, s, H-9),  
2.84 (3 H, s, H-15). δ13C (101 MHz, CDCl3) 171.7 (C-7), 160.1 (C-4), 149.1 (C-14), 146.4 (C-6),  
131.0 (C-12), 129.8 (C-2), 129.7 (C-10), 119.2 (C-8), 118.5 (C-13), 115.1 (C-11), 112.11 (C-1, C-3 or C-5), 
112.05 (C-1 Hz, C-3 or C-5), 110.5 (C-1 Hz, C-3 or C-5), 55.4 (C-16), 38.0 (C-9), 30.3 (C-15).  
IR (film, cm-1) νmax 3395 (N–H), 2921 (C–H), 1632 (C=O), 1582, 1042 (C–O). HRMS (ESI+) m/z calcd for 
C16H19N2O2+ [M+H]+ 271.1441; found: 271.1445. 
N-Methyl-2-(methylamino)-N-(naphthalen-1-yl)benzamide – 2.42j 
Following GP2.2 on a 0.3 mmol scale, the title compound was obtained as 
a white solid (57 mg, 65%). Rf 0.38 (25% EtOAc/Petrol). m.p.: 166 ‒ 167 °C. 
δ1H (400 MHz, CDCl3) 8.01 (1 H, d, J = 8.5 Hz, H-19), 7.85 (1 H, d, J = 8.2 Hz, 
H-16), 7.69 (1 H, d, J = 8.3 Hz, H-3), 7.60 (1 H, ddd, J = 8.4, 6.8, 1.3 Hz,  
H-18), 7.52 (1 H, ddd, J = 8.1, 6.8, 1.2 Hz, H-17), 7.26 (1 H, br. s, H-2),  
7.12 (1 H, br. s, H-1), 6.97 (1 H, br. s, H-12), 6.67 (1 H, s, H-10), 6.52 (1 H, d, J = 8.3 Hz, H-13),  
5.99 (1 H, br. s, H-11), 5.95 (1 H, br. s, NH), 3.51 (3 H, s, H-9), 2.85 (3 H, s, H-15) δ13C (101 MHz, CDCl3) 
172.8 (C-7), 148.9 (C-14), 141.7 (C-6), 134.6 (C-4), 131.1 (C-12), 129.8 (C-5), 128.8 (C-16), 128.3 (C-10), 
127.9 (C-3), 127.2 (C-18), 126.4 (C-17), 125.7 (C-2), 125.5 (C-1), 122.8 (C-19), 118.8 (C-8), 114.7 (C-11), 
110.6 (C-13), 38.4 (C-9), 30.2 (C-15). IR (film, cm-1) νmax 3392 (N–H), 1632 (C=O), 1513. HRMS (ESI+) 
C19H19N2O+ 291.1492; found: 291.1499. 
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N,N'-(1,3-Phenylene)bis(N-methyl-2-(methylamino)benzamide) - 2.42k 
Following GP2.2 on a 0.45 mmol scale, the title compound was 
obtained as a white solid (0.15 g, 85%). Rf 0.37  
(50% EtOAc/Petrol). m.p.: 70 ‒ 72 °C. Mixture of conformers in 
a 1:0.15 ratio. δ1H (400 MHz, CDCl3)  
7.11 (2 Hmaj + min, ddd, J = 8.2, 7.3, 1.6 Hz, H-10), 6.99 (1 Hmaj + min, t, J = 7.6 Hz, H-2), 6.86 (3 Hmin, m),  
6.74 (1 Hmaj, t, J = 1.8 Hz, H-3), 6.72 (2 Hmaj, dd, J = 7.9, 2.0 Hz, H-1), 6.60 (2 Hmaj, dd, J = 8.3, 1.0 Hz,  
H-11), 6.53 (2 Hmaj, dd, J = 7.7, 1.6 Hz, H-8), 6.30 (2 Hmaj, td, J = 7.5, 1.1 Hz, H-9),  
6.19 (2 Hmin, dddd, J = 13.9, 7.8, 2.2, 0.9), 6.01 (1 Hmin, t, J = 2.2), 5.67 (2 Hmaj, br. s, NH),  
3.30 (6 Hmaj, s, H-7), 3.17 (6 Hmin, d, J = 3.5), 2.84 (6 Hmaj, br. s, H-13), 2.69 (6 Hmin, s).  
δ13C (101 MHz, CDCl3) 171.4 (C-5), 149.0 (C-12), 145.7 (C-4), 131.0 (C-10), 129.7 (C-8), 129.3 (C-2),  
123.7 (C-1), 123.6 (C-3), 118.6 (C-6), 115.0 (C-9), 110.6 (C-11), 37.5 (C-7), 30.1 (C-13). IR (film, cm-1) 
νmax 3390 (N–H), 1633 (C=O), 1579. HRMS (ESI+) m/z calcd for C24H26N2O2Na+ [M+Na]+ 425.1948; found: 
425.1949. 
N-(2,6-Diisopropylphenyl)-N-methyl-2-(methylamino)benzamide – 2.42l 
 Following GP2.2 on a 1.2 mmol scale, the title compound was obtained as a 
white solid (0.33 g, 83%). Rf 0.64 (25% EtOAc/Petrol). m.p.: 111 ‒ 112 °C. 
Mixture of conformers in a 1:0.33 ratio. δ1H (400 MHz, CDCl3)  
7.39 – 7.28 (2 Hmin, m, ArCH), 7.24 (1 Hmin, s, ArCH), 7.20 (1 H maj, t, J = 7.7 Hz, 
ArCH), 7.05 (2 H maj, d, J = 7.6 Hz, ArCH), 7.03 (1 Hmaj, td, J = 7.8, 1.2 Hz, ArCH),  
6.74 (2 Hmin, dd, J = 8.2, 5.9 Hz, ArCH), 6.62 (1 Hmaj, dd, J = 7.8, 1.6 Hz, ArCH), 6.53 (1 Hmaj, d, J = 8.4 Hz, 
ArCH), 6.31 (1 Hmaj, br. s, NH), 6.12 (1 Hmaj, t, J = 7.3 Hz, ArCH), 5.38 (1 Hmin, br. s, NH), 3.31 (3 Hmaj, s, 
NCH3), 3.22 (3 Hmin, s, NCH3), 3.08 (2 Hmin, hept, J = 5.8 Hz, CH(CH3)2), 3.01 (2 Hmaj, hept, J = 5.8 Hz, 
CH(CH3)2), 2.84 (3 Hmin, s, NHCH3), 2.83 (3 Hmaj, s, NHCH3), 1.29 (CHAHB, 6 Hmin, d, J = 5.8 Hz, CH(CH3)2),  
1.27 (CHAHB, 6 Hmin, d, J = 5.8 Hz, CH(CH3)2), 1.19 (CHAHB, 6 Hmaj, d, J = 5.8 Hz, CH(CH3)2),  
1.00 (CHAHB, 6 Hmaj, d, J = 5.8 Hz, CH(CH3)2). δ13C (101 MHz, CDCl3) 171.9 (C=O), 171.5 (C=O),  
149.4 (ArCmaj), 148.7 (ArCmin), 145.7 (ArCmaj), 145.5 (ArCmin), 140.3 (ArCmaj), 137.9 (ArCmin),  
131.3 (ArCHmin), 131.2 (ArCHmaj), 129.3 (ArCHmaj), 128.7 (ArCHmin), 128.3 (ArCHmaj), 127.7 (ArCHmin), 
124.4 (ArCHmaj), 119.5 (ArCmin), 117.0 (ArCHmaj), 115.6 (ArCHmin), 113.6 (ArCHmaj), 111.3 (ArCHmin),  
110.5 (ArCHmaj), 41.6 (NCH3min), 38.9 (NCH3maj), 30.5 (NHCH3min), 30.1 (NHCH3maj), 28.8 (CH(CH3)2min), 
28.4 (CH(CH3)2maj), 26.0 (CH(CH3)2maj), 24.5 (CH(CH3)2min), 24.3 (CH(CH3)2min), 22.9 (CH(CH3)2maj).  
IR (film, cm-1) νmax 3394 (N–H), 2963, 2927 (C–H), 1628 (C=O), 1516, 1358. HRMS (ESI+) m/z calcd for 
C21H29N2O+ [M+H]+ 325.2274; found: 325.2268. 
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N-(2-(tert-Butyl)-6-methylphenyl)-N-methyl-2-(methylamino)benzamide - 2.42m 
 Following GP2.2 on a 1.3 mmol scale, the title compound was obtained 
as a white solid (195 mg, 47%). Rf 0.52 and 0.63 (two conformers)  
(25% EtOAc/Petrol). m.p.: 129 ‒ 130 °C. Mixture of conformers in a 
1:0.07 ratio. Only major peaks were assigned in the 1H NMR spectrum.  
δ1H (400 MHz, CDCl3) 7.40 (1 Hmin, t, J = 4.8), 7.35 (1 Hmin, dd, J = 7.7, 1.4),  
7.31 (1 Hmaj + 1 Hmin, d, J = 8.0 Hz, H-4), 7.20 (2 Hmin, d, J = 5.0), 7.13 (1 Hmaj, t, J = 7.7 Hz, H-12),  
7.08 – 7.04 (1 Hmaj, m, H-3), 7.02 (1 Hmaj, d, J = 7.2 Hz, H-2), 6.83 (1 Hmaj, br. s, NH),  
6.75 – 6.67 (2 Hmin, m), 6.60 – 6.53 (2 Hmaj, m, H-13 + H-10), 6.09 (1 Hmaj, t, J = 7.6 Hz, H-11),  
3.29 (3 Hmaj, s, H-9), 3.27 (3 Hmin, s), 2.84 (3 Hmaj, s, H-15), 2.81 (3 Hmin, s), 2.26 (3 Hmin, s),  
2.18 (3 Hmaj, s, H-16), 1.48 (9 Hmin, s), 1.27 (9 Hmaj, s, H-18). δ13C (101 MHz, CDCl3) 172.5 (C-7min),  
170.2 (C-7maj), 150.3 (C-14maj), 149.6 (C-14min), 146.9 (C-5min), 146.1 (C-5maj), 141.3 (C-6maj),  
137.2 (C-1maj), 136.1 (C-1min), 131.6 (C-3min), 131.3 (C-3maj), 130.0 (C-10min), 129.11 (C-10maj),  
129.05 (C-2maj), 128.5 (C-4maj), 128.0 (C-4min), 127.8 (C-12maj), 126.6 (C-12min), 116.7 (C-8maj),  
115.2 (C-8min), 113.4 (C-11maj), 111.4 (C-13min), 110.8 (C-13maj), 42.3 (C-9min), 39.8 (C-9 maj), 36.6 (C-17maj), 
32.4 (C-18maj), 32.2 (C-18min), 30.3 (C-15min), 30.1 (C-15 maj), 18.7 (C-16 maj). IR (film, cm-1) νmax  
3383 (N–H), 2958 (C–H), 1627 (C=O), 1516, 1359. HRMS (ESI+) m/z calcd for C20H27N2O+ [M+H]+ 
311.2118; found: 311.2117. 
N-(2-(tert-Butyl)-6-methylphenyl)-N,3-dimethyl-2-(methylamino)benzamide -2.42n 
Following GP2.2 1-(2-bromo-6-methylphenyl)-3-(2-(tert-butyl)-6-
methylphenyl)-1,3-dimethylurea 2.41n (790 mg, 1.96 mmol, 1 eq.),  
sec-BuLi (1.80 mL, 2.16 mmol, 1.1 eq., 1.20 M in cyclohexane, added 
over 30 min), in THF (9.8 mL, 0.2 M) were stirred at −78 °C for 24 h. 
Purification by flash column chromatography eluting with (2% to 30% 
EtOAc/Petrol) yielded a residue which was dissolved in Et2O (10 mL). HCl (2.0 mL, 2.0 mmol, 1.0 M in 
Et2O) was added and the resultant off-white precipitate filtered. The solid was Partitioned between 
CH2Cl2 and a saturated solution of aqueous NaHCO3 and extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried over MgSO4, filtered and concentrated in vacuo to yield the title 
compound as a yellow oil (191 mg, 30%). Rf 0.33 (30% EtOAc/Petrol). Mixture of conformers in a 
1.0:0.15 ratio. Only major peaks were assigned in the 13C spectrum. δ1H (400 MHz, CDCl3)  
7.41 (1 Hmaj, m, H-3), 7.30 (2 Hmin, dd, J = 8.3, 1.4 Hz), 7.24 (1 Hmaj, dd, J = 7.5, 1.4 Hz, H-10),  
7.21 (3 Hmaj, m, H-2 + H-4 + H-12), 7.14 (2 Hmin, t, J = 7.7 Hz), 7.06 – 6.97 (2 Hmin, m),  
6.94 (1 Hmaj + 1 Hmin, t, J = 7.5 Hz, H-11), 6.48 (1 Hmin, dd, J = 7.8, 1.6 Hz), 6.28 (1 Hmin, t, J = 7.7 Hz),  
4.69 (1 Hmaj, br. s, NH), 3.32 (3 Hmin, s, H-9), 3.18 (3 Hmaj, s, H-9), 2.85 (3 Hmin, s, H-15), 2.83 (3 Hmaj, s,  
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H-15), 2.37 (3 Hmaj, s, H-19), 2.33 (3 Hmaj, s, H-16), 2.29 (3 Hmin, s, H-19), 2.21 (3 Hmin, s, H-16),  
1.50 (9 Hmaj, s, H-18), 1.28 (9 Hmin, s, H-18). δ13C (101 MHz, CDCl3) 172.0 (C-7maj), 170.1 (Cmin),  
148.1 (C-14maj), 146.9 (C-5maj), 146.0 (Cmin), 141.10 (C-6maj), 141.05 (Cmin), 136.9 (Cmin), 136.3 (C-1maj), 
133.7 (Cmin), 133.0 (C-12maj), 131.6 (C-13maj), 129.9 (C-2maj), 129.0 (Cmin), 128.5 (Cmin), 127.9 (C-4maj), 
127.84 (Cmin), 127.77 (C-8maj), 126.75 (C-3maj), 126.3 (Cmin), 125.1 (Cmin), 125.0 (C-10maj), 123.6 (Cmin), 
121.0 (C-11maj), 117.9 (Cmin), 42.0 (C-9maj), 39.9 (Cmin), 36.6 (Cmin), 36.2 (C-17maj), 36.1 (C-15maj),  
35.2 (Cmin), 32.5 (Cmin), 32.2 (C-18maj), 20.4 (Cmin), 19.1 (C-19maj), 18.8 (Cmin), 18.6 (C-16maj).  
IR (film, cm-1) νmax 3367 (N–H), 2958 (C–H), 1644 (C=O), 1449, 1352. HRMS (ESI+) m/z calcd for 
C21H29N2O+ [M+H]+ 325.2274; found: 325.2277. 
N,3-Dimethyl-2-(methylamino)-N-(2-methylnaphthalen-1-yl)benzamide 2.42o 
 Following GP2.2 1-(2-bromo-6-methylphenyl)-1,3-dimethyl-3-(2-
methylnaphthalen-1-yl)urea 2.41o (646 mg, 1.62 mmol, 1 eq.),  
s-BuLi (1.37 mL, 1.78 mmol, 1.1 eq., 1.30 M in cyclohexane) in THF 
(8.1 mL, 0.2 M) were stirred at −78 °C for 24 h. The compound was 
purified by flash column chromatography eluting with (10% to 70% Et2O/Petrol). The residue was 
dissolved in Et2O and HCl 2 M in Et2O was added. The white precipitate was filtered, dissolved in CH2Cl2, 
and the organic phase was washed with a saturated solution of aqueous NaHCO3. Evaporation of the 
volatiles yielded the title compound as a yellow oil (161 mg, 32%). Rf 0.20 (30% EtOAc/Petrol). Mixture 
of conformers A:B:C in a 1.0:0.4:0.1 ratio. Only major peaks were assigned in the 1H and 13C spectra. 
δ1H (400 MHz, CDCl3) 8.00 (1 HC, dd, J = 8.4, 1.0 Hz), 7.96 (1 HB, ddd, J = 8.4, 1.9, 1.0 Hz),  
7.93 (1 HA, dd, J = 8.5, 1.0 Hz, H-17), 7.87 (1 HB, dt, J = 8.1, 0.7 Hz), 7.82 – 7.79 (1 HC, m),  
7.78 (1 HA, dd, J = 8.2, 0.6 Hz, H-20), 7.78 (1 HC, d, J = 8.2 Hz), 7.61 (1 HA, d, J = 8.4 Hz, H-3),  
7.61 – 7.54 (1 HA + 2 HB, m, H-18A), 7.50 – 7.42 (1 HA + 2 HB + 2 HC, m, H-21A),  
7.37 (1 HB, ddd, J = 7.5, 1.6, 0.6 Hz), 7.22 (1 HB, ddd, J = 7.5, 1.6, 0.8 Hz), 7.17 (1 HA, d, J = 8.5 Hz, H-2),  
7.15 – 7.12 (1 HC, m), 6.99 (1 HB, t, J = 7.5 Hz), 6.80 (1 HA, ddd, J = 7.5, 1.7, 0.9 Hz, H-10),  
6.75 (1 HC, ddd, J = 7.3, 1.6, 0.8 Hz), 6.57 (1 HA, ddd, J = 7.8, 1.6, 0.6 Hz, H-12),  
6.48 (1 HC, ddd, J = 7.8, 1.4, 0.5 Hz), 6.11 (1 HA, t, J = 7.6 Hz, H-11), 5.91 (1 HC, t, J = 7.6 Hz),  
5.08 (1 HA, s), 4.97 (1 HB, s), 3.46 (3 HA, s, H-9), 3.45 (3 HC, s), 3.25 (3 HB, s), 3.00 (3 HB, s),  
2.91 (3 HA, s, H-16), 2.54 (3 HB, s), 2.37 (3 HB, s), 2.30 (3 HA, s, H-16), 2.25 (3 HC, s), 2.23 (3 HA, s H-19), 
2.06 (3 HC, s). δ13C (101 MHz, CDCl3) 172.7 (CC), 172.4 (C-7A), 171.4 (CB), 149.1 (C-14A), 146.5 (CB),  
145.3 (CC), 138.7 (CC), 138.6 (C-6A), 136.8 (CB), 133.5 (CB), 132.48 (C-10A), 133.4 (CC), 133.03 (C-4A), 
132.99 (CB), 132.6 (C-1A), 132.1 (CB), 131.8 (CC), 130.6 (CC), 130.5 (C-5A), 129.9 (CB), 129.6 (CB),  
129.3 (C-13A), 129.1 (CB), 128.9 (CC), 128.8 (C-2A), 128.54 (CB), 128.49 (C-20A), 128.47 (CC), 127.9 (CB), 
127.7 (C-3A), 127.5 (CC), 127.43 (CC), 127.36 (C-18A), 127.3 (CC), 126.9 (CB), 126.0 (CC), 125.7 (CB),  
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125.53 (C-12A), 125.49 (C-21A), 125.4 (CC), 125.3 (CB), 124.2 (C-8A), 122.7 (CC), 122.6 (C-17A), 122.0 (CB), 
120.8 (CB), 118.2 (C-11A), 117.8 (CC), 115.2 (CB), 39.4 (CB) 37.0 (C-9A), 36.8 (CC), 36.1 (CB), 35.4 (C-16A), 
19.8 (C-19A), 18.4 (CB), 18.2 (C-15A), 18.01 (CC), 17.96 (CB), 17.5 (CC). IR (film, cm-1) νmax 2925 (C–H), 
1652 (C=O), 1596, 1494, 1351. HRMS (ESI+) m/z calcd for C21H23N2O+ [M+H]+ 319.1805; found: 
319.1801. 
1,3-dimethyl-1-(4'-nitro-[1,1'-biphenyl]-2-yl)urea – 2.43 
Following GP2.2 on a 1.4 mmol scale, the title compound was obtained as a 
yellow oil (166 mg, 39%). Rf 0.14 (80% EtOAc/Petrol). δ1H (400 MHz, CDCl3)  
8.27 (2 H, d, J = 7.7 Hz, H-12), 7.50 (2 H, d, J = 9.0 Hz, H-11), 7.46 (3 H, m,  
H-4 + H-5 + H-6), 7.35 (1 H, dt, J = 7.6, 1.0 Hz, H-7), 4.28 (1 H, q, J = 5.0 Hz, NH),  
2.91 (3 H, s, H-9), 2.70 (3 H, d, J = 4.7 Hz, H-10). δ13C (101 MHz, CDCl3)  
157.7 (C-1), 147.4 (C-13), 145.5 (C-8), 140.7 (C-2), 138.5 (C-3), 131.5 (C-6), 
130.65 (C-5), 129.55 (C-4), 129.4 (C-11), 128.7 (C-7), 124.0 (C-12), 36.8 (C-9),  
27.6 (C-10). IR (film, cm-1) νmax 3446, 3346 (N–H), 1651 (C=O), 1515 (N=O), 1349 (C–N). HRMS (ESI+) 
m/z calcd for C15H15N3O3Na+ [M+Na]+ 308.1011; found 308.0971. 
N-(2,6-diisopropylphenyl)-3-methoxy-N-methyl-2-nitrobenzamide – 2.45 
To a solution of 3-methoxy-2-nitrobenzoic acid (2.0 g, 10.1 mmol, 1 eq.) 
in toluene (10 mL, 1 M) under nitrogen was added thionyl chloride (2.2 
mL, 30.3 mmol, 3.0 eq.) before heating to reflux for 2 h. The reaction 
mixture was concentrated in vacuo, before adding toluene (20 mL) to 
azeotropically remove traces of thionyl chloride. The resulting residue was dissolved in MeCN (20 mL, 
0.5 M) and, Et3N (2.3 mL, 16.2 mmol, 1.6 eq.) followed by N-methyl-2,6-diisopropylaniline[3] (2.1 g,  
11.2 mmol, 1.1 eq.) were added at 0 °C before warming to rt and stirring for 16 h. The reaction mixture 
was quenched with sat. NH4Cl (aq.) and extracted with EtOAc, dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography eluting with (5% to 60% 
EtOAc/Petrol) followed by trituration in Et2O yielded the title compound (2.6 g, 71%) as a white solid. 
Rf 0.14 & 0.22 (30% EtOAc/Petrol). m.p.: 152 ‒ 154 °C. Mixture of conformers in a 1.0:0.4 ratio  
δ1H (400 MHz, CDCl3) 7.56 (1 Hmaj, dd, J = 8.5, 7.6 Hz, ArCH), 7.35 (1 Hmaj, dd, J = 8.4, 7.0 Hz, ArCH),  
7.32 – 7.28 (1 Hmin, m, ArCH), 7.25 – 7.22 (2 Hmaj, d, J = 7.3 Hz, ArCH), 7.15 (1 Hmaj, dd, J = 8.7, 1.1 Hz, 
ArCH), 7.13 (2 Hmin, d, J = 7.8 Hz, ArCH), 7.08 (1 Hmaj, dd, J = 7.6, 1.1 Hz, ArCH), 6.98 – 6.89 (2 Hmin, m, 
ArCH), 6.30 (1 Hmin, dd, J = 5.9, 2.1 Hz, ArCH), 3.94 (3 Hmaj, s, OCH3), 3.83 (3 Hmin, s, OCH3),  
3.33 (3 Hmin, s, CH3), 3.23 (2 Hmin, hept, J = 5.9 Hz, CH(CH3)2), 3.17 (3 Hmaj, s, CH3),  
3.10 (2 Hmaj, hept, J = 5.9 Hz, CH(CH3)2), 1.30 (CHAHB, 6 Hmaj, d, J = 5.9 Hz, CH(CH3)2),  
1.25 (CHAHB, 6 Hmaj, d, J = 5.8 Hz, CH(CH3)2), 1.21 (CHAHB, 6 Hmin, d, J = 5.8 Hz, CH(CH3)2),  
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1.02 (CHAHB, 6 Hmin, d, J = 5.8 Hz, CH(CH3)2). δ13C (101 MHz, CDCl3) 166.4 (Cmaj), 165.0 (Cmin),  
152.1 (Cmaj), 151.5 (Cmin), 146.3 (Cmin), 146.1 (Cmaj), 138.8 (Cmin), 138.6 (Cmin), 136.9 (Cmaj), 133.0 (Cmaj), 
132.5 (CHmaj), 129.4 (CHmin), 129.3 (CHmin), 129.0 (CHmaj), 124.9 (CHmin), 124.5 (CHmaj), 120.2 (CHmin), 
118.6 (CHmaj), 114.4 (CHmin), 114.0 (CHmaj), 56.96 (CH3maj), 56.94 (CH3min), 40.9 (CH3maj), 39.5 (CH3min), 
28.7 (CHmaj), 28.2 (CHmin), (CH3min), 24.7 (CH3maj), 24.3 (CH3maj), 23.3 (CH3min). IR (film, cm-1) νmax  
2966 (C–H), 1643 (C=O), 1537 (N=O), 1457, 1363 (C–N), 1285; HRMS (MALDI+) C21H26N2O4Na+ [M+Na]+ 
393.1785; found: 393.1778. 
2-amino-N-(2,6-diisopropylphenyl)-3-methoxy-N-methylbenzamide 
Pd/C (10 wt. % loading, 0.16 g, 1 mol% Pd) was suspended in a solution of 
N-(2,6-diisopropylphenyl)-3-methoxy-N-methyl-2-nitrobenzamide 2.45 
(1.6 g, 4.7 mmol, 1 eq.) in EtOH (19 mL, 0.25 M) under nitrogen. Nitrogen 
was bubbled through the solution for 15 mins. The contents of the flask 
were placed under a hydrogen atmosphere using a two-way three-necked tap with a balloon of 
hydrogen attached. The solution was saturated with hydrogen three times using a vacuum/hydrogen 
cycle. The reaction was stirred under a hydrogen atmosphere for 16 h. The contents of the flask were 
placed under a nitrogen atmosphere and the hydrogen balloon removed. The crude reaction solution 
was filtered through a pad of Celite and washed with MeOH and was concentrated in vacuo. 
Purification by flash column chromatography eluting with (5% to 35% EtOAc/Petrol) to give the title 
compound (1.45 g, 99%) as a white solid. Rf 0.29 (20% EtOAc/Petrol). m.p.: 126 ‒ 127 °C. Mixture of 
conformers in a 1.0:0.5 ratio. δ1H (400 MHz, CDCl3) 7.37 (1 Hmin, dd, J = 8.4, 7.0 Hz, ArCH),  
7.27 (2 Hmin, d, J = 8.0 Hz, ArCH), 7.23 (1 Hmaj, dd, J = 8.2, 7.3 Hz, ArCH), 7.09 (2 Hmaj, d, J = 7.7 Hz, ArCH), 
6.99 (1 Hmin, dd, J = 7.6, 1.4 Hz, ArCH), 6.85 (1 Hmin, dd, J = 8.1, 1.4 Hz, ArCH), 6.78 (1 Hmin, t, J = 7.8 Hz, 
ArCH), 6.58 (1 Hmaj, dd, J = 7.9, 1.3 Hz, ArCH), 6.26 (1 Hmaj, dd, J = 8.1, 1.3 Hz, ArCH),  
6.14 (1 Hmaj, t, J = 8.0 Hz, ArCH), 5.25 (2 Hmaj, s, NH2), 4.65 (1 Hmin, s, NH2), 3.90 (3 Hmin, s, OCH3),  
3.79 (3 Hmaj, s, OCH3), 3.35 (3 Hmaj, s, CH3), 3.24 (3 Hmin, s, CH3), 3.13 (2 Hmin, hept, J = 5.9 Hz, CH(CH3)2), 
3.05 (2 Hmaj, hept, J = 5.8 Hz, CH(CH3)2), 1.32 (CHAHB, 6 Hmin, d, J = 2.8 Hz, CH(CH3)2),  
1.30 (CHAHB, 6 Hmin, d, J = 2.7 Hz, CH(CH3)2), 1.22 (CHAHB, 6 Hmaj, d, J = 5.8 Hz, CH(CH3)2),  
1.04 (CHAHB, 6 Hmaj, 6 H, d, J = 5.8 Hz, CH(CH3)2). δ13C (101 MHz, CDCl3) 171.2 (Cmaj), 171.0 (Cmin),  
148.2 (Cmin), 147.5 (Cmaj), 145.7 (2 * Cmaj), 145.6 (2 * Cmin), 140.2 (Cmin), 138.7 (Cmaj), 138.0 (Cmin),  
136.6 (Cmaj), 128.6 (CHmin), 128.3 (CHmaj), 124.4 (2 * CHmaj + 2 * CHmin), 121.2 (CHmaj), 120.1 (Cmin),  
119.5 (CHmin), 117.4 (Cmaj), 116.8 (CHmin), 114.1 (CHmaj), 111.2 (CHmin), 111.1 (CHmaj), 55.9 (CH3maj),  
55.8 (CH3min), 41.3 (CH3min), 39.0 (CH3maj), 28.7 (CHmin), 28.3 (CHmaj), 25.9 (CH3maj), 24.5 (CH3min),  
24.2 (CH3min), 22.9 (CH3maj). IR (film, cm-1) νmax 3480 (N–H), 3373 (N–H), 2963 (C–H), 1626 (C=O), 1553, 
1464, 1361, 1230, 1046 (C–O); HRMS (MALDI+) C21H28N2O2Na+ [M+Na]+ 363.2043; found: 363.2053. 
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N-(2,6-diisopropylphenyl)-3-methoxy-N-methyl-2-(methylamino)benzamide – 2.46 
To a solution of 2-amino-N-(2,6-diisopropylphenyl)-3-methoxy-N-
methylbenzamide 2.45 (0.56 g, 1.6 mmol, 1 eq.) in 1,4-dioxane (16 mL, 
0.1 M) was added Cu(OAc)2 (0.75 g, 11 mmol, 2.5 eq.) and pyridine  
(0.45 mL, 15.6 mmol, 3.5 eq.) at rt under an atmosphere of air. The 
reaction mixture was stirred for 15 min before methylboronic acid (0.25 g, 11 mmol, 2.5 eq.) was 
added and the reaction mixture heated to reflux until consumption of the aniline was observed by LC-
MS. After 4 h the reaction was cooled to rt and filtered through a plug of Celite, washing with EtOAc, 
and was concentrated in vacuo. Purification by flash column chromatography eluting with (5% to 40% 
EtOAc/Petrol) yielded the title compound (0.51 g, 90%) as a yellow oil. Rf 0.31 (30% EtOAc/Petrol). 
Mixture of conformers in a 1.0:0.3 ratio. δ1H (400 MHz, CDCl3) 7.34 (1 Hmaj, dd, J = 8.4, 7.0 Hz, ArCH), 
7.24 (2 Hmaj, d, J = 7.3 Hz, ArCH), 7.21 (1 Hmin, d, J = 7.8 Hz, ArCH), 7.06 (2 Hmin, d, J = 7.7 Hz, ArCH),  
6.93 (1 Hmaj, dd, J = 7.3, 2.0 Hz, ArCH), 6.89 (1 Hmaj, t, J = 7.6 Hz, ArCH), 6.86 (1 Hmaj, dd, J = 7.8, 2.1 Hz, 
ArCH), 6.64 (1 Hmin, dd, J = 7.8, 1.6 Hz, ArCH), 6.31 (1 Hmin, dd, J = 8.0, 1.6 Hz, ArCH),  
6.25 (1 Hmin, t, J = 7.9 Hz, ArCH), 4.59 (1 Hmaj, br. s, NH), 3.88 (3 Hmaj, s, OCH3), 3.75 (3 Hmin, s, OCH3), 
3.34 (3 Hmin, s, NCH3), 3.16 (2 Hmaj, hept, J = 5.9 Hz, CH(CH3)2), 3.12 (3 Hmaj, s, NCH3),  
3.05 – 2.98 (2 Hmin, m, CH(CH3)2), 3.01 (3 Hmin, s, CH3), 2.96 (3 Hmaj, s, CH3),  
1.30 (CHAHB, 6 Hmaj, d, J = 3.5 Hz, CH(CH3)2), 1.28 (CHAHB, 6 Hmaj, d, J = 3.6 Hz, CH(CH3)2),  
1.19 (CHAHB, 6 Hmin, d, J = 5.8 Hz, CH(CH3)2), 1.05 (CHAHB, 6 Hmin, d, J = 5.8 Hz, CH(CH3)2).  
δ13C (101 MHz, CDCl3) 171.2 (Cmaj), 171.1 (Cmin), 151.2 (Cmin), 150.7 (Cmaj), 145.9 (Cmaj), 145.6 (Cmin),  
141.0 (Cmin), 140.1 (Cmin), 138.0 (Cmaj), 137.8 (Cmaj), 128.6 (CHmaj), 128.5 (CHmin), 125.8 (Cmaj),  
124.5 (CHmaj), 124.4 (CHmin), 122.0 (Cmin), 121.9 (CHmin), 120.0 (CHmaj), 119.7 (CHmaj), 116.6 (CHmin), 
114.05 (CHmin), 111.2 (CHmaj), 56.2 (CH3min), 55.9 (CH3maj), 40.7 (CH3maj), 39.3 (CH3min), 35.2 (CH3maj),  
34.3 (CH3min), 28.6 (CHmaj), 28.5 (CHmin), 25.9 (CH3min), 24.5 (CH3maj), 24.4 (CH3maj), 23.2 (CH3min).  
IR (film, cm-1) νmax 3376 (N–H), 2963 (C–H), 1645 (C=O), 1467, 1374, 1361, 1257, 1046 (C–O). HRMS 
(MALDI+) C22H30N2O2Na+ [M+Na]+ 377.2199; found: 377.2192. 
N-Methyl-2-(methyl(phenyl)amino)benzamide - 2.48a 
Following GP2.3 on a 6.0 mmol scale, the title compound was obtained as a 
colourless oil (1.4 g, 83%). Rf 0.13 (25% EtOAc/Petrol). δ1H (400 MHz, CDCl3)  
8.22 (1 H, dd, J = 7.9, 1.7 Hz, H-4), 8.17 (1 H, br. s, NH),  
7.43 (1 H, ddd, J = 7.9, 7.3, 1.7 Hz, H-6), 7.33 (1 H, ddd, J = 7.9, 7.3, 1.4 Hz, 
H-5), 7.28 – 7.19 (2 H, m, H-11), 7.08 (1 H, dd, J = 7.9, 1.4 Hz, H-7), 6.90 (1 H, tt, J = 7.4, 1.1 Hz, H-10), 
6.78 (2 H, dd, J = 8.8, 1.1 Hz, H-12), 3.16 (3 H, s, H-9), 2.89 (3 H, d, J = 4.9 Hz, H-3).  
δ13C (101 MHz, CDCl3) 166.6 (C-1), 149.3 (C-13), 148.2 (C-8), 132.6 (C-6), 131.6 (C-4), 131.0 (C-2),  
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129.3 (C-11), 127.9 (C-7), 126.7 (C-5), 120.2 (C-10), 116.3 (C-12), 40.9 (C-9), 26.7 (C-3).  
IR (film, cm-1) νmax 3340 (N–H), 1591 (C=O). HRMS (ESI+) m/z calcd for C15H17N2O+ [M+H]+ 241.1335; 
found: 241.1334. 
2-((4-Fluorophenyl)(methyl)amino)-N-methylbenzamide – 2.48b  
Following GP2.3 on a 0.42 mmol scale, the title compound was obtained as 
a yellow oil (108 mg, 99%). Rf 0.35 (40% EtOAc/Petrol).  
δ1H (400 MHz, CDCl3) 8.23 (1 H, br. s, NH), 8.21 (1 H, dd, J = 7.8, 1.5 Hz,  
H-4), 7.43 (1 H, td, J = 7.8, 1.5 Hz, H-5), 7.33 (1 H, td, J = 7.8, 1.5 Hz, H-6), 
7.05 (1 H, dd, J = 7.8, 1.5 Hz, H-7), 6.99 – 6.90 (2 H, m, H-13), 6.77 – 6.66 (2 H, m, H-12), 3.15 (3 H, s, 
H-9), 2.90 (3 H, d, J = 4.9 Hz, H-3). δ13C (101 MHz, CDCl3) 166.6 (C-1), 157.5 (d, J = 240 Hz, C-10),  
148.5 (C-8), 145.8 (d, J = 2 Hz, C-11), 132.7 (C-5), 131.7 (C-4), 130.7 (C-2), 127.3 (C-7), 126.7 (C-6),  
117.9 (d, J = 8 Hz, C-12), 115.9 (d, J = 23 Hz, C-13), 41.5 (C-9), 26.8 (C-3). δ19F NMR (376 MHz, CDCl3)  
-124.0 (dp, J = 8.6, 4.6 Hz, C–F). IR (film, cm-1) νmax 3303 (N–H), 1644 (C=O), 1504, 1223 (C–F).  
HRMS (ESI+) m/z calcd for C15H15FN2ONa+ [M+Na]+ 281.1061; found: 281.1065. 
N-Methyl-2-(methyl(4-(trifluoromethyl)phenyl)amino)benzamide – 2.48c 
Following GP2.3 on a 0.33 mmol scale, the title compound was obtained 
as a colourless oil (94 mg, 92%). Rf 0.45 (40% EtOAc/Petrol).  
δ1H (400 MHz, CDCl3) 8.10 (1 H, dd, J = 7.7, 1.8 Hz, H-4),  
7.49 (1 H, td, J = 7.7, 1.8 Hz, H-6), 7.46 (2 H, d, J = 9.1 Hz, H-13),  
7.40 (1 H, td, J = 7.7, 1.3 Hz, H-5), 7.23 (1 H, br. s, NH), 7.12 (1 H, dd, J = 7.7, 1.3 Hz, H-7),  
6.76 (2 H, d, J = 9.1 Hz, H-12), 3.23 (3 H, s, H-9), 2.86 (3 H, d, J = 4.9 Hz, H-3). δ13C (101 MHz, CDCl3)  
166.8 (C-1), 151.6 (q, J = 1 Hz, C-11), 146.1 (C-8), 132.8 (C-6), 132.3 (C-2), 131.5 (C-4), 128.4 (C-7),  
127.6 (C-5), 126.6 (q, J = 4 Hz, C-13), 125.6 (q, J = 271 Hz, C-14), 120.9 (q, J = 33 Hz, C-10), 114.5 (C-12),  
40.6 (C-9), 26.9 (C-3). δ19F NMR (376 MHz, CDCl3) -61.74 (s, CF3). IR (film, cm-1) νmax 3383 (N–H), 2958, 
1636 (C=O), 1516, 1359 (C–F). HRMS (ESI+) m/z calcd for C16H15F3N2ONa + [M+Na]+ 331.1029; found: 
331.1044. 
2-((3-Methoxyphenyl)(methyl)amino)-N-methylbenzamide – 2.48g 
 Following GP2.3 on a 0.40 mmol scale, the title compound was 
obtained as a yellow oil (87 mg, 80%). Rf 0.23 (50% EtOAc/Petrol).  
δ1H (400 MHz, CDCl3) 8.21 (1 H, ddd, J = 7.9, 1.8, 0.4 Hz, H-4),  
8.01 (1 H, br. s, NH), 7.43 (1 H, ddd, J = 7.9, 7.3, 1.8 Hz, H-6),  
7.34 (1 H, ddd, J = 7.9, 7.3, 1.3 Hz, H-5), 7.14 (1 H, td, J = 8.2, 0.4 Hz, H-15),  
7.10 (1 H, ddd, J = 7.9, 1.3, 0.4 Hz, H-7), 6.45 (1 H, ddd, J = 8.2, 2.3, 0.8 Hz, H-14),  
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6.35 (1 H, ddd, J = 8.2, 2.3, 0.8 Hz, H-10), 6.32 (1 H, t, J = 2.3 Hz, H-12), 3.74 (3 H, s, H-16),  
3.15 (3 H, s, H-9), 2.90 (3 H, d, J = 4.9 Hz, H-3). δ13C (101 MHz, CDCl3) 166.7 (C-1), 160.7 (C-11),  
150.6 (C-13), 147.8 (C-8), 132.6 (C-6), 131.6 (C-4), 131.2 (C-2), 130.1 (C-15), 128.1 (C-7), 126.9 (C-5), 
109.0 (C-10), 104.7 (C-14), 102.7 (C-12), 55.3 (C-16), 40.9 (C-9), 26.8 (C-3). IR (film, cm-1) νmax  
3318 (N–H), 2939, 2477, 1645, 1594 (C=O), 1489, 1048 (O-CH3). HRMS (ESI+) m/z calcd for 
C16H18N2O2Na+ [M+Na]+ 293.1260; found: 293.1263. 
N-Methyl-2-(methyl(naphthalen-1-yl)amino)benzamide 2.48j 
Following GP2.3 on a 0.34 mmol scale, the title compound was obtained as 
a yellow oil (100 mg, quant.). Rf 0.19 (40% EtOAc/Petrol).  
δ1H (400 MHz, CDCl3) 8.15 (1 H, br. s, NH), 8.04 (1 H, dd, J = 7.8, 1.8 Hz,  
H-4), 7.85 (1 H, dd, J = 8.3, 1.3 Hz, H-19), 7.82 (1 H, d, J = 8.4 Hz, H-16),  
7.64 (1 H, dt, J = 8.2, 1.1 Hz, H-10), 7.46 – 7.41 (2 H, m, H-11 + H-18),  
7.38 (1 H, ddd, J = 8.4, 6.8, 1.3 Hz, H-17), 7.28 (1 H, td, J = 7.8, 1.8 Hz, H-6),  
7.19 (1 H, dd, J = 7.5, 1.1 Hz, H-12), 7.15 (1 H, td, J = 7.8, 1.2 Hz, H-5), 6.92 (1 H, dd, J = 7.8, 1.2 Hz,  
H-7), 3.32 (3 H, s, H-9), 2.59 (3 H, d, J = 4.9 Hz, H-3). δ13C (101 MHz, CDCl3) 167.5 (C-1), 150.1 (C-8),  
146.5 (C-13), 135.1 (C-15), 132.0 (C-6), 131.7 (C-4), 129.0 (C-19), 128.5 (C-14), 128.1 (C-2),  
126.3 (C-17), 126.0 (C-11 + C-18), 125.1 (C-10), 124.1 (C-5), 123.3 (C-16), 122.2 (C-7), 118.6 (C-12),  
43.7 (C-9), 26.3 (C-3). IR (film, cm-1) νmax 3304 (N–H), 3050, 1645 (C=O). HRMS (ESI+) m/z calcd for 
C19H18N2ONa + [M+Na]+ requires 313.1311; found 313.1304. 
2,2'-(1,3-Phenylenebis(methylazanediyl))bis(N-methylbenzamide) - 2.48k 
Following GP2.3 on a 0.31 mmol scale, the title compound was 
obtained as a yellow oil (60 mg, 48%). Rf 0.38 (EtOAc).  
δ1H (400 MHz, CDCl3) 8.11 (2 H, dd, J = 7.8, 1.8 Hz, H-10),  
7.91 (2 H, br. s, NH), 7.40 (2 H, td, J = 7.8, 1.8 Hz, H-8),  
7.30 (2 H, td, J = 7.8, 1.4 Hz, H-9), 7.08 (2 H, dd, J = 7.8, 1.4 Hz, H-7), 7.06 (1 H, t, J = 8.3, overlaps, H-1)  
6.28 (2 H, dd, J = 8.3, 2.3 Hz, H-2), 6.10 (1 H, t, J = 2.3 Hz, H-4), 3.09 (6 H, s, H-6),  
2.88 (6 H, d, J = 4.9 Hz, H-13). δ13C (101 MHz, CDCl3) 166.8 (C-12), 150.4 (C-3), 147.6 (C-5), 132.4 (C-8), 
131.4 (C-10), 131.3 (C-11), 129.9 (C-1), 127.7 (C-7), 126.7 (C-9), 108.3 (C-2), 103.8 (C-4), 40.8 (C-6), 
26.8 (C-13). IR (film, cm-1) νmax 3304 (N–H), 1645 (C=O), 1594, 1482. HRMS (ESI+) m/z calcd for 




A solution of 2.48a (51 mg, 0.21 mmol, 1.0 eq.), CuBr (3.1 mg, 0.021 mmol, 
10 mol%) and tert-butyl hydroperoxide (5.0–6.0 M in decane, 86 μL,  
0.43–0.51 mmol, 2.0 to 2.4 eq.) in acetonitrile (0.86 mL, 0.25 M) was kept 
under air at 60 °C for 4 h. The reaction mixture was quenched with ethyl 
acetate, volatiles were removed in vacuo. Purification by flash column chromatography yielded the 
title compound as a yellow oil (17 mg, 35%). δ1H (400 MHz, CDCl3) 9.21 (1 H, br. s, NH),  
7.32 (1 H, dd, J = 7.9, 1.6 Hz, ArCH), 7.27 (1 H, dd, J = 8.4, 1.2 Hz, ArCH), 7.24 – 7.15 (3 H, m, ArCH),  
7.15 – 7.07 (2 H, m, ArCH), 6.92 (1 H, tt, J = 7.4, 1.2 Hz, ArCH), 6.68 (1 H, ddd, J = 7.8, 7.1, 1.2 Hz, ArCH),  
6.12 (1 H, br. s, NH), 2.90 (3 H, d, J = 4.9 Hz, CH3). δ13C (101 MHz, CDCl3) 170.3 (C=O), 145.4 (ArC), 141.7 
(ArC), 132.2 (ArCH), 129.4 (2* ArCH), 127.5 (ArCH), 122.4 (ArCH), 120.8 (2* ArCH), 118.7 (ArC), 118.1 
(ArCH), 115.6 (ArCH), 26.8 (CH3). Data consistent with that reported in the literature.[311]  
N-Methyl-N-(naphthalen-1-yl)-2-nitrobenzamide  
To a solution of anthranilic acid (0.5 g, 3.0 mmol, 1 eq.) in toluene (3 mL,  
1 M) under nitrogen was added thionyl chloride (0.55 mL, 7.5 mmol, 2.5 eq.) 
before heating to reflux for 2 h. The reaction mixture was concentrated in 
vacuo, before adding toluene (10 mL) to azeotropically remove traces of 
thionyl chloride. The resulting residue was dissolved in CH2Cl2 (12 mL, 0.25 M) and pyridine (0.51 mL, 
6.3 mmol, 2.1 eq.) followed by N-methyl-1-naphthylamine hydrochloride (0.64 g, 3.3 mmol, 1.1 eq.) 
were added at 0 °C before warming to rt and stirring for 16 h. The reaction mixture was quenched 
with sat. NH4Cl (aq.) and extracted with EtOAc, dried over MgSO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography eluting with (10% to 70% EtOAc/Petrol) yielded the title 
compound (0.61 g, 67%) as a brown solid. Rf 0.37 (50% EtOAc/Petrol). m.p.: 183 ‒ 184 °C. Mixture of 
conformers in a 1:0.1 ratio. δ1H (400 MHz, CDCl3) 8.31 (1 Hmin, dd, J = 8.3, 1.2), 7.99 (1 Hmaj, dd, J = 8.5, 
1.0 Hz, H-17), 7.94 – 7.89 (2 Hmin, m), 7.85 (1 Hmaj, d, J = 7.6 Hz, H-3), 7.80 (1 Hmaj, d, J = 8.3 Hz, H-14),  
7.74 (1 Hmin, dd, J = 7.6, 1.4), 7.71 – 7.63 (1 Hmaj, m, H-16), 7.66 – 7.59 (1 Hmaj, m, H-11),  
7.60 – 7.55 (2 Hmin, m), 7.52 (1 Hmaj, ddd, J = 8.2, 6.9, 1.2 Hz, H-15), 7.41 (1 Hmaj, dd, J = 7.3, 1.2 Hz,  
H-10), 7.27 – 7.20 (1 Hmaj, m, H-9), 7.20 – 7.15 (1 Hmaj, m, H-1), 7.15 – 7.12 (2 Hmaj, m, H-6 + H-2),  
3.59 (3 Hmaj, s, H-18), 3.25 (3 Hmin, s, H-18). δ13C (101 MHz, CDCl3) 168.0 (C-7), 145.7 (C-4),  
139.3 (C-8), 134.5 (C-12), 133.3 (C-2), 133.1 (C-5), 129.9 (C-13), 129.5 (C-1), 129.1 (C-16), 128.8 (C-14), 
127.6 (C-6 and C-11), 126.7 (C-15), 125.7 (C-9), 125.6 (C-10), 124.3 (C-3), 122.5 (C-17), 37.5 (C-18).  
IR (film, cm-1) νmax 1650 (C=O), 1526 (N–O), 1346 (N–O). HRMS (ESI+) m/z calcd for C18H14N2O3Na+ 
[M+Na]+ 329.0897; found: 329.0888. 
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2-Amino-N-methyl-N-(naphthalen-1-yl)benzamide – 2.51 
Pd/C (10 wt. % loading, 58 mg, 1 mol% Pd) was suspended in a solution of 
N-Methyl-N-(naphthalen-1-yl)-2-nitrobenzamide (0.58 g, 1.9 mmol, 1 eq.) 
in EtOH (4.0 mL, 0.5 M) under nitrogen. Nitrogen was bubbled through the 
solution for 15 mins. The contents of the flask were placed under a 
hydrogen atmosphere using a two-way three-necked tap with a balloon of hydrogen attached. The 
solution was saturated with hydrogen three times using a vacuum/hydrogen cycle. The reaction was 
stirred under a hydrogen atmosphere for 16 h. The contents of the flask were placed under a nitrogen 
atmosphere and the hydrogen balloon removed. The crude reaction solution was filtered through a 
pad of Celite and washed with MeOH and was concentrated in vacuo. Purification by flash column 
chromatography eluting with (10% to 50% EtOAc/Petrol) yielded the title compound (0.45 g, 86%) as 
a yellow solid. Rf 0.33 (50% EtOAc/Petrol). m.p.: 189 ‒ 190 °C. δ1H (400 MHz, CDCl3)  
8.02 (1 H, d, J = 7.9 Hz, H-17), 7.85 (1 H, d, J = 7.9 Hz, H-14), 7.69 (1 H, d, J = 8.2 Hz, H-11),  
7.61 (1 H, t, J = 7.9 Hz, H-16), 7.52 (1 H, t, J = 7.9 Hz, H-15), 7.26 (1 H, br. s, H-10), 7.17 (1 H, br. s, H-9), 
6.84 (1 H, br. s, H-2), 6.63 (1 H, br. s, H-6), 6.53 (1 H, d, J = 8.1 Hz, H-1), 6.03 (1 H, br. s, H-3),  
4.78 (2 H, br. s, NH2), 3.52 (3 H, s, H-18). δ13C (101 MHz, CDCl3) 172.3 (C-7), 146.8 (C-4), 141.5 (C-8), 
134.6 (C-12), 130.6 (C-2), 129.8 (C-13), 128.8 (C-14), 128.1 (C-6), 128.0 (C-11), 127.2 (C-16),  
126.4 (C-15), 125.7 (C-10), 125.5 (C-9), 122.8 (C-17), 119.6 (C-5), 116.4 (C-1 and C-3), 38.3 (C-18).  
IR (film, cm-1) νmax 3452 (N–H), 3352 (N–H), 1616 (C=O), 1586 (N–H), 1362 (C–N). HRMS (ESI+) m/z 
calcd for C18H17N2O+ [M+H]+ 277.1335; found: 277.1341. 
2-(Benzylamino)-N-methyl-N-(naphthalen-1-yl)benzamide – 2.52 
A flame-dried round bottom flask was allowed to cool to rt in vacuo. To 
this was added 2-Amino-N-methyl-N-(naphthalen-1-yl)benzamide 2.51 
(0.10 g, 0.37 mmol, 1 eq.), anhydrous toluene (3.7 mL, 1 M), molecular 
sieves 4 Å, and benzaldehyde (42 μL, 0.41 mmol, 1.1 eq.). The reaction 
mixture was allowed to stir at rt for 6 h. Extra benzaldehyde (84 μL, 0.82 
mmol, 2.0 eq.) was added and the reaction mixture was stirred for 16 h. 
The reaction mixture was filtered and concentrated in vacuo. This 
residue was dissolved in MeOH (1.8 mL, 0.2 M), and NaBH4 (83 mg, 2.2 mmol, 6.0 eq.) was added 
portion wise at 0 °C. The reaction mixture was allowed to stir at rt for 1 h. The reaction mixture was 
quenched with H2O and extracted with EtOAc. The combined organic phases were washed with brine, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography 
eluting with (2% to 30% EtOAc/Petrol) yielded the title compound (97 mg, 72%) as a white solid Rf 0.46 
(40% EtOAc/Petrol). m.p.: 145 ‒ 146 °C. δ1H (400 MHz, CDCl3) 8.03 (1 H, d, J = 8.4 Hz, H-17),  
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7.86 (1 H, d, J = 8.1 Hz, H-14), 7.71 (1 H, d, J = 8.2, H-11), 7.61 (1 H, t, J = 7.6 Hz, H-16),  
7.53 (1 H, t, J = 7.5 Hz, H-15), 7.43 (2 H, d, J = 7.1 Hz, H-23), 7.38 (2 H, t, J = 7.5 Hz, H-22),  
7.34 – 7.27 (2 H, m, H-21 + H-10), 7.24 – 7.15 (1 H, m, H-9), 6.89 (1 H, br. s, H-2), 6.76 (1 H, br. s, H-6), 
6.50 (2 H, d, J = 9.3 Hz, NH + H-3), 6.03 (1 H, br. s, H-1), 4.41 (2 H, s, H-19), 3.54 (3 H, s, H-18).  
δ13C (101 MHz, CDCl3) 172.7 (C-7), 147.6 (C-4), 141.7 (C-8), 139.5 (C-20), 134.6 (C-12), 129.8 (C-13), 
128.78 (C-14), 128.75 (C-2), 128.7 (C-22), 128.5 (C-6), 128.0 (C-11), 127.30 (C-23), 127.25 (C-16),  
127.1 (C-21), 126.4 (C-15), 125.7 (C-10), 125.5 (C-9), 122.7 (C-17), 119.1 (C-5), 115.1 (C-1), 111.6 (C-3), 
47.6 (C-19), 38.4 (C-18). IR (film, cm-1) νmax 3380 (N–H), 2927 (C–H), 1629 (C=O), 1510, 1357 (C–N). 
HRMS (ESI+) m/z calcd for C25H22N2ONa+ [M+Na]+ 389.1624; found: 389.1609. 
1-(2-Bromophenyl)-1-(tert-butyl)-3-(naphthalen-1-yl)urea – 2.55 
To a solution of triphosgene (0.58 g, 2.0 mmol, 0.45 eq.) in CH2Cl2  
(11.0 mL, 0.4 M) at -78 °C was added 2,6-lutidine (0.61 mL, 5.3 mmol,  
1.2 eq.) and 2-bromo-N-(tert-butyl)aniline[312] (1.0 g, 4.4 mmol, 1.0 eq.). 
The reaction mixture was kept at rt for 2 h. The reaction mixture was 
diluted in CH2Cl2, washed with HCl (aq. 1 M), sat. NaHCO3 (aq.), and brine. The combined organic 
phases were dried over Na2SO4, filtered and concentrated in vacuo to give (2-bromophenyl)(tert-
butyl)carbamoyl chloride as a yellow solid (1.0 g, 78%) which was used directly in the next step. This 
crude carbamoyl chloride (0.77 g, 2.6 mmol, 1.2 eq.), 1-naphthylamine (0.42 g, 2.2 mmol, 1.0 eq.), 
Et3N (0.46 mL, 3.3 mmol, 1.5 eq.) in toluene (2.2 mL, 1 M) were heated to reflux for 48 h. The reaction 
mixture was diluted in ethyl acetate, washed with HCl (aq. 1 M), brine, and the combined organic 
phases were dried over MgSO4. Purification by flash column chromatography eluting with (5% to 75% 
Et2O/Petrol) yielded the title compound as a yellow oil (0.73 g, 82%). δ1H (400 MHz, CDCl3)  
7.86 (1 H, dd, J = 7.6, 1.0 Hz, ArCH), 7.83 (1 H, dd, J = 8.3, 1.4 Hz, ArCH), 7.78 (1 H, dd, J = 7.3, 1.4 Hz, 
ArCH), 7.57 (1 H, d, J = 8.2 Hz, ArCH), 7.54 – 7.47 (2 H, m, ArCH), 7.44 (1 H, d, J = 7.8 Hz, ArCH),  
7.42 – 7.30 (4 H, m, ArCH) 6.05 (1 H, br. s, NH), 1.55 (9 H, s, C(CH3)3). δ13C (101 MHz, CDCl3)  
154.0 (C=O), 141.0 (ArC), 134.5 (ArCH), 134.2 (ArC), 133.8 (ArC), 132.5 (ArCH), 130.4 (ArCH),  
129.2 (ArCH), 128.7 (ArCH), 127.6 (ArC), 127.1 (ArC), 126.0 (ArCH), 125.9 (ArCH), 125.7 (ArCH),  
124.4 (ArCH), 120.6 (ArCH), 120.1 (ArCH), 59.1 (CCH3), 29.7 (CCH3). IR (film, cm-1) νmax 1783, 1731 1504, 
1478, 1247, 1210, 1167.  
1-(2-Bromophenyl)-1-(tert-butyl)-3-methyl-3-(naphthalen-1-yl)urea – 2.56 
Following GP2.1 (Part 2) 1-(2-bromophenyl)-1-(tert-butyl)-3-(naphthalen-
1-yl)urea 2.55 (0.53 g, 1.3 mmol, 1 eq.), NaH (0.11 g, 2.7 mmol, 2.0 eq., 
60% in mineral oil), MeI (0.25 mL, 4.0 mmol, 3.0 eq) in THF (2.7 mL,  
0.5 M) were stirred at rt for 1 h. Purification by flash column 
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chromatography yielded the title compound as a white solid (0.49 g, 92%). Rf 0.52 (30% EtOAc/Petrol). 
m.p.: 95 – 96 °C. δ1H (400 MHz, CDCl3) 7.78 – 7.38 (4 H, m, ArCH) 7.31 (1 H, br. s, ArCH),  
7.21 (2 H, br. s, ArCH), 7.00 (1 H, s, ArCH), 6.36 (1 H, br. s, ArCH), 6.16 (1 H, br. s, ArCH),  
5.65 (1 H, br. s, ArCH), 3.21 (3 H, s, CH3), 1.39 (9 H, s, C(CH3)3). δ13C (101 MHz, CDCl3) 161.4 (C=O), 
143.4 (ArC), 140.1 (ArC), 134.4 (ArC), 134.2 (ArCH), 133.4 (ArCH), 129.9 (ArC), 127.8 (ArCH),  
126.8 (ArCH), 126.5 (ArCH), 125.9 (ArCH), 125.73 (ArCH), 125.67 (ArCH), 125.57 (ArCH), 125.2 (ArCH), 
123.5 (ArC), 123.2 (ArCH), 59.3 (CCH3), 40.3 (CH3), 30.2 (CCH3). IR (film, cm-1) νmax 2973 (C–H),  
1656 (C=O), 1323 (C–N). HRMS (ESI+) m/z calcd for C22H23N2OBrNa+ [M+Na]+ 433.0886; found 
433.0870. 
2-(Tert-butylamino)-N-methyl-N-(naphthalen-1-yl)benzamide – 2.57 
Following GP2.2 1-(2-bromophenyl)-1-(tert-butyl)-3-methyl-3-(napht-
halen-1-yl)urea 2.56 (0.41 g, 0.95 mmol, 1 eq.), n-BuLi (0.79 mL,  
1.1 mmol, 1.1 eq., 1.4 M in hexanes) in THF (5.0 mL, 0.2 M) were stirred 
at −78 °C for 2 h. Purification by flash column chromatography yielded 
the title compound as a white solid (0.28 g, 85%). Rf 0.41 (30% 
EtOAc/Petrol). m.p.: 148 – 149 °C. δ1H (400 MHz, CDCl3) 7.97 (1 H, m, H-16), 7.84 (1 H, d, J = 8.1 Hz, 
H-19), 7.69 (1 H, d, J = 8.3 Hz, H-13), 7.57 (1 H, ddd, J = 8.4, 6.8, 1.4 Hz, H-17),  
7.50 (1 H, ddd, J = 8.1, 6.8, 1.3 Hz, H-18), 7.29 (1 H, s, H-14), 7.17 (1 H, s, H-15), 6.86 (1 H, br. s, H-2), 
6.78 (1 H, br. s, H-1), 6.73 (1 H, br. s, H-4), 5.95 (2 H, br. s, NH + H-3), 3.50 (3 H, s, H-20),  
1.44 (9 H, s, H-8). δ13C (101 MHz, CDCl3) 173.1 (C-9), 146.5 (C-6), 141.7 (C-10), 134.6 (C-12),  
130.2 (C-2), 129.8 (C-11), 128.81 (C-4), 128.76 (C-19), 127.9 (C-13), 127.1 (C-17), 126.4 (C-18),  
125.7 (C-14), 125.3 (C-15), 122.9 (C-16), 120.4 (C-5), 114.3 (C-1 + C-3), 50.8 (C-7), 38.5 (C-20),  
30.2 (C-8). IR (film, cm-1) νmax 3373 (N–H), 2976 (C–H), 1633 (C=O). HRMS (ESI+) m/z calcd for 
C22H25N2O+ [M+H]+ 333.1961; found 333.1963. 
2-(Benzyl(naphthalen-1-yl)amino)-N-methylbenzamide – 2.58 
Following GP2.3 on an 87 μmol scale (16 h reaction time), the title compound 
was obtained as a yellow solid (26 mg, 80%). Rf 0.18 (50% EtOAc/Petrol).  
m.p.: 175 ‒ 177 °C. δ1H (400 MHz, CDCl3) 8.07 (1 H, dd, J = 8.1, 1.5 Hz, ArCH),  
7.97 – 7.83 (2 H, m, ArCH), 7.66 (1 H, d, J = 8.2 Hz, ArCH), 7.54 – 7.42 (3 H, m, 
ArCH + NH), 7.42 – 7.30 (4 H, m, ArCH), 7.30 – 7.22 (2 H, m, ArCH),  
7.19 – 7.10 (2 H, m, ArCH), 7.03 (1 H, dd, J = 8.2, 1.1 Hz, ArCH), 5.03 (2 H, s, NCH2),  
2.36 (3 H, d, J = 4.9 Hz, NHCH3). δ13C (101 MHz, CDCl3) 167.8 (C=O), 148.2 (ArC), 145.5 (ArC),  
137.8 (ArC), 135.2 (ArC), 131.36 (ArCH), 131.34 (ArCH), 129.24 (ArC), 129.17 (ArC), 129.1 (ArCH),  
128.8 (ArCH), 127.1 (ArCH), 126.60 (ArCH), 126.57 (ArCH), 126.1 (ArCH), 125.9 (ArCH), 125.4 (ArCH), 
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123.7 (ArCH), 123.0 (ArCH), 122.9 (ArCH), 121.1 (ArCH), 58.8 (NCH2), 26.1 (NHCH3). IR (film, cm-1) νmax 
3314 (N–H), 3060, 1651 (C=O), 1531. HRMS (ESI+) m/z calcd for C25H22N2ONa+ [M+Na]+ 389.1624; 
found: 389.1630. 
N-Methyl-2-(naphthalen-1-ylamino)benzamide – 2.59 
Pd/C (10 wt. % loading, 15 mg, 2 mol% Pd) was suspended in a solution of  
5-methoxy-N-methyl-2-nitro-N-phenylbenzamide 2.58 (75 mg, 0.21 mmol,  
1 eq.) in EtOH (1.0 mL, 0.2 M) under nitrogen. Nitrogen was bubbled through 
the solution for 15 mins. The contents of the flask were placed under a 
hydrogen atmosphere using a two-way three-necked tap with a balloon of 
hydrogen attached. The solution was saturated with hydrogen three times using a vacuum/hydrogen 
cycle. The reaction was stirred under a hydrogen atmosphere for 24 h. The contents of the flask were 
placed under a nitrogen atmosphere and the hydrogen balloon removed. The crude reaction solution 
was filtered through a pad of Celite and washed with MeOH and was concentrated in vacuo. 
Purification by flash column chromatography eluting with (5% to 40% EtOAc/Petrol) yielded the title 
compound (47 mg, 83%) white solid. m.p.: 143 – 144 °C. Rf 0.18 (30% EtOAc/Petrol).  
δ1H (400 MHz, CDCl3) 9.92 (1 H, br. s, NH), 8.23 – 8.13 (1 H, m, H-17), 7.92 – 7.82 (1 H, m, H-14),  
7.63 (1 H, d, J = 8.0 Hz, H-11), 7.55 – 7.47 (3 H, m, H-15 + H-16 + H-9), 7.47 – 7.39 (2 H, m, H-10 + H-3),  
7.21 (1 H, ddd, J = 8.5, 7.0, 1.6 Hz, H-2), 7.14 (1 H, dd, J = 8.5, 1.2 Hz, H-6),  
6.73 (1 H, ddd, J = 8.1, 7.1, 1.3 Hz, H-1), 6.31 (1 H, br. s, NH), 3.01 (3 H, d, J = 4.9 Hz, H-18).  
δ13C (101 MHz, CDCl3) 170.6 (C-7), 147.0 (C-8), 137.6 (C-8), 134.9 (C-12), 132.3 (C-2), 129.0 (C-13), 
 128.4 (C-14), 127.4 (C-3), 126.3 (C-15 or C-16), 126.1 (C-15 or C-16), 125.9 (C-10), 123.9 (C-11),  
122.7 (C-17), 118.1 (C-9), 117.7 (C-5), 117.6 (C-1), 115.6 (C-6), 26.8 (C-18). IR (film, cm-1) νmax  
3317 (N–H), 1633 (C=O), 1578 (N–H), 1521, 1450, 1406, 1282 (C–N). HRMS (ESI+) m/z calcd for 
C18H16N2ONa+ [M+Na]+ 299.1155; found 299.1157. 
2-((2,6-Diisopropylphenyl)(methyl)amino)-N-methylbenzamide – 2.48l 
Following GP2.3 on a 0.4 mmol scale (16 h reaction time, reflux 
temperature), the title compound was obtained as a white solid (129 mg, 
98%). Rf 0.61 (40% EtOAc/Petrol). m.p.: 134 ‒ 135 °C.  
δ1H (400 MHz, CDCl3) 7.33 (1 H, t, J = 7.7 Hz, H-10), 7.29 (1 H, d, J = 8.0 Hz, 
H-4), 7.24 (2 H, d, J = 7.5 Hz, H-11), 7.00 (1 H, t, J = 8.0 Hz, H-5), 6.64 (1 H, t, J = 8.0 Hz, H-6),  
6.16 (1 H, d, J = 8.0 Hz, H-7), 5.97 (1 H, br. s, NH), 3.23 (3 H, s, H-9), 3.09 (2 H, sept., J = 5.9, H-14),  
3.04 (3 H, d, J = 4.9 Hz, H-3), 1.22 (CHAHB, 6 H, d, J = 5.9 Hz, H-15), 1.06 (CHAHB, 6 H, d, J = 5.9 Hz,  
H-15). δ13C (101 MHz, CDCl3) 172.2 (C-1), 147.9 (C-12), 147.7 (C-8), 142.4 (C-13), 130.0 (C-6),  
129.6 (C-4), 128.0 (C-10), 125.0 (C-11), 121.3 (C-2), 117.0 (C-7), 116.3 (C-5), 42.5 (C-9), 28.2 (C-14), 
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27.1 (C-3), 24.7 (C-11), 24.1 (C-11). IR (film, cm-1) νmax 3296 (N–H), 2960 (C–H), 1633 (C=O), 1493. 
HRMS (ESI+) m/z calcd for C21H28N2ONa + [M+Na]+ 347.2094; found: 347.2088. 
2-((2-(Tert-butyl)-6-methylphenyl)(methyl)amino)-N-methylbenzamide -2.48m 
 Following GP2.3 on a 0.34 mmol scale (16 h reaction time, reflux 
temperature), the title compound was obtained as a white solid (91 mg, 
77%). Rf 0.59 (40% EtOAc/Petrol). m.p.: 205 ‒ 206 °C. δ1H (400 MHz, CDCl3) 
7.41 – 7.37 (1 H, m, H-10), 7.31 (1 H, dd, J = 7.5, 1.7 Hz, H-4),  
7.22 – 7.18 (2 H, m, H-11 + H-15), 7.00 (1 H, ddd, J = 8.7, 7.5, 1.7 Hz, H-6), 6.66 (1 H, td, J = 7.5, 1.0 Hz, 
H-5), 6.08 (1 H, dd, J = 8.7, 1.0 Hz, H-7), 5.95 (1 H, br. q, J = 5.0 Hz, NH), 3.22 (3 H, s, H-9),  
3.03 (3 H, d, J = 4.9 Hz, H-3), 2.01 (3 H, s, H-16), 1.34 (9 H, s, H-18). δ13C (101 MHz, CDCl3) 172.1 (C-1), 
148.7 (C-12), 148.0 (C-8), 145.3 (C-13), 139.0 (C-14), 130.4 (C-15), 129.8 (C-6), 129.6 (C-4),  
127.2 (C-11), 126.2 (C-10), 121.9 (C-2), 116.8 (C-7), 116.6 (C-5), 43.8 (C-9), 35.7 (C-17), 31.7 (C-18), 
26.8 (C-3), 18.9 (C-16). IR (film, cm-1) νmax 3282 (N–H), 2954 (C–H), 1634 (C=O), 1490. HRMS (ESI+) m/z 
calcd for C20H26N2ONa + [M+Na]+ 333.1937; found: 333.1929. Supplementary crystallographic data can 
be obtained free of charge from The Cambridge Crystallographic Data Centre (CCDC 1557197). 
N,3-Dimethyl-2-(methyl(2-methylnaphthalen-1-yl)amino)benzamide – 2.48n 
 Following GP2.3 on a 0.49 mmol scale (16 h reaction time, reflux 
temperature), the title compound was obtained off-white solid  
(108 mg, 70%). Rf 0.40 (75% EtOAc/Petrol). m.p.: 204 ‒ 206 °C.  
δ1H (400 MHz, CDCl3) 8.19 – 8.12 (1 H, m, H-21),  
7.80 (1 H, dd, J = 8.0, 1.5 Hz, H-18), 7.57 (1 H, d, J = 8.3 Hz, H-10), 7.45 (1 H, ddd, J = 8.5, 6.8, 1.5 Hz,  
H-20), 7.39 (1 H, ddd, J = 8.0, 6.8, 1.3, H-19), 7.23 (1 H, d, J = 8.3 Hz, H-15),  
7.17 (1 H, dd, J = 7.5, 1.8 Hz, H-4), 7.03 (1 H, dd, J = 7.5, 1.8 Hz, H-6), 6.83 (1 H, t, J = 7.5 Hz, H-5),  
5.74 (1 H, q, J = 5.3 Hz, NH), 3.45 (3 H, s, H-9), 2.84 (3 H, d, J = 4.9 Hz, H-3), 2.32 (3 H, s, H-16),  
1.64 (3 H, s, H-17). δ13C (101 MHz, CDCl3) 172.5 (C-1), 146.7 (C-8), 142.7 (C-13), 134.0 (C-6),  
133.9 (C-11), 132.9 (C-14), 131.3 (C-7), 131.0 (C-12), 130.3 (C-15), 128.5 (C-18), 128.0 (C-2),  
127.5 (C-4), 125.9 (C-20), 125.6 (C-10), 124.9 (C-19 or C-21), 124.8 (C-19 or C-21), 120.3 (C-5),  
42.6 (C-9), 27.1 (C-3), 21.3 (C-17), 19.7 (C-16). IR (film, cm-1) νmax 3303 (N–H), 2957, 2921 (C–H),  
1635 (C=O), 1411. HRMS (ESI+) m/z calcd for C21H22N2ONa+ [M+Na]+ 341.1624; found: 341.1622. 
Supplementary crystallographic data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre (CCDC 1557204). 
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2-((2-(Tert-Butyl)-6-methylphenyl)(methyl)amino)-N,3-dimethylbenzamide – 2.48o 
Following GP2.3 on a 0.42 mmol scale (96 h reaction time, reflux 
temperature) yielded the unreacted starting material (40 mg, 29%) and 
the title compound as a yellow solid (77 mg, 57%, 80% brsm). Rf 0.26 (50% 
EtOAc/Petrol). m.p.: 203 – 205 °C. δ1H (400 MHz, CDCl3)  
7.31 (1 H, dd, J = 7.7, 1.6 Hz, H-11), 7.18 (1 H, br. s, H-4), 7.13 (1 H, t, J = 7.7 Hz, H-10),  
7.02 (1 H, dd, J = 7.7, 1.6 Hz, H-15), 6.91 (1 H, d, J = 7.4 Hz, H-6), 6.61 (1 H, t, J = 7.4 Hz, H-5),  
5.91 (1 H, br. s, NH), 3.26 (3 H, s, H-9), 2.98 (3 H, br. s, H-3), 2.14 (3 H, s, H-16), 1.54 (3 H, br. s, H-17), 
1.42 (9 H, s, H-19). δ13C (101 MHz, CDCl3) 173.1 (C-1), 147.8 (C-13), 147.7 (C-12), 146.4 (C-8),  
139.5 (C-14), 135.2 (C-6), 128.8 (C-15), 128.6 (C-4), 126.8 (C-10), 126.3 (C-11), 125.0 (C-2 or C-7),  
124.6 (C-2 or C-7), 117.0 (C-5), 47.2 (C-9), 36.2 (C-18), 31.9 (C-19), 26.9 (C-3), 22.7 (C-17), 19.1 (C-16). 
IR (film, cm-1) νmax 3302 (N–H), 2957 (C–H), 1634 (C=O), 1467, 1404. HRMS (ESI+) m/z calcd for 
C21H28N2ONa+ [M+Na]+ 347.2094; found: 347.2102. 
2-((2,6-Diisopropylphenyl)(methyl)amino)-3-methoxy-N-methylbenzamide 2.48p 
A flame-dried Biotage microwave vial was allowed to cool to rt in vacuo. 
To this was added N-(2,6-diisopropylphenyl)-3-methoxy-N-methyl-2-
(methylamino)benzamide 2.42p (141 mg, 0.4 mmol, 1 eq.), and 
anhydrous THF (2.0 mL, 0.2 M). NaHMDS (0.44 mL, 0.44 mmol, 1.1 eq.,  
1.0 M in THF) was added dropwise and the vial was sealed. The reaction was allowed to stir at 150 °C 
for 16 h under microwave irradiation, then quenched with MeOH, and the subsequent solution 
concentrated in vacuo to yield the crude diarylamine. Purification by flash column chromatography 
eluting with (10% to 90% Et2O/Petrol) yielded the title compound as a white solid (101 mg, 72%).  
Rf 0.42 (75% Et2O/Petrol). m.p.: 174 – 176 °C. δ1H (500 MHz, CDCl3) 7.16 (1 H, dd, J = 8.4, 6.8 Hz,  
H-10), 7.12 – 7.02 (2 H, dd, J = 7.6, 0.8 Hz, H-11), 6.89 (1 H, br. s, H-4), 6.77 – 6.65 (2 H, m, H-5 + H-6),  
5.89 (1 H, br. s, NH), 3.55 – 3.37 (2 H, m, H-14), 3.21 (3 H, br. s, H-16), 3.20 – 3.08 (3 H, m, H-9),  
2.99 (3 H, br. S, H-3), 1.48 – 1.12 (CHAHB, 6 H, br. d, J = 3.5), 1.00 – 0.76 (CHAHB, 6 H, br. d, J = 3.5 Hz, 
H-15). δ13C (101 MHz, CDCl3) 172.1 (C-1), 151.8 (C-7), 146.5 (C-12), 145.8 (C-13), 138.8 (C-8),  
126.0 (C-10), 125.3 (C-2), 124.0 (C-11), 122.0 (C-4), 118.5 (C-6), 114.4 (C-5), 55.4 (C-16), 43.5 (C-9), 
27.7 (C-14), 27.3 (C-3), 25.2 (C-15), 23.7 (C-15). IR (film, cm-1) νmax 3291 (N–H), 2961 (C–H), 1638 (C=O), 




2-((2-(Tert-Butyl)-6-methylphenyl)(methyl)amino)-N,N,3-trimethylbenzamide – 2.61  
 A flame-dried round bottom flask was allowed to cool to rt in vacuo. To 
this was added 2-((2-(tert-Butyl)-6-methylphenyl)(methyl) amino)-N,3-
dimethylbenzamide 2.48o (30.1 mg, 0.0928 mmol, 1.0 eq.) and anhydrous 
THF (0.4 mL, 0.23 M) and the reaction mixture was cooled to 0 °C. NaH  
(7.4 mg, 0.18 mmol, 2.0 eq.) was added portion wise, followed by dropwise addition of MeI (17 μL, 
0.28 mmol, 3.0 eq.). The reaction mixture was allowed to stir at rt for 20 h. The reaction mixture was 
quenched with sat. Na2S2O3 (aq.) and extracted with Et2O. The combined organic phases were washed 
with brine, dried over MgSO4, filtered and concentrated in vacuo to yield the crude methylated urea. 
Purification by flash column chromatography eluting with (5% to 50% EtOAc/Petrol) yielded the title 
compound 10 (23.6 mg, 75%) as a colourless oil. Rf 0.26 (50% EtOAc/Petrol). Mixture of conformers in 
a 1.0:0.8 ratio. Only major peaks were assigned in the 1H NMR spectrum. δ1H (400 MHz, CDCl3)  
7.35 (1 Hmaj, dd, J = 8.1, 1.6 Hz, H-11), 7.30 (1 Hmin, dd, J = 8.1, 1.6), 7.14 (1 Hmin, t, J = 7.7),  
7.09 (1 Hmaj, t, J = 7.7 Hz, H-10), 7.05 (1 Hmin, dd, J = 7.5, 1.6), 6.97 – 6.87 (3 Hmaj + 1 Hmin, m,  
H-4 + H-6 + H-15), 6.84 (1 Hmin, dd, J = 7.5, 1.8), 6.64 (1 Hmaj, t, J = 7.4 Hz, H-5),  
6.58 (1 Hmin, t, J = 7.4 Hz), 3.17 (3 Hmin, s), 3.14 (3 Hmin, s), 3.12 (3 Hmin, s), 3.11 (3 Hmaj, s, H-3),  
3.10 (3 Hmaj, s, H-9), 3.07 (3 Hmaj, s, H-3), 2.16 (3 Hmin, s), 2.11 (3 Hmaj, s, H-16), 1.62 (3 Hmaj, s, H-17), 
1.47 (3 Hmin, s), 1.46 (9 Hmaj, s, H-19), 1.39 (9 Hmin, s). δ13C (101 MHz, CDCl3) 173.8 (C-1maj),  
173.5 (C-1min), 149.7 (C-12min), 148.8 (C-13min), 146.5 (C-13maj), 146.2 (C-8min), 145.6 (C-12maj),  
144.7 (C-8maj), 139.6 (C-14min), 139.0 (C-14maj), 135.0 (C-6min), 134.3 (C-6maj), 128.7 (C-15min),  
128.4 (C-15maj), 128.3 (C-11maj), 127.9 (C-4min), 127.8 (C-4maj), 127.0 (C-10min), 126.3 (C-10maj),  
125.7 (C-11min), 125.6 (C-7maj), 124.8 (C-7min), 122.5 (C-2maj), 122.4 (C-2min), 117.4 (C-5maj), 116.6 (C-5min), 
46.0 (C-3min), 45.1 (C-3maj), 40.4 (C-3min), 40. 0 (C-3maj), 36.7 (C-18maj), 36.2 (C-18min), 35.3 (C-9min),  
35.2 (C-9maj), 32.6 (C-19maj), 31.8 (C-19min), 23.2 (C-17maj), 22.8 (C-17min), 19.3 (C-16min), 18.9 (C-16maj). 
IR (film, cm-1) νmax 2958 (C–H), 2925 (C–H), 1638 (C=O). HRMS (ESI+) m/z calcd for C22H31N2O+ [M+H]+ 
339.2431; found: 339.2446. 
General Procedure 2.4 (GP2.4): One-pot anionic Fries-Smiles rearrangement: A flame-dried 
round bottom flask was allowed to cool to rt in vacuo and refilled with nitrogen. To this was added 
the required urea 2.41 (1.0 eq.) and anhydrous THF (0.2 M) and the reaction mixture was cooled to 
−78 °C. n-BuLi (1.4 M in hexanes, 1.1 eq.) was added dropwise and the reaction was allowed to stir at 
−78 °C for 2 h. DMPU (5.0 eq.) was added, and the reaction mixture was allowed to warm up to rt and 
stir for 4 h. The reaction was quenched with MeOH, and the subsequent solution concentrated in 
vacuo. Purification by flash column chromatography yielded the desired product 
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N-Methyl-2-(methyl(phenyl)amino)benzamide - 2.48a  
Following GP2.4 on a 0.4 mmol scale, the title compound was only observed as trace amounts by  
1H NMR of the crude reaction mixture after quench.  
2-((4-Fluorophenyl)(methyl)amino)-N-methylbenzamide - 2.48b  
Following GP2.4 on a 0.75 mmol scale, the title compound was isolated as a yellow oil (48 mg, 25%). 
N-Methyl-2-(methyl(naphthalen-1-yl)amino)benzamide – 2.48j 
Following GP2.4 on a 0.4 mmol scale, the title compound was isolated as a colourless oil (67 mg, 58%). 
Chapter 3 
General Procedure 3.1 (GP3.1), Ring opening of anthranilamides: In a flame-dried microwave vial 
under nitrogen, anthranilamides 3.17 (1 eq.) was added. The vial was capped with a septum, 
evacuated in vacuo and refilled with nitrogen. Dry THF (0.2 M) was added and NaHMDS (1 M in THF, 
1.1 eq.) was added dropwise at rt. The vial was sealed, and the reaction mixture was heated to  
100 °C under microwave irradiation for 15 min and was quenched with MeOH. The organic phase was 
evaporated under reduced pressure and the residue was purified by silica gel column chromatography 
eluting with a gradient of petroleum ether /EtOAc.  
13-Methyl-6,7,8,13-tetrahydro-5H-dibenzo[b,h][1,5]diazonin-5-one – 3.18a 
Prepared with modification to GP3.1 (4 h reaction time at 120 °C) on a  
0.4 mmol scale, the title product was obtained as a colourless solid (70 mg, 
70%). 1:0.15 mixture of conformers. Crystals suitable for X-ray analysis 
were obtained by vapour diffusion of n-hexane in a saturated solution of 
the title compound in CH2Cl2. m.p.: 163 – 164 °C (degradation).  
δ1H (400 MHz, CDCl3) 7.43 (1 Hmaj + 1 Hmin, td, J = 7.8, 1.7 Hz, H-15),  
7.36 (1 Hmaj + 1 Hmin, dd, J = 7.4, 1.7 Hz, H-13), 7.25 (1 Hmaj + 1 Hmin, d, J = 7.3 Hz, H-16),  
7.22 (1 Hmaj + 1 Hmin, td, J = 5.2, 1.5 Hz, H-12), 7.18 (1 Hmaj, dd, J = 7.3, 1.5 Hz, H-11),  
7.14 (1 Hmaj + 1 Hmin, td, J = 7.4, 2.1 Hz, H-10), 7.00 (1 Hmaj + 2 Hmin, td, J = 7.5, 1.0 Hz, H-14),  
6.87 (1 Hmin, td, J = 7.5, 1.1 Hz), 6.78 (1 Hmaj, dd, J = 7.6, 1.6 Hz, H-9), 5.87 (1 Hmaj, d, J = 11.9 Hz, NH),  
5.14 (1 Hmin, d, J = 12.8 Hz, NH), 3.85 (CHAHB, 1 Hmaj + 1 Hmin, tdd, J = 12.8, 11.8, 2.5 Hz, H-4),  
2.41 – 3.34 (CHAHB, 1 Hmaj + 1 Hmin, m, H-4), 3.29 (CHAHB, 1 Hmaj + 1 Hmin, td, J = 13.0, 3.8 Hz, H-3),  
3.13 (3 Hmin, s, H-8), 3.05 (3 Hmaj, s, H-8), 2.72 (CHAHB, 1 Hmaj + 1Hmin, dt, J = 13.2, 2.4 Hz, H-3).  
δ13C (101 MHz, CDCl3) 173.3 (C-5min), 173.0 (C-5maj), 152.2 (C-1maj), 151.0 (C-7maj), 148.0 (ArCmin),  
146.6 (ArCmin), 137.9 (ArCmin), 136.8 (C-2maj), 132.5 (ArCHmin), 131.9 (ArCHmin), 131.3 (C-12maj),  
131.1 (C-15maj), 131.0 (ArCHmin), 129.9 (C-6maj), 129.3 (ArCHmin), 129.2 (C-10maj), 128.9 (C-13maj),  
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128.7 (ArCHmin), 128.6 (C-9maj), 128.1 (ArCHmin), 128.0 (C-11maj), 124.3 (ArCmin), 121.6 (C-14maj),  
119.1 (ArCHmin), 116.9 (C-16maj), 114.3 (ArCHmin), 44.9 (C-4maj), 41.9 (C-8maj), 40.9 (C-4min), 40.3 (C-8min), 
35.5 (C-3maj), 34.7 (C-3min). IR (film, cm-1) νmax 3321 (N–H), 3063, 2933 (C–H), 1674 (C=O), 1451, 1308. 
HRMS (ESI+) m/z calcd for C17H19N2O+ [M+H]+ 267.1492; found 267.1498. Supplementary 
crystallographic data can be obtained free of charge from The Cambridge Crystallographic Data Centre 
(CCDC 1571681). 
14-Methyl-7,8,9,14-tetrahydrodibenzo[b,i][1,5]diazecin-5(6H)-one – 3.18 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as a 
white solid (77 mg, 72%). Following GP3.1 on a 3.0 mmol scale, the title 
product was obtained as a white solid (0.63 g, 79%). Following GP3.1 on a 
0.4 mmol scale in 2-Methyltetrahydrofuran, the title product was obtained 
as an off-white solid (71 mg, 67%). Crystals suitable for X-ray analysis were 
obtained by vapour diffusion of n-hexane in a saturated solution of the title compound in CH2Cl2.  
m.p.: 162 – 164 °C. δ1H (400 MHz, CDCl3) 7.45 – 7.39 (2 H, m, H-9 + H-11),  
7.32 (1 H, dd, J = 7.7, 1.7 Hz, H-16), 7.20 (1 H, dd, J = 8.2, 1.0 Hz, H-12), 7.16 (1 H, td, J = 7.7, 1.3 Hz,  
H-15), 7.09 (1 H, td, J = 7.7, 1.7 Hz, H-14), 7.00 (1 H, td, J = 7.5, 1.0 Hz, H-10),  
6.72 (1 H, dd, J = 7.7, 1.3 Hz, H-13), 6.46 (1 H, br. t, J = 7.6 Hz, NH), 3.28 – 3.17 (CHAHB, 2 H, m,  
H-4 + H-6), 3.07 (3 H, s, H-17), 3.05 – 2.99 (CHAHB, 1 H, m, H-6),  
2.69 (CHAHB, 1 H, ddd, J = 14.1, 6.6, 2.3 Hz, H-4), 2.25 – 2.08 (2 H, m, H-5). δ13C (101 MHz, CDCl3)  
169.7 (C-7), 151.1 (C-2), 149.0 (C-1), 137.2 (C-3), 131.0 (C-11), 130.4 (C-9), 130.3 (C-16), 128.5 (C-8), 
128.0 (C-14), 127.1 (C-13), 126.6 (C-15), 121.4 (C-10), 116.9 (C-12), 42.7 (C-17), 37.0 (C-6), 26.3 (C-5), 
24.1 (C-4). IR (film, cm-1) νmax 3303 (N–H), 2926 (C–H), 1658 (C=O). HRMS (ESI+) m/z calcd for 
C16H16N2ONa+ [M+Na]+ 275.115; found: 275.115. Supplementary crystallographic data can be obtained 
free of charge from The Cambridge Crystallographic Data Centre (CCDC 1571682). 
15-Methyl-6,7,8,9,10,15-hexahydro-5H-dibenzo[b,j][1,5]diazacycloundecin-5-one – 3.18c 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as a 
white solid (92 mg, 82%). Crystals suitable for X-ray analysis were obtained 
by vapour diffusion of n-hexane in a saturated solution of the title 
compound in CH2Cl2. m.p.: 171 – 173 °C. δ1H (400 MHz, CDCl3)  
7.72 (2 H, dd, J = 7.6, 1.8 Hz, NH + H-10), 7.46 (1 H, td, J = 7.7, 1.7 Hz, H-12),  
7.33 (1 H, dd, J = 8.1, 1.1 Hz, H-13), 7.29 (1 H, dt, J = 7.8, 1.2 Hz, H-17), 7.12 (1 H, td, J = 7.5, 1.2 Hz,  
H-11), 7.08 (1 H, td, J = 7.5, 1.4 Hz, H-16), 6.99 (1 H, td, J = 7.7, 1.6 Hz, H-15),  
6.54 (1 H, dd, J = 8.0, 1.3 Hz, H-14), 3.89 – 3.77 (CHAHB, 1 H, m, H-6),  
3.12 (CHAHB, 1 H, ddd, J = 14.9, 13.4, 4.4 Hz, H-3), 3.05 (3 H, s, H-18), 2.89 – 2.79 (CHAHB, 1 H, m, H-3), 
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2.80 – 2.71 (CHAHB, 1 H, m, H-6), 2.27 – 2.12 (CHAHB, 1 H, m, H-4), 2.02 – 1.91 (CHAHB, 1 H, m, H-4), 
1.62 – 1.40 (2 H, m, H-5). δ13C (101 MHz, CDCl3) 166.8 (C-7), 151.2 (C-1), 148.7 (C-9), 136.1 (C-2),  
131.05 (C-10 or C-12), 131.01 (C-10 or C-12), 129.4 (C-8), 129.2 (C-17), 127.4 (C-15),  
125.7 (C-14 or C-16), 125.6 (C-14 or C-16), 123.0 (C-11), 119.2 (C-13), 42.6 (C-18), 40.3 (C-7),  
28.7 (C-6), 27.1 (C-3), 25.5 (C-5). IR (film, cm-1) νmax 3323 (N–H), 2925 (C–H), 1644 (C=O), 1586, 1483, 
1449, 1306 (C–N). HRMS (ESI+) m/z calcd for C18H21N2O+ [M+H]+ 281.1648; found: 281.1659. 
Supplementary crystallographic data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre (CCDC 1571683). 
16-Methyl-7,8,9,10,11,16-hexahydrodibenzo[b,k][1,5]diazacyclododecin-5(6H)-one– 3.18d 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as a 
white solid (quant.). Crystals suitable for X-ray analysis were obtained in a 
saturated solution of the title compound in toluene. m.p.: 137 – 138 °C.  
δ1H (400 MHz, CDCl3) 9.10 (1 H, br. s, NH), 8.18 (1 H, dd, J = 7.8, 1.8 Hz,  
H-15), 7.43 (1 H, ddd, J = 8.2, 7.3, 1.8 Hz, H-17), 7.29 – 7.21 (3 H, m,  
H-14 + H-16 + H-18), 7.12 (2 H, pd, J = 7.3, 1.8 Hz, H-12 + H-13), 6.96 (1 H, d, J = 7.4 Hz, H-11),  
3.85 (CHAHB, 1 H, q, J = 9.8 Hz, H-7), 3.13 (3 H, s, H-19), 3.06 – 2.94 (CHAHB, 1 H, m, H-7),  
2.81 – 2.69 (CHAHB, 1 H, m, H-3), 2.69 – 2.57 (CHAHB, 1 H, m, H-3), 2.02 – 1.90 (CHAHB, 1 H, m, H-4), 
1.88 – 1.78 (CHAHB, 1 H, m, H-6), 1.77 – 1.66 (CHAHB, 2 H, m, H-4 + H-5), 1.62 – 1.46 (CHAHB, 1 H, m,  
H-6), 1.44 – 1.31 (CHAHB, 1 H, m, H-5). δ13C (101 MHz, CDCl3) 166.4 (C-8), 149.7 (C-1), 149.3 (C-10),  
137.4 (C-2), 132.0 (C-15), 131.7 (C-17), 130.1 (C-14), 129.1 (C-9), 126.9 (C-13), 125.4 (C-12),  
124.7 (C-17), 123.9 (C-11), 123.7 (C-16), 44.4 (C-19), 40.3 (C-7), 29.9 (C-4), 28.7 (C-3), 26.5 (C-6),  
25.4 (C-5). IR (film, cm-1) νmax 3312 (N–H), 2930, 2864 (C–H), 1650 (C=O), 1532, 1486, 1449,  
1290 (C–N). HRMS (ESI+) m/z calcd for C19H22N2ONa+ [M+Na]+ 317.1624; found: 317.1638. 
Supplementary crystallographic data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre (CCDC 1571684). 
11-Chloro-14-methyl-7,8,9,14-tetrahydrodibenzo[b,i][1,5]diazecin-5(6H)-one –3.18e 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as a 
yellow solid (53 mg, 44%), together with recovered starting material  
(20 mg, 17%). m.p.: 217 – 218 °C Mixture of conformers in a 1:0.08 ratio. 
Only the major conformer is reported. δ1H (400 MHz, CDCl3)  
7.43 – 7.38 (2 H, m, H-9 + H-11), 7.27 (1 H, dd, J = 2.5, 0.7 Hz, H-16),  
7.18 (1 H, dd, J = 8.6, 1.0 Hz, H-12), 7.02 (1 H, dd, J = 8.5, 2.6 Hz, H-14), 6.99 (1 H, td, J = 7.5, 1.0 Hz,  
H-10), 6.64 (1 H, d, J = 8.5 Hz, H-13), 6.44 (1 H, d, J = 8.0 Hz, NH), 3.34 – 3.12 (CHAHB , 2 H, m,  
H-3 + H-5), 3.02 (3 H, s, H-17), 3.02 – 2.96 (CHAHB, 1 H, m, H-5),  
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2.63 (CHAHB 1 H, ddd, J = 14.1, 6.6, 2.3 Hz, H-3), 2.24 – 2.04 (2 H, m, H-4). δ13C (101 MHz, CDCl3)  
169.4 (C-6), 149.6 (C-1), 148.5 (C-8), 139.4 (C-2) 131.8 (C-7), 131.1 (C-9 or C-11), 130.4 (C-9 or C-11), 
130.2 (C-16), 128.51 (C-15), 128.46 (C-13), 128.1 (C-14), 121.7 (C-11), 116.9 (C-12), 42.6 (C-17),  
36.8 (C-5), 26.2 (C-4), 24.1 (C-3). IR (film, cm-1) νmax 3297 (N–H), 2932, 2874 (C–H), 1648 (C=O), 1600, 




Following GP3.1 on a 0.4 mmol scale, the title product was obtained as a 
white solid (106 mg, 84%). m.p.: 207 – 208 °C. δ1H (400 MHz, CDCl3)  
7.67 (1 H, d, J = 7.6 Hz, H-10), 7.48 (1 H, br. s, NH), 7.45 (1 H, t, J = 7.7 Hz, 
H-12), 7.30 (1 H, d, J = 8.2 Hz, H-13), 7.24 (1 H, d, J = 2.5 Hz, H-17),  
7.12 (1 H, t, J = 7.5 Hz, H-11), 6.94 (1 H, dd, J = 8.6, 2.5 Hz, H-15),  
6.48 (1 H, d, J = 8.6 Hz, H-14), 3.83 (CHAHB, 1 H, p, J = 5.7 Hz, H-6), 3.16 – 3.04 (CHAHB, 1 H, m, H-3), 
3.01 (3 H, s, H-18), 2.85 – 2.69 (CHAHB, 2 H, m, H-3 + H-6), 2.13 (CHAHB, 1 H, dtd, J = 13.6, 8.6, 4.0 Hz, 
H-4), 1.96 (CHAHB, 1 H, tt, J = 11.0, 3.9 Hz, H-4), 1.67 – 1.39 (2 H, m, H-5). δ13C (101 MHz, CDCl3)  
166.8 (C-7), 149.8 (C-1), 148.3 (C-9), 138.3 (C-2), 131.14 (C-8), 131.10 (C-12), 131.0 (C-10),  
129.4 (C-16), 129.0 (C-17), 127.6 (C-15), 127.2 (C-14), 123.2 (C-11), 119.0 (C-13), 42.7 (C-18),  
40.3 (C-6), 28.4 (C-5), 27.1 (C-3), 25.2 (C-5). IR (film, cm-1) νmax 3311 (N–H), 2926 (C–H), 1640 (C=O), 
1534, 1476, 1308 (C–N), 1109. HRMS (ESI+) m/z calcd for C18H19ClN2ONa+ [M+Na]+ 337.1078; found: 
337.1067. 
1-Fluoro-14-methyl-7,8,9,14-tetrahydrodibenzo[b,i][1,5]diazecin-5(6H)-one – 3.18g 
Prepared with slight modification to GP3.1 (45 minutes reaction time) 
on a 0.4 mmol scale, the title product was obtained as a yellow solid  
(51 mg, 45%), together with recovered starting material (50 mg, 44%). 
m.p.: 197 – 199 °C. δ1H (400 MHz, CDCl3) 7.28 – 7.23 (2 H, m,  
H-13 + H-12), 7.20 – 7.11 (2 H, m, H-10 + H-14),  
7.08 (1 H, td, J = 7.5, 1.8 Hz, H-15), 7.03 (1 H, tdd, J = 8.1, 4.5, 0.6 Hz, H-11),  
6.92 (1 H, dd, J = 7.8, 1.2 Hz, H-16), 6.82 (1 H, br. s, NH), 2.48 – 3.36 (CHAHB, 1 H, m, H-1),  
3.32 (3 H, d, J = 5.6 Hz, H-17), 3.25 – 3.14 (CHAHB, 1 H, m, H-1),  
3.06 (CHAHB, 1 H, ddd, J = 14.1, 11.5, 4.9 Hz, H-3), 2.73 (CHAHB, 1 H, dt, J = 14.2, 4.7 Hz, H-3),  
2.30 – 2.16 (CHAHB, 1 H, m, H-2), 2.14 – 2.06 (CHAHB, 1 H, m, H-2). δ13C (101 MHz, CDCl3)  
168.2 (d, J = 3.6 Hz, C-8), 158.2 (d, J = 247.5 Hz, C-9), 149.7 (C-5), 138.3 (C-4), 135.8 (d, J = 9.7 Hz, 
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C-6), 134.1 (d, J = 3.2 Hz, C-7), 130.9 (C-13), 127.9 (C-15), 127.7 (d, J = 1.4 Hz, C-16), 126.5 (C-14), 
125.7 (d, J = 3.0 Hz, C-12), 124.2 (d, J = 8.3 Hz, C-11), 119.1 (d, J = 22.4 Hz, C-10),  
44.7 (d, J = 11.6 Hz, C-17), 37.5 (C-1), 27.7 (C-2), 25.3 (C-3). IR (film, cm-1) νmax 3292 (N–H),  
2928 (C–H), 1644 (C=O), 1541, 1455, 1308 (C–N), 1236. HRMS (ESI+) m/z calcd for C17H17FN2ONa+ 
[M+Na]+ 307.1217; found: 307.1229. 
1-Fluoro-15-methyl-6,7,8,9,10,15-hexahydro-5H-dibenzo[b,j][1,5]diazacycloundecin-5-one – 
3.18h 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as a 
white solid (93 mg, 78%). m.p.: 164 – 166 °C. δ1H (400 MHz, CDCl3)  
8.17 (1 H, br. s, NH), 7.64 (1 H, ddd, J = 7.5, 1.9, 0.9 Hz, H-10),  
7.31 (1 H, dt, J = 7.6, 1.1 Hz, H-17), 7.29 – 7.17 (2 H, m, H-11 + H-12),  
7.10 (1 H, td, J = 7.4, 1.5 Hz, H-16), 7.04 (1 H, td, J = 7.6, 1.8 Hz, H-15),  
6.78 (1 H, dt, J = 7.9, 1.6 Hz, H-14), 4.05 – 3.90 (CHAHB, 1 H, m, H-6), 3.30 (3 H, d, J = 5.4 Hz, H-18),  
3.11 (CHAHB, 1 H, td, J = 14.5, 14.1, 4.5 Hz, H-3), 2.94 – 2.89 (CHAHB, 1 H, m, H-6),  
2.89 – 2.81 (CHAHB, 1 H, m, H-3), 1.28 – 2.14 (CHAHB, 1 H, m, H-4), 2.02 – 1.89 (CHAHB, 1 H, m, H-4), 
1.63 – 1.51 (CHAHB, 1 H, m, H-5), 1.44 – 1.30 (CHAHB, 1 H, m, H-5). δ13C (101 MHz, CDCl3)  
165.5 (d, J = 3.5 Hz, C-7), 160.3 (d, J = 249.2 Hz, C-13), 149.2 (d, J 0.9 Hz, C-1), 135.3 (d, J = 10.7 Hz,  
C-9), 135.1 (C-2), 134.1 (d, J = 2.9 Hz, C-8), 129.4 (C-17), 127.3 (C-15), 126.6 (d, J = 2.9 Hz, C-10),  
126.0 (d, J = 8.7 Hz, C-11), 125.5 (d, J = 1.3 Hz, C-14), 125.4 (C-16), 119.2 (d, J = 22.0 Hz, C-12),  
44.4 (d, J = 11.1 Hz, C-18), 40.2 (C-6), 29.1 (C-4), 27.5 (C-3), 25.3 (C-5). IR (film, cm-1) νmax 3312 (N–H), 
2920 (C–H), 1641 (C=O), 1539, 1457, 1307 (C–N), 1237. HRMS (ESI+) m/z calcd for C18H19FN2O+ [M+H]+ 
321.1374; found: 321.1381. 
3-Fluoro-14-methyl-7,8,9,14-tetrahydrodibenzo[b,i][1,5]diazecin-5(6H)-one – 3.18i 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as a 
white solid (89 mg, 78%). m.p.: 159 – 161 °C. δ1H (400 MHz, CDCl3)  
7.30 (1 H, dd, J = 7.6, 1.6 Hz, H-13), 7.19 – 7.13 (3 H, m,  
H-9 + H-12 + H-14), 7.12 – 7.05 (2 H, m, H-10 + H-15), 6.70 (1 H, br. s, NH),  
6.68 (1 H, dd, J = 7.9, 1.4 Hz, H-16), 3.28 – 3.15 (CHAHB, 2 H, m, H-1 + H-3), 
3.04 (3 H, s, H-17), 3.04 – 2.99 (CHAHB, 1 H, m, H-1), 2.69 (CHAHB, 1 H, ddd, J = 14.1, 6.5, 2.4 Hz, H-3), 
2.26 – 2.06 (2 H, m, H-2). δ13C (101 MHz, CDCl3) 168.1 (d, J = 1.9 Hz, C-8), 157.9 (d, J = 241.8 Hz, C-11), 
150.9 (C-5), 145.3 (d, J = 2.5 Hz, C-6), 137.2 (C-4), 130.4 (C-13), 130.0 (d, J = 5.7 Hz, C-7), 128.0 (C-15), 
126.8 (C-16), 126.6 (C-14), 118.4 (d, J = 7.5 Hz, C-9), 117.4 (d, J = 10.5 Hz, C-12), 117.2 (d, J = 9.0 Hz,  
C-10), 43.1 (C-17), 37.1 (C-1), 26.3 (C-2), 24.1 (C-3). IR (film, cm-1) νmax 3306 (N–H), 2934, 2870 (C–H), 
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1650 (C=O), 1522, 1482. HRMS (ESI+) m/z calcd for C17H17FN2ONa+ [M+Na]+ 307.1217; found: 
307.1209. 
3-Bromo-14-methyl-7,8,9,14-tetrahydrodibenzo[b,i][1,5]diazecin-5(6H)-one – 3.18j 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as 
a yellow solid (72 mg, 52%) together with recovered starting material 
(31 mg, 22%). m.p.: 184 – 185 °C. δ1H (400 MHz, CDCl3)  
7.54 – 7.46 (2 H, m, H-10 + H-12), 7.31 (1 H, dd, J = 8.0, 1.4 Hz, H-13), 
7.18 (1 H, td, J = 7.5, 1.4, H-14), 7.10 (1 H, td, J = 7.7, 1.7 Hz, H-15),  
7.06 (1 H, d, J = 8.3 Hz, H-9), 6.70 (1 H, dd, J = 7.9, 1.4 Hz, H-16), 6.36 (1 H, d, J = 7.9 Hz, NH),  
3.25 – 3.14 (CHAHB, 2 H, m, H-1 + H-3), 3.04 (3 H, s, H-17), 3.03 – 2.96 (CHAHB, 1 H, m, H-1),  
2.68 (CHAHB, 1 H, ddd, J = 14.1, 6.5, 2.5 Hz, H-3), 2.24 – 2.07 (2 H, m, H-2). δ13C (101 MHz, CDCl3) 168.0 
(C-8), 150.5, 148.1, 137.2 (C-4), 133.6 (C-12), 133.1 (C-10), 130.4 (C-13), 130.2 (C-7), 128.1 (C-15),  
127.0 (C-16), 126.9 (C-14), 118.6 (C-9), 114.0 (C-11), 42.8 (C-17), 37.0 (C-1), 26.1 (C-2), 24.0 (C-3).  
IR (film, cm-1) νmax 3300 (N–H), 2928 (C–H), 1649 (C=O), 1477, 1321 (C–N), 1104. HRMS (ESI+) m/z calcd 
for C17H17N2OBrNa+ [M+Na]+ 367.0416; found: 367.0425. 
15-Methyl-3-(trifluoromethoxy)-6,7,8,9,10,15-hexahydro-5H-
dibenzo[b,j][1,5]diazacycloundecin-5-one – 3.18k 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained 
as a white solid (120 mg, 82%). m.p.: 192 – 193 °C. δ1H (400 MHz, 
CDCl3) 7.70 (1 H, br. d, J = 8.7 Hz, NH), 7.58 (1 H, d, J = 2.6 Hz, H-10),  
7.37 – 7.20 (3 H, m, H-12 + H-13 + H-17), 7.10 (1 H, td, J = 7.5, 1.4,  
H-16), 7.01 (1 H, td, J = 7.7, 1.6 Hz, H-15),  
6.53 (1 H, dd, J = 8.0, 1.4 Hz, H-14), 3.89 – 3.72 (CHAHB, 1 H, m, H-6), 3.18 – 2.97 (4 H, m, H-3 + H-18), 
2.83 (CHAHB, 1 H, dt, J = 15.0, 4.5, H-3), 2.76 (CHAHB, 1 H, ddt, J = 10.5, 6.2, 3.6 Hz, H-6),  
2.19 (CHAHB, 1 H, tq, J = 13.9, 4.9 Hz, H-4), 2.04 – 1.91 (CHAHB, 1 H, m, H-4),  
1.59 – 1.41 (2 H, m, J = 12.5, 9.6, 5.5, 2.6 Hz, H-5). δ13C (101 MHz, CDCl3) 165.7 (C-7), 150.7 (C-1),  
147.4 (C-9), 144.64 (q, JF 2.1 Hz, C-11), 136.2 (C-2), 130.8 (C-8), 129.3 (C-17), 127.6 (C-15),  
126.0 (C-16), 125.6 (C-14), 123.8 (C-10), 123.4 (C-12), 120.6 (q, JF 257.1 Hz, C-19), 120.3 (C-13),  
43.1 (C-18), 40.4 (C-6), 28.5 (C-4), 27.1 (C-3), 25.4 (C-5). IR (film, cm-1) νmax 3247 (N–H), 3082,  
2938 (C–H), 1631 (C=O), 1256, 1218, 1158, 1151. HRMS (ESI+) m/z calcd for C19H19N2O2F3Na+ [M+Na]+ 




Following GP3.1 on a 0.4 mmol scale , the title product was obtained as a 
white solid (67 mg, 57%), together with recovered starting material (27 mg, 
23%). Crystals suitable for X-ray analysis were obtained by vapour diffusion 
of n-hexane in a saturated solution of the title compound in CH2Cl2. 
 m.p.: 203 – 204 °C. δ1H (400 MHz, CD3OD) 7.29 (1 H, d, J = 7.9 Hz, H-17),  
7.26 (1 H, t, J = 7.8 Hz, H-12), 7.13 (1 H, d, J = 8.1 Hz, H-13), 7.08 (1 H, td, J = 7.5, 1.4 Hz, H-16),  
6.99 (1 H, tdd, J = 7.3, 1.7, 0.8 Hz, H-15), 6.83 (1 H, dt, J = 7.5, 0.9 Hz, H-11),  
6.68 (1 H, dd, J = 7.9, 1.4 Hz, H-14), 3.50 (CHAHB, 1 H, ddd, J = 13.7, 5.0, 2.0 Hz, H-6),  
2.41 (CHAHB, 1 H, ddd, J = 14.7, 13.5, 4.4 Hz, H-3), 2.99 (3 H, s, H-18),  
2.81 (CHAHB, 1 H, ddd, J = 13.4, 11.3, 1.8 Hz, H-6), 2.66 (CHAHB, 1 H, dt, J = 14.7, 4.4, H-3),  
2.29 – 2.19 (CHAHB, 1 H, m, H-4), 2.18 (3 H, s, H-19), 1.98 – 1.88 (CHAHB, 1 H, m, H-4),  
1.82 (CHAHB, 1 H, dtt, J = 14.1, 11.5, 2.4 Hz, H-5), 1.42 – 1.25 (CHAHB, 1 H, m, H-5).  
δ13C (101 MHz, CD3OD) 170.7 (C-7), 152.4 (C-1), 150.0 (C-9), 138.8 (C-2), 138.3 (C-10), 131.3 (C-8),  
130.5 (C-12), 129.9 (C-17), 128.0 (C-15), 127.6 (C-14), 126.3 (C-16), 124.4 (C-11), 116.9 (C-13),  
42.9 (C-18), 42.4 (C-6), 29.1 (C-4), 27.4 (C-3), 24.2 (C-5), 20.0 (C-19). IR (film, cm-1) νmax 3319 (N–H), 
2920, 2856 (C–H), 1641 (C=O), 1521, 1464, 1317 (C–N). HRMS (ESI+) m/z calcd for C19H22N2ONa+ 
[M+Na]+ 317.1624; found: 317.1630. Supplementary crystallographic data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre (CCDC 1571685). 
5-Methyl-5,11,16,17-tetrahydro-10H-tribenzo[b,f,j][1,5]diazacycloundecin-10-one – 3.18m 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as an 
off-white solid (129 mg, 98%). m.p.: 189 – 191 °C. δ1H (400 MHz, CDCl3)  
10.19 (1 H, br. s, NH), 8.06 (1 H, dd, J = 8.1, 1.3 Hz, ArCH),  
7.97 (1 H, dd, J = 7.7, 1.8 Hz, ArCH), 7.54 (1 H, ddd, J = 8.1, 7.3, 1.8 Hz, ArCH), 
7.40 (1 H, dd, J = 8.2, 1.0 Hz, ArCH), 7.26 – 7.21 (2 H, m, ArCH),  
7.20 – 7.14 (1 H, m, ArCH), 7.02 (2 H, qd, J = 7.5, 1.8 Hz, ArCH),  
6.86 – 6.77 (3 H, m, ArCH), 3.57 – 2.42 (CHAHB, 2 H, m, CH2), 3.35 (3 H, s, 
CH3), 2.99 – 2.84 (CHAHB, 2 H, m, CH2). δ13C (101 MHz, CDCl3) 164.3 (C=O), 150.8 (ArC), 148.5 (ArC),  
136.6 (ArC), 134.4 (ArC), 133.9 (ArCH), 132.1 (ArCH), 132.0 (ArCH), 129.5 (ArC), 129.4 (ArCH),  
128.4 (ArC), 128.3 (ArCH), 127.6 (ArCH), 125.5 (ArCH), 124.5 (ArCH), 123.6 (ArCH), 123.4 (ArCH),  
120.3 (ArCH), 119.9 (ArCH), 41.5 (CH3), 36.5 (CH2), 29.4 (CH2). IR (film, cm-1) νmax 3345 (N–H),  
3064 (C–H), 2944 (C–H), 1678 (C=O), 1592, 1539, 1455, 1327 (C–N), 1303. HRMS (ESI+) m/z calcd for 
C22H21N2O+ [M+H]+ 329.1648; found: 329.1654. Supplementary crystallographic data can be obtained 




5-one – 3.18n 
Following GP3.1 on a 0.4 mmol scale, the title product was obtained as an 
off-white solid (119 mg, 91%). m.p.: 191 – 193 °C. δ1H (400 MHz, CDCl3)  
7.66 (1 H, dd, J = 7.6, 1.7 Hz, H-9), 7.55 (1 H, br. s, NH),  
7.49 – 7.45 (1 H, m, H-11), 7.44 (1 H, d, J = 8.1 Hz, H-16),  
7.31 (1 H, dd, J = 8.1, 1.0 Hz, H-12), 7.15 (1 H, td, J = 7.5, 1.1 Hz, H-10),  
7.05 (1 H, dd, J = 8.3, 2.2 Hz, H-15), 6.50 (1 H, d, J = 2.2 Hz, H-13), 3.99 (CHAHB, 1 H, d, J = 13.3 Hz,  
H-3), 3.63 (CHAHB, 1 H, d, J = 13.3 Hz, H-3), 3.58 – 3.50 (CHAHB, 1 H, m, H-5), 3.14 – 3.07 (CHAHB, 1 H, 
m, H-5), 3.05 (3 H, s, H-17), 2.77 (CHAHB, 1 H, ddd, J = 13.4, 10.7, 2.4 Hz, H-4), 2.61 (3 H, s, H-18),  
2.44 (CHAHB, 1 H, ddd, J = 14.6, 4.1, 2.0 Hz, H-4). δ13C (101 MHz, CDCl3) 166.9 (C-6), 151.9 (C-1),  
147.6 (C-8), 133.8 (C-14), 132.5 (C-16), 131.9 (C-2), 131.3 (C-12), 131.1 (C-9), 129.9 (C-7),  
125.84 (C-13 or C-15), 125.78 (C-13 or C-15), 123.8 (C-10), 119.9 (C-12), 55.4 (C-3), 51.4 (C-4),  
43.5 (C-18), 42.8 (C-17), 35.1 (C-5). IR (film, cm-1) νmax 3300 (N–H), 2926 (C–H), 1637 (C=O), 1537, 1472, 
1306 (C–N). HRMS (ESI+) m/z calcd for C18H21ClN2O+ [M+H]+ 330.1368; found: 330.1373. 
14-Methyl-5,7,8,14-tetrahydrodibenzo[b,i][1,4,7]triazecin-9(6H)-one - 3.18o 
In a flame-dried microwave vial under nitrogen, tert-butyl 4-(2-(methyl 
amino)benzoyl)-3,4-dihydroquinoxaline-1(2H)-carboxylate 4.17o (147 mg, 
0.4 mmol, 1 eq.) was added. The vial was capped with a septum, evacuated 
in vacuo and refilled with nitrogen. Dry THF (2 mL) was added and NaHMDS 
(1 M in THF, 0.8 mmol, 2.0 eq., 0.8 mL) was added dropwise at rt. The vial was 
sealed, and the reaction mixture was heated to 100 °C under microwave irradiation for 60 min. The 
vial was opened to air and hydrochloric acid (aq. 6 N, 2 mL) was added. The vial was sealed and stirred 
vigorously at 80 °C in an oil bath for 30 min. The reaction mixture was poured onto aqueous sodium 
bicarbonate (20 mL) and extracted with EtOAc (2 × 20 mL). The combined organic phases were washed 
with brine, evaporated under reduced pressure and the residue was purified by silica gel column 
chromatography eluting with a gradient of CH2Cl2/MeOH 20:1 to 10:1. The fractions containing the 
product were evaporated under reduced pressure to give the title product as a yellow oil (58 mg, 54%). 
δ1H (400 MHz, CDCl3) 7.73 (1 H, dd, J = 8.0, 1.7 Hz, H-8), 7.38 – 7.29 (1 H, m, H-10),  
7.23 – 7.18 (1 H, m, H-15), 7.13 (2 H, d, J = 3.8 Hz, H-12 + H-13), 7.11 – 7.04 (1 H, m, H-14),  
7.01 (2 H, d, J = 7.9 Hz, H-9 + H-11), 4.61 (CHAHB, 1 H, ddd, J = 13.5, 7.5, 5.6 Hz, H-4),  
3.82 (CHAHB, 1 H, dt, J = 13.9, 5.4 Hz, H-4), 3.71 (2 H, br. s, 2 * NH), 3.29 (3 H, s, H-16),  
3.17 – 3.03 (CHAHB, 1 H, m, H-3), 2.99 – 2.85 (CHAHB, 1 H, m, H-3). δ13C (101 MHz, CDCl3) 169.7 (C-5), 
154.1 (C-7), 149.3 (C-1), 135.6 (C-2), 132.2 (C-10), 131.9 (C-8), 127.8 (C-6), 126.4 (C-12), 124.8 (C-14), 
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124.3 (C-15), 123.3 (C-9), 118.7 (C-13), 115.9 (C-11), 51.9 (C-4), 40.0 (C-3), 36.8 (C-16).  
IR (film, cm-1) νmax 2927 (C–H), 1627 (C=O), 1456,1394, 1248. HRMS (ESI+) m/z calcd for C16H18N3O+ 
[M+H]+ 268.1444; found: 268.1454. 
1-(3,4-Dihydroquinolin-1(2H)-yl)-3-(trimethylsilyl)prop-2-yn-1-one - 3.23 
To a solution of 3-(trimethylsilyl)propynoic acid (0.59 g, 4.1 mmol, 1.0 eq.) 
and tetrahydroisoquinoline (0.61 mL, 5.0 mmol, 1.2 eq.) in CH2Cl2 (8.2 mL, 
0.5 M) at 0 °C was added DCC (0.93 g, 4.5 mmol, 1.1 eq.) and DMAP (50 mg, 
0.41 mmol, 0.1 eq.) and the reaction mixture was stirred at rt for 3 h. The 
slurry was filtered over Celite and rinsed with ethyl acetate. The combined organic phases were 
washed with HCl (1 M aq.), brine, dried over MgSO4, filtered  and concentrated under reduced pressure 
and the residue was purified by silica gel column chromatography to give the title product as a 
colourless oil (0.60 g, 60%). Mixture of slowly interconverting rotamers in a 1:0.8 ratio. Major/minor 
13C peaks could not be distinguished. δ1H (400 MHz, CDCl3) δ 7.98 (1 Hmin, d, J = 8.1 Hz, ArCH),  
7.65 (1 Hmaj, br. s, ArCH), 7.14 (3 Hmaj+min, br. s, ArCH), 4.06 (2 Hmin, br. s, NCH2),  
3.84 (2 Hmaj, br. t, J = 5.6 Hz, NCH2), 2.85 (2 Hmin, br. s, NCH2CH2), 2.76 (2 Hmaj, br. t, J = 7.0 Hz, NCH2CH2), 
2.05 (2 Hmin, br. s, CCH2), 1.97 (2 Hmaj, br. s, CCH2), 0.27 (9 Hmin, br. s, Si(CH3)3), 0.15 (9 Hmaj, br. s, 
Si(CH3)3). δ13C (101 MHz, CDCl3) . 152.8 (C=Omaj+min), 137.6 (ArCmaj), 137.0 (ArCmin), 132.8 (ArCmaj+min), 
129.1 (ArCHmin), 128.3 (ArCHmaj), 126.1 (ArCHmin), 125.9 (ArCHmaj), 125.5 (ArCHmaj), 125.1 (ArCHmin), 
124.9 (ArCHmaj), 124.4 (ArCHmin), 98.7 (C≡Cmaj), 97.7 (C≡Cmin), 97.4  (C≡Cmaj), 96.9 (C≡Cmin),  
47.5 (NCH2min), 42.8 (NCH2maj), 27.0 (CCH2maj+min), 23.6 (NCH2CH2maj+min), -0.5 (Si(CH3)3min), -0.8 (Si(CH3)3). 
1-(3,4-Dihydroquinolin-1(2H)-yl)-3-(methylamino)prop-2-en-1-one – 3.24 
To a solution of 1-(3,4-dihydroquinolin-1(2H)-yl)-3-(trimethylsilyl)prop-2-yn-
1-one 3.23 (0.47 g, 1.9 mmol, 1.0 eq.) in MeOH (18 mL, 0.1 M) was added 
MeNH2 (8 M in ethanol, 0.46 mL, 3.7 mmol, 2.0 eq.) and the reaction mixture 
was stirred at rt for 18 h. The reaction mixture was concentrated under 
reduced pressure and the residue was purified by silica gel column chromatography to give the title 
product as a yellow oil (0.40 g, 99%). Mixture of Z/E isomers in a 1:0.3 ratio. δ1H (400 MHz, CDCl3)  
8.42 (1 HZ, br. s, NH), 7.63 (1HE, dd, J = 12.8, 7.5 Hz, H-2), 7.36 (1 HZ, dd, J = 8.3, 1.1 Hz, H-10),  
7.33 (1 HE, dd, J = 8.4, 1.3 Hz, H-10), 7.20 – 7.07 (2 HZ + 2 HE m, H-7 + H-9),  
7.01 (1 HZ + 1 HE, qd, J = 7.6, 7.0, 1.3 Hz, H-8), 6.49 (1 HZ, dd, J = 12.7, 8.2 Hz, H-1),  
5.19 (1 HE, d, J = 12.8 Hz, H-2), 4.88 (1 HZ, d, J = 8.2 Hz, H-2), 4.58 (1 HE, s, NH),  
3.82 (2 HE, t, J = 5.5 Hz, H-13), 3.75 (2 HZ, t, J = 5.5 Hz, H-13), 2.93 (3 HZ, d, J = 5.0 Hz, H-4),  
2.74 – 2.63 (2 HZ + 2 HE, m, H-11), 2.02 – 1.87 (2 HZ + 2 HE, m, H-12). δ13C (101 MHz, CDCl3)  
170.8 (C-3Z), 168.9 (C-3E), 152.0 (C-2Z), 148.9 (C-2E), 140.2 (C-6E), 140.0 (C-6Z), 132.7 (C-5E),  
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132.4 (C-5Z), 128.4 (C-9Z+E), 125.7 (C-7Z), 125.6 (C-7E), 125.3 (C-10E), 125.1 (C-10Z), 124.0 (C-8E),  
123.9 (C-8Z), 88.2 (C-1E), 83.6 (C-1Z), 42.9 (C-13E), 42.6 (C-13Z), 34.9 (C-4Z+E), 27.22 (C-11E),  
27.20 (C-11Z), 24.43 (C-12E), 24.38 (C-12Z). 
1-((2-Nitrophenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline – 3.27 
To a solution of 2-nitrobenzenesulfonyl chloride (1.0 g, 4.7 mmol, 1.0 eq.) 
in CH2Cl2 (12 mL, 0.4  M) was sequentially added pyridine (0.76 mL,  
9.4 mmol, 2.0 eq.) and 1,2,3,4-Tetrahydroquinoline (0.70 mL, 5.6 mmol,  
1.2 eq.) at 0 °C before warming to rt and stirring for 20 h. The reaction 
mixture was diluted in CH2Cl2 and washed with HCl (1 M aq.), sat. NaHCO3 
(aq.) and brine. The combined organic phases were dried over MgSO4, filtered and concentrated in 
vacuo. The crude residue obtained was purified by flash column chromatography to give the title 
compound (0.88 g, 59%) as a light brown solid. δ1H (400 MHz, CDCl3) 7.73 – 7.65 (2 H, m, H-2 + H-3),  
7.60 (1 H, dd, J = 8.0, 1.4 Hz, H-6), 7.56 (1 H, td, J = 7.7, 1.4 Hz, H-1), 7.52 (1 H, dd, J = 8.0, 1.3 Hz,  
H-12), 7.16 (1 H, td, J = 8.2, 7.6, 2.4 Hz, H-13), 7.13 – 7.06 (2 H, m, H-14 + H-15), 3.86 (2 H, t, J = 5.1 Hz, 
H-11), 2.63 (2 H, t, J = 5.8 Hz, H-9), 1.92 – 1.83 (2 H, m, H-10). δ13C (101 MHz, CDCl3) 148.1 (C-4),  
136.5 (C-7), 133.9 (C-2), 133.2 (C-5), 131.7 (C-1), 131.2 (C-8), 130.6 (C-3), 129.4 (C-15), 126.7 (C-13), 
125.6 (C-14), 124.20 (C-6 or C-12), 124.19 (C-6 or C-12), 46.7 (C-11), 26.6 (C-9), 22.6 (C-10).  
HRMS m/z (ESI+) m/z calcd for C15H15N2O2S+ [M+H]+ requires: 319.0747; found: 319.0756. 
1-((2-Nitrophenyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepine– 3.28 
Pd/C (10 wt. % loading, 0.08 gm 1 mol%) was suspended in a solution of 
3.27 (0.84 g, 2.6 mmol, 1.0 eq.) in EtOH ( 13 mL, 0.2 M) under nitrogen. 
Nitrogen was bubbled through the solution for 15 mins. The contents of 
the flask were placed under a hydrogen atmosphere using a two-way 
three-necked tap with a balloon of hydrogen attached. The solution was saturated with hydrogen 
three times using a vacuum/hydrogen cycle. The reaction was stirred under a hydrogen atmosphere 
for 20 h. The crude reaction solution was filtered through a pad of Celite and washed with MeOH. The 
resulting filtrate was concentrated in vacuo to give the aniline which was taken onto the next step 
(0.75 g, quant.). To a solution of the aniline (0.75 g, 2.6 mmol, 1.0 eq.) in 1,4-dioxane (26 mL, 0.1 M) 
was added Cu(OAc)2 (1.2 g, 6.5 mmol, 2.5 eq.) and pyridine (0.75 mL, 9.1 mmol, 3.5 eq.) at rt under an 
atmosphere of air. The reaction mixture was stirred for 15 min before methylboronic acid (0.39 g, 6.5 
mmol, 2.5 eq.) was added and the reaction mixture heated to reflux for 4 h. The reaction was cooled 
to rt and filtered through a plug of Celite, washing with EtOAc. The resulting filtrate was concentrated 
in vacuo to give a crude residue, which was purified by flash column chromatography to give the title 
compound (0.36 g, 46%) as a yellow solid. m.p.: 105 – 107 °C. δ1H (400 MHz, CDCl3)  
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7.64 (1 H, dd, J = 8.1, 1.2 Hz, H-15), 7.52 (1 H, dd, J = 8.0, 1.6 Hz, H-6), 7.44 – 7.29 (1 H, m, H-3),  
7.17 (1 H, tdt, J = 7.1, 1.7, 0.9 Hz, H-14), 7.06 (1 H, td, J = 7.3, 1.2 Hz, H-13), 7.04 – 6.99 (1 H, m, H-12), 
6.60 (1 H, td, J = 7.3, 1.2 Hz, H-1), 6.57 (1 H, d, J = 8.5 Hz, H-2), 5.64 (1 H, br. s, NH),  
3.75 – 3.68 (2 H, m, H-11), 2.56 (3 H, d, J = 5.0 Hz, H-16), 2.50 (2 H, t, J = 5.8 Hz, H-9),  
1.70 – 1.60 (2 H, m, H-10). δ13C (101 MHz, CDCl3)  147.5 (C-4), 137.6 (C-7), 134.6 (C-3), 131.4 (C-8),  
130.5 (C-6), 129.0 (C-12), 126.3 (C-14), 125.4 (C-15), 125.2 (C-13), 120.8 (C-5), 115.2 (C-1), 111.5 (C-2), 
46.1 (C-11), 29.9 (C-16), 26.4 (C-9), 21.5 (C-10). 
(2-(Allylamino)phenyl)(3,4-dihydroquinolin-1(2H)-yl)methanone – 3.31 
To a solution of (2-aminophenyl)(3,4-dihydroquinolin-1(2H)-yl) 
methanone 3.30[178] (0.50 g, 2.0 mmol, 1.0 eq.) and allyl bromide (0.21 mL, 
2.4 mmol, 1.2 eq.) in MeCN (4.0 mL, 0.5 M) at 0 °C was added K2CO3  
(0.28 g, 2.0 mmol, 1.0 eq.). The reaction mixture was heated to 60 °C for 20 h, cooled to rt and filtered 
through a plug of Celite, washing with EtOAc. The resulting filtrate was concentrated in vacuo to give 
a crude residue, which was purified by flash column chromatography to give the title compound (0.35 
g, 60%) as a colourless oil. Mixture of rotamers in a 1:0.4 ratio. 1H NMR of the minor rotamer is broad 
and overlaps with the major species. δ1H (400 MHz, CDCl3) 7.19 – 7.14 (1 H, m, ArCH),  
7.14 – 7.11 (1 H, m, ArCH), 7.05 (1 H, td, J = 7.5, 1.1 Hz, ArCH), 6.99 (1 H, td, J = 7.4, 1.5 Hz, ArCH),  
6.92 (1 H, td, J = 7.6, 7.1, 1.6 Hz, ArCH), 6.88 – 6.85 (1 H, m, ArCH), 6.84 (1 H, dd, J = 7.7, 1.7 Hz, ArCH), 
6.66 (1 H, dd, J = 8.4, 1.0 Hz, ArCH), 6.41 (1 H, td, J = 7.5, 1.1 Hz, ArCH), 6.05 – 5.88 (1 H, m, NHCH2CH), 
5.30 (1 H, ddd, J = 17.2, 3.5, 1.7 Hz, CH=CH2), 5.17 (1 H, ddd, J = 17.2, 3.5, 1.7 Hz, CH=CH2),  
3.94 – 3.84 (2 H, m, NCH2CH2), 3.81 (2 H, br. s, NHCH2), 2.83 (2 H, t, J = 5.7 Hz, CCH2),  
2.04 (2 H, p, J = 5.6 Hz, NCH2CH2). δ13C (101 MHz, CDCl3) 171.3 (C=Omaj), 170.8 (C=Omin), 148.3 (ArCmaj), 
147.7 (ArCmin), 139.5 (ArC), 135.1 (CH=CH2), 134.3 (ArC), 131.5 (ArCH), 131.1 (ArC), 129.9 (ArCH),  
128.5 (ArCH), 125.9 (ArCH), 125.1 (ArCH), 124.6 (ArCH), 119.1 (ArC), 116.3(CH=CH2), 115.5 (ArCH), 
111.8 (ArCH), 55.5 (NHCH2maj+min), 46.0 (NCH2CH2maj), 44.7 (NCH2CH2min), 27.0 (CCH2maj+min),  
24.4 (NCH2CH2maj), 23.8 (NCH2CH2min). IR (film, cm-1) νmax = 3380 (N-H), 1629 (C=O), 1491, 1375 (C-N). 
6,14-Dimethyl-7,8,9,14-tetrahydrodibenzo[b,i][1,5]diazecin-5(6H)-one – 3.36 
To a solution of 14-Methyl-7,8,9,14-tetrahydrodibenzo[b,i][1,5]diazecin-
5(6H)-one 3.18b (50 mg, 0.19 mmol, 1 eq.) in THF (0.6 mL, 0.3 M) was added 
NaHMDS (1 M in THF, 0.21 mL, 0.21 mmol, 1.1 eq.) at 0 °C, followed by 
methyl iodide (24 µL, 0.38 mmol, 2.0 eq.). The reaction mixture was stirred 
at rt for 2 h, quenched with MeOH and evaporated under reduced pressure. 
The residue was purified by silica gel column chromatography eluting with a gradient of CH2Cl2/MeOH 
99.5:/0.5 to 97:3 to give the corresponding product as a colourless oil (41 mg, 77%).  
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δ1H (400 MHz, CD3OD) 7.41 – 7.29 (2 H, m, H-10 + H-13), 7.20 (1 H, td, J = 7.5, 1.5 Hz, H-16),  
7.10 (1 H, td, J = 7.6, 1.6 Hz, H-15), 7.03 (2 H, d, J = 8.0 Hz, H-9 + H-14), 6.90 (1 H, dd, J = 7.6, 1.8 Hz,  
H-12), 6.77 (1 H, td, J = 7.4, 1.0 Hz, H-11), 3.62 (CHAHB, 1 H, ddd, J = 14.7, 12.9, 2.0 Hz, H-1),  
3.23 (3 H, s, H-17), 3.14 – 3.03 (CHAHB, 1 H, m, H-1), 2.95 (CHAHB, 1 H, td, J = 13.2, 4.1 Hz, H-3),  
2.65 (CHAHB, 1 H, dt, J = 13.5, 3.9 Hz, H-3), 2.41 (3 H, s, H-18), 2.20 – 2.04 (CHAHB, 1 H, m, H-2),  
1.64 (CHAHB, 1 H, dqd, J = 14.9, 3.8, 2.0 Hz, H-2). δ13C (101 MHz, CD3OD) 173.2 (C-8), 147.0 (C-5),  
146.4 (C-6), 141.3 (C-4), 131.4 (C-10), 130.5 (C-12), 130.2 (C-13), 130.0 (C-16), 128.9 (C-14),  
128.6 (C-15), 123.6 (C-7), 118.2 (C-11), 114.2 (C-9), 52.2 (C-1), 42.5 (C-17), 31.9 (C-18), 30.0 (C-3),  
25.7 (C-2). IR (film, cm-1) νmax 2922 (C–H), 1620 (C=O), 1597, 1486, 1342 (C–N). HRMS (MALDI+) m/z 
calcd for C18H20N2ONa+ [M+Na]+ 303.1468; found: 303.1479. 
16-Methyl-5,6,7,8,9,10,11,16-octahydrodibenzo[b,k][1,5]diazacyclododecine – 3.38 
In a microwave vial, to a solution of 16-methyl-7,8,9,10,11,16-hexahydro- 
dibenzo[b,k][1,5]diazacyclododecin-5(6H)-one 3.18d (44 mg, 0.15 mmol, 1 eq.) in 
THF (1.5 mL, 0.1 M) was added BH3.SMe2 (2 M in THF, 0.15 mL, 0.3 mmol, 2.0 eq.) 
dropwise. The tube was sealed and the reaction mixture was stirred at 80 °C for 
18 h. The reaction mixture was cooled down to rt, quenched with aqueous 
sodium hydroxide (2 M, 1 mL) and the biphasic mixture was vigorously stirred at rt for 15 min. The 
reaction mixture was diluted with 10 mL water and extracted with 10 mL ethyl acetate three times. 
The combined organic phases were washed with brine and evaporated under reduced pressure. The 
residue was purified by silica gel column chromatography eluting with a gradient of Pentane/EtOAc 
20:1 to 10:1 to give the corresponding product as a colourless oil (21 mg, 50%). δ1H (400 MHz, CDCl3) 
7.28 – 7.27 (2 H, m, ArCH), 7.21 – 7.07 (5 H, m, ArCH), 6.73 (1 H, dd, J = 7.9, 1.3 Hz, ArCH),  
6.11 (1 H, br s, NH), 4.68 (CHAHB, 1 H, dd, J = 15.4 Hz, CH2), 3.69 (CHAHB, 1 H, dd, J = 15.4, 9.2 Hz, CH2), 
3.22 (3 H, s, CH3), 2.86 (CHAHB, 1 H, t, J = 11.80 Hz, CH2), 2.76 – 2.68 (CHAHB, 1 H, m, CH2),  
2.41 – 2.32 (CHAHB, 1 H, m, CH2), 2.24 – 2.07 (2 H, m, CH2), 1.69 – 1.59 (CHAHB, 1 H, m, CH2),  
1.55 – 1.45 (2 H, m, CH2), 1.33 – 1.26 (2 H, m, CH2). δ13C (101 MHz, CDCl3) 152.0 (ArC), 148.0 (ArC), 
135.4 (ArC), 132.3 (ArCH), 131.7 (ArCH), 129.9 (ArCH), 127.5 (ArC), 127.1 (ArCH), 124.7 (ArCH),  
124.4 (ArCH), 124.3 (ArCH), 121.0 (ArCH), 61.3 (CH2), 54.5 (CH2), 41.0 (CH3), 31.2 (CH2), 30.7 (CH2),  
26.3 (CH2), 22.6 (CH2). IR (film, cm-1) νmax 3168, 2923, 1487, 1450, 1166. HRMS (MALDI+) m/z calcd for 





2,4-Di-tert-butyl-1-bromobenzene – 4.25 
To a solution of 1,3-di-tert-butylbenzene (2.48 g, 13.0 mmol, 1.0 eq.) in TMPO 
(26 mL) at 70 °C was added dropwise a solution of bromine (0.84 mL, 16.4 mmol, 
1.25 eq) in TMPO (14 mL). The reaction mixture was stirred at this temperature 
for 20 h and extracted with petroleum ether. The combined extraction layers 
were washed with a saturated aqueous solution of Na2SO3, brine, dried over 
MgSO4 and concentrated in vacuo to yield to the title compound as a colourless oil (3.50 g, 13.0 mmol, 
quant.) δ1H (400 MHz, CDCl3) 7.49 (1 H, d, J = 8.3 Hz, H-1), 7.46 (1 H, d, J = 2.4 Hz, H-4),  
7.05 (1 H, dd, J = 8.3, 2.5 Hz, H-2), 1.51 (9 H, s, H-9), 1.30 (9 H, s, H-10). δ13C (101 MHz, CDCl3)  
150.1 (C-5), 146.9 (C-3), 135.3 (C-1), 125.3 (C-4), 124.7 (C-2), 119.5 (C-6), 36.9 (C-7), 34.9 (C-8),  
31.4 (C-10), 29.8 (C-9). Data consistent with that reported in the literature.[310] 
Bis(2,4-di-tert-butylphenyl)amine– 4.26 
Distilled toluene was added to a mixture of compound 4.24 
(0.99 mg, 4.84 mmol, 1.0 eq.), compound 4.25 (1.57 g,  
5.83 mmol, 1.2 eq.), NaOtBu (0.59 mg, 6.13 mmol, 1.25 eq.), 
Pd2(dba)3 (89 mg, 0.097 mmol, 2 mol%) and dppf (81 mg,  
0.146 mmol, 3 mol%). The reaction mixture was degassed by 
sonication under vaccum, and heated under reflux under an argon atmosphere for 16 h. Filtration on 
a plug of silica (SiO2, petroleum ether) yield the title compound as a white solid (1.21 g, 3.1 mmol, 
65%), m.p.: 158 – 159 °C. δ1H (500 MHz, CDCl3) 7.41 (2 H, d, J = 2.3 Hz, H-5),  
7.09 (2 H, dd, J = 8.4, 2.3 Hz, H-3), 6.87 (2 H, d, J = 8.4 Hz, H-2), 5.27 (1 H, br. s, NH), 1.50 (18 H, s, H-9), 
1.33 (18 H, s, H-10). δ13C (126 MHz, CDCl3) 143.7 (C-4), 141.5 (C-1), 139.5 (C-6), 123.7 (C-3),  
123.6 (C-5), 122.6 (C-2), 34.9 (C-7), 34.5 (C-8), 31.8 (C-10), 30.8 (C-9). IR (film, cm-1) νmax 2956 (C–H), 
2904 (C–H), 2867 (C–H), 1499 (N–H), 1394; HRMS (ESI+) m/z calcd for C28H44N [M+H]+ 394.3474, found 
394.3473.  
2,4-Di-tert-butyl-N-methylaniline – 4.28 
To a solution of compound 4.24 (300 mg, 1.56 mmol, 1.0 eq.) and 
succinimide (168 mg, 1.70 mmol, 1.1 eq.) in ethanol (1 mL) was added 
formaldehyde 37% in water (137 µL, 1.70 mmol, 1.1 eq.). The reaction 
mixture was heated under reflux for 4 h, concentrated in vacuo, and dry 
DMSO (1 mL) and NaBH4 (65 mg, 1.72 mmol, 1.1 eq.) were added. The 
reaction mixture was reflux for 1 h and an aqueous solution of LiCl was added. The solution was 
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extracted with CH2Cl2, dried over Na2SO4 and concentrated in vacuo. Purification by flash column 
chromatography (SiO2, petroleum ether/CH2Cl2, 70:30) yielded the title compound as a yellow oil  
(115 mg, 0.56 mmol, 36%). δ1H (400 MHz, CDCl3) 7.33 (1 H, d, J = 2.4 Hz, H-2),  
7.21 (1 H, dd, J = 8.4, 2.4 Hz, H-4), 6.65 (1 H, d, J = 8.4 Hz, H-5), 3.87 (1 H, br. s, NH), 2.92 (3 H, s, H-10), 
1.45 (9 H, s, H-11), 1.32 (9 H, s, H-12). δ13C (101 MHz, CDCl3) 145.2 (C-6), 139.3 (C-3), 132.9 (C-1),  
123.7 (C-4), 123.5 (C-2), 111.1 (C-5), 34.6 (C-9), 34.2 (C-8), 31. 8 (C-12), 31.5 (C-10), 30.1 (C-11). Data 
consistent with that reported in the literature.[308] 
N-(2,4-Di-tert-butylphenyl)acetamide – 4.29 
To a solution of compound 4.24 (219 mg, 1.14 mmol, 1.0 eq.) and Et3N  
(0.17 mL, 1.21 mmol, 1.1 eq.) in CH2Cl2 (2.3 mL) at 0 °C was added acetyl 
chloride (89 µL, 1.25 mmol, 1.1 eq.). The reaction mixture was allowed to 
warm up to rt and stirred for 16 h. Water was added to the reaction mixture, 
and the aqueous phase was extracted with CH2Cl2. The organic phases were 
combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by flash 
column chromatography (SiO2, petroleum ether) yielded the title compound as a white solid (249 mg, 
1.06 mmol, 96%), m.p.: 153 – 154 °C, Mixture of rotamers in a 1:0.4 ratio. δ1H (400 MHz, CDCl3)  
7.47 (1 Hmin, d, J = 1.8 Hz, H-2), 7.41 (1 Hmaj+min, d, J = 2.2 Hz, H-2), 7.38 (1 Hmaj, d, J = 8.3 Hz, H-5),  
7.25 (1 H, dd, J = 8.3, 2.1 Hz, H-4), 7.04 (1 Hmaj, br. s, NH), 7.01 (1 Hmin, d, J = 8.1 Hz, H-5),  
6.92 (1 Hmin, br. s, NH), 2.20 (3 Hmaj, s, H-12), 1.89 (3 Hmin, s, H-12), 1.41 (9 Hmaj, s, H-9), 1.39 (9 Hmin, s, 
H-9), 1.33 (9 Hmin, s, H-10), 1.30 (9 Hmaj, s, H-10). δ13C (101 MHz, CDCl3) 172.9 (C-11min), 168.7 (C-11maj),  
151.0 (C-3min), 149.2 (C-3maj), 145.6 (C-1min), 142.7 (C-1maj), 133.4 (C-6min), 132.4 (C-6maj), 130.6 (C-5min),  
128.4 (C-5maj), 124.3 (C-4min), 124.0 (C-2min), 123.9 (C-4maj), 123.8 (C-2maj), 35.5 (C-7min), 35.0 (C-7maj), 
35.0 (C-8min), 34.8 (C-8maj), 31.5 (C-10maj+min), 30.9 (C-9maj), 30.7 (C-9min), 24.5 (C-12maj), 21.2 (C-12min). 
Data consistent with that reported in the literature.[58] 
4-Methylnaphthalen-1-amine – 4.32 
To a solution of 1-bromo-4-methylnaphthalene 4.31 (2.0 mL, 12.8 mmol, 1 eq.) in 
formamide (60 mL) was added K2CO3 (4.4 g, 31.8 mmol, 2.5 eq) and CuSO4.5H2O 
(3.9 g, 15.6 mmol, 1.2 eq.). The reaction mixture was heated to 150 °C for 2 h. 
Water was added, and the reaction mixture was extracted with CH2Cl2. The organic 
phases were combined, washed with brine, dried over MgSO4 and concentrated in vacuo. The resulting 
brown solid was taken in ethanol (125 mL) and an aqueous solution of 0.5 M NaOH (30 mL, 15.0 mmol, 
1.2 eq.) was added. The reaction mixture was heated under reflux for 2 h, concentrated in vacuo, and 
extracted with CH2Cl2. The organic phases were combined, washed with brine, dried over Na2SO4 and 
concentrated in vacuo. Purification by flash column chromatography (SiO2, petroleum ether/EtOAc, 
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8515) yielded the title compound as a brown oil (1.6 g, 10.1 mmol, 79%). δ1H (400 MHz, CDCl3)  
7.98 (1 H, d, J = 7.9 Hz, H-7), 7.87 (1 H, d, J = 7.7 Hz, H-11), 7.54 (1 H, dt, J = 5.8, 1.3, H-9),  
7.50 (1 H, dt, J = 5.8, 1.3 Hz, H-10), 7.15 (1 H, d, J = 7.4 Hz, H-5), 6.72 (1 H, d, J = 7.4 Hz, H-4),  
4.04 (2 H, br. s, NH2), 2.61 (3 H, s, H-8). δ13C (101 MHz, CDCl3) 140.5 (C-6), 133.3 (C-2), 126.9 (C-11), 
125.8 (C-10), 125.04 (C-3), 124.99 (C-9), 124.7 (C-4), 124.2 (C-1), 121.5 (C-7), 109.7 (C-5), 19.1 (C-8). 
Data consistent with that reported in the literature.[313] 
Bis(4-methylnaphthalen-1-yl)amine – 4.30 
Distilled toluene was added to a mixture of compound 4.32 (1.0 g, 6.3 
mmol, 1.0 eq.), 4.31 (1.2 mL, 7.7 mmol, 1.2 eq.), NaOtBu (0.77 g, 8.0 
mmol, 1.25 eq.), Pd2(dba)3 (116 mg, 0.127 mmol, 2 mol%) and dppf 
(105 mg, 0.189 mmol, 3 mol%). The reaction mixture was degassed by 
sonication in vacuo, and heated under reflux under an argon atmosphere for 16 h. Filtration on a plug 
of silica (SiO2, petroleum ether) yield the title compound as a yellow solid (1.83 g, 6.1 mmol, 96%), 
m.p.: 98 – 99 °C. δ1H (400 MHz, CDCl3) 8.16 (2 H, d, J = 8.4 Hz, H-7), 8.07 (2 H, d, J = 8.4 Hz, H-8),  
7.60 (2 H, t, J = 7.5 Hz, H-10), 7.51 (2 H, t, J = 7.5 Hz, H-9), 7.20 (2 H, d, J = 7.5 Hz, H-3),  
6.89 (2 H, d, J = 7.5 Hz, H-2), 6.19 (1 H, br. S, NH), 2.70 (6 H, s, H-11). δ13C (101 MHz, CDCl3)  
139.4 (C-1), 133.7 (C-6), 128.6 (C-7), 127.4 (C-5), 127.0 (C-3), 126.1 (C-10), 125.5 (C-9), 125.1 (C-8), 
122.7 (C-7), 115.6 (C-2), 19.4 (C-2). IR (film, cm-1) νmax 3385 (N–H), 3067 (C–H), 2924 (C–H),  
2854 (C–H), 1582 (N–H); HRMS (ESI+) m/z calcd for C22H20N [M+H]+ 298.1596, found 298.1593.  
Bis(2-bromo-4-methylnaphthalen-1-yl)amine – 4.19 
To a solution of compound 4.30 (600 mg, 2.0 mmol, 1 eq.) in AcOH  
(10 mL) was added dropwise bromine (205 µL, 4.0 mmol, 2.0 eq.). The 
reaction mixture was stirred for 3 h, and an aqueous solution of 3% 
Na2S2O4 was added. The precipitate was filtered, rinsed with water, 
taken up in CH2Cl2, washed with brine, dried over MgSO4 and 
concentrated in vacuo. Purification by flash column chromatography (SiO2, petroleum ether/EtOAc, 
991) followed by trituration in Et2O yielded the title compound as an off-white solid (673 g, 1.5 mmol, 
73%), m.p.: 165 °C (degradation). δ1H (400 MHz, CDCl3) 7.93 (2 H, d, J = 8.4 Hz, H-7),  
7.81 (2 H, d, J = 8.5, H-10), 7.48 (2 H, s, H-5), 7.45 (2 H, t, J = 7.2 Hz, H-8), 7.24 (2 H, t, J = 7.3 Hz, H-9), 
6.23 (1 H, s, NH), 2.65 (6 H, s, H-11). δ13C (101 MHz, CDCl3) 137.1 (C-1), 132.8 (C-4), 130.8 (C-5 + C-3), 
129.4 (C-2), 126.1 (C-9 + C-8), 124.9 (C-7), 123.7 (C-10), 113.7 (C-6), 19.1 (C-4). IR (film, cm-1) νmax  
3363 (N–H), 3069 (C–H), 2922 (C–H), 2856 (C–H), 1571 (N–H), 1391; HRMS (ESI+) m/z calcd for 
C22H18NBr2 [M+H]+ 453.9806, found 453.9815.  
195 
 
1,3-Di-tert-butyl-5-fluorobenzene – 4.38 
To NaOH (675 mg, 16.9 mmol, 1.2 eq.) in MeOH (30 mL) was added 4.37 (3.3 g, 
14.1 mmol, 1.0 eq.). After stirring for 15 min, the reaction mixture was cooled to 0 
°C and AgOTf (10.8 g, 42 mmol, 3.0 eq.) was added. After stirring for 30 min at 0 
°C, the solvent was removed under reduced pressure at 0 °C and azeotroped with 
acetone. To the residue was added acetone (70 mL), 3Å molecular sieves (7 g), 
Selectfluor® (5.2 g, 14.8 mmol, 1.05 eq.) and the reaction mixture was stirred for 1 h. The reaction 
mixture was concentrated in vacuo, taken up in CH2Cl2, filtered over Celite and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, petroleum ether) yielded the title compound as a 
colourless oil (1.75 g, 60%). δ1H (400 MHz, CDCl3) 7.19 (1 H, t, J = 1.7 Hz, H-2),  
6.90 (2 H, dd, J = 10.7, 1.7 Hz, H-3), 1.32 (18 H, s, H-6). δ13C (101 MHz, CDCl3) 162.9 (d, J = 242.3 Hz,  
C-4), 153.3 (d, J = 5.7 Hz, C-1), 117.9 (d, J = 2.2 Hz, C-2), 109.6 (d, J = 21.7 Hz, C-3), 35.1 (d, J = 1.9 Hz, 
C-5), 31.5 (C-6). Data consistent with that reported in the literature.[314] 
2-Bromo-1,5-di-tert-butyl-3-fluorobenzene – 4.36a 
To a solution of 4.38 (1.0 g, 4.8 mmol, 1.0 eq.) in TFA (10 mL) at 0 °C was added 
Br2 (0.33 mL, 6.4 mmol, 1.2 eq.) dropwise. The reaction mixture was allowed to 
warm up to rt and stirred overnight. The reaction mixture was poured on ice and 
Na2S2O3 was added. The aqueous phase was extracted with CH2Cl2, organic 
phases were combined, washed with brine, dried over MgSO4 and concentrated 
in vacuo. Purification by flash column chromatography (SiO2, petroleum ether) yielded the title 
compound as a yellow oil (1.1 g, 80%). NMR contains around 12% of the non-fluorinated analogue as 
an unseparable impurity. δ1H (400 MHz, CDCl3) 7.26 (1 H, dd, J = 2.3, 1.3 Hz, H-2),  
7.02 (1 H, dd, J = 10.3, 2.3 Hz, H-4), 1.53 (9 H, s, H-9), 1.31 (9 H, s, H-10). δ13C (101 MHz, CDCl3)  
159.5 (d, J = 241.5 Hz, C-5), 151.8 (d, J = 5.9 Hz, C-3), 149.4 (d, J = 0.7 Hz, C-1), 120.2 (d, J = 2.3 Hz,  
C-2), 111.3 (d, J = 25.2 Hz, C-4), 106.7 (d, J = 20.7 Hz, C-6), 37.5 (d, J = 1.9 Hz, H-7), 35.1 (d, J = 1.8 Hz, 
C-8), 31.3 (C-6), 30.0 (C-9). IR (film, cm-1) νmax 2964 (C–H), 1401 (C–F); HRMS (EI+) m/z calcd for 




Diphenyl(1-(phenylamino)naphthalen-2-yl)phosphine oxide – 4.43a 
To a solution of aniline (28 μL, 0.30 mmol, 1.1 eq.) in THF (0.5 mL) at -78 °C 
was added n-BuLi (1.4 M in hexanes, 0.2 mL, 0.28 mmol, 1.0 eq.). The 
reaction mixture was stirred for 30 min and allowed to warm up to rt for 30 
min. The reaction mixture was cooled to 0 °C and 4.41 (100 mg,  
0.28 mmol, 1.0 eq.) was added. The reaction mixture was heated to 60 °C 
overnight and quenched with sat. NH4Cl (aq.) and extracted with Et2O. The 
organic phases were combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, petroleum ether/EtOAc, 70:30) yielded the title 
compound as a light brown solid (35 mg, 30%), m.p.: 195 °C. δ1H (400 MHz, CDCl3) 8.54 (1 H, s, NH),  
7.93 (1 H, d, J = 8.6 Hz, ArCH), 7.82 (1 H, d, J = 8.2 Hz, ArCH), 7.65 (4 H, dd, J = 12.2, 7.0 Hz, ArCH),  
7.52 (2 H, t, J = 8.7 Hz, ArCH), 7.44 (2 H, t, J = 7.3 Hz, ArCH), 7.35 (5 H, m, ArCH),  
7.03 (1 H, dd, J = 12.1, 8.5 Hz, ArCH), 6.89 (2 H, t, J = 7.8 Hz, ArCH), 6.64 (1 H, t, J = 7.3 Hz, ArCH),  
6.42 (2 H, d, J = 7.9 Hz, ArCH). δ13C (101 MHz, CDCl3) 146.5 (d, J = 3.9 Hz, ArC), 145.6 (ArC),  
136.4 (d, J = 1.9 Hz, ArC), 132.1 (d, J = 9.9 Hz, ArCH), 131.99 (d, J = 104.9 Hz, ArC), 131.98 (d, J = 2.8 Hz, 
ArCH), 129.2 (d, J = 8.7 Hz, ArC), 128.6 (ArCH), 128.50 (ArCH), 128.48 (ArCH), 128.3 (d, J = 7.0 Hz, ArCH), 
127.9 (d, J = 11.5 Hz, ArCH), 126.3 (ArCH), 126.1 (ArCH), 123.3 (d, J = 12.6 Hz, ArCH),  
121.0 (d, J = 103.7 Hz, ArC), 119.7 (ArCH), 116.4 (ArCH). IR (film, cm-1) νmax 3267 (N–H), 3056 (C–H), 
1601 (N–H), 1118 (P=O); HRMS (ESI+) m/z calcd for C28H23NOP [M+H]+ 420.1512, found 420.1492. 
(1-((2-(Tert-butyl)phenyl)amino)naphthalen-2-yl)diphenylphosphine oxide – 4.43b 
To a solution of 2-tert-butylaniline (47 μL, 0.30 mmol, 1.1 eq.) in THF  
(0.5 mL) at -78 °C was added n-BuLi (1.4 M in hexanes, 0.2 mL, 0.28 mmol, 
1.0 eq.). The reaction mixture was stirred for 30 min and allowed to warm 
up to rt for 30 min. The reaction mixture was cooled to 0 °C and 4.41 (100 
mg, 0.28 mmol, 1.0 eq.) was added. The reaction mixture was heated to 60 
°C overnight and quenched with sat. NH4Cl (aq.) and extracted with Et2O. 
The organic phases were combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, petroleum ether/EtOAc, 80:20) yielded the title 
compound as an orange oil (63 mg, 47%), δ1H (400 MHz, CDCl3) 8.63 (1 H, s, NH), 7.77 (3 H, m, ArCH), 
7.66 (3 H, m, ArCH), 7.59 (1 H, J = 7.4, 1.3 Hz, ArCH), 7.53 (2 H, m, ArCH), 7.41 (2 H, m, ArCH),  
7.34 (1 H, J = 7.6, 1.1 Hz, ArCH), 7.27 (3 H, m, ArCH), 7.20 (1 H, t, J = 8.6 Hz, ArCH),  
7.04 (1 H, td , J = 12.4, 8.5 Hz, ArCH), 6.73 (1 H, td , J = 7.6, 1.1 Hz, ArCH),  
6.55 (1 H, td, J = 7.6, 1.1 Hz, ArCH), 5.97 (1 H, d, J = 8.0 Hz, ArCH), 1.63 (9 H, s, CCH3).  
δ13C (126 MHz, CDCl3) 148.2 (d, J = 4.1 Hz, ArC), 143.9 (ArC), 138.8 (ArC), 136.9 (d, J = 1.9 Hz, ArC),  
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132.5 (d, J = 9.8 Hz, ArCH), 132.4 (d, J = 50.5 Hz, ArC), 132.2 (d, J = 2.8 Hz, ArCH), 131.9 (d, J = 10.0 Hz, 
ArCH), 131.8 (d, J = 2.8 Hz, ArCH), 131.6 (d, J = 51.5 Hz, ArC), 128.7 (d, J = 12.2 Hz, ArCH), 128.4 (ArCH),  
128.3 (d, J = 12.2 Hz, ArCH), 128.01 (ArCH), 127.99 (d, J = 8.8 Hz, ArC), 127.9 (ArCH), 126.49 (ArCH),  
126.48 (ArCH), 125.9 (ArCH), 125.6 (d, J = 1.1 Hz, ArCH), 121.8 (d, J = 12.9 Hz, ArCH), 121.4 (ArCH), 
121.2 (ArCH), 118.6 (d, J = 105.1 Hz, ArC), 35.0 (CCH3), 30.2 (CCH3). IR (film, cm-1) νmax 3267 (N–H), 
3056 (C–H), 1601 (N–H), 1118 (P=O); HRMS (ESI+) m/z calcd for C32H31NOP [M+H]+ 476.2138, found 
476.2131. 
(1-((2,4-Di-tert-butyl-6-methylphenyl)amino)naphthalen-2-yl)diphenylphosphine oxide – 
4.43c 
To a solution of aniline 1.27 (66 mg, 0.30 mmol, 1.1 eq.) in THF  
(0.5 mL) at -78 °C was added n-BuLi (1.4 M in hexanes, 0.2 mL, 0.28 
mmol, 1.0 eq.). The reaction mixture was stirred for 30 min and 
allowed to warm up to rt for 30 min. The reaction mixture was 
cooled to 0 °C and 4.41 (100 mg, 0.28 mmol, 1.0 eq.) was added. The 
reaction mixture was heated to 60 °C overnight and quenched with 
sat. NH4Cl (aq.) and extracted with Et2O. The organic phases were combined, washed with brine, dried 
over Na2SO4 and concentrated in vacuo. Purification by flash column chromatography (SiO2, petroleum 
ether /EtOAc, 80:20) yielded the title compound as a light brown solid (70 mg, 53%), m.p.: > 200 °C.  
δ1H (400 MHz, CDCl3) 9.86 (1 H, s, NH), 7.78 (2 H, dd, J = 11.3, 8.0 Hz, ArCH),  
7.71 (2 H, dd, J = 11.3, 8.0 Hz, ArCH), 7.64 (1 H, d, J = 8.2 Hz, ArCH), 7.55 (2 H, m, ArCH),  
7.47 (4 H, m, ArCH), 7.39 (1 H, d, J = 1.8 Hz, ArCH), 7.33 (1 H, t, J = 7.8 Hz, ArCH),  
7.26 (1 H, d, J = 5.8 Hz, ArCH), 7.06 (1 H, dd, J = 8.1, 1.9 Hz, ArCH), 6.91 (3 H, m, ArCH),  
1.53 (9 H, s, CCH3), 1.36 (3 H, s, CH3), 1.32 (9 H, s, CCH3). δ13C (126 MHz, CDCl3) 151.8 (d, J = 4.4 Hz, 
ArC), 147.8 (ArC), 144.5 (ArC), 138.3 (ArC), 137.2 (d, J = 1.8 Hz, ArC), 134.5 (d, J = 134.4 Hz, ArC),  
132.9 (d, J = 39.4 Hz, ArC), 132.5 (d, J = 2.5 Hz, ArCH), 132.4 (d, J = 2.7 Hz, ArCH), 132.02 (d, J = 2.7 Hz, 
ArCH), 131.98 (ArC), 131.96 (d, J = 2.7 Hz, ArCH), 129.0 (d, J = 11.9 Hz, ArCH), 128.6 (d, J = 5.2 Hz, ArCH),  
128.5 (d, J = 5.2 Hz, ArCH), 128.2 (ArCH), 127.8 (ArCH), 126.1 (ArCH), 125.1 (ArCH), 124.9 (d, J = 8.9 Hz, 
ArC), 124.0 (ArCH), 122.0 (ArCH), 116.5 (d, J = 13.7 Hz, ArCH), 105.7 (d, J = 107.0 Hz, ArC), 36.0 (CCH3), 
34.7 (CCH3), 31.6 (CCH3), 31.0 (CCH3), 19.6 (CH3). IR (film, cm-1) νmax 3244 (N–H), 3055 (C–H), 1118 
(P=O); HRMS (ESI+) m/z calcd for C37H41NOP [M+H]+ 546.2920, found 546.2900. 
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(1-(Benzylamino)naphthalen-2-yl)diphenylphosphine oxide – 4.44 
To a solution of benzylamine (163 μL, 1.5 mmol, 2.2 eq.) in THF (3.0 mL) 
at -78 °C was added n-BuLi (1.4 M in hexanes, 1.1 mL, 1.5 mmol, 2.2 eq.). 
The reaction mixture was stirred for 10 min and allowed to warm up to 
0 °C for 1 h. The reaction mixture was cooled to -20 °C and 4.41 (250 mg, 
0.7 mmol, 1.0 eq.) was added. The reaction mixture was allowed to 
warm up to rt and stirred for 2 h, quenched with sat. NH4Cl (aq.) and 
extracted with Et2O. The organic phases were combined, washed with brine, dried over Na2SO4 and 
concentrated in vacuo. Purification by flash column chromatography (SiO2, petroleum ether/EtOAc, 
80:20) yielded the title compound as a white solid (249 mg, 83%), m.p.: 142 – 143 °C.  
δ1H (400 MHz, CDCl3) 8.26 (1 H, d, J = 8.5 Hz, ArCH), 7.78 (1 H, d, J = 8.1 Hz, ArCH),  
7.66 (4 H, dd, J = 12.0, 7.5 Hz, ArCH), 7.54 (3 H, q, J = 7.7 Hz, ArCH), 7.45 (5 H, tt, J = 9.4, 4.9 Hz, ArCH), 
7.36 – 7.18 (6 H, m, ArCH), 7.12 (1, H, t, J = 7.3 Hz, NH), 6.91 (1 H, dd, J = 12.5, 8.5 Hz, ArCH),  
4.24 (2 H, d, J = 5.9 Hz, NCH2). δ13C (101 MHz, CDCl3) 155.1 (d, J = 4.7 Hz, ArC), 139.9 (ArC),  
136.8 (d, J = 2.1 Hz, ArC), 133.3 (d, J = 104.0 Hz, ArC), 132.2 (d, J = 10.1 Hz, ArCH), 132.0 (d, J = 2.9 Hz, 
ArCH), 128.6 (d, J = 12.1 Hz, ArCH), 128.4 (2*ArCH), 128.3 (d, J = 9.2 Hz, ArC), 128.2 (ArCH),  
128.0 (d, J = 12.4 Hz, ArCH), 127.5 (ArCH), 127.0 (ArCH), 125.7 (ArCH), 125.4 (ArCH),  
120.5 (d, J = 13.0 Hz, ArCH), 115.1 (d, J = 105.5 Hz, ArC), 54.4 (NCH2). IR (film, cm-1) νmax 3271 (N–H), 
3054 (C–H), 1116 (P=O); HRMS (ESI+) m/z calcd for C29H24NOPNa [M+Na]+ 456.1488, found 456.1479. 
(1-Aminonaphthalen-2-yl)diphenylphosphine oxide – 4.42 
To a solution of 4.44 (110 mg, 0.25 mmol, 1.0 eq.) in MeOH (1.5 mL) and HCl 
(1 M in MeOH, 0.5 mL) was added Pd/C (10%, 20 mg) and the reaction mixture 
was placed under an atmosphere of hydrogen. The reaction mixture was 
stirred overnight, filtered over Celite and concentrated in vacuo. Purification 
by flash column chromatography (SiO2, petroleum ether/EtOAc, 2575) yielded 
the title compound as a light brown oil (83 mg, 95%). δ1H (400 MHz, CDCl3) 
7.87 (1 H, d, J = 8.4 Hz, H-3), 7.77 – 7.64 (5 H, m, H-13 + H-6),  
7.53 (3 H, qd, J = 5.7, 6.3, 1.3 Hz, H-14 + H-2), 7.46 (5 H, m, H-1 + H-12), 7.05 (1 H, dd, J = 8.6, 2.6 Hz, 
H-7), 6.84 (1 H, dd, J = 12.7, 8.5 Hz, H-8), 6.40 (2 H, s, NH). δ13C (101 MHz, CDCl3) 151.1 (d, J = 4.4 Hz, 
C-10), 136.0 (d, J = 1.9 Hz, C-4), 133.0 (d, J = 104.1 Hz, C-11), 132.2 (d, J = 10.1 Hz, C-13),  
132.0 (d, J = 2.7 Hz, C-14), 128.61 (d, J = 12.1 Hz, C-12), 128.60 (C-2), 128.4 (d, J = 11.9 Hz, C-8),  
128.3 (C-6), 125.6 (C-1), 123.4 (d, J = 9.6 Hz, C-5), 121.2 (C-3), 116.2 (d, J = 13.2 Hz, C-7),  
103.0 (d, J = 107.7 Hz, C-9). IR (film, cm-1) νmax 3397 (N–H), 3328 (N–H), 3234 (N–H), 1117 (P=O);  
HRMS (ESI+) m/z calcd for C22H19NOP [M+H]+ 344.1199, found 344.1202. 
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1,5-Di-tert-butyl-2-methoxy-3-nitrobenzene – 4.47 
To a suspension of NaH (150 mg, 3.7 mmol, 1.1 eq. 60% in mineral oil) in THF 
(1.5 mL) at 0 °C was added dropwise a solution of 2,4-di-tert-butyl-6-
nitrophenol (840 mg, 3.3 mmol, 1.0 eq.) in THF (1.5 mL). The suspension was 
diluted with 5 mL of THF and stirred for 2 h at rt. The reaction mixture was 
cooled to 0 °C and MeI (0.41 mL, 6.6 mmol, 2.0 eq.) was added dropwise, followed by DMF (3.5 mL). 
The reaction mixture was allowed to warm up to rt, stirred overnight and quenched with MeOH. The 
reaction mixture was filtered, concentrated in vacuo and purification by flash column chromatography 
(SiO2, petroleum ether/Et2O, 9010) yielded the title compound as a yellow solid (484 mg, 55%),  
m.p.: 55 – 56 °C. δ1H (400 MHz, CDCl3) 7.59 (1 H, d, J = 2.5 Hz, H-5), 7.55 (1 H, d, J = 2.5 Hz, H-3),  
3.78 (3 H, s, H-11), 1.41 (9 H, s, HtBu), 1.32 (9 H, s, HtBu). δ13C (101 MHz, CDCl3) 151.0 (C-1), 145.9 (ArC), 
144.5 (ArC), 143.9 (C-6), 128.6 (C-3), 120.5 (C-5), 61.4 (C-11), 35.9 (ArC), 34.9 (ArC), 31.3 (CH3),  
30.7 (CH3). IR (film, cm-1) νmax 2962 (C–H), 1527 (N–O), 1353 (C–N), 1245 (C–O); HRMS (ESI+) m/z calcd 
for C15H23NONa [M+Na]+ 288.1570, found 288.1576 
3,5-Di-tert-butyl-N,N-dimethyl-2-nitroaniline – 4.49 
To a solution of 4.48 (418 mg, 1.67 mmol, 1.0 eq.) in anhydrous THF (2.0 mL) 
at 0 °C was added NaH (98 mg, 4.1 mmol, 2.5 eq., 60% in mineral oil) and the 
reaction mixture was stirred for 30 min. MeI (0.25 mL, 4.0 mmol, 2.4 eq.) was 
added and the reaction mixture was stirred at 0 °C for 30 min, after which it 
was allowed to warm up to rt and stir 20 h. The reaction mixture was 
quenched with water, diluted in sat. NaHCO3 (aq.) and extracted with CH2Cl2. Organic phases were 
combined, washed with brine, dried over MgSO4 and concentrated in vacuo to yield 60 as a yellow 
solid (451 mg, 97%), m.p.: 123 – 124 °C. δ1H (400 MHz, CDCl3) 7.30 (1 H, d, J = 1.9 Hz, H-3),  
7.22 (1 H, d, J = 1.9 Hz, H-5), 2.66 (6 H, s, H-11), 1.37 (9 H, s, C-9), 1.32 (9 H, s, C-10).  
δ13C (101 MHz, CDCl3) 152.9 (C-4), 146.9 (C-6), 146.7 (C-1), 140.3 (C-2), 121.4 (C-3), 117.9 (C-5),  
46.2 (C-11), 36.0 (C-8), 35.4 (C-7), 31.4 (C-10), 31.1 (C-9). IR (film, cm-1) νmax 2959 (C–H), 1532 (N–O), 
1378 (C–N); HRMS (ESI+) m/z calcd for C16H27N2O2 [M+H]+ 279.2067, found 279.2065. 
3,5-Di-tert-butyl-N,N-dimethyl-2-nitroaniline – 4.46 
To a solution of 4.49 (394 mg, 1.4 mmol, 1.0 eq.) in anhydrous THF (12 mL) 
was added LiAlH4 (266 mg, 7.0 mmol, 5.0 eq.) portionwise. THF mixture was 
heated under reflux overnight, quenched with water and extracted with ethyl 
acetate. Organic phases were combined, washed with brine, dried over 
Na2SO4 and concentrated in vacuo. Purification by flash column 
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chromatography (SiO2, petroleum ether/Et2O, 85:15) yielded the title compound as a white solid  
(286 mg, 81%), δ1H (400 MHz, CDCl3) 7.11 (1 H, d, J = 2.2 Hz, H-3), 7.04 (1 H, d, J = 2.2 Hz, H-5),  
4.34 (2 H, br. s, NH), 2.68 (6 H, s, H-11), 1.46 (9 H, s, H-9), 1.32 (9 H, s, H-10). δ13C (101 MHz, CDCl3)  
141.1 (C-6), 139.7 (C-4), 137.6 (C-1), 133.1 (C-2), 119.2 (C-3), 114.6 (C-5), 44.5 (C-11), 35.0 (C-8),  
34.6 (C-7), 31.9 (C-10), 29.9 (C-9). IR (film, cm-1) νmax 3478, 3331 (N–H), 2955 (C–H), 1575 (N–H), 1478, 
1449; HRMS (ESI+) m/z calcd for C16H27N2O2 [M+H]+ 279.2067, found 279.2065 
2-(4,5-Dihydrooxazol-2-yl)naphthalen-1-amine – 4.56 
To a suspension of 4.55[257] (0.40 g, 2.4 mmol, 1.0 eq.) and ZnCl2 (32 mg,  
0.24 mmol, 0.1 eq.) in chlorobenzene (3.4 mL, 0.7 M), was added 
ethanolamine (0.43 mL, 7.2 mmol, 3.0 eq.) and the reaction mixture was 
slowly heated to 130 °C for 24 h. After cooling back to rt, ethyl acetate was 
added, and the organic phase was washed with HCl (1 M aq.), brine, dried over Na2SO4 and 
concentrated in vacuo. Trituration in Et2O yielded the title compound as an off-white solid (0.39 g, 
77%). m.p.: 124 – 125 °C. δ1H (400 MHz, CDCl3) 7.90 (1 H, dd, J = 8.6, 1.0 Hz, H-6),  
7.79 (1 H, d, J = 8.7 Hz, H-8), 7.76 (1 H, dd, J = 7.9, 1.4 Hz, H-3), 7.51 (1 H, ddd, J = 8.1, 6.8, 1.3 Hz,  
H-2), 7.45 (1 H, ddd, J = 8.3, 6.8, 1.5 Hz, H-1), 7.14 (1 H, d, J = 8.8 Hz, H-7), 7.11 (2 H, br. s, NH2),  
4.36 (2 H, td, J = 9.2, 1.1 Hz, H-12), 4.16 (2 H, td, J = 9.2, 1.1, H-13). δ13C (101 MHz, CDCl3) 165.8 (C-11), 
146.2 (C-10), 135.6 (C-5), 128.6 (C-3), 127.6 (C-2), 126.0 (C-8), 125.1 (C-1), 123.0 (C-4), 121.6 (C-6), 
115.8 (C-7), 102.8 (C-9), 65.9 (C-12), 55.1 (C-13). IR (film, cm-1) νmax 3474 (C–H), 3243 (C–H), 3185, 
1607 (C=N), 1246 (C–N), 1057 (C–O). HRMS (ESI+): m/z calcd for C13H13N2O [M+H]+ 213.122, found 
213.1028. 
N-(2-(Benzyloxy)ethyl)-2-(4,5-dihydrooxazol-2-yl)naphthalen-1-amine - 4.57 
A solution of 4.54 (50 mg, 0.23 mmol, 1.0 eq.), BnOCH2CH2I  
(78 μL, 0.46 mmol, .2.0 eq.), DIPEA (55 μL, 0.35 mmol, 1.5 eq.) 
in DMF (0.5 mL, 0.5 M), was heated to 150 °C for 4 h in a 
microwave oven. After cooling back to rt, ethyl acetate was 
added and the organic phase was washed with LiCl (5% aq.), 
brine, dried over MgSO4 and concentrated in vacuo. Purification by flash column chromatography 
yielded the title compound as a brown oil (16 mg, 20%). Mixture of conformers in a 4:1 ratio. Only the 
major conformer is reported. δ1H (400 MHz, CDCl3) 8.39 (1 H, dd, J = 8.1, 1.5 Hz, H-6),  
7.86 (1 H, dd, J = 7.8, 1.6 Hz, H-3), 7.80 – 7.71 (2 H, m, H-7 + H-8), 7.59 – 7.50 (1 H, m, H-2),  
7.53 – 7.47 (1 H, m, H-1), 7.34 – 7.27 (4 H, m, H-18 + H-19 + H-20), 7.11 (1 H, t, J = 5.9 Hz, NH),  
4.43 (2 H, s, H-16), 3.69 (2 H, t, J = 5.8 Hz, H-15), 3.54 (4 H, dd, J = 9.5, 4.1 Hz, H-12 + H-13),  
3.30 (2 H, q, J = 5.9 Hz, H-14). δ13C (101 MHz, CDCl3) 173.5 (C-11), 145.0 (C-10), 138.5 (C-17),  
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136.5 (C-5), 132.4 (C-4), 131.2 (C-9), 128.4 (C-19), 128.3 (C-3), 127.7 (C-18), 127.6 (C-20), 127.5 (C-2), 
126.4 (C-1), 126.2 (C-7), 126.0 (C-8), 125.3 (C-6), 73.3 (C-16), 69.7 (C-12), 57.9, (C-13) 57.6 (C-15),  
41.4 (C-14). IR (film, cm-1) νmax 3295 (N–H), 2927 (C–H), 2856 (C–H), 1646 (C=N), 1102 (C–O).  
HRMS (ESI+): m/z calcd for C22H23N2O2 [M+H]+ 347.1754, found 347.1763. 
 
Chapter 5 
General procedure 5.1 (GP5.1) : formation of the isoxindole ring: To a solution of aniline  
(1 eq.) in CH2Cl2 (0.1 M) was added 2-(chloromethyl)benzoyl chloride and Et3N at 0 °C under an 
atmosphere of nitrogen. The reaction mixture was stirred at rt until consumption of the aniline was 
observed by TLC. DBU was added and the reaction mixture was stirred at rt until consumption of the 
intermediate amide was observed by TLC. The reaction mixture was diluted in ethyl acetate and 
washed with 1M HCl (aq.), brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude 
residue obtained was purified by flash column chromatography. 
General procedure 5.2 (GP5.2) – deprotection of the TMS group: To a solution of the rquired 
TMS-protected alkyne (1.0 eq.) in MeOH (0.5 M) was added K2CO3 (1.5 eq.) at rt. The reaction mixture 
was stirred at rt until consumption of the aniline was observed by TLC, quenched with water, and 
extracted with CH2Cl2. The combined organic phases were washed with brine, dried over MgSO4, 
filtered and concentrated in vacuo. Purification by flash column chromatography yielded the desired 
product. 
General procedure 5.3 (GP5.3) – Sonogashira coupling: A microwave vial was filled with nitrogen. 
To this was added the required iodo anilide (1.0 eq.), PdCl2(PPh3)2 (2 mol%), CuI (5 mol%), and Et3N of 
a mixture of Et3N /DMF (1:1, 0.3 M). The reaction mixture was degassed by sonication in vacuo 
followed refill with nitrogen. The required alkyne (1.0 eq.) was added and the reaction allowed to stir 
at 90 °C until consumption of the staRTing materials was observed by TLC. The reaction mixture was 
diluted in ethyl acetate and washed with 1M HCl (aq.), brine, dried over MgSO4, filtered, and 
concentrated in vacuo. The crude residue obtained was purified by flash column chromatography. 
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2,2'-(Ethyne-1,2-diylbis(2,1-phenylene))bis(isoindolin-1-one) – 5.20 
Following GP5.1 using 2,2'-(ethyne-1,2-diyl)dianiline 5.22[315] (75 mg,  
0.36 mmol, 1 eq.), 2-(chloromethyl)benzoyl chloride 5.21 (0.11 mL,  
0.76 mmol, 2.1 eq.) and Et3N (0.16 mL, 1.1 mmol, 3.1 eq.) in CH2Cl2  
(3.6 mL, 0.1 M) for 1 h, followed by DBU (0.16 mL, 1.1 mmol, 3.1 eq.) for 
2 h. Purification by flash column chromatography yielded the title 
compound (31 mg, 20%) as a yellow solid. m.p.: 220 °C (degradation).  
δ1H (400 MHz, CDCl3) 7.73 (2 H, d, J = 7.5 Hz, H-15),  
7.57 (2 H, t, J = 7.5 Hz, H-13), 7.48 – 7.41 (6 H, m, H-1 + H-12 + H-14), 7.39 (1 H, d, J = 7.7 Hz, H-2), 
 7.32 (2 H, d, J = 7.7 Hz, H-4), 7.21 (2 H, t, J = 7.6 Hz, H-3), 4.89 (4 H, s, H-8). δ13C (101 MHz, CDCl3)  
168.2 (C-11), 141.6 (C-9), 139.8 (C-6), 133.6 (C-4), 132.1 (C-14 or C-16), 131.9 (C-10), 129.7 (C-2),  
128.2 (C-14 or C-16), 127.9 (C-1), 127.3 (C-3), 124.2 (C-15), 123.0 (C-13), 120.5 (C-5), 91.5 (C-7),  
52.4 (C-8). IR (film, cm-1) νmax 2923 (C–H), 1689 (C=O), 1450, 1383. HRMS (ESI+): m/z calcd for 
C30H20N2O2Na+ [M+Na]+ 463.1417, found 463.1407 
2-(2-Iodo-4,6-dimethylphenyl)isoindolin-1-one – 5.23 
Following GP5.1 using 2-iodo-4,6-dimethylaniline[316] (0.25 g, 1.0 mmol, 1 eq.),  
2-(chloromethyl)benzoyl chloride (0.16 mL, 1.1 mmol, 1.1 eq.) and Et3N (0.29 mL,  
2.1 mmol, 2.1 eq.) in CH2Cl2 (10 mL, 0.1 M) for 3 h, followed by DBU (0.33 mL, 2.2 
mmol, 2.2 eq.) for 20 h. Purification by flash column chromatography yielded the title 
compound (0.26 g, 71%) as an off-white solid. m.p.: 146 – 148 °C.  
δ1H (400 MHz, CDCl3) 7.96 (1 H, d, J = 8.1 Hz, H-13), 7.64 – 7.59 (2 H, m, H-4 + H-16), 
7.56 – 7.48 (2 H, m, H-14 + H-15), 7.10 (1 H, s, H-2), 4.87 (CHAHB, 1 H, d, J = 16.7 Hz, 
H-12), 4.48 (CHAHB, 1 H, d, J = 16.4 Hz, H-12), 2.31 (3 H, s, H-8), 2.21 (3 H, s, H-7). δ13C (101 MHz, CDCl3)  
167.7 (C-9), 141.7 (C-11), 140.6 (C-3), 138.5 (C-1), 137.8 (C-4), 136.6 (C-6), 132.4 (C-10),  
132.0 (C-2 + C-16), 128.3 (C-14), 124.6 (C-13), 123.1 (C-15), 99.6 (C-5), 50.9 (C-12), 20.7 (C-8),  
19.2 (C-7). IR (film, cm-1) νmax 1690 (C=O), 1469, 1385, 732 (C–I). HRMS (ESI+) m/z calcd for 
C16H14NOINa+ [M+Na]+ 386.0012, found 386.0020. 
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2-(2,4-Dimethyl-6-((trimethylsilyl)ethynyl)phenyl)isoindolin-1-one  - 5.24 
Following GP5.3 using 2-(2-iodo-4,6-dimethylphenyl)isoindolin-1-one 5.23 
(0.15 g, 0.41 mmol, 1 eq.), PdCl2(PPh3)2 (6.0 mg, 0.0085 mmol, 2 mol%) and 
CuI (4.0 mg, 0.021 mmol, 5 mol%) in Et3N (1.2 mL, 0.3 M), followed by 
ethynyltrimethylsilane (0.12 mL, 0.87 mmol, 2.1 eq.) at 90 °C for 16 h. 
Purification by flash column chromatography yielded the title compound 
(0.13 g, quant) as a yellow oil. δ1H (400 MHz, CDCl3) 7.95 (1 H, d, J = 7.3 Hz,  
H-14), 7.58 (1 H, d, J = 7.8 Hz, H-16), 7.49 (2 H, d, J = 7.7 Hz, H-15 + H-17),  
7.21 (1 H, br. s, H-4), 7.11 (1 H, br. s, H-2), 5.01 (CHAHB, 1 H, d, J = 16.5 Hz, H-13),  
4.51 (CHAHB, 1 H, d, J = 16.6 Hz, H-13), 2.31 (3 H, s, H-8), 2.22 (3 H, s, H-7), -0.12 (9 H, s, H-19).  
δ13C (101 MHz, CDCl3) 168.1 (C-10), 142.2 (C-12), 138.1 (C-3), 137.5 (C-6) , 136.8 (C-1) , 132.6 (C-11), 
132.2 (C-2), 131.7 (C-16), 131.1 (C-4), 128.1 (C-15), 124.3 (C-14), 122.7 (C-17), 122.6 (C-5), 101.7 (C-9), 
98.6 (C-18), 51.3 (C-13), 21.0 (C-8), 18.2 (C-7), -0.5 (C-19). IR (film, cm-1): νmax 2154 (C≡C), 1694 (C=O), 
1469, 1384, 1249 (C–Si), 839. HRMS (ESI+): m/z calcd for C21H23NOSiNa+ [M+Na]+ 356.1441, found 
356.1442 
2-(2-Ethynyl-4,6-dimethylphenyl)isoindolin-1-one – 5.25 
 Following GP5.2 using 2-(2,4-dimethyl-6-((trimethylsilyl)ethynyl)phenyl) 
isoindolin-1-one 5.24 (1.1 g, 3.3 mmol, 1.0 eq.) and K2CO3 (0.69 g, 5.0 mmol,  
1.5 eq.) in MeOH (6.6 mL, 0.5M) for 2 h. Purification by flash column 
chromatography yielded the title compound (0.75 g, 87%) as a pink solid.  
m.p.: 138 °C (degradation). δ1H (400 MHz, CDCl3) 7.96 (1 H, dd, J = 8.2, 1.1 Hz, 
H-14), 7.60 (1 H, td, J = 7.3, 1.2 Hz, H-16), 7.55 – 7.44 (2 H, m, H-15 + H-17),  
7.27 (1 H, d, J = 2.1 Hz, H-4), 7.14 (1 H, dd, J = 1.9, 1.1 Hz, H-2),  
5.01 (CHAHB, 1 H, d, J = 16.7 Hz, H-13), 4.51 (CHAHB, 1 H, d, J = 16.7 Hz, H-13), 2.99 (1 H, s, H-18),  
2.33 (3 H, s, H-8), 2.20 (3 H, s, H-7). δ13C (101 MHz, CDCl3) 168.0 (C-10), 142.1 (C-12), 138.3 (C-3),  
137.5 (C-1), 136.4 (C-6), 132.6 (C-11), 132.4 (C-2), 132.0 (C-4), 131.7 (C-16), 128.2 (C-15), 124.5 (C-14),  
122.9 (C-17), 121.8 (C-5), 81.1 (C-18), 80.5 (C-9), 51.5 (C-13), 21.0 (C-8), 18.2 (C-7). IR (film, cm-1): νmax 




2,2'-(Ethyne-1,2-diylbis(4,6-dimethyl-2,1-phenylene))bis(isoindolin-1-one) – 5.26 
Following GP5.3 using 2-(2-iodo-4,6-dimethylphenyl)isoindolin-1-one 
5.23 (0.14 g, 0.39 mmol, 1 eq.), PdCl2(PPh3)2 (5.5 mg, 0.0078 mmol, 2 
mol%) and CuI (3.7 mg, 0.02 mmol, 5 mol%) in Et3N (1.2 mL, 0.3 M), 
followed by 2-(2-ethynyl-4,6-dimethylphenyl)isoindolin-1-one 5.25 
(0.10 g, 0.39 mmol, 1 eq.) at 90 °C for 18 h. Purification by flash column 
chromatography yielded the title compound (0.13 g, 70%) as a white 
solid. m.p.: 205 °C (degradation). Mixture of conformers in a 1:0.3 ratio 
in CDCl3. δ1H (400 MHz, CDCl3) 7.99 (1 Hmaj, dt, J = 7.6, 1.0 Hz, H-14), 7.84 (1 Hmin, dt, J = 7.5, 1.1 Hz,  
H-14), 7.65 (1 Hmaj, td, J = 7.5, 1.2 Hz, H-16), 7.61 (1 Hmin, td, J = 7.5, 1.3 Hz, H-16),  
7.61 – 7.51 (2 Hmaj, m, H-15 + H-17), 7.53 – 7.50 (1 Hmin, m, H-15), 7.46 (1 Hmin, dt, J = 7.5, 0.9 Hz, H-17),  
7.02 (1 Hmin, dd, J = 1.4, 0.7 Hz, H-4), 6.99 (1 Hmaj, dt, J = 2.1, 0.7 Hz, H-4),  
6.56 (1 Hmin, dt, J = 2.1, 0.7 Hz, H-2), 6.14 (1 Hmin, dt, J = 2.1, 0.7 Hz, H-2),  
4.94 (CHAHB, 1 Hmaj + min, d, J = 16.6 Hz, H-13), 4.52 (CHAHB, 1 Hmaj, d, J = 16.8 Hz, H-13),  
4.43 (CHAHB, 1 Hmin, d, J = 16.6 Hz, H-13), 2.18 (3 Hmaj , s, H-7), 2.13 (6 Hmin, br. s, H-7 + H-8),  
2.04 (3 Hmaj, s, H-8). δ13C (101 MHz, CDCl3) 168.6 (C-10maj), 167.9 (C-10min), 142.4 (C-12maj),  
142.0 (C-12min), 138.0 (C-3maj+min), 137.4 (C-1min), 137.3 (C-1maj), 136.0 (C-6maj), 135.7 (C-6min),  
132.5 (C-11maj), 132.3 (C-11min), 132.2 (C-4min), 132.0 (C-4maj), 131.8 (C-16maj), 131.7 (C-16min),  
131.4 (C-2min), 130.9 (C-2maj), 128.14 (C-2min), 128.1 (C-15maj), 124.6 (C-15min), 124.5 (C-14maj),  
123.2 (C-17majl), 123.0 (C-17min), 122.32 (C-5min), 122.30 (C-5maj), 90.3 (C-9min), 90.1 (C-9maj),  
51.9 (C-13maj), 51.7 (C-13min) 20.85 (C-8min), 20.82 (C-8maj), 18.2 (C-7min), 18.0 (C-7maj).  
IR (film, cm-1) νmax 1693 (C=O), 1468, 1385. HRMS (ESI+) m/z calcd for C34H28N2ONa+ [M+Na]+ 519.2043; 
found: 519.2044. Supplementary crystallographic data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre (CCDC 1861805). 
5-Iodo-2,3-dimethylpyridin-4-amine – 5.27 
To a refluxing solution of 2,3-dimethylpyridin-4-amine[317] (0.60 g, 4.9 mmol, 1.0 eq.) 
in conc. H2SO4 (0.45 mL), H20 (2.4 mL) and AcOH (8.4 mL) was added H5IO6 (0.44 g,  
1.9 mmol, 0.4 eq) and I2 (0.88 g, 2.5 mmol, 0.5 eq.) and the reaction mixture was 
stirred at reflux for 3 h. The reaction mixture was allowed to cool down to rt and Na2SO3 sat was added 
until the colour changed to a clear solution. The reaction mixture was extracted with CH2Cl2, organic 
phases were combined, dried with MgSO4, filtered, and concentrated in vacuo to give the title 
compound (0.92 g, 63%) as a white solid which was used without further purification. m.p.: 101 – 103 
°C (degradation). δ1H (400 MHz, CDCl3) 8.33 (1 H, s, H-4), 4.52 (2 H, br. s, NH2), 2.42 (3 H, s, H-7),  
2.12 (3 H, s, H-6). δ13C (101 MHz, CDCl3) 156.0 (C-5), 153.2 (C-4), 150.6 (C-2), 115.3 (C-1), 80.5 (C-3),  
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22.6 (C-7), 13.5 (C-6). IR (film, cm-1) νmax 2958 (C–H), 1479, 1272, 1044 (C–I). HRMS (ESI+) m/z calcd for 
C7H10N2I+ [M+H]+ 248.9889, found 248.9892. 
2-(5-Iodo-2,3-dimethylpyridin-4-yl)isoindolin-1-one – 5.28 
To a solution of 5-iodo-2,3-dimethylpyridin-4-amine 5.27 (0.92 g, 3.7 mmol, 1.0 eq.) 
in CH2Cl2 (37 mL, 0.1 M) was added 2-(chloromethyl)benzoyl chloride 5.21 (0.58 mL,  
4.1 mmol, 1.1 eq.) and Et3N (0.61 mL, 4.4 mmol, 1.2 eq.) at 0 °C under an atmosphere 
of nitrogen. The reaction mixture was stirred at rt for 6 h, washed with sat. NaHCO3 
(aq.), water, brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude 
mixture was diluted in CH2Cl2 (37 mL, 0.1 M), DBU (0.61 mL, 4.4 mmol, 1.2 eq.) was 
added and the reaction mixture was stirred at rt for 22 h. The reaction mixture was washed with sat. 
NaHCO3 (aq.), water, brine, dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash 
column chromatography yielded the title compound (0.30 g, 22%) as a pink solid. m.p.: 192 °C 
(degradation) δ1H (400 MHz, CDCl3) 8.75 (1 H, s, H-3), 8.07 – 7.88 (1 H, m, H-10), 7.65 (1 H, td, J = 7.2, 
6.8, 1.2 Hz, H-12), 7.56 (2 H, t, J = 7.2 Hz, H-11 + H-13), 4.90 (CHAHB, 1 H, d, J = 16.4 Hz, H-9),  
4.48 (CHAHB, 1 H, d, J = 16.4 Hz, H-9), 2.54 (3 H, s, H-15), 2.20 (3 H, s, H-14). δ13C (101 MHz, CDCl3)  
167.3 (C-6), 159.2 (C-2), 154.5 (C-3), 146.8 (C-5), 141.6 (C-7), 133.5 (C-1), 132.4 (C-12), 131.8 (C-7), 
128.6 (C-11), 124.8 (C-10), 123.3 (C-13), 94.9 (C-4), 50.6 (C-9), 23.0 (C-15), 15.2 (C-14).  
IR (film, cm-1) νmax 1694 (C=O), 1455. HRMS (ESI+) m/z calcd for C15H13N2OINa+ [M+Na]+ 386.9970, 
found 386.9977. 
2-(2,3-Dimethyl-5-((trimethylsilyl)ethynyl)pyridin-4-yl)isoindolin-1-one – 5.29 
Following GP5.3 using 2-(5-iodo-2,3-dimethylpyridin-4-yl)isoindolin-1-one 
5.28 (0.36 g, 1.0 mmol, 1 eq.), PdCl2(PPh3)2 (14 mg, 0.02 mmol, 2 mol%) and 
CuI (9.5 mg, 0.05 mmol, 5 mol%) in Et3N (3.5 mL, 0.3 M), followed by 
ethynyltrimethylsilane (0.29 mL, 2.1 mmol, 2.1 eq.) at 90 °C for 2 h. 
Purification by flash column chromatography yielded the title compound  
(0.26 g, 78%) as a yellow oil. δ1H (400 MHz, CDCl3) 8.50 (1 H, s, H-3),  
7.95 (1 H, dt, J = 7.7, 1.2 Hz, H-11), 7.62 (1 H, td, J = 7.6, 1.2 Hz, H-13), 7.57 – 7.48 (2 H, m,  
H-12 + H-14), 5.14 (CHAHB, 1 H, d, J = 16.4 Hz, H-10), 4.50 (CHAHB, 1 H, d, J = 16.4 Hz, H-10),  
2.59 (3 H, s, H-16), 2.19 (3 H, s, H-15), -0.07 (9 H, s, H-18). δ13C (101 MHz, CDCl3) 167.7 (C-7),  
159.2 (C-2), 150.1 (C-3), 146.5 (C-5), 142.1 (C-9), 132.2 (C-13), 131.9 (C-8), 131.0 (C-1), 128.4 (C-12), 
124.6 (C-11), 122.9 (C-14), 117.0 (C-4), 102.3 (C-17), 98.8 (C-6), 51.0 (C-10), 23.6 (C-16), 14.3 (C-15),  
-0.5 (C-18). IR (film, cm-1): νmax 2958 (C–H), 2156 (C≡C), 1700 (C=O), 1378, 1250 (C–Si), 843.  




Following GP5.2 using 2-(2,3-dimethyl-5-((trimethylsilyl)ethynyl)pyridin-4-yl 
)isoindolin-1-one 5.29 (0.23 g, 0.69 mmol, 1.0 eq.) and K2CO3 (0.14 g, 1.0 mmol,  
1.5 eq.) in MeOH (2.3 mL, 0.3M) for 45 minutes. Purification by flash column 
chromatography yielded the title compound (0.16 g, 89%) as a white solid.  
m.p.: 151 °C (degradation). δ1H (400 MHz, CDCl3) 8.55 (1 H, s, H-3),  
7.95 (1 H, dd, J = 7.8, 1.5 Hz, H-11), 7.63 (1 H, td, J = 7.0, 1.1 Hz, H-13),  
7.56 – 7.50 (2 H, m, H-12 + H-14), 5.14 (CHAHB, 1 H, d, J = 16.4 Hz, H-10),  
4.50 (CHAHB, 1 H, d, J = 16.5 Hz, H-10), 3.17 (1 H, s, H-17), 2.59 (3 H, s, H-16), 2.15 (3 H, s, H-15).  
δ13C (101 MHz, CDCl3) 167.5 (C-7), 159.7 (C-2), 150.9 (C-3), 146.1 (C-5), 142.0 (C-9), 132.2 (C-13),  
131.7 (C-8), 130.9 (C-1), 128.4 (C-12), 124.6 (C11), 123.1 (C-14), 116.1 (C-4), 84.1 (C-6), 77.9 (C-17), 
51.1 (C-10), 23.7 (C-16), 14.4 (C-15). IR (film, cm-1): νmax 3291 (C≡C–H), 3221, 1692 (C=O), 1470, 1142. 
HRMS (ESI+) m/z calcd for C17H14N2ONa [M+Na]+ 285.1004, found 285.1010 
2,2'-(Ethyne-1,2-diylbis(5,6-dimethylpyridine-3,4-diyl))bis(isoindolin-1-one) 5.30 
Following GP5.3 using 2-(5-iodo-2,3-dimethylpyridin-4-yl)isoindolin-
1-one (0.17 g, 0.48 mmol, 1 eq.), PdCl2(PPh3)2 (6.7 mg, 9.5 μmol, 2 
mol%) and CuI (4.6 mg, 0.024 mmol, 5 mol%) in Et3N/DMF (1:1,  
1.6 mL, 0.3 M), followed by 2-(5-ethynyl-2,3-dimethylpyridin-4-yl) 
isoindolin-1-one (0.10 g, 0.39 mmol, 1 eq.) at 90 °C for 18 h. 
Purification by flash column chromatography yielded the title 
compound (5 mg, 2%) as a colourless oil. Mixture of conformers in a 
1:0.4 ratio in CDCl3. δ1H (500 MHz, CDCl3) 8.24 (2 Hmin, s, H-3), 7.97 (2 Hmaj, d, J = 7.6 Hz, H-12),  
7.77 (2 Hmaj, s, H-3), 7.70 – 7.65 (2 Hmaj + 2Hmin, m, H-13maj + H-12min), 7.62 (1 Hmin, t, J = 7.3 Hz, H-13),  
7.60 – 7.53 (4 Hmaj, m, H-14 + H-15), 7.50 (1 Hmin, t, J = 7.5 Hz, H-14), 7.45 (1 Hmin, d, J = 7.6 Hz, H-15),  
5.10 (CHAHB, 2 Hmin, d, J = 16.4 Hz, H-11), 5.04 (CHAHB, 2 Hmaj, d, J = 16.5 Hz, H-11),  
4.51 (CHAHB, 2 Hmaj, d, J = 16.5 Hz, H-11), 4.39 (CHAHB, 2 Hmin, d, J = 16.4 Hz, H-11), 2.55 (6 Hmin, s,  
H-16), 2.53 (6 Hmaj, s, H-16), 2.16 (6 Hmaj, s, H-6), 2.07 (6 Hmin, s, H-6). δ13C (126 MHz, CDCl3)  
168.1 (C-8maj), 167.4 (C-8min), 159.73 (C-1min), 159.69 (C-1maj), 150.3 (C-3min), 149.7 (C-3maj),  
145.7 (C-5maj), 145.3 (C-5min), 141.9 (C-10maj), 141.7 (C-10min), 132.7 (C-14maj), 132.5 (C-14min),  
131.5 (C-9maj), 131.14 (C-1maj), 131.08 (C-9min), 130.8 (C-1min), 128.8 (C-13maj), 128.5 (C-13min),  
124.7 (C-12min), 124.6 (C-12maj), 123.3 (C-15maj), 123.1 (C-15min), 116.5 (C-4maj), 116.2 (C-4min),  
90.2 (C-7min), 90.0 (C-7maj), 51.5 (C-11maj), 51.3 (C-11min), 23.7 (C-16min), 23.6 (C-16maj), 14.6 (C-6min),  
14.3 (C-6maj). IR (film, cm-1) νmax 2924 (C–H), 1701 (C=O), 1468, 1409, 1378, 1143. HRMS (ESI+) m/z 
calcd for C32H26N4O2+ [M+H]+ 499.2128; found: 499.2141. 
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2-Iodo-4-isopropyl-6-((triisopropylsilyl)ethynyl)aniline – 5.32 
Following GP5.3 using 2,6-diiodo-4-isopropylaniline 5.31[318] (0.80 g,  
2.1 mmol, 1 eq.), PdCl2(PPh3)2 (29 mg, 0.042 mmol, 2 mol%) and CuI (20 mg, 
0.11 mmol, 5 mol%) in Et3N (7.0 mL, 0.3 M), followed by 
(triisopropylsilyl)acetylene (0.46 mL, 2.1 mmol, 1.0 eq.) at 90 °C for 15 h. 
Purification by flash column chromatography yielded the title compound 
(0.26 g, 28%) as a yellow oil. δ1H (400 MHz, CDCl3) 7.47 (1 H, d, J = 2.0 Hz, H-2), 7.15 (1 H, d, J = 2.0 Hz, 
H-4), 4.59 (2 H, br. s, NH2), 2.73 (1 H, hept, J = 5.9 Hz, H-7), 1.19 (6 H, d, J = 5.9 Hz, H-9),  
1.14 (21 H, br. s, H-11 + H-12). δ13C (101 MHz, CDCl3) 146.5 (C-6), 139.8 (C-3), 137.72 (C-2),  
130.5 (C-4), 108.1 (C-5), 103.8 (C-8), 96.4 (C-10), 83.2 (C-1), 33.0 (C-7), 24.1 (C-9), 18.9 (C-12),  
11.4 (C-11). IR (film, cm-1): νmax 3475 (N–H), 3376 (N–H), 2967 (C–H), 2941 (C–H), 2864 (C–H), 2143 
(C≡C), 1609, 1583, 1464. HRMS (ESI+): m/z calcd for C20H33NOISi [M+H]+ 442.1422, found 442.1406. 
2-(2-Iodo-4-isopropyl-6-((triisopropylsilyl)ethynyl)phenyl)isoindolin-1-one – 5.33 
To a solution of 2-iodo-4-isopropyl-6-((triisopropylsilyl)ethynyl)aniline 5.32 
(0.23 g, 0.5 mmol, 1 eq.) in CH2Cl2 (2.6, 0.1 M) was added 2-
(chloromethyl)benzoyl chloride 5.21 (0.15 mL, 1.0 mmol, 2.1 eq.) and Et3N 
(0.22 mL, 1.6 mmol, 3.1 eq.) at rt under an atmosphere of nitrogen. The 
reaction mixture was stirred at rt for 24h. The reaction mixture was diluted 
in ethyl acetate and washed with 1M HCl (aq.), brine, dried over MgSO4, 
filtered, and concentrated in vacuo. The crude residue obtained was 
dissolved in CH2Cl2 (2.6 mL, 0.1 M) and DBU (0.24 mL, 1.6 mmol, 3.1 eq.) was added. The reaction 
mixture was heated under reflux for 24 h, diluted in ethyl acetate and washed with 1M HCl (aq.), brine, 
dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column chromatography 
yielded the title compound (0.13 g, 45%) as a yellow oil. δ1H (400 MHz, CDCl3)  
7.93 (1 H, dt, J = 7.5, 1.0 Hz, H-13), 7.74 (1 H, d, J = 2.0 Hz, H-2), 7.58 (1 H, td, J = 7.5, 1.2 Hz, H-15), 
7.52 – 7.44 (2 H, m, H-14 + H-16), 7.39 (1 H, d, J = 1.9 Hz, H-4), 4.83 (CHAHB, 1 H, d, J = 16.2 Hz, H-12), 
4.73 (CHAHB, 1 H, d, J = 16.2 Hz, H-12), 2.87 (1 H, hept, J = 5.9 Hz, H-7), 1.26 (6 H, d, J = 5.9 Hz, H-20), 
0.90 – 0.82 (21 H, m, H-18 + H-19). δ13C (101 MHz, CDCl3) 167.5 (C-9), 151.0 (C-3), 142.0 (C-11),  
140.3 (C-6), 137.8 (C-2), 132.6 (C-10), 131.9 (C-15 or C-4), 131.8 (C-15 or C-4), 128.1 (C-14),  
124.6 (C-13), 124.4 (C-5), 122.9 (C-16), 102.6 (C-1), 99.9 (C-8), 96.2 (C-17), 50.9 (C-12), 33.7 (C-7),  
23.8 (C-20), 18.4 (C-19), 11.2 (C-18). IR (film, cm-1): νmax 2942 (C–H), 2863 (C–H), 1705 (C=O), 1460. 




((triisopropylsilyl)ethynyl) phenyl)isoindolin-1-one – 5.34 
Following GP5.3 using 2-(2-iodo-4-isopropyl-6-((triisopropyl 
silyl)ethynyl)phenyl)isoindolin-1-one 533 (0.13 g, 0.23 mmol, 
1.0 eq.), PdCl2(PPh3)2 (6.5 mg, 0.0092 mmol, 4 mol%) and CuI 
(4.4 mg, 0.023 mmol, 10 mol%) in Et3N/DMF (1:1, 0.77 mL, 0.3 
M), followed by 2-(2-ethynyl-4,6-dimethylphenyl)isoindolin-1-
one 5.25 (0.12 g, 0.46 mmol, 2.0 eq.) at 90 °C for 18 h. 
Purification by flash column chromatography yielded the title compound (0.12 g, 75%) as an off-white 
solid. m.p.: 107 – 111 °C. Mixture of conformers in a 1:0.3 ratio in CDCl3. δ1H (500 MHz, CDCl3)  
7.99 (1 Hmaj, d, J = 7.6 Hz, ArCH), 7.96 (1 Hmaj, d, J = 7.6 Hz, ArCH), 7.86 (1 Hmin, d, J = 7.5 Hz, ArCH),  
7.81 (1 Hmin, d, J = 7.6 Hz, ArCH), 7.67 – 7.58 (2 Hmaj + 1 Hmin, m, ArCH), 7.57 – 7.44 (4 Hmaj + 3 Hmin, m, 
ArCH), 7.38 (1 Hmin, d, J = 7.6 Hz, ArCH), 7.33 (1 Hmin, d, J = 7.6 Hz, ArCH) , 7.29 (1 Hmin, d, J = 2.1 Hz, 
ArCH), 7.26 (1 Hmaj, s, ArCH), 7.05 (1 Hmin, s, ArCH), 7.02 (1 Hmaj, s, ArCH), 6.93 – 6.87 (2 Hmin, m, ArCH),  
6.41 (2 Hmaj, dd, J = 13.4, 2.0 Hz, ArCH), 5.01 (1 Hmaj, d, J = 16.8 Hz, NCH2), 4.85 (1 Hmaj, d, J = 16.3 Hz, 
NCH2), 4.82 (1 Hmin, d, J = 16.8 Hz, NCH2), 4.76 (1 Hmin, d, J = 16.2 Hz, NCH2), 4.73 (1 Hmaj, d, J = 16.3 Hz, 
NCH2), 4.54 (1 Hmaj + 1 Hmin, d, J = 16.9 Hz, NCH2), 4.36 (1 Hmin, d, J = 16.7 Hz, NCH2),  
2.72 (1 Hmin, hept, J = 5.9 Hz, CCH(CH3)2), 2.58 (1 Hmaj, hept, J = 7.0 Hz, CCH(CH3)2), 2.20 (3 Hmin, s, CCH3), 
2.19 (3 Hmaj, s, CCH3), 2.12 (3 Hmin, s, CCH3), 2.09 (3 Hmaj, s, CCH3), 1.13 (6 Hmin, dd, J = 7.0, 3.6 Hz, 
CCH(CH3)2), 1.01 (6 Hmaj, dd, J = 5.9, 2.5 Hz, CCH(CH3)2), 0.89 (21 Hmaj, s, SiCH(CH3)2+ CCH(CH3)2),  
0.85 (21 Hmin, d, J = 3.5, SiCH(CH3)2 + SiCH(CH3)2). δ13C (126 MHz, CDCl3) 168.5 (C=Omaj), 168.1 (C=Omaj), 
167.8 (C=Omin), 167.6 (C=Omin), 148.8 (ArCmaj + min), 142.4 (ArCmaj), 142.3 (ArCmaj), 142.00 (ArCmin),  
141.96 (ArCmin), 139.4 (ArCmaj), 138.9 (ArCmin), 138.12 (ArCmin), 138.10 (ArCmaj), 137.31 (ArCmaj),  
137.26 (ArCmin), 136.1 (ArCmaj), 135.5 (ArCmin), 132.6 (ArCmaj), 132.48 (ArCmaj), 132.46 (ArCmin),  
132.34 (ArCHmin), 132.30 (ArCmin), 132.2 (ArCHmaj), 132.0 (ArCHmin), 131.89 (ArCHmaj), 131.87 (ArCHmin), 
131.7 (2 ArCHmaj + 1 ArCHmin), 131.6 (ArCHmin), 131.5 (ArCHmin), 131.1 (ArCHmaj), 130.7 (ArCHmaj),  
128.2 (ArCHmaj), 128.17 (ArCHmin), 127.93 (ArCHmin), 127.91 (ArCHmaj), 124.6 (ArCHmin), 124.5 (ArCHmin), 
124.41 (ArCHmaj), 124.40 (ArCHmaj), 123.8 (ArCmaj), 123.7 (ArCmin), 123.6 (ArCmin), 123.4 (ArCmaj),  
123.2 (ArCHmaj), 123.0 (ArCHmaj), 122.92 (ArCHmin), 122.91 (ArCHmin), 122.3 (ArCmin), 122.2 (ArCmaj), 
102.8 (C≡Cmin), 102.7 (C≡Cmaj), 95.81 (C≡Cmin), 95.76 (C≡Cmaj), 90.5 (C≡Cmin), 90.4 (C≡Cmaj), 89.8 (C≡Cmin), 
89.6 (C≡Cmaj), 51.9 (NCH2maj), 51.7 (NCH2maj), 51.6 (NCH2min), 51.5 (NCH2min), 33.7 (CCH(CH3)2min),  
33.6 (CCH(CH3)2maj), 23.64 (CCH(CH3)2min), 23.56 (CCH(CH3)2maj), 23.52 (CCH(CH3)2maj), 20.90 (CCH3min), 
20.87 (CCH3maj), 18.50 (SiCH(CH3)2maj), 18.47 (SiCH(CH3)2min), 18.2 (CCH3min), 18.1 (CCH3maj),  
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11.19 (SiCH(CH3)2maj), 11.16 (SiCH(CH3)2min). IR (film, cm-1) νmax 2943 (C–H), 2864 (C–H), 1702 (C=O), 
1468, 1384. HRMS (ESI+) m/z calcd for C46H50N2O2SiNa+ [M+Na]+ 713.3534; found: 713.3563. 
2,2'-(((5-Isopropyl-2-(1-oxoisoindolin-2-yl)-1,3-phenylene)bis(ethyne-2,1-diyl))bis(4,6-
dimethyl-2,1-phenylene))bis(isoindolin-1-one) – 5.35 
To a solution of 2-(2-((3,5-dimethyl-2-(1-oxoisoindolin-2-
yl)phenyl)ethynyl)-4-isopropyl-6-((triisopropylsilyl)ethynyl) 
phenyl)isoindolin-1-one 5.34 (110 mg, 0.16 mmol, 1.0 eq.) 
in THF (1.0 mL, 0.15M) was added TBAF (1.0M in THF,  
0.24 mL, 0.24 mmol, 1.5 eq.) and the reaction mixture was 
stirred at rt for 30 min. Brine was added and the reaction 
mixture was extracted with CH2Cl2. The combined organic phases were dried over MgSO4, filtered and 
concentrated in vacuo. The crude deprotected alkyne was used without further purification. Following 
GP5.3 using 2-(2-iodo-4,6-dimethylphenyl)isoindolin-1-one 5.23 (110 g, 0.32 mmol, 2.0 eq.), 
PdCl2(PPh3)2 (4.5 mg, 0.0064 mmol, 4 mol%) and CuI (3.0 mg, 0.016 mmol, 10 mol%) in Et3N/DMF (1:2, 
0.8 mL, 0.2 M), followed by the previously deprotected alkyne (0.16 mmol, 1.0 eq.) at 90 °C for 20 h. 
Purification by flash column chromatography yielded the title compound (91 mg, 74%) as a yellow 
solid. m.p.: 204 °C (degradation). Mixture of conformers in CDCl3: A(syn, syn): 8% ; B(anti, anti): 49% ; 
C(anti, syn) 43%. Not every signal for isomer A were visible by NMR. δ1H (400 MHz, CDCl3)  
8.01 (1 HB, dt, J = 7.6, 1.0 Hz, ArCH), 7.96 (2 HB + 1 HC, dt, J = 7.5, 0.9 Hz, ArCH),  
7.88 (1 HC, dt, J = 7.5, 1.0 Hz, ArCH), 7.77 (1 HB, d, J = 7.6 Hz, ArCH), 7.70 – 7.66 (1 HC, m, ArCH),  
7.65 (1 HB, td, J = 4.5, 1.2 Hz, ArH ArCH 7.63 – 7.48 (6 HB + 7HC, m, ArCH), 7.47 – 7.43 (2 HB, m, ArCH), 
7.32 (1 HC, d, J = 7.5 Hz, ArCH), 7.05 (1 HC, d, J = 2.0 Hz, ArCH), 7.02 (2 HB, d, J = 2.0 Hz, ArCH), 
6.99 (1 HC, d, J = 1.7 Hz, ArCH), 6.94 (1 HC, d, J = 2.0 Hz, ArCH), 6.79 (1 HC, d, J = 2.1 Hz, ArCH),  
6.47 (1 HB + 1 HC, d, J = 2.0 Hz, ArCH), 6.32 (2 HB, s, ArH), 6.23 (1 HC, d, J = 2.1 Hz, ArCH),  
6.16 (1 HC, d, J = 2.0 Hz, ArCH), 4.97 (CHAHB, 2 HB, d, J = 16.6 Hz, NCH2),  
4.94 (CHAHB, 1 HC, d, J = 16.9 Hz, NCH2), 4.86 (CHAHB, 1 HC, d, J = 16.7 Hz, NCH2),  
4.78 (CHAHB, 2 HA, d, J = 16.7), 4.73 (2 HB, br. s, NCH2), 4.60 (2 HC, br. s, NCH2),  
4.54 (CHAHB, 1 HC, d, J = 16.9 Hz, NCH2), 4.50 (CHAHB, 2 HB, d, J = 16.8 Hz, NCH2),  
4.37 (CHAHB, 1 HC, d, J = 16.7 Hz, NCH2), 4.31 (CHAHB, 2 HA, d, J = 16.9 Hz, NCH2), 2.53 (1HA, br. s, 
CH(CH3)2), 2.38 (1 HC, hept, J = 7.0 Hz, CH(CH3)2), 2.31 – 2.24 (1 HB, m, CH(CH3)2), 2.22 (3 HC, s, CCH3),  
2.21 – 2.17 (6 HA + 6 HB + 3 HC, m, CCH3), 2.14 – 2.09 (6 HA + 6 HB + 3 HC, m, CCH3), 2.06 (3 HC, s, CCH3), 
0.99 (6 HA, d, J = 5.9 Hz, CH(CH3)2), 0.87 (6 HC, d, J = 5.9 Hz, CH(CH3)2), 0.80 (6 HB, d, J = 5.9 Hz, CH(CH3)2).  
δ13C (126 MHz, CDCl3) 168.8 (CB=O), 168.6 (CC=O), 168.5 (CC=O), 168.4 (CB=O), 167.83 (CC=O),  
167.81 (CA=O), 148.65 (ArCB), 148.62 (ArCC), 148.59 (ArCA), 142.6 (ArCB), 142.5 (ArCC), 142.4 (ArCC), 
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142.3 (ArCB), 141.9 (ArCB), 138.8 (ArCB), 138.7 (ArCC), 138.16 (ArCB), 138.14 (ArCB), 138.10 (ArCA), 
138.08 (ArCC), 137.37 (ArCB), 137.34 (ArCC), 137.30 (ArCC), 136.12 (ArCB), 136.10 (ArCC), 135.7 (ArCC), 
135.6 (ArCA), 132.46 (ArCHB+C), 132.44 (ArCHC), 132.38 (ArCHA), 132.32 (ArCHB), 132.23 (ArCHC),  
132.17 (ArCHC), 132.16 (ArCHA), 132.0 (ArCHC), 131.90 (ArCHA), (ArCHC) 131.86 (ArCHB), 131.83 (ArCHC), 
131.76 (ArCHA), 131.71 (ArCHB), 131.69 (ArCHA), 131.66 (ArCHC), 131.04 (ArCHC), 130.96 (ArCHB), 
130.87 (ArCHA), 128.22 (ArCHB), 128.19 (ArCHC), 128.18 (ArCHC), 128.16 (ArCHA), 128.03 (ArCHB), 
128.00 (ArCHA), 127.96 (ArCHC), 124.82 (ArCHA), 124.67 (ArCHC), 124.46 (ArCHC), 124.44 (ArCHB), 
124.41 (ArCHC), 123.54 (ArCHB), 123.47 (ArCHC), 123.35 (ArCHA), 123.23 (ArCHC), 123.16 (ArCB),  
123.14 (ArCHC), 123.13 (ArCHB), 123.04 (ArCC), 122.92 (ArCHB), 122.90 (ArCHA), 122.25 (ArCC),  
122.18 (ArCA), 122.16 (ArCB), 122.12 (ArCC), 90.75 (CA≡C), 90.65 (CC≡C), 90.63 (CC≡C), 90.53 (CB≡C), 
89.67 (CA≡C), 89.63 (CC≡C), 89.51 (CC≡C), 89.45 (CB≡C), 52.1 (NCBH2), 52.0 (NCCH2), 51.9 (NCCH2),  
51.8 (NCBH2), 51.7 (NCAH2), 51.61 (NCCH2), 51.56 (NCAH2), 33.5 (CAH(CH3)2),33.4 (CCH(CH3)2),  
33.3 (CBH(CH3)2), 23.5 (CH(CAH3)2), 23.39 (CH(CCH3)2), 23.38 (CH(CCH3)2), 23.3 (CH(CBH3)2), 20.94 (CCH3), 
20.90 (CBH3), 20.86 (CCH3), 18.20 (CCH3), 18.18 (CAH3), 18.09 (CBH3), 18.04 (CCH3). IR (film, cm-1) νmax 
1698 (C=O), 1468, 1384. HRMS (ESI+) m/z calcd for C53H44N3O3+ [M+H]+ 770.3377; found: 770.3408. 
6,6'-(Ethyne-1,2-diyl)bis(2,4-dimethylaniline) -5.42 
Following GP5.2 using 2,4-dimethyl-6-((trimethylsilyl)ethynyl)aniline 
5.41[319] (0.72 g, 3.3 mmol, 1.0 eq.) and K2CO3 (0.69 g, 5.0 mmol, 1.5 eq.) 
in MeOH (6.6 mL, 0.5M) to yield 2-ethynyl-4,6-dimethylaniline which 
was used without further purification. Following GP5.3 using 2-iodo-4,6-
dimethyl aniline[316] (0.81 g, 3.3 mmol, 1 eq.), PdCl2(PPh3)2 (46 mg,  
0.066 mmol, 2 mol%) and CuI (31 mg, 0.16 mmol, 5 mol%) in Et3N (11 
mL, 0.3 M), followed by 2-ethynyl-4,6-dimethylaniline (3.3 mmol, 1.0 eq.) at 90 °C for 18 h. Purification 
by flash column chromatography yielded the title compound (0.38 g, 43%) as a brown oil.  
δ1H (400 MHz, CDCl3) 7.08 (2 H, br. s, H-4), 6.87 (2 H, br. s, H-2), 4.12 (4 H, br. s, NH), 2.22 (6 H, s, H-
8), 2.17 (6 H, s, H-7). δ13C (101 MHz, CDCl3) 143.6 (C-6), 131.9 (C-2), 129.9 (C-4), 127.0 (C-8), 122.0 (C-
1), 108.1 (C-5), 91.3 (C-9), 20.4 (C-8), 17.7 (C-7). IR (film, cm-1) νmax 3415 (N–H), 3329 (N–H), 1625, 






1-(2-Iodo-4,6-dimethylphenyl)-3-methyl-1,3-dihydro-2H-imidazol-2-one – 5.44a 
To a solution of 2-iodo-4,6-dimethylaniline[316] (0.60 g, 2.4 mmol, 1 eq.) in CH2Cl2  
(6 mL, 0.4 M) at -78 °C was added pyridine (0.23 mL, 2.9 mmol, 1.2 eq.), followed by 
triphosgene (0.33 g, 1.1 mmol, 0.45 eq.). The reaction mixture was allowed to warm 
up to rt and stirred for 2 h. The reaction mixture was concentrated in vacuo, dissolved 
in CH2Cl2 (24 mL, 0.1 M) and (methylamino)acetaldehyde dimethyl acetal (0.46 mL, 
1.5 eq.). The reaction mixture was heated under reflux for 24 h, concentrated in vacuo, diluted in ethyl 
acetate, and washed with sat. NaHCO3 (aq.), sat. NH4Cl (aq.) and brine. The organic phase was dried 
over MgSO4, filtered, and concentrated in vacuo. The crude residue was dissolved in chloroform (8 mL, 
0.25 M) with TFA (0.38 mL, 5.1 mmol, 2.1 eq.), heated to 60 °C for 4 h and concentrated in vacuo. 
Purification by flash column chromatography yielded the title compound  
(0.63 g, 80%) as an off-white solid. m.p.: 136 – 138 °C. δ1H (400 MHz, CDCl3) 7.67 – 7.53 (1 H, m, H-4), 
7.14 – 6.87 (1 H, m, H-2), 6.33 (1 H, d, J = 2.9 Hz, H-10), 6.14 (1 H, d, J = 2.9 Hz, H-9), 3.34 (3 H, s,  
H-12), 2.29 (3 H, s, H-8), 2.16 (3 H, s, H-7). δ13C (101 MHz, CDCl3) 151.8 (C-11), 140.9 (C-3),  
138.4 (C-1), 137.7 (C-4), 135.7 (C-6), 131.8 (C-2), 112.6 (C-10), 111.0 (C-9), 99.3 (C-5), 30.9 (C-12),  
20.7 (C-8), 19.1 (C-7). IR (film, cm-1) νmax 1682 (C=O), 1481. HRMS (ESI+) m/z calcd for C12H13N2OINa+ 
[M+Na]+ 350.9965; found: 350.9981. 
Methyl 2-(N-(2-iodo-4,6-dimethylphenyl)sulfamoyl)benzoate – 5.45 
To a solution of 2-iodo-4,6-dimethylaniline[316] (0.60 g, 2.4 mmol, 1.0 eq.) in pyridine 
(12 mL, 0.2 M) was added methyl 2-(chlorosulfonyl)benzoate (0.63 g, 2.7 mmol,  
1.1 eq.) under an atmosphere of nitrogen. The reaction mixture was stirred at 60 °C 
for 72 h and concentrated in vacuo. The reaction mixture was diluted in ethyl 
acetate and washed with 1M HCl (aq.), brine, dried over MgSO4, filtered, and 
concentrated in vacuo. Purification by flash column chromatography yielded the 
title compound (0.40 g, 37%) as an off-white solid. m.p.: 136 – 138 °C.  
δ1H (400 MHz, CDCl3) 7.96 (1 H, br. s, NH), 7.93 – 7.85 (2 H, m, H-12 + H-13),  
7.64 (1 H, td, J = 7.7, 1.6 Hz, H-10), 7.59 (1 H, td, J = 7.6, 1.5 Hz, H-14), 7.43 (1 H, br. s, H-4),  
7.04 (1 H, br. s, H-2), 4.05 (3 H, s, H-16), 2.42 (3 H, s, H-7), 2.24 (3 H, s, H-8). δ13C (101 MHz, CDCl3)  
168.3 (C-15), 142.2 (C-9), 140.2 (C-6), 139.5 (C-3), 137.9 (H-4), 134.9 (C-1), 132.5 (C-10), 132.3 (C-2), 
132.2 (C-14), 130.7 (C-12), 130.4 (C-11), 129.1 (C-13), 99.4 (C-5), 53.6 (C-16), 20.7 (C-7), 20.5 (C-8).  
IR (film, cm-1) νmax 3268 (N–H), 1717 (C=O), 1459, 1294, 1170 (S=O). HRMS (ESI+) m/z calcd for 
C16H16N2OSNa+ [M+Na]+ 467.9737; found: 467.9744. 
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2-(2Iodo-4,6-dimethylphenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide - 5.44b 
To a suspension of LiAlH4 (70 mg, 1.8 mmol, 2.1 eq.) in THF (14 mL), at 0 °C under a 
nitrogen atmosphere was added dropwise a solution of methyl 2-(N-(2-iodo-4,6-
dimethylphenyl)sulfamoyl) benzoate 5.45 (0.39 g, 0.88 mmol, 1.0 eq.) in THF (9 mL, 
0.1 M). The reaction was stirred for 2 h at 0 °C and then quenched with water. The 
reaction was filtered through Celite, diluted in ethyl acetate and washed with 1M 
NaOH (aq.), brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude 
product was dissolved in THF (11 mL, 0.08 M), and PBr3 (0.42 mL, 4.4 mmol, 5.0 eq.) 
was added dropwise at 0 °C under a nitrogen atmosphere. The reaction was stirred for 5 min at 0 °C 
and 1 h at rt, and then quenched with sat. Na2CO3 (aq,) and stirred overnight. The aqueous phase was 
extracted with EtOAc. The combined organic phases were washed with brine, dried with Na2SO4 and 
concentrated in vacuo. Purification by flash column chromatography yielded the title compound  
(0.16 g, 45%) as a brown solid. m.p.: 180 °C (degradation). δ1H (400 MHz, CDCl3)  
7.87 (1 H, dt, J = 7.7, 0.9 Hz, H-12), 7.65 (1 H, td, J = 7.6, 1.3 Hz, H-14), 7.63 – 7.62 (1 H, m, H-4),  
7.58 (1 H, td, J = 7.6, 1.0 Hz, H-13), 7.46 (1 H, dt, J = 7.8, 0.9 Hz, H-15), 7.12 – 7.08 (1 H, m, H-2),  
4.94 (CHAHB, 1 H, d, J = 13.9 Hz, H-11), 4.69 (CHAHB, 1 H, d, J = 13.9 Hz, H-11), 2.47 (3 H, s, H-7),  
2.29 (3 H, s, H-8). δ13C (101 MHz, CDCl3) 142.4 (C-6), 141.5 (C-3), 138.9 (C-4), 135.8 (C-9), 133.4 (C-10), 
133.0 (C-1), 132.7 (C-14), 132.5 (C-2), 129.3 (C-13), 124.5 (C-15), 121.6 (C-12), 102.5 (C-5), 51.2 (C-11), 
20.7 (C-8), 20.0 (C-7). IR (film, cm-1) νmax 1458, 1292 (S=O), 1170 (S=O). HRMS (ESI+) m/z calcd for 
C15H14NO2IS+ [M+Na]+ 421.9682; found: 421.9686. 
3-(2-Iodo-4,6-dimethylphenyl)oxazolidin-2-one – 5.44c 
To a solution of 2-iodo-4,6-dimethylaniline[316] (0.60 g, 2.4 mmol, 1.0 eq.) in CH2Cl2  
(12 mL, 0.2 M) was added 2-chloroethyl chloroformate (0.30 mL, 2.9 mmol, 1.2 eq.) 
and pyridine (0.58 mL, 7.2 mmol, 3.0 eq.) under an atmosphere of nitrogen. The 
reaction mixture was stirred at rt for 20 h, and DBU (1.1 mL, 7.2 mmol, 3.0 eq.) was 
added dropwise. The reaction mixture was stirred at rt for 3 h and concentrated in 
vacuo. The crude mixture was diluted in ethyl acetate and washed with 1M NaOH 
(aq.), brine, dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography yielded the title compound (0.70 g, 92%) as an off-white solid. m.p.: 150 – 151 °C.  
δ1H (400 MHz, CDCl3) 7.67 – 7.46 (1 H, m, H-4), 7.17 – 6.89 (1 H, m, H-2), 4.62 – 4.44 (2 H, m, H-10),  
4.04 (CHAHB, 1 H, ddd, J = 9.0, 8.4, 6.0 Hz, H-11), 3.76 (CHAHB, 1 H, dt, J = 9.1, 8.2 Hz, H-11),  
2.30 (3 H, s, H-7), 2.26 (3 H, s, H-8). δ13C (101 MHz, CDCl3) 156.2 (C-9), 140.9 (C-3), 138.4 (C-1),  
137.9 (C-6), 134.8 (C-4), 132.2 (C-2), 99.6 (C-5), 62.8 (C-10), 45.8 (C-11), 20.6 (C-8), 18.9 (C-7).  
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IR (film, cm-1) νmax 1745 (C=O), 1477, 1406, 1225 (C–N), 1106. HRMS (ESI+) m/z calcd for C11H12NO2INa+ 
[M+Na]+ 339.9805; found: 339.9815. 
1-(2,4-Dimethyl-6-((trimethylsilyl)ethynyl)phenyl)-3-methyl-1,3-dihydro-2H-imidazol-2-one 
5.46a 
Following GP5.3 using 1-(2-iodo-4,6-dimethylphenyl)-3-methyl-1,3-dihydro-
2H-imidazol-2-one 5.44a (0.29 g, 0.88 mmol, 1.0 eq.), PdCl2(PPh3)2 (12.3 mg,  
0.018 mmol, 2 mol%) and CuI (8.4 mg, 0.044 mmol, 5 mol%) in Et3N (3.0 mL,  
0.3 M), followed by ethynyltrimethylsilane (0.24 mL, 1.8 mmol, 2.0 eq.) at  
90 °C for 20 h. Purification by flash column chromatography yielded the title 
compound (0.17 g, 65%) as a yellow oil. δ1H (400 MHz, CDCl3) 7.18 (1 H, dt, J = 2.0, 0.6 Hz, H-4),  
7.06 (1 H, dt, J = 2.1, 0.7 Hz, H-2), 6.28 (1 H, d, J = 2.9 Hz, H-13), 6.26 (1 H, d, J = 3.0 Hz, H-12),  
3.33 (3 H, s, H-15), 2.29 (3 H, s, H-8), 2.17 (3 H, s, H-7), 0.13 (9 H, s, H-11). δ13C (101 MHz, CDCl3)  
152.2 (C-14), 138.3 (C-3), 137.0 (C-1), 135.2 (C-6), 132.1 (C-2), 131.1 (C-4), 122.7 (C-5),  
112.1 (C-12 or C-13), 111.7 (C-12 or C-13), 101.5 (C-9), 98.9 (C-10), 30.7 (C-15), 21.0 (C-8), 18.1 (C-7),  
-0.1 (C-11). IR (film, cm-1) νmax 2957 (C–H), 1689 (C=O), 1483, 1249 (C–Si). HRMS (ESI+) m/z calcd for 
C17H22N2OSiNa+ [M+Na]+ 321.1394; found: 321.1398. 
1-(2-Ethynyl-4,6-dimethylphenyl)-3-methyl-1,3-dihydro-2H-imidazol-2-one 
Following GP5.2 using 1-(2,4-dimethyl-6-((trimethylsilyl)ethynyl)phenyl)-3-
methyl-1,3-dihydro-2H-imidazol-2-one 5.46a (0.17 g, 0.57 mmol, 1.0 eq.) and 
K2CO3 (0.12 g, 0.85 mmol, 1.5 eq.) in MeOH (1.2 mL, 0.5M) for 2.5 h. Purification 
by flash column chromatography yielded the title compound (0.11 g, 82%) as a 
yellow oil. δ1H (400 MHz, CDCl3) 7.23 – 7.19 (1 H, d, J = 2.2 Hz, H-4),  
7.09 – 7.05 (1 H, d, J = 2.2 Hz, H-2), 6.30 (1 H, d, J = 3.0 Hz, H-12), 6.24 (1 H, d, J = 2.9 Hz, H-11), 3.31 (3 
H, s, H-14), 3.04 (1 H, s, H-10), 2.29 (3 H, s, H-8), 2.14 (3 H, s, H-7). δ13C (101 MHz, CDCl3) 152.2 (C-13),  
138.4 (C-3), 137.0 (C-1), 135.0 (C-6), 132.4 (C-2), 131.8 (C-4), 121.6 (C-5), 112.1 (C-12), 111.7 (C-11), 
81.2 (C-10), 80.2 (C-9), 30.7 (C-14), 20.9 (C-8), 18.0 (C-7). IR (film, cm-1) νmax 3287 (C≡C–H),  
3203 (C=C–H), 2924 (C–H), 1681 (C=O), 1485, 1457, 1406, 1258. HRMS (ESI+) m/z calcd for 




2-one) – 5.47a 
Following GP5.3 using 1-(2-iodo-4,6-dimethylphenyl)-3-methyl-1,3-
dihydro-2H-imidazol-2-one (0.14 g, 0.44 mmol, 1 eq.), PdCl2(PPh3)2  
(6.2 mg, 0.0088 mmol, 2 mol%) and CuI (4.2 mg, 0.022 mmol, 5 mol%) 
in Et3N (1.5 mL, 0.3 M), followed by 1-(2-ethynyl-4,6-dimethylphenyl)-3-
methyl-1,3-dihydro-2H-imidazol-2-one (0.10 g, 0.44 mmol, 1 eq.) at 90 
°C for 24 h. Purification by flash column chromatography yielded the title compound (31 mg, 16%) as 
a light brown solid. m.p.: 205 °C (degradation). Mixture of conformer in a 1:0.45 ratio in CDCl3.  
δ1H (400 MHz, CDCl3) 7.11 – 7.07 (2 Hmin, m, H-4min), 7.05 (2 Hmaj + 2 Hmin, dt, J = 2.2, 0.7 Hz, H-2),  
7.03 – 6.98 (2 Hmaj, m, H-4), 6.31 (2 Hmaj, d, J = 3.0 Hz, H-11), 6.26 (2 Hmin, d, J = 3.0 Hz, H-11),  
6.24 (2 Hmin, d, J = 3.0 Hz, H-12), 6.23 (2 Hmaj, d, J = 3.0 Hz, H-12), 3.33 (6 Hmin, s, H-13), 3.32 (6 Hmaj, s, 
H-13), 2.29 (6 Hmaj + 6 Hmaj, s, H-8), 2.18 (6 Hmaj, s, H-7), 2.16 (6 Hmin, s, H-7). δ13C (101 MHz, CDCl3)  
152.2 (C-10maj), 152.1 (C-10min), 138.1 (C-3min), 138.0 (C-3maj), 137.0 (C-1min), 136.9 (C-1maj),  
134.4 (C-6maj), 134.3 (C-6min), 132.1 (C-2maj + C-2min), 131.2 (C-4min), 131.0 (C-4maj), 122.4 (C-5min),  
122.3 (C-5maj), 112.3 (C-12maj), 112.0 (C-12min), 111.9 (C-11min), 111.8 (C-11maj), 90.2 (C-9maj),  
89.9 (C-9min), 30.84 (C-13maj), 30.76 (C-13min), 21.01 (C-8maj), 20.99 (C-8min), 18.20 (C-7maj), 18.18 (C-7min). 
IR (film, cm-1) νmax 1683 (C=O), 1486, 1456. HRMS (ESI+) m/z calcd for C26H26N4O2Na+ [M+Na]+ 
449.1948; found: 449.1948. 
3-(2,4-Dimethyl-6-((trimethylsilyl)ethynyl)phenyl)oxazolidin-2-one – 5.46b 
Following GP5.3 using 3-(2-iodo-4,6-dimethylphenyl)oxazolidin-2-one  5.44c 
(0.35 g, 1.1 mmol, 1.0 eq.), PdCl2(PPh3)2 (15.4 mg, 0.022 mmol, 2 mol%) and 
CuI (10.5 mg, 0.055 mmol, 5 mol%) in Et3N (3.7 mL, 0.3 M), followed by 
ethynyltrimethylsilane (0.30 mL, 2.2 mmol, 2.0 eq.) at 90 °C for 24 h. 
Purification by flash column chromatography yielded the title compound  
(0.21 g, 66%) as a yellow oil. δ1H (400 MHz, CDCl3) 7.20 – 7.13 (1 H, m, H-4), 7.06 – 6.97 (1 H, m, H-2), 
4.57 – 4.35 (2 H, m, H-13), 4.15 (CHAHB, 1 H, ddd, J = 9.1, 8.3, 7.3 Hz, H-14),  
3.73 (CHAHB, 1 H, ddd, J = 8.9, 8.3, 6.6 Hz, H-14), 2.26 (3 H, s, H-8), 2.24 (3 H, s, H-7), 0.23 (9 H, s,  
H-11). δ13C (101 MHz, CDCl3) 156.8 (C-12), 138.4 (C-3), 137.3 (C-1 or C-6), 134.9 (C-1 or C-6),  
132.4 (C-2), 131.6 (C-4), 122.5 (C-5), 101.4 (C-9), 99.2 (C-10), 62.8 (C-13), 46.3 (C-14), 20.9 (C-8),  
17.8 (C-7), 0.01 (C-11).IR (film, cm-1) νmax 2155 (C≡C), 1750 (C=O), 1479, 1405, 1248, 1221 (C–N).  
HRMS (ESI+) m/z calcd for C16H21NO2SiNa+ [M+Na]+ 310.1234; found: 310.1246. 
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3,3'-Dimethyl-[1,1'-biphenyl]-2,2'-diamine – 5.49 
Pd/C (10 wt. % loading, 35 mg, 1 mol%/Pd) was suspended in a solution of  
3,3'-dimethyl-2,2'-dinitro-1,1'-biphenyl 5.48[299] (0.35 g, 1.3 mmol, 1.0 eq.) in 
MeOH (13 mL, 0.1 M) under nitrogen. Nitrogen was bubbled through the 
solution for 15 mins. The contents of the flask were placed under a hydrogen 
atmosphere using a two-way three-necked tap with a balloon of hydrogen attached. The solution was 
saturated with hydrogen three times using a vacuum/hydrogen cycle and was stirred under a 
hydrogen atmosphere for 20 h. The crude reaction solution was filtered through a pad of Celite and 
washed with MeOH. The resulting filtrate was concentrated in vacuo and purified by flash column 
chromatography to give the title product (96 mg, 35%) as an off-white solid m.p.: 245 – 247 °C.  
δ1H (400 MHz, CDCl3) 7.09 (2 H, dd, J = 7.4, 1.7 Hz, H-2), 7.01 (2 H, dd, J = 7.6, 1.6 Hz, H-4),  
6.77 (2 H, t, J = 7.5 Hz, H-3), 3.62 (4 H, br. s, NH2), 2.24 (6 H, s, H-7). δ13C (101 MHz, CDCl3) 142.6 (C-6), 
130.0 (C-2), 128.8 (C-4), 124.5 (C-5), 122.6 (C-1), 118.4 (C-3), 18.0 (C-7). IR (film, cm-1) νmax  
3484 (N–H), 3393 (N–H), 1525, 1364. HRMS (ESI+) m/z calcd for C14H17N2+ [M+H]+ 213.1386; found: 
213.1382. 
2,2'-(3,3'-Dimethyl-[1,1'-biphenyl]-2,2'-diyl)bis(isoindolin-1-one) – 5.50 
To a solution of 3,3'-dimethyl-[1,1'-biphenyl]-2,2'-diamine 5.49 (0.85 mg,  
0.4 mmol, 1 eq.) in CH2Cl2 (4.0 mL, 0.1 M) was added 2-(chloromethyl)benzoyl 
chloride 5.21 (0.14 mL, 1.0 mmol, 2.5 eq.) and Et3N (0.17 mL, 1.2 mmol,  
3.1 eq.) at rt under an atmosphere of nitrogen. The reaction mixture was 
stirred at rt for 18h. The reaction mixture was washed with 1M HCl (aq.), 
brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude 
residue obtained was dissolved in CH2Cl2 (4.0 mL, 0.1 M) and DBU (0.18 mL, 
1.2 mmol, 3.1 eq.) was added. The reaction mixture stirred at rt for 20 h, diluted in ethyl acetate and 
washed with 1M HCl (aq.), brine, dried over MgSO4, filtered, and concentrated in vacuo. Purification 
by flash column chromatography yielded the title compound (90 mg, 51%) as a white solid.  
m.p.: 225 – 227 °C. Mixture of conformers in a 1:1 ratio. δ1H (500 MHz, CDCl3) 7.92 (1 H, d, J = 7.5 Hz, 
ArCH), 7.86 (1 H, d, J = 7.8 Hz, ArCH), 7.55 (1 H, t, J = 7.5 Hz, ArCH), 7.51 – 7.42 (3 H, m, ArCH),  
7.41 – 7.36 (1 H, m, ArCH), 7.33 (1 H, d, J = 7.3 Hz, ArCH), 7.28 – 7.27 (1 H, m, ArCH),  
7.14 (2 H, d, J = 7.5 Hz, ArCH), 7.09 – 7.02 (2 H, m, ArCH), 6.80 (1 H, t, J = 7.6 Hz, ArCH),  
5.32 (CHAHB, 1 H, d, J = 14.2 Hz, NCH2), 5.17 (CHAHB, 1 H, d, J = 14.6 Hz, NCH2),  
4.44 (CHAHB, 1 H, d, J = 17.3 Hz, NCH2), 4.28 (CHAHB, 1 H, d, J = 17.3 Hz, NCH2), 2.21 (3 H, s, CH3),  
2.17 (3 H, s, CH3). δ13C (126 MHz, CDCl3) 168.7 (C=O), 157.9 (ArC), 144.3 (ArC), 143.5 (ArC), 142.4 (ArC), 
139.7 (ArC), 137.0 (ArC), 134.7 (ArC), 132.4 (ArC), 132.0 (ArCH), 132.0 (ArCH), 131.3 (ArCH),  
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129.9 (ArC), 129.6 (ArCH), 128.9 (ArCH), 128.8 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.3 (ArCH), 124.3 
(ArCH), 124.2 (ArCH), 123.3 (ArCH), 122.8 (ArCH), 121.6 (ArCH), 72.4 (NCH2), 51.3 (NCH2),18.6 (2*CH3). 
IR (film, cm-1) νmax 2971 (C–H), 1693 (C=O), 1468. HRMS (ESI+) m/z calcd for C30H25N2O2+ [M+H]+ 
445.1910; found: 445.1919. 
2,2'-(Buta-1,3-diyne-1,4-diylbis(4,6-dimethyl-2,1-phenylene))bis(isoindolin-1-one) – 5.51 
A microwave vial was filled with nitrogen. To this was added 2-(2-
ethynyl-4,6-dimethylphenyl)isoindolin-1-one (50 mg, 0.19 mmol, 
1.0 eq.), CuI (3.6 mg, 0.019 mmol, 10 mol%), and pyrrolidine  
(16 μL, 0.19mmol, 1.0 eq.) in CH2Cl2 (0.4 mL, 0.5 M) and the 
reaction mixture was allowed to stir at rt for 2 h in an open vial. 
The reaction mixture was directly purified by flash column 
chromatography to give the title compound (50 mg, quantitative) as a brown solid. m.p.: 113 – 115 °C. 
Mixture of conformer in a 1:0.7 ratio in CDCl3. δ1H (400 MHz, CDCl3) 7.95 (2 Hmaj, dt, J = 7.6, 1.0 Hz,  
H-14), 7.88 (2 Hmin, dt, J = 7.4, 1.0 Hz, H-14), 7.61 (2 Hmaj, td, J = 7.5, 1.2 Hz, H-16),  
7.57 (2 Hmin, td, J = 7.5, 1.2 Hz, H-16), 7.53 (2 Hmaj, dd, J = 7.4, 1.1 Hz, H-17),  
7.51 – 7.46 (2 Hmaj + 2 Hmin, m, H-15), 7.43 (2 Hmin, dt, J = 7.5, 1.0 Hz, H-17), 7.20 (2 Hmin, d, J = 2.0 Hz, 
H-4), 7.15 – 7.05 (4 Hmaj + 2 Hmin, m, H-2maj + H-4maj + H-2min), 4.96 (CHAHB, 2 Hmaj, d, J = 16.8 Hz, H-13),  
4.89 (CHAHB, 2 Hmin, d, J = 16.7 Hz, H-13), 4.44 (CHAHB, 2 Hmaj, d, J = 16.7 Hz, H-13),  
4.40 (CHAHB, 2 Hmin, d, J = 16.7 Hz, H-13), 2.29 (6 Hmin, s, H-8), 1.28 (6 Hmaj, s, H-8), 2.14 (6 Hmaj, s, H-7), 
2.13 (6 Hmin, s, H-7). δ13C (101 MHz, CDCl3) 168.0 (C-10maj), 167.9 (C-10min), 142.1 (C-12maj),  
142.0 (C-12min), 138.2 (C-1maj + C-1min), 137.54 (C-3maj), 137.52 (C-3min), 136.7 (C-6maj), 136.6 (C-6min), 
133.2 (C-2min), 133.1 (C-2maj), 132.8 (C-4min), 132.5 (C-4maj), 132.2 (C-11maj), 132.1 (C-11min),  
131.84 (C-16maj), 131.77 (C-16min), 128.15 (C-15min), 128.11 (C-15maj), 124.4 (C-14min), 124.3 (C-14maj), 
123.2 (C-17maj), 122.9 (C-17min), 121.27 (C-5min), 121.26 (C-5maj), 79.3 (C-9min), 79.2 (C-9maj),  
77.4 (C-18min), 77.3 (C-18maj), 51.7 (C-13maj), 51.6 (C-13min), 20.9 (C-8maj + C-8min), 18.2 (C-7maj + C-7min). 
IR (film, cm-1) νmax 3672, 2972 (C–H), 2922 (C–H), 1696 (C=O), 1468, 1384. HRMS (ESI+) m/z calcd for 
C36H28N2O2Na+ [M+Na]+ 543.2043; found: 543.2029. Supplementary crystallographic data can be 




phenylene)) bis(isoindolin-1-one) – 5.52 
Following GP5.3 using 4-(tert-butyl)-2,5-diiodo-toluene[320] 
(73 mg, 0.18 mmol, 1 eq.), PdCl2(PPh3)2 (2.5 mg, 3.6 μmol, 
2 mol%) and CuI (1.7 mg, 8.9 μmol, 5 mol%) in Et3N (0.6 mL, 
0.3 M), followed by 2-(2-ethynyl-4,6-dimethylphenyl) 
isoindolin-1-one 5.25 (100 mg, 0.38 mmol, 2.1 eq.) at 90 °C 
for 19 h. Purification by flash column chromatography 
yielded the title compound (75 mg, 61%) as an off-white 
solid. m.p.: 158 – 161 °C. Mixture of conformers in a 1:1 ratio in CDCl3; consequently, some peaks of 
the 13C spectrum are doubled. δ1H (400 MHz, CDCl3) 7.97 (2 H, dd, J = 7.5, 1.0 Hz, H-14),  
7.59 (2 H, tdd, J = 7.4, 4.8, 1.3 Hz, H-16), 7.54 – 7.51 (2 H, m, H-15), 7.53 – 7.44 (2 H, m, H-17),  
7.31 – 7.28 (2 H, m, H-4), 7.17 – 7.11 (2 H, m, H-2), 6.85 (1 H, s, H-22), 6.79 (1 H, s, H-22),  
5.05 (CHAHB, 2 H, d, J = 16.8 Hz, H-13), 4.54 (CHAHB, 2 H, d, J = 16.8 Hz, H-13), 2.36 (6 H, s, H-8),  
2.23 (6 H, s, H-7), 2.04 (1.5 H, s, H-24), 1.94 (1.5 H, s, H-24), 0.93 (4.5 H, s, H-25), 0.89 (4.5 H, s, H-25). 
δ13C (126 MHz, CDCl3) 168.0 (C-10), 148.25 (C-21), 148.23 (C-21), 142.09 (C-12), 142.06 (C-12),  
138.54 (C-20), 138.52 (C-20), 138.3 (C-3), 137.5 (C-1), 135.68 (C-6), 135.64 (C-6), 132.53 (C-11),  
132.52 (C-11), 132.1 (C-2), 131.90 (C-16), 131.86 (C-16), 131.25 (C-4), 131.21 (C-4), 129.5 (C-22), 
128.33 (C-15), 128.28 (C-15), 124.5 (C-14), 124.4 (C-14), 122.98 (C-17), 122.94 (C-5 or C-19),  
122.92 (C-17), 122.8 (C-5 or C-19), 92.32 (C-18), 92.29 (C-18), 89.6 (C-9), 51.6 (C-13), 33.94 (C-23), 
33.89 (C-23), 30.92 (C-25), 30.89 (C-25), 21.1 (C-8), 18.2 (C-7), 18.0 (C-24), 17.9 (C-24).  
IR (film, cm-1) νmax 2956 (C–H), 2923 (C–H), 1698 (C=O), 1469, 1386. HRMS (ESI+) m/z calcd for 
C47H43N2O2Na+ [M+Na]+ 689.3138; found: 689.3133. 
2,2'-((Pyridine-2,6-diylbis(ethyne-2,1-diyl))bis(4,6-dimethyl-2,1-phenylene))bis(isoindolin-1-
one) – 5.53 
Following GP5.3 using 2-(2-ethynyl-4,6-dimethylphenyl) 
isoindolin-1-one 5.25 (100 mg, 0.38 mmol, 2.1 eq.), 
PdCl2(PPh3)2 (2.5 mg, 0.0036 mmol, 2 mol%) and CuI  
(1.7 mg, 8.9 μmol, 5 mol%) in Et3N (0.6 mL, 0.3 M), followed 
by 2,5-dibromopyridine (43 mg, 0.18 mmol, 1 eq.) at 90 °C 
for 15 h. Purification by flash column chromatography 
followed by trituration in Et2O yielded the title compound (18 mg, 17%) as a yellow solid. Mixture of 
conformers in a 1:0.85 ratio in CDCl3. δ1H (400 MHz, CDCl3) 7.97 (2 Hmin, d, J = 3.9 Hz, H-14),  
7.96 (2 Hmaj, d, J = 3.9 Hz, H-14), 7.62 – 7.55 (2 Hmaj + 2Hmin, qd, J = 7.2, 1.2 Hz, H-16),  
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7.54 – 7.45 (4 Hmaj + 4Hmin, m, H-15 + H-17), 7.35 (2 Hmaj + 2Hmin, d, J = 2.1 Hz, H-4),  
7.17 (2 Hmaj + 2Hmin, d, J = 1.9 Hz, H-2), 7.12 (1 Hmin, t, J = 7.9 Hz, H-20), 7.06 (1 Hmaj, t, J = 7.8 Hz, H-20), 
6.56 (2 Hmin, d, J = 7.8 Hz, H-21), 6.44 (2 Hmaj, d, J = 7.8 Hz, H-21), 5.05 (CHAHB, 2 Hmin, d, J = 16.9 Hz, H-
13), 5.02 (CHAHB, 2 Hmaj, d, J = 16.9 Hz, H-13), 4.59 (CHAHB, 2 Hmaj, d, J = 16.9 Hz, H-13),  
4.55 (CHAHB, 2 Hmin, d, J = 16.9 Hz, H-13), 2.35 (6 Hmaj + 6 Hmin, s, H-8), 2.24 (6 Hmaj, s, H-7),  
2.24 (6 Hmin, s, H-7). δ13C (126 MHz, CDCl3) 168.3 (C-10maj), 168.2 (C-10min), 143.30 (C-19min),  
143.26 (C-19maj), 142.24 (C-12min), 142.22 (C-12maj), 138.49 (C-3maj), 138.46 (C-3min), 137.6 (C-6maj+min), 
136.6 (C-1maj), 136.5 (C-1min), 136.09 (C-20maj), 136.08 (C-20min), 133.02 (C-2maj+min), 132.42 (C-11min), 
132.37 (C-11maj), 131.88 (C-16min), 131.80 (C-16maj), 131.79 (C-4maj), 131.75 (C-4min), 128.23 (C-15maj), 
128.20 (C-18min), 126.3 (C-21min), 126.2 (C-21maj), 124.51 (C-14min), 124.46 (C-14maj), 123.2 (C-17maj), 
123.1 (C-17min), 121.7 (C-5maj+min), 91.96 (C-18min), 91.93 (C-18maj), 86.49 (C-9min), 86.46 (C-9maj),  
51.92 (C-13maj), 51.88 (C-13min), 21.13 (C-8maj), 21.11 (C-8min), 18.23 (C-7min), 18.20 (C-7maj).  
IR (film, cm-1) νmax 2923 (C–H), 1697 (C=O), 1469, 1449, 1385, 1066. HRMS (ESI+) m/z calcd for 
C41H32N3O2+ [M+H]+ 598.2489; found: 598.2481. 
2,2'-(((3,6-Di-tert-butyl-9H-carbazole-1,8-diyl)bis(ethyne-2,1-diyl))bis(4,6-dimethyl-2,1-
phenylene))bis(isoindolin-1-one)– 5.54a 
Following GP5.3 using 3,6-di-tert-butyl-1,8-diiodo-
9H-carbazole[321] (69 mg, 0.13 mmol, 1.0 eq.), 
PdCl2(PPh3)2 (3.6 mg, 5.2 μmol, 4 mol%) and CuI  
(2.5 mg, 0.013 mmol, 10 mol%) in Et3N (0.45 mL,  
0.3 M), followed by 2-(2-ethynyl-4,6-dimethyl 
phenyl)isoindolin-1-one 5.25 (70 mg, 0.27 mmol,  
2.1 eq.) at 90 °C for 16 h. Purification by flash column 
chromatography yielded the title compound (60 mg, 
58%) as a yellow solid. m.p.: 213 °C (degradation). Mixture of conformers in a 1:0.35 ratio in CDCl3; 
some peaks overlap in the 13C spectrum. δ1H (500 MHz, CDCl3) 10.59 (1 Hmaj, s, NH), 10.22 (1 Hmin, s, 
NH), 8.15 (2 Hmaj, d, J = 7.7 Hz, H-14), 8.10 (2 Hmin, d, J = 7.6 Hz, H-14),  
7.91 (2 Hmaj + 2 Hmin, d, J = 2.0 Hz, H-24), 7.64 (2 Hmaj + 2 Hmin, d, J = 1.9 Hz, H-4),  
7.58 – 7.44 (2 Hmaj + 4 Hmin, m, H-16 + H-17min), 7.47 (2 Hmaj, d, J = 7.4 Hz, H-17),  
7.43 (2 Hmaj + 2 Hmin, t, J = 5.9 Hz, H-15), 7.13 (2 Hmin, d, J = 1.9 Hz, H-2), 7.11 (2 Hmaj, d, J = 1.9 Hz, H-2), 
7.08 (2 Hmaj, d, J = 2.0 Hz, H-22), 7.03 (2 Hmin, d, J = 2.0 Hz, H-22), 5.03 (CHAHB, 2 Hmin, d, J = 16.7 Hz,  
H-13), 4.95 (CHAHB, 2 Hmaj, d, J = 16.8 Hz, H-13), 4.74 (CHAHB, 2 Hmin, d, J = 16.8 Hz, H-13),  
4.71 (CHAHB, 2 Hmaj, d, J = 16.8 Hz, H-13), 2.31 (12 Hmaj, s, H-7 + H-8), 2.29 (12 Hmin, s, H-7 + H-8), 
 1.25 (18 Hmaj, s, H-26), 1.24 (18 Hmin, s, H-26). δ13C (126 MHz, CDCl3) 169.0 (C-10maj), 168.7 (C-10min), 
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142.2 (C-12min), 142.1 (C-12maj), 141.9 (C-23min), 141.8 (C-23maj), 139.3 (C-20maj), 139.2 (C-20min),  
138.2 (C-1min or C-3min), 138.1 (C-1maj or C-3maj), 136.7 (C-1min or C-3min), 136.6 (C-1maj or C-3maj),  
135.84 (C-6maj), 135.82 (C-6min), 132.7 (C-11min), 132.5 (C-11maj), 131.9 (C-2min or C-16min),  
131.8 (C-2maj or C-16maj), 131.82 (C-2maj or C-16maj), 131.77 (C-2min or C-16min), 131.69 (C-4min),  
131.67 (C-4maj), 128.7 (C-15maj), 128.4 (C-15min), 126.96 (C-22maj), 126.95 (C-22min), 125.0 (C-14maj), 
124.9 (C-14min), 123.22 (C-5maj), 123.19 (C-5min), 123.16 (C-21maj+min), 122.93 (C-17min), 122.88 (C-17maj), 
117.4 (C-24min), 117.3 (C-24maj), 105.0 (C-19maj+min), 91.1 (C-18maj), 91.0 (C-18min), 90.3 (C-9maj+min),  
52.2 (C-13maj), 52.1 (C-13min), 34.5 (C-25maj+min), 31.9 (C-26maj+min), 21.1 (C-8maj+min), 18.24 (C-7min),  
18.22 (C-7maj). IR (film, cm-1) νmax 2959 (C–H), 1684 (C=O), 1479, 1389. HRMS (ESI+) m/z calcd for 
C56H52N3O2+ [M+H]+ 798.4054; found: 798.4053. 
3,6-Di-tert-butyl-1,8-diiodo-9-methyl-9H-carbazole 
To a solution of 3,6-di-tert-butyl-1,8-diiodo-9H-carbazole[321] (0.30 g,  
0.57 mmol, 1.0 eq.) in DMF (2.8 mL, 0.2 M) was added NaH (44 mg, 1.1 
mmol, 2.0 eq., 60% in mineral oil) and the green solution was stirred at 
rt for 10 minutes. Methyl iodide (69 μL, 1.1 mmol, 2.0 eq.) was added 
and the reaction mixture was stirred at 40 °C for 5 h, during which the 
solution went from green to yellow to a white suspension. The reaction mixture was diluted in ethyl 
acetate, washed with LiCl (5% aq.), brine, dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by trituration in Et2O yielded the title compound (0.31 g, quant.) as a white solid.  
m.p.: 191 – 193 °C. δ1H (500 MHz, CDCl3) 7.97 (1 H, d, J = 1.8 Hz, H-3), 7.95 (1 H, d, J = 1.8 Hz, H-5),  
4.31 (3 H, s, H-9), 1.43 (18 H, s, H-8). δ13C (101 MHz, CDCl3) 145.4 (C-4), 142.4 (C-2), 137.0 (C-5),  
126.0 (C-1), 116.2 (C-3), 74.4 (C-6), 37.1 (C-9), 34.6 (C-7), 31.9 (C-8). IR (film, cm-1) νmax 1960, 1479, 
1285, 1178. No major peak could be found by HRMS (ESI, EI, APCI). 
2,2'-(((3,6-Di-tert-butyl-9-methyl-9H-carbazole-1,8-diyl)bis(ethyne-2,1-diyl))bis(4,6-dimethyl-
2,1-phenylene))bis(isoindolin-1-one) – 5.54b 
Following GP5.3 using 3,6-di-tert-butyl-1,8-diiodo-9-
methyl-9H-carbazole (54 mg, 0.10 mmol, 1.0 eq.), 
PdCl2(PPh3)2 (2.8 mg, 0.004 mmol, 4 mol%) and CuI 
(1.9 mg, 0.01 mmol, 10 mol%) in Et3N/DMF (1:1, 0.5 
mL, 0.2 M), followed by ethynyltrimethylsilane (65 
mg, 0.25 mmol, 2.5 eq.) at 90 °C for 20 h. Purification 
by flash column chromatography yielded the title 
compound (49 mg, 60%) as a white solid.  
220 
 
m.p.: >250 °C. Mixture of conformers in a 1:0.80 ratio in CDCl3. δ1H (400 MHz, CDCl3)  
7.98 (2 Hmin, dt, J = 7.6, 1.0 Hz, H-14), 7.93 (2 Hmaj, dt, J = 7.5, 1.0 Hz, H-14), 7.88 (2 Hmaj, d, J = 1.9 Hz, 
H-22), 7.87 (2 Hmin, d, J = 2.0 Hz, H-22), 7.60 – 7.40 (6 Hmaj+min, m, H-15 + H-16 + H-17),  
7.49 (2 Hmaj+min, m, H-4), 7.19 (2 Hmaj+min, t, J = 2.5 Hz, H-2), 7.12 (2 Hmaj, d, J = 1.9 Hz, H-24),  
6.99 (2 Hmin, d, J = 1.9 Hz, H-24), 5.25 (CHAHB, 2 Hmin, d, J = 16.9 Hz, H-13),  
5.22 (CHAHB, 2 Hmaj, d, J = 16.9 Hz, H-13), 4.65 (CHAHB, 2 Hmin, d, J = 16.9 Hz, H-13),  
4.61 (CHAHB, 2 Hmaj, d, J = 16.9 Hz, H-13), 4.48 (3 Hmin, s, H-27), 4.24 (3 Hmaj, s, H-27), 2.47 (3 Hmaj, s,  
H-8), 2.45 (3 Hmin, s, H-8), 2.29 (6 Hmaj+min, s, H-7), 1.22 (18 Hmaj, s, H-26), 1.17 (18 Hmin, s, H-26).  
δ13C (101 MHz, CDCl3) 168.10 (C-10maj), 168.09 (C-10min), 142.13 (CArmin), 142.08 (CArmaj), 141.96 (CArmin), 
141.95 (CArmaj), 138.69 (CArmin), 138.68 (CArmaj), 138.5 (CArmaj+min), 137.61 (CArmin), 137.60 (CArmaj),  
135.56 (CArmin), 135.5 (CArmaj), 132.6 (CArmin), 132.5 (CArmaj), 132.06 (C-2maj), 132.03 (C-2min),  
131.96 (C-16maj), 131.88 (C-16min), 131.0 (C-4maj), 130.7 (C-4min), 129.88 (C-24maj), 129.87 (C-24min), 
128.5 (C-15maj), 128.4 (C-15min), 124.5 (C-14min), 124.4 (C-14maj), 123.4 (CArmaj+min), 123.26 (CArmaj),  
123.25 (CArmin), 123.09 (C-17maj), 123.07 (C-17min), 117.2 (C-22maj+min), 104.6 (CArmaj+min), 92.4 (C-18min), 
92.2 (C-18maj), 90.0 (C-9maj), 89.9 (C-9min), 51.9 (C-13maj), 51.8 (C-13min), 34.4 (C-25maj), 34.3 (C-25min), 
33.1 (C-27maj), 32.9 (C-27min), 31.8 (C-26maj), 31.7 (C-26min), 21.16 (C-8min), 21.14 (C-8maj), 18.32 (C-7maj), 
18.30 (C-7min). IR (film, cm-1) νmax 2957 (C–H), 2243 (C≡C), 2206 (C≡C), 1690 (C=O), 1468, 1286, 1274. 
HRMS (ESI+) m/z calcd for C57H54N3O2 [M+H]+ 812.4211, found 812.4236. 
9-Benzyl-3,6-di-tert-butyl-1,8-diiodo-9H-carbazole  
To a solution of 3,6-di-tert-butyl-1,8-diiodo-9H-carbazole[321] (0.30 g,  
0.57 mmol, 1.0 eq.) in DMF (2.8 mL, 0.2 M) was added NaH (44 mg, 1.1 
mmol, 2.0 eq. 60% in mineral oil) and the green solution was stirred at 
rt for 10 minutes. Benzyl bromide (0.13 mL, 1.1 mmol, 2.0 eq.) was 
added and the reaction mixture was stirred at 40 °C for 4 h, during which 
the solution went from green to yellow to a white suspension. The 
reaction mixture was diluted in ethyl acetate, washed with LiCl (5% aq.), brine, dried over MgSO4, 
filtered, and concentrated in vacuo. Purification by flash column chromatography yielded the title 
compound (0.32 g, 91%) as a white foam. m.p.: 108 – 110 °C. δ1H (400 MHz, CDCl3)  
8.04 (2 H, d, J = 1.9 Hz, H-3), 7.94 (2 H, d, J = 1.8 Hz, H-5), 7.24 – 7.16 (3 H, m, H-12 + H-13),  
6.92 (2 H, dd, J = 8.0, 1.6 Hz, H-11), 6.46 (2 H, s, H-9), 1.42 (18 H, s, H-8). δ13C (101 MHz, CDCl3)  
145.2 (C-4), 140.1 (C-10), 139.5 (C-2), 138.1 (C-5), 128.4 (C-12), 126.8 (C-13), 126.4 (C-11), 125.8 (C-1), 
116.1 (C-3), 73.4 (C-6), 46.9 (C-9), 34.6 (C-7), 31.9 (C-8). IR (film, cm-1) νmax 2960 (C–H), 1479, 1285, 





Following GP5.3 using 9-benzyl-3,6-di-tert-butyl-1,8-
diiodo-9H-carbazole (62 mg, 0.10 mmol, 1.0 eq.), 
PdCl2(PPh3)2 (2.8 mg, 0.004 mmol, 4 mol%) and CuI 
(1.9 mg, 0.01 mmol, 10 mol%) in Et3N/DMF (1:1, 
 0.5 mL, 0.2 M), followed by ethynyltrimethylsilane 
(65 mg, 0.25 mmol, 2.5 eq.) at 90 °C for 20 h. 
Purification by flash column chromatography yielded 
the title compound (52 mg, 58%) as an off-white 
solid. m.p.: 192 – 195 °C (degradation). Broad signals in the 1H NMR spectrum at rt due to slow blond 
rotation. Mixture of conformers A/B in a 1:1 ratio in CDCl3. δ1H (400 MHz, CDCl3) 7.99 (2 HA, br. s,  
H-14), 7.97 (2 HB, br. s, H-14), 7.93 (2 HA+B, t, J = 2.2 Hz, H-22), 7.60 – 7.53 (2 HA+B, m, H-16),  
7.52 – 7.40 (4 HA+B, m, H-15 + H-17), 7.29 – 7.20 (4 HA+B, m, H-29 + H-30), 7.18 – 7.13 (1 HA+B, m, H-31), 
7.12 – 7.06 (2 HA+B, m, H-2), 6.97 (2 HA, br. s, H-24), 6.93 (2 HB, br. s, H-24), 6.71 (2 HA+B, br. s, H-4),  
6.43 (2 HA, br. s, H-27), 6.38 (2 HB, br. s, H-27), 5.21 (CHAHB, 2 HA, br. s, H-27),  
4.95 (CHAHB, 2 HB, br. s, H-27), 4.47 (CHAHB, 2 HA+B, br. s, H-27), 2.34 (6 HA, s, H-8), 2.32 (6 HB, s, H-8), 
2.22 (6 HA+B, s, H-7), 1.17 (18 HB, br. s, H-26), 1.15 (18 HA, br. s, H-26). δ13C (101 MHz, CDCl3)  
168.01 (C-10A), 167.97 (C-10B), 142.4 (broad, ArCA+B), 142.14 (ArCA+B), 142.08 (ArCA+B), 140.9 (ArCA+B), 
138.4 (ArCA), 138.3 (ArCB), 138.1 (ArCA), 138.0 (ArCB), 137.3 (ArCA), 137.2 (ArCB), 135.5 (ArCA+B),  
132.56 (ArCA), 132.54 (ArCB), 131.84 (C-2A), 131.83 (C-2B), 131.80 (C-16A), 131.79 (C-16B),  
130.98 (C-4A), 130.97 (C-4B), 130.2 (broad, C-24A+B), 128.64 (C-29A or C-30A), 128.57 (C-29B or C-30B), 
128.4 (C-15A), 128.3 (C-15B), 126.7 (C-29A+B or C-30A+B), 126.17 (C-21A), 126.14 (C-21B), 124.50 (C-14A), 
124.47 (C-14B), 123.8 (broad, ArCA+B), 123.1 (C-17A), 123.0 (C-17B), 122.88 (ArCA), 122.85 (ArCB),  
117.24 (C-22A), 117.23 (C-22B), 104.7 (C-18A+B), 91.7 (C-9A+B), 51.71 (C-13A), 51.68 (C-13B),  
48.5 (C-27A+B), 34.32 (C-25A), 34.29 (C-25B), 31.71 (C-26A), 31.69 (C-26B), 21.06 (C-8A), 21.05 (C-8B), 
18.25 (C-7A), 18.22 (C-7B). IR (film, cm-1) νmax 2958 (C–H), 1697 (C=O), 1478, 1386, 1207. HRMS (ESI+) 





Chapter 1 - VT 1H NMR experiments 
1H NMR spectra of a solution of the corresponding diarylamine in deuterated solvent were recorded 
at different temperatures until coalescence was reached. Their slow exchange spectra were simulated 
using the Spinworks 4 (available at  ftp://davinci.chem.umanitoba.ca/pub/marat/SpinWorks/), and for 
each temperature, the corresponding rate of enantiomerisation kenant was calculated using the DNMR 
simulation module MEXICO. From an Eyring plot, their enthalpy ΔH≠ and entropy ΔS≠ were calculated, 
and their corresponding Gibbs free energy ΔG≠ were found at 25 °C. Using the following equations, 
their rate of enantiomerisation and half-life to enantiomerisation at 25 °C were calculated: 
𝛥𝐺𝑇
‡ = 𝑅 ∗ 𝑇 ∗ ln (
𝑘B∗𝑇
ℎ∗𝑘enant






Alkyl region (2.7 – 0.8 ppm) of 1.28e in toluene-d8 (top to bottom: 60 °C to -10 °C, 10 °C step) 
 




Alkyl region (2.7 – 0.8 ppm) of 1.28e in CD3CN (top to bottom: 30 °C, to -10 °C, 10 °C step) 
 
Calculation in tol-d8 with coalescence of the signal centred around 1.28 ppm for the CHMe2 protons. 









Calculation in tol-d8 with coalescence of the signal centred around 2.49 ppm for the CH2CH3 protons. 











Calculation in C2D5OD with coalescence of the signal centred around 1.23 ppm for the CHMe2 proton 







Calculation in C2D5OD with coalescence of the signal centred around 2.45 ppm for the CH2CH3 proton 








Calculation in CD3CN with coalescence of the signal centred around 1.33 ppm for the CHMe2 protons 












CHMe2 region (1.5 – 0.7 ppm) of 1.28g in toluene-d8 (top to bottom: 50 °C, to 1 °C, 10 °C step) 
Calculation in tol-d8 with coalescence of the signal centred around 1.13 ppm for the CHMe2 protons. 














Calculation in tol-d8 with coalescence of the signal centred around 1.14 ppm for the CHMe2 protons. 










CHMe2 region (1.5 – 0.8 ppm) of 1.28j in DMSO-d6 (top to bottom: 80 °C, to 23 °C, 10 °C step) 
Calculation in DMSO-d6 with coalescence of the signal centred at 1.02 ppm for the CHMe2 protons. 












CHMe2 region (1.6 – 0.7 ppm) of 1.28k in toluene-d8 (top to bottom: 90 °C to 30 °C, 10 °C step) 
Calculation in tol-d8 with coalescence of the signal centred around 1.10 ppm for the CHMe2 protons. 









Chapter 1 - Chiral VT-HPLC experiments 
Separation of both enantiomers of the corresponding comound by chiral HPLC was performed on an 
Agilent 1260 Infinity. Temperature of the eluent and of the column was controlled with a ± 0.3 °C error 
margin. For each temperature, the corresponding rate of enantiomerisation was calculated using the 
Trapp equation.[51] From an Eyring plot, their enthalpy ΔH≠ and entropy ΔS≠ were calculated, and their 
corresponding Gibbs free energy ΔG≠ were found at 25 °C. Using the following equations, their rate of 
enantiomerisation and half-life to enantiomerisation at 25 °C were calculated: 
𝛥𝐺𝑇
‡ = 𝑅 ∗ 𝑇 ∗ ln (
𝑘B∗𝑇
ℎ∗𝑘enant







Conditions: Daicel OD-H, n-hexane/2-propanol (98:2), flow: 0.8 mL/min. 
 
 
Temperature (K) k (Hz) 
276 9.41 10−4 
279 1.18 10−3 











Temperature (K) k (Hz) 
278 4.87 10−4 
281 5.86 10−4 
284 7.74 10−4 
287 1.00 10−3 




Conditions: Daicel OD-H, n-hexane, flow: 0.8 mL/min. 
 
 
Temperature (K) k (Hz) 
281 1.04 10−3 
284 1.25 10−3 
287 1.48 10−3 
290 1.79 10−3 






Conditions: Daicel OD-H, n-hexane/2-propanol (99:1), flow: 0.8 mL/min. 
 
 
Temperature (K) k (Hz) 
288 5.91 10−4 
293 8.05 10−4 
298 1.07 10−3 
303 1.47 10−3 
308 1.96 10−3 
313 2.45 10−3 
 
Diarylamine 1.28q 






Temperature (K) k (Hz) 
293 6.98 10−4 
296 8.77 10−4 
299 1.04 10−3 
302 1.25 10−3 
305 1.53 10−3 
311 2.17 10−3 
313 2.46 10−3 
 
Chapter 1 - Decay of enantiomeric excess  
Separation of both enantiomers of the respective compounds by chiral HPLC was performed on an 
Agilent 1260 Infinity. The pure fractions of each enantiomer were combined, diluted and toluene and 
left at room temperature or heated to 100 °C for 1.28u and 1.28x respectively. Aliquots of the solution 
were taken, diluted in n-hexane and ran on HPLC using the conditions stated below. 
The ln of the enantiomeric excess was plotted against time, and their rate of racemisation krac was 
obtained with the slope of the trendline. (Caution!: krac = 2* kenant).Their Gibbs free energy and half-
life to enantiomerisation were calculated at 25 °C and 100 °C, respectively, using: 
𝛥𝐺𝑇
‡ = 𝑅 ∗ 𝑇 ∗ ln (
𝑘B∗𝑇
ℎ∗𝑘enant


































Chapter 2 - Decay of enantiomeric excess  
Separation of both enantiomers of compound 2.48m by chiral HPLC was possible at low temperature 
(273 K). However, the absence of observable plateau due to moderate separation as well as 
temperature-dependant retention time precluded calculation of the barrier to rotation. 
2.48m: RegisTech Alpha Burke 2, n-hexane/2-propanol (99:1), flow: 0.8 mL/min. The following traces 
were run at 5 °C, 20 °C and 35 °C respectively. 
         
Following time-dependent decrease in the enantiomeric purity of the enantioenriched samples by 
chiral stationary phase HPLC. Time-dependent decrease in the enantiomeric purity of 2.48o and 2.61 
at 60 °C in toluene was monitored by HPLC analysis. The slope of the plot of the decay of enantiomeric 
excess versus time indicates the barrier to racemisation.  
Barrier to racemisation of 2.48o 
2.48o: Daicel Chiralpak OD-H, n-hexane/2-propanol (90:10), flow: 1.0 mL/min, tR= 5.9, 7.0 min. 
 
 
         
 
k = 1.37 × 10−4 s–1 ; t1/2 = 84 min ; ΔG≠333 K = 106.5 kJ.mol–1 









Barrier to racemisation of 2.61 




 k = 2.87 × 10−4 s–1; t1/2 = 40 min ; ΔG≠333 K = 104.4 kJ.mol–1 
Chapter 3 - EXSY experiments 
The EXSY experiments were performed on a Varian 500 MHz spectrometer using the standard 
noesygpph pulse program. The acquired data points were zerofilled to 1K x 1K. The data were 
processed using MestReNova and the integration of the various signals was analysed using the 
EXSYCalc program from MestReC to obtain the rate constant. 
Enantiomerisation of 3.18a 
 
EXSY spectrum of 3.18a in toluene-d8, at 60 °C, 500 ms mixing time. 









EXSY spectrum of 3.18a in toluene-d8, at 60 °C, 500 ms mixing time, 2.5-4.0 ppm region. 
 
EXSY spectrum of 3.18a in toluene-d8, at 65 °C, 500 ms mixing time, 2.5-4.0 ppm region. 
 
EXSY spectrum of 3.18a in toluene-d8, at 70 °C, 500 ms mixing time, 2.5-4.0 ppm region. 
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Solvent Temperature Mixing time kenant (s–1) 
toluene-d8 
60 °C 500 ms 0.499 
65 °C 500 ms 0.804 
70 °C 500 ms 1.383 
Enantiomerisation of 3.18a in toluene-d8 
 
Eyring plot for the enantiomerisation of 3.18a in toluene-d8 
Enantiomerisation of 3.18b 
Solvent Temperature Mixing time kenant (s–1) 
DMSO-d6 
40 °C 800 ms 0.162 
45 °C 500 ms 0.509 
50 °C 500 ms 1.126 
CDCl3 
40 °C 2000 ms 0.0525 
45 °C 1000 ms 0.216 
50 °C 1000 ms 0.430 
 
Enantiomerisation of 3.18c 
Solvent Temperature Mixing time kenant (s–1) 
DMSO-d6 25 °C 400 ms 0.164 
CDCl3 
40 °C 1000 ms 0.184 
45 °C 700 ms 0.410 





Enantiomerisation of 3.18d 
Solvent Temperature Mixing time kenant (s–1) 
CD3OD 
3 °C 100 ms 1.780 
8 °C 100 ms 4.279 
13 °C 100 ms 6.613 
CDCl3 25 °C 150 ms 4.582 
 
Enantiomerisation of 3.18l 
Solvent Temperature Mixing time kenant (s–1) 
DMSO-d6 
40 °C 1000 ms 0.435 
45 °C 1000 ms 1.019 
50 °C 600 ms 1.711 
CDCl3 
40 °C 1000 ms 0.260 
45 °C 1000 ms 0.527 
50 °C 600 ms 0.967 
 






k1 (s–1) k–1 (s–1) 
CD3OD 25 °C 30 ms 1000 ms 0.326 0.099 
toluene-d8 25 °C 30 ms 600 ms 0.306 0.035 
 






k1 (s–1) k–1 (s–1) 
DMSO-d6 
80 °C 30 ms 500 ms 0.409 0.098 
85 °C 30 ms 500 ms 0.680 0.166 
90 °C 30 ms 500 ms 1.11 0.245 
CDCl3 
40 °C 30 ms 1000 ms 0.071 0.020 
45 °C 30 ms 1000 ms 0.156 0.036 




Chapter 4 - Chiral VT-HPLC experiments 
Barrier to enantiomerisation of 4.43b 
Separation of both enantiomers of the corresponding compound by chiral HPLC was performed on an 
Agilent 1260 Infinity. Temperature of the eluent and of the column was controlled with a ± 0.3 °C error 
margin. For each temperature, the corresponding rate of enantiomerisation was calculated using the 
Trapp equation.[51] From an Eyring plot, their enthalpy ΔH≠ and entropy ΔS≠ were calculated, and their 
corresponding Gibbs free energy ΔG≠ were found at 25 °C. Using the following equations, their rate of 
enantiomerisation and half-life to enantiomerisation at 25 °C were calculated: 
𝛥𝐺𝑇
‡ = 𝑅 ∗ 𝑇 ∗ ln (
𝑘B∗𝑇
ℎ∗𝑘enant




Conditions: Daicel OD-H, n-hexane, flow: 1.0 mL/min. 
 
Temperature (K) k (Hz) 
301 3.81 10−4 
304 5.01 10−4 
307 6.54 10−4 
310 9.13 10−4 
313 11.7 10−4 
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Chapter 5 - Chiral VT-HPLC experiments 
Barrier to enantiomerisation of 5.24 
Separation of both enantiomers of 5.24 by chiral HPLC was performed on an Agilent 1260 Infinity. 
Temperature of the eluent and column was controlled with a ± 0.3 °C margin. For each temperature, 
the corresponding rate of enantiomerisation was calculated using the Trapp equation.[51] From an 
Eyring plot, the enthalpy ΔH≠ and entropy ΔS≠ were calculated, and the Gibbs free energy ΔG≠ was 
found at 25 °C. Using the following equations, the rate of enantiomerisation and half-life to 
enantiomerisation at 25 °C were calculated: 
𝛥𝐺𝑇
‡ = 𝑅 ∗ 𝑇 ∗ ln (
𝑘B∗𝑇
ℎ∗𝑘enant




Conditions: Daicel AD-H, n-hexane/2-propanol (98:2), flow: 1.0 mL/min. 
Temperature (K) k (Hz) 
295 1.87 10−4 
298 3.70 10−4 
301 4.19 10−4 
304 5.72 10−4 
307 7.61 10−4 
310 10.1 10−4 




Chapter 5 - Determination of conformers distribution of 5.35 
 
13C spectrum of 5.35 in CDCl3, alkyne region 
 
13C spectrum of 5.35 in CD3OD, alkyne region 
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